{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already up-to-date: gensim in c:\\anaconda\\lib\\site-packages (3.8.3)\n",
      "Requirement already satisfied, skipping upgrade: scipy>=0.18.1 in c:\\anaconda\\lib\\site-packages (from gensim) (1.4.1)\n",
      "Requirement already satisfied, skipping upgrade: Cython==0.29.14 in c:\\anaconda\\lib\\site-packages (from gensim) (0.29.14)\n",
      "Requirement already satisfied, skipping upgrade: six>=1.5.0 in c:\\anaconda\\lib\\site-packages (from gensim) (1.14.0)\n",
      "Requirement already satisfied, skipping upgrade: smart-open>=1.8.1 in c:\\anaconda\\lib\\site-packages (from gensim) (2.1.0)\n",
      "Requirement already satisfied, skipping upgrade: numpy>=1.11.3 in c:\\anaconda\\lib\\site-packages (from gensim) (1.18.1)\n",
      "Requirement already satisfied, skipping upgrade: requests in c:\\anaconda\\lib\\site-packages (from smart-open>=1.8.1->gensim) (2.22.0)\n",
      "Requirement already satisfied, skipping upgrade: boto3 in c:\\anaconda\\lib\\site-packages (from smart-open>=1.8.1->gensim) (1.14.20)\n",
      "Requirement already satisfied, skipping upgrade: boto in c:\\anaconda\\lib\\site-packages (from smart-open>=1.8.1->gensim) (2.49.0)\n",
      "Requirement already satisfied, skipping upgrade: idna<2.9,>=2.5 in c:\\anaconda\\lib\\site-packages (from requests->smart-open>=1.8.1->gensim) (2.8)\n",
      "Requirement already satisfied, skipping upgrade: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in c:\\anaconda\\lib\\site-packages (from requests->smart-open>=1.8.1->gensim) (1.25.8)\n",
      "Requirement already satisfied, skipping upgrade: certifi>=2017.4.17 in c:\\anaconda\\lib\\site-packages (from requests->smart-open>=1.8.1->gensim) (2019.11.28)\n",
      "Requirement already satisfied, skipping upgrade: chardet<3.1.0,>=3.0.2 in c:\\anaconda\\lib\\site-packages (from requests->smart-open>=1.8.1->gensim) (3.0.4)\n",
      "Requirement already satisfied, skipping upgrade: s3transfer<0.4.0,>=0.3.0 in c:\\anaconda\\lib\\site-packages (from boto3->smart-open>=1.8.1->gensim) (0.3.3)\n",
      "Requirement already satisfied, skipping upgrade: jmespath<1.0.0,>=0.7.1 in c:\\anaconda\\lib\\site-packages (from boto3->smart-open>=1.8.1->gensim) (0.10.0)\n",
      "Requirement already satisfied, skipping upgrade: botocore<1.18.0,>=1.17.20 in c:\\anaconda\\lib\\site-packages (from boto3->smart-open>=1.8.1->gensim) (1.17.20)\n",
      "Requirement already satisfied, skipping upgrade: python-dateutil<3.0.0,>=2.1 in c:\\anaconda\\lib\\site-packages (from botocore<1.18.0,>=1.17.20->boto3->smart-open>=1.8.1->gensim) (2.8.1)\n",
      "Requirement already satisfied, skipping upgrade: docutils<0.16,>=0.10 in c:\\anaconda\\lib\\site-packages (from botocore<1.18.0,>=1.17.20->boto3->smart-open>=1.8.1->gensim) (0.15.2)\n"
     ]
    }
   ],
   "source": [
    "from fuzzywuzzy import fuzz, process\n",
    "import json\n",
    "import requests \n",
    "from requests.auth import HTTPBasicAuth\n",
    "\n",
    "# Install the genism Library to help remove stopwords to make analysis easier and faster and possibly more accurate\n",
    "!python -m pip install -U gensim\n",
    "from gensim.parsing.preprocessing import remove_stopwords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter your age: 58\n",
      "Enter your gender: Male\n",
      "Where is the cancer located? Pancreas\n",
      "What is the cancer type? (If cancer's location is skin, is it squamous cell carcinoma or basal cell carcinoma?): Exocrine (Nonendocrine) Pancreatic Cancer\n",
      "What is the cancer's stage? III\n",
      "What is your zip code? 30101\n",
      "How far are you willing to travel? (miles): 500\n"
     ]
    }
   ],
   "source": [
    "# Patient Data\n",
    "# Let a user enter their personal data to make a list of things to search and match with in trial data\n",
    "\n",
    "p_age = input(\"Enter your age: \")\n",
    "p_gender = input(\"Enter your gender: \")\n",
    "c_location = input(\"Where is the cancer located? \")\n",
    "c_type = input(\"What is the cancer type? (If cancer's location is skin, is it squamous cell carcinoma or basal cell carcinoma?): \")\n",
    "c_stage = input(\"What is the cancer's stage? \")\n",
    "p_zip_code = input(\"What is your zip code? \")\n",
    "max_dis = input(\"How far are you willing to travel? (miles): \")\n",
    "patient_data = [p_age,p_gender,c_location,c_type,c_stage,p_zip_code,max_dis]\n",
    "# create a subset of the patients' cancer data\n",
    "patient_cancer_data = [c_location, c_type, 'stage ' + c_stage]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00719303_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner\\u2019s tumor or adenocarcinoma not otherwise specified (N.O.S.); however, the histologic features of the tumor must be compatible with a primary Mullerian epithelial adenocarcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks, prior to enrollment and must be in complete remission; consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy (chemo) or biological therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have achieved a documented complete response to treatment based on normal cancer antigen (CA)-125 (per the institution\\u2019s upper limit of normal) and computed tomography (CT) scan or magnetic resonance imaging (MRI) with contrast (i.e. there must be no clinical evidence of persistent or recurrent disease based on CA-125 and CT scan or MRI with contrast)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have a Gynecologic Oncology Group (GOG) performance grade of 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must not be currently enrolled in an ongoing (participating for 6 months or longer) medically prescribed diet or physical activity regimen\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must have no other chronic disease that would preclude randomization into a lifestyle intervention trial; such diseases include recent myocardial infarction or unstable angina (in the previous 6 months), chronic hepatitis, rheumatoid disease, renal or hepatic disease/dysfunction and diabetics receiving insulin; or other clinical condition limiting ability to walk (recent leg fracture, significant osteoarthritis, related orthopedic conditions, degenerative neurological conditions, etc.)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must not have a serious psychiatric illness (e.g. lifetime bipolar disorder, schizophrenia or other psychosis, serious personality disorder, severe major depressive disorder or recent suicide or psychiatric hospitalization) (previous 12 months), or a history of an eating disorder (anorexia nervosa or bulimia nervosa)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must complete all pre-entry assessments\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must have signed an approved informed consent and authorization permitting release of personal health information\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must be willing to provide name and appropriate telephone contact information and be willing to be contacted periodically via telephone by The University of Arizona Cancer Center (AZCC) staff for completion of individualized lifestyle intervention coaching, completion of the Pittsburgh Sleep Quality Index, and for clarification of patient-completed responses if necessary; patient must be willing to have Arizona Food Frequency Questionnaire (AFFQ), Arizona Physical Activity Questionnaire (APAQ), baseline questionnaire, and personal contact information sent to AZCC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients with GOG performance grade of 3 or 4\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients may not have a history of other invasive malignancies within the last five years, with the exception of non-melanoma skin cancer or stage 1A endometrioid adenocarcinoma of the uterus\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients diagnosed with chronic disease/illness precluding their participation (i.e., diabetics receiving insulin, myocardial infarction or unstable angina within previous 6 months, chronic hepatitis, rheumatoid disease, renal or hepatic disease/dysfunction)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients with a histological diagnosis of clinical stage I epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients who are currently undergoing treatment (primary or consolidation) for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks ago\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with a life expectancy of less than one year\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients with body mass index (BMI) < 20 kg/m^2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Vegan vegetarians\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients enrolled in a weight loss program or who are taking weight loss medications or dietary supplements and are unwilling to discontinue\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients who have participated in a marathon, triathlon, or other endurance-related physical activity within the previous 24 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients who have had surgery for weight loss\\r\\n* Note: women will not be excluded if their baseline lifestyle assessment indicates a healthy eating and moderate physical activity with the exception of the exclusion criteria above\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Other Female Genital\",\n",
      "        \"Ovary\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2009-00595\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00956007_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically (histologically) proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma not otherwise specified [NOS], etc.) of the head/neck (oral cavity, oropharynx or larynx); note: hypopharynx primaries are excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases, based upon the following minimum diagnostic workup:\\r\\n* General history and physical examination by a radiation oncologist and/or medical oncologist within 8 weeks prior to registration\\r\\n* Examination by an ear, nose and throat (ENT) or head & neck surgeon, within 8 weeks prior to registration; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is recommended but not required\\r\\n* Chest x-ray (at a minimum) or chest computed tomography (CT) scan (with or without contrast) or CT/positron emission tomography (PET) of chest (with or without contrast) within 8 weeks prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration with surgical pathology demonstrating one or more of the following \\u201cintermediate\\u201d risk factors:\\r\\n* Perineural invasion\\r\\n* Lymphovascular invasion\\r\\n* Single lymph node > 3 cm or >= 2 lymph nodes (all < 6 cm) (no extracapsular extension)\\r\\n* Close margin(s) of resection, defined as cancer extending to within 5 mm of a surgical margin, and/or an initially focally positive margin that is subsequently superseded by intraoperative negative margins; similarly, patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient\\r\\n* Pathologically confirmed T3 or T4a primary tumor; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient\\r\\n* T2 oral cavity cancer with > 5 mm depth of invasion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Zubrod performance status 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Absolute granulocyte count (AGC) >= 1,500/mm\\u00b3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Platelet count >= 100,000/mm\\u00b3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Total bilirubin < 2 x institutional upper limit of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Serum creatinine < 2 x institutional ULN or; creatinine clearance (CC) >= 50 mL/min determined by 24-hour collection or estimated by Cockcroft-Gault formula\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"The following assessments are required within 2 weeks prior to the start of registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; note: patients with an initial magnesium < 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator\\u2019s discretion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for EGFR and for oropharyngeal patients, HPV analyses\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago; patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with primary tumor (T)1-2, nearby lymph nodes (N)0, metastasis (M)0 resected differentiated thyroid carcinoma, who are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Per the operative and/or pathology report, positive margin(s) (defined as tumor present at the cut or inked edge of the tumor), nodal extracapsular extension, and/or gross residual disease after surgery; note: patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Prior systemic chemotherapy or anti-EGF therapy for the study cancer; note: prior chemotherapy or anti-EGF therapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration\\r\\n* Transmural myocardial infarction within 6 months prior to registration\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n* Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration\\r\\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients\\r\\n* Grade 3-4 electrolyte abnormalities (CTCAE, v. 4):\\r\\n** Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels\\r\\n** Glucose < 40 mg/dl (< 2.2 mmol/L) or > 250 mg/dl (> 14 mmol/L)\\r\\n** Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels\\r\\n** Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels\\r\\n** Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Prior allergic reaction to cetuximab\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Larynx\",\n",
      "        \"Lip, Oral Cavity and Pharynx\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-00878\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00887146_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"PRE-REGISTRATION INCLUSION CRITERIA:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"United States (US) and Canadian sites:\\r\\n* This review is mandatory prior to registration to confirm eligibility; patients must be willing to submit tissue samples for mandatory central pathology review submission; it should be initiated as soon after surgery as possible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Tissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review\\r\\n* Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility, the 1p/19q analysis results will be accepted from the local site, as determined by either a locally available or reference laboratory (for US, must be Clinical Laboratory Improvement Act [CLIA] certified); acceptable methods for determination of 1p/19q loss include fluorescent in-situ hybridization (FISH), by genomic sequencing or methylomic analyses; US and Canadian sites must send a copy of the official report to the pathology coordinator and quality assurance specialist (QAS)\\r\\n* Tumor must also show evidence of IDH mutation by immunohistochemistry or genomic analyses; this should be performed at the local site (US: performed in a CLIA certified laboratory); the site must send a copy of the official report to the pathology coordinator and QAS\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"REGISTRATION INCLUSION CRITERIA:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Newly diagnosed and =< 3 months from surgical diagnosis; patients are also eligible if they have had a prior surgical procedure > 3 months earlier for low grade glioma, as long as the patient has not received prior radiation or prior chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Histological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p/19q loss and the presence of an either IDH1 or IDH2, both as established by a local or referenced laboratory qualified for the study\\r\\n* Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19q\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients with codeleted low grade gliomas must also be considered \\u201chigh risk\\u201d by exhibiting one or more of the following characteristics:\\r\\n* Age >= 40 and any surgical therapy\\r\\n* Age < 40 with prior and subtotal resection or biopsy (i.e., anything less than gross total resection)\\r\\n* Documented growth following prior surgery (NOTE: patients with prior surgery cannot have received prior radiation, chemotherapy or targeted therapy)\\r\\n* Intractable seizures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mm^3 (obtained =< 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Platelet (PLTs) count >= 100,000/mm^3 (obtained =< 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Hemoglobin (Hgb) > 9.0 g/dL (obtained =< 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN (obtained =< 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Creatinine =< 1.5 x ULN obtained =< 21 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Willingness and ability to personally complete neurocognitive testing (without assistance) and willingness to complete the QOL testing, (either personally or with assistance)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Willingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Willingness to allow the provision of tissue samples for correlative research, as long as adequate tissues are available; patients will not be excluded from participation in the study, if they are willing to allow provision of tissues for the correlative research, but there are insufficient quantities of tissue for the correlative analyses (e.g., a patient otherwise eligible and willing who had biopsy only)\\r\\nWillingness to allow the provision of blood samples for correlative research; patients are not excluded from participation in the study, if they are willing to provide the mandatory biospecimens for translational/correlative research, but for logistical reasons the specimens(s) were not obtainable or if the volume collected was insufficient\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"The following categories are ineligible:\\r\\n* Pregnant women\\r\\n* Nursing women\\r\\n* Men or women of childbearing potential who are unwilling to employ adequate contraception or contraceptive method during this study and 6 months following the completion of chemotherapy treatments\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"History of prior radiation therapy or chemotherapy for glioma; note: patients who have a history of prior low grade glioma (with or without a distant history of prior surgery for that glioma), but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Concomitant serious immunocompromised status (other than that related to concomitant steroids) that would compromise the safety of the patient on the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Other active malignancy within 5 years of registration; exceptions: non-melanotic skin cancer or carcinoma-in-situ of the cervix; note: if there is a history of prior malignancy, the patient is not eligible if they are receiving other specific treatment (with the exclusion of hormonal therapy or Her-2 inhibitors) for their cancer or if they have received prior total body irradiation which included the brain\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01915\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00392327_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Newly diagnosed, previously untreated: (1) M0 medulloblastoma with > 1.5 cm^2 residual; (2) M+ medulloblastoma; patients with diffusely anaplastic medulloblastoma are eligible regardless of M-stage or residual tumor\\r\\n* As of amendment # 2, enrollment of patients with supratentorial PNET has been discontinued\\r\\n* All patients with M4 disease are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"A pre-operative magnetic resonance imaging (MRI) scan of the brain with and without contrast is required; NOTE: computed tomography (CT) scans are NOT sufficient for study eligibility\\r\\n* Post-operative head MRI scan with and without contrast (preferably within 72 hours post-surgery); for patients who undergo stereotactic biopsy only, either a pre or post-operative MRI is sufficient; for patients with M2 and M3 disease, a post-op MRI is strongly encouraged, but not mandatory\\r\\n* Spinal MRI imaging with and without gadolinium is required within 10 days of surgery if done pre-operatively or within 28 days of surgery if done post-operatively; for posterior fossa tumors, pre-operative MRI scans are preferred\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Lumbar cerebrospinal fluid (CSF) cytology examination must be obtained pre-operatively or within 31 days following surgery; the optimal time for obtaining CSF is prior to surgery or 1-3 weeks following surgery; ventricular CSF (either pre- or post-op) may be used only if a post-operative spinal tap is contraindicated; if a spinal tap is contraindicated and there is no ventricular CSF available, then CSF cytology can be waived for patients with supratentorial tumors or if there is documentation of spinal subarachnoid metastases (M3); patients who are categorized as M1 must have either an intra-operative positive CSF (via lumbar puncture at the end of the procedure) or a positive lumbar CSF obtained > 7 days post-operatively\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"No previous chemotherapy or radiation therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Corticosteroids should not be used during chemotherapy administration as an antiemetic\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Selected strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (cytochrome P450 3A4) include azole antifungals, such as fluconazole, voriconazole, itraconazole, ketoconazole, and strong inducers include drugs such as rifampin, phenytoin, phenobarbitol, carbamazepine, and St. John\\u2019s wort; the use of these drugs should be avoided with vincristine (vincristine sulfate)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"CYP450 3A4 stimulators or inhibitors should be avoided or used with great caution when taking cyclophosphamide; aprepitant should also be used with caution with etoposide or vincristine chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Cisplatin should be used with caution with nephrotoxic drug; aminoglycoside should be avoided or used with caution during or shortly after cisplatin administration and concomitant use with amphotericin B should probably also be avoided; patients receiving cisplatin and other potentially ototoxic drugs such as aminoglycoside or loop diuretics concomitantly should be closely monitored for signs of ototoxicity\\r\\n* Plasma levels of anticonvulsant agents should be monitored and doses adjusted during therapy with cisplatin\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"No other experimental therapy is permitted while on study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:            \\r\\n* 0.8 mg/dL (2 to < 6 years of age)\\r\\n* 1.0 mg/dL (6 to < 10 years of age)\\r\\n* 1.2 mg/dL (10 to < 13 years of age)\\r\\n* 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)\\r\\n* 1.7 mg/dL (male) or 1.4 mg/dL (female) (>= 16 years of age)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Total bilirubin < 1.5 x upper limit of normal (ULN) for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age; for patients on anti-seizure medications, SGOT (AST) or SGPT (ALT) must be < 5 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,000/uL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Platelets >= 100,000/uL (untransfused)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Hemoglobin >= 8 g/dl (may be transfused)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Female patients who are post-menarchal must have a negative pregnancy test; lactating female patients must agree not to breast-feed while on this trial; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"21 Years\",\n",
      "          \"max_age_number\": 21,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 21,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"3 Years\",\n",
      "          \"min_age_number\": 3,\n",
      "          \"min_age_in_years\": 3\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2009-00336\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00983697_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Participant with histologic confirmation of newly diagnosed squamous cell carcinoma (SCC) of the head and neck\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Participant with unilateral or bilateral neck dissection planned for care; an N0 neck must be planned to be dissected for the patient to be eligible; the N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Participant with confirmed head and neck SCC:\\r\\n* CT and/or MR imaging has been completed within six (6) weeks prior to enrollment, even if the SCC diagnosis has been made via other methods, and will be submitted to American College of Radiology Imaging Network (ACRIN);\\r\\n* Simultaneous diagnostic CT with PET will not be excluded, but in such cases PET cannot be used as part of the criteria to define the N0 neck as required for entrance to the trial;\\r\\n* If sites received CT and/or MR images from institutions other than their own, ACRIN recommends a re-read by a local neuroradiologist to ensure compliance with protocol eligibility requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Participant with at least one neck that is clinically N0 as defined by clinical exam (physical exam with CT and/or MRI as the gold standard of the N0 neck); stages T2, T3, or T4. N0\\u2013N3, excluding N2c for bilateral disease based on criteria from the American Joint Commission on Cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Participant in whom it may be considered a viable clinical option to perform neck dissection when primary cancers are at high risk for neck metastasis (see definition above);\\r\\n* These will include: 1) oral cavity cancer; 2) oropharynx cancer, including base of tongue and tonsil cancers; 3) larynx cancer; or 4) supraglottic cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Participant willing to provide a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patient who is pregnant and/or breastfeeding\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patient with sinonasal carcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patient with tumors in the head and neck that are not SCC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patient with salivary gland malignancies\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patient with thyroid cancers\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patient with advanced skin cancers\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patient with nasopharyngeal carcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patient with poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL; optimally participants will have glucose < 150 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patient not a candidate for surgery (neck dissection) because of an underlying medical condition\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patient who weighs more than the weight limit for the PET table\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Larynx\",\n",
      "        \"Lip, Oral Cavity and Pharynx\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01972\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01272037_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have a histologically confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2 status; estrogen and progesterone receptor positivity must be assessed according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as either estrogen receptor (ER) or progesterone receptor (PR) >= 1% positive nuclear staining; HER-2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using immunohistochemistry (IHC), in situ hybridization (ISH) or both; HER-2 is negative if a single test (or all tests) performed in a tumor specimen show: a) IHC negative (0 or 1+) or b) ISH negative using single probe or dual probe (average HER-2 copy number < 4.0 signals per cell by single probe or HER-2/CEP ration < 2.0 with an average copy number < 4.0 signals per cell by dual probe); if HER-2 IHC is 2+, evaluation for gene amplification (ISH) must be performed and the ISH must be negative; ISH is not required if IHC is 0 or 1+; HER-2 equivocal is not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients with multifocal, multicentric and synchronous bilateral breast cancers are allowed\\r\\n* Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant; (NOTE: the Oncotype DX testing must be completed on the largest lesion)\\r\\n* Multicentric disease is defined as more than one invasive cancer >= 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants (NOTE: Oncotype DX testing should be completed on all tumors and the determination for eligibility should be made on the highest recurrence score)\\r\\n* Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other; (NOTE: the Oncotype DX testing should be completed on both tumors and the tumor with the highest recurrence score should be used)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients will have undergone axillary staging by sentinel node biopsy or axillary lymph nodes dissection (ALND); patients must have at least one, but no more than three known positive lymph nodes (pN1a, pN1b or pN1c); patients with micrometastases as the only nodal involvement (pN1mi) are not eligible; patients with positive sentinel node are not required to undergo full axillary lymph node dissection; this is at the discretion of the treating physician; axillary node evaluation is to be performed per the standard of care at each institution\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must not have inflammatory breast cancer and must not have metastatic disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients with a prior diagnosis of contralateral ductal carcinoma in situ (DCIS) are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation; prior partial breast irradiation, including brachytherapy, is not allowed; patients with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received radiation to that breast are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation); patients must have clear margins from both invasive breast cancer and DCIS (as per local institutional guidelines); lobular carcinoma in situ (LCIS) at the margins is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Registration of patients who have not yet undergone Oncotype DX screening must occur no later than 56 days after definitive surgery; (for all patients, Step 2 Registration must occur within 84 days after definitive surgery); if the Oncotype DX Breast Cancer Assay has not been performed, patients must be willing to submit tissue samples for testing to determine the Recurrence Score value; a representative block or unstained sections from the representative block are sent directly to Genomic Health for Oncotype DX Breast Cancer Assay which will be performed according to the standard commercial process\\r\\n* If the Oncotype DX Recurrence Score is already known and is 25 or less, the patient must be registered to Step 2 immediately following Step 1 registration; if the Oncotype DX Recurrence Score is already known and is greater than 25, the patient is ineligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must have a complete history and physical examination within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must have a performance status of 0-2 by Zubrod criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must be able to receive taxane and/or anthracycline based chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agents\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must not be pregnant or nursing; women of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \\\"reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/12; patients who consented to QOL prior to 12/1/12 should continue to complete QOL forms per their expectation report; patients who are able to complete a questionnaire in English must be offered the opportunity to participate in the Quality of Life and Economic Substudy; (The Quality of Life and Economic Substudy is available to U.S. INSTITUTIONS ONLY); patients who are not able to complete a questionnaire in English are registered to S1007 without participating in the Quality of Life and Economic Substudy\\r\\n* Patients who consent to participate in the Quality of Life and Economic Substudy and who do not yet know the results of their Oncotype DX screening must agree to complete the S1007 Health-Related Quality of Life Questionnaire: Enrollment between 14 days prior to and 7 days after Step 1 Registration\\r\\n* Patients who consent to participate in the Quality of Life and Economic Substudy and who do already know their Oncotype DX Recurrence Score (and it is 25 or less) will proceed to Step 2 Registration without completing the S1007 Health-Related Quality of Life Questionnaire Enrollment Form (but will complete the S1007 Health-Related Quality of Life Questionnaire: Randomized Study Form)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for Step 1 registration of patients who have not yet submitted specimens for the Oncotype DX Breast Cancer Assay, the appropriate consent form is the Step 1 Consent Form; for both Step 1 and Step 2 registration of patients whose Recurrence Score is already known and is 25 or less, the appropriate consent form is the Step 2 Consent Form\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"STEP 2 REGISTRATION\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Recurrence score (RS) by Oncotype DX must be =< 25\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Step 2 Registration must take place within 84 days after definitive surgery; patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients randomized to either arm may also co-enroll in phase III trials that compare local therapies, or compare systemic therapies (such as chemotherapy, if randomized to Arm I of S1007)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/12; patients at U.S. INSTITUTIONS who consent to participate in the Quality of Life and Economic Substudy must agree to complete the S1007 Health-Related Quality of Life Questionnaire: Randomized Study Form after Recurrence Score results and randomized treatment status are known but before treatment has been initiated\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for all patients the appropriate consent form for this registration is the Step 2 Consent\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02623\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01190930_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"B-ALL patients must be enrolled on AALL08B1 or APEC14B1 (if open for the classification of newly diagnosed ALL patients) prior to treatment and enrollment on AALL0932\\r\\n* Note: B-LLy patients are not eligible for AALL08B1, and can enroll directly onto AALL0932\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"B-ALL patients must have an initial white blood cell count < 50,000/uL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have newly diagnosed National Cancer Institute (NCI) Standard Risk B-ALL or B-LLy Murphy stages I or II; patients with Down syndrome are also eligible\\r\\n* Note: for B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL; for tissue processed by other means (i.e. paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and NCI requirements for human studies must be met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"With the exception of steroid pretreatment (defined below) or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL0932\\r\\n* Patients receiving prior steroid therapy may be eligible for AALL0932\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients with central nervous system 3 (CNS3) leukemia\\r\\n* CNS status must be known prior to enrollment; (Note: the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment); B-LLy patients with CNS3 disease are not eligible for this protocol or the COG HR ALL protocol; it is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar puncture; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; this is allowed prior to registration; systemic chemotherapy must begin within 72 hours of the first dose of intrathecal therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"B-ALL patients with testicular leukemia are not eligible for AALL0932\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"For B-LLy patients the following additional exclusion criteria apply:\\r\\n* T-lymphoblastic lymphoma\\r\\n* Morphologically unclassifiable lymphoma\\r\\n* Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma\\r\\n* CNS3-positive disease or testicular involvement\\r\\n* M2 (5% - 25% blasts) or M3 (> 25% blasts) marrow\\r\\n* Female patients who are pregnant are ineligible\\r\\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants\\r\\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\\r\\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"30 Years\",\n",
      "          \"max_age_number\": 30,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 30,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"1 Years\",\n",
      "          \"min_age_number\": 1,\n",
      "          \"min_age_in_years\": 1\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lymphoid Leukemia\",\n",
      "        \"Non-Hodgkin's Lymphoma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02599\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01231906_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients with newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or primitive neuroectodermal tumor (PNET) of bone or soft tissue are eligible for this study; note:\\r\\n* For the purpose of this study, chest wall tumors with ipsilateral pleural effusions, ipsilateral positive pleural fluid cytology or ipsilateral pleural based secondary tumor nodules will be considered localized disease\\r\\n* Patients with regional node involvement, based on clinical suspicion confirmed by pathologic documentation are considered to be non-metastatic\\r\\n* Patients with discontinuous osseous lesions within the same bone are considered to be non-metastatic\\r\\n* Tumors arising in the bony skull (extra-dural) are considered to be extracranial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patient eligibility will be based on a diagnosis of Ewing sarcoma or PNET by institutional pathologist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"No prior chemotherapy or radiation therapy is allowed; patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70mL/min/1.73 m^2 or serum creatinine based on age/gender as follows:\\r\\n* 1 month to < 6 months: 0.4 mg/dL\\r\\n* 6 months to < 1 year: 0.5 mg/dL\\r\\n* 1 to < 2 years: 0.6 mg/dL\\r\\n* 2 to < 6 years: 0.8 mg/dL\\r\\n* 6 to < 10 years: 1 mg/dL\\r\\n* 10 to < 13 years: 1.2 mg/dL\\r\\n* 13 to < 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)\\r\\n* >= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Total bilirubin < 1.5 x upper limit of normal (ULN) for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must have no evidence of metastatic disease; metastatic disease:\\r\\n* Are lesions which are discontinuous from the primary tumor, are not regional lymph nodes and do not share a body cavity with the primary tumor; if there is any doubt whether lesions are metastatic, a biopsy of those lesions should be taken\\r\\n* Skeletal lesions in adjacent bones (trans-articular)\\r\\n* Contralateral pleural effusion and contralateral pleural nodules\\r\\n* Distant lymph node involvement\\r\\n* Patients with pulmonary nodules are considered to have metastatic disease if the patient has:\\r\\n** Solitary nodule > 0.5 cm or multiple nodules of > 0.3 cm unless biopsied and negative for Ewing's\\r\\n** Biopsies of solitary nodule =< 0.5 cm or multiple nodules =< 0.3 cm are not required but if performed and positive indicate metastatic disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients whose tumors arise in the dural and intra-dural soft tissues of the cranium and spine are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients with pathologic diagnoses other than Ewing sarcoma will be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients diagnosed with Ewing Sarcoma as a second malignant neoplasm are not eligible if they have received chemotherapy or radiation for the treatment of their primary malignancy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Pregnant women will not be entered on this study; pregnancy tests must be obtained in female patients who are post-menarchal; lactating females may not participate unless they have agreed not to breastfeed their infants; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"50 Years\",\n",
      "          \"max_age_number\": 50,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 50,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"0 Years\",\n",
      "          \"min_age_number\": 0,\n",
      "          \"min_age_in_years\": 0\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\",\n",
      "        \"Soft Tissue / Sarcoma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02611\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01386385_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have histologically or cytologically-proven new diagnosis of unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed)\\r\\n* Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and pericardial are now considered stage M1a disease; when pleural fluid is visible on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is required to confirm that the pleural fluid is cytologically negative; patients with exudative pleural effusions are excluded, regardless of cytology; patients with effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible; a small effusion that has positive fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients with brain metastases are ineligible; all patients must have a pretreatment CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must not have received prior chest radiation therapy for NSCLC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must have Zubrod performance status 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must have tumor tissue available for submission to assess gene expression of ERCC1 and XRCC1; patients must also be offered participation in banking for future use of specimens\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Absolute neutrophil count >= 1,500/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Platelets >= 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Hemoglobin >= 9.0 g/dl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Total bilirubin within institutional upper limit of normal (IULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x IULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \\\"reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must have a serum creatinine =< the IULN AND measured or calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients must have pulmonary function tests (PFTs) including forced expiratory volume in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50% predicted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients may not be planning to receive any other investigational agents\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients must not have more than 10% weight loss in the past 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patient must not have any uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must not currently have a > grade 1 symptomatic neuropathy-sensory (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients must not have a history of seizures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients must be able to swallow whole capsules\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Prestudy history and physical must be obtained within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution\\u2019s identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have undergone restaging tests according to the study calendar and determined to have no evidence of disease progression\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have a serum creatinine =< (IULN) AND measured of calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Absolute neutrophil count >= 1,500 mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =< 2.5 x IULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have Zubrod performance status 0-1\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lung\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02592\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01573442_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Receiving anastrozole (1 mg) or letrozole (2.5 mg) orally once a day, for >= 21 days prior to registration and plan to continue throughout the duration of study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Body mass index (BMI) between 18 and 35 kg/m^2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Women who have undergone a total mastectomy or breast-conserving surgery for primary breast cancer +/- chemotherapy, +/- radiotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Must have BOTH estrogen receptor (ER) and progesterone receptor (PR)-positive tumors and BOTH must be >= 26% positive; alternatively, if ER and PR are determined by Allred score, the score needs to be 5 or higher\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Women who are postmenopausal by surgery, radiotherapy, or presence of natural amenorrhea >= 12 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \">= 5/10 arthralgia (in hands, wrist, knees, or hips) while being treated with anastrozole or letrozole which is felt by the patient to be caused by their aromatase inhibitor, as measured by verbally addressing the following question: please rate your pain by picking a number, from 0 to 10 (0 being none and 10 being as bad as you can imagine) that best describes your pain from your aromatase inhibitor breast cancer medication on AVERAGE, over the past week\\r\\n* Note: Patients may, or may not, be taking non-opioid analgesics\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Ability to complete questionnaire(s) by themselves or with assistance\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Willing to provide informed written consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Willing to return to an Alliance enrolling institution for follow-up\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Willing to provide blood samples for correlative research purposes\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Creatinine =< 1.5 x upper limit of normal (ULN) (=< 365 days prior to registration, without medical situations that should change these parameters since they were done)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Hemoglobin > 11 g/dL (=< 365 days prior to registration, without medical situations that should change these parameters since they were done)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"White blood cell (WBC) > 3.0 (=< 365 days prior to registration, without medical situations that should change these parameters since they were done)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Platelet count > 100,000 (=< 365 days prior to registration, without medical situations that should change these parameters since they were done)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULN (=< 365 days prior to registration, without medical situations that should change these parameters since they were done)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Presence of residual or recurrent cancer (locally or metastatic)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Diabetes mellitus or glucose intolerance, defined as a fasting glucose > 125 mg/dL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"History of coronary artery disease (angina or myocardial infarction)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients on hormone-replacement therapy (HRT) =< 4 weeks prior to registration; this includes the use of vaginal estrogen therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Known hypersensitivity to any component of testosterone\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Prolonged systemic corticosteroid treatment, except for topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops, or local insertion (e.g., intra-articular)\\r\\n* Note: Short duration (< 2 weeks) of systemic corticosteroids is allowed (e.g., for chronic obstructive pulmonary disease), but not within 30 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Receiving any other investigational agent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"History of a deep venous thrombosis or a thromboembolism\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Concurrent use of the aromatase inhibitor exemestane\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Concurrent radiation therapy or chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Current or planned use of cyclosporine, anticoagulants, insulin, oral or injectable vitamin D doses over 4,000 IU/day, or tamoxifen\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-00719\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01556243_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Life expectancy of at least 5 years, excluding diagnosis of breast cancer (comorbid conditions should be taken into consideration, but breast cancer diagnosis is not a consideration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Men are excluded from this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Upon clinical exam and pre-operative imaging by mammogram +/- MRI, two or three foci of biopsy proven breast cancer separated by >= 2 cm of normal breast tissue; foci must include at least one focus of invasive breast carcinoma with another focus of either invasive breast carcinoma or ductal carcinoma in situ (DCIS); no more than 2 quadrants with biopsy proven breast cancer; Note: the shortest distance between lesions must be reported on mammogram +/- MRI and eligibility criteria must be met on both, if both are obtained; Note: patient is eligible for study if lesion is not visualized on all imaging modalities (i.e., any of the lesion [s] is/are visualized on MRI but not on mammogram OR visualized on mammogram but not on MRI); ultrasound cannot be used to determine patient eligibility; eligibility to be determined by bilateral mammogram +/- MRI only; fine needle aspirate of the second or third lesion to document malignancy is allowed if the first focus is shown to be invasive by core needle biopsy; patient may remain on study if, upon pathological assessment, two or three lesions identified on pre-operative imaging represent one contiguous lesion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients may be registered AFTER surgery and PRIOR TO radiation therapy if either of the criteria is met:\\r\\n* An area of atypia > 2 cm from the index lesion excised at the time of cancer operation is upgraded to DCIS or invasive carcinoma thereby identifying MIBC OR\\r\\n* Patient underwent resection of two or three foci of malignancy by breast conservation surgery with a minimum of one invasive focus of breast cancer and a minimum of 2 cm of normal breast tissue between the lesions on final pathology\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Bilateral mammogram =< 90 days prior to date of surgery; Note: for patients undergoing more than 1 breast operation, this is the date of the first breast surgery for breast cancer treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"cN0 or cN1 disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Ability to complete questionnaire(s) by themselves or with assistance\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Ability to provide written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study; patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Any of the following:\\r\\n* Pregnant women\\r\\n* Nursing women\\r\\n* Women of childbearing potential who are unwilling to employ adequate contraception (as determined by the treating physician)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Largest single focus of disease > 5 centimeters by either mammogram or MRI or both; Note: measurement of the largest single focus should include any satellite lesions within 1 centimeter of the index lesion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Surgical axillary staging procedure prior to first definitive breast operation; Note: fine-needle aspiration (FNA) or core needle biopsy of axillary node is permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Clinical or radiographic evidence of metastatic disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Prior history of ipsilateral breast cancer (DCIS, LCIS [lobular cancer in situ] or invasive)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"cNX, cN2, or cN3 disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Breast implants at time of diagnosis; Note: patients who have had implants previously removed prior to diagnosis are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would interfere significantly with whole-breast irradiation (such as connective tissue disorders, lupus, or scleroderma)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Prior or current LCIS, DCIS or invasive breast cancer in the opposite breast (i.e., bilateral disease is not allowed)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Treatment including radiation therapy, chemotherapy, biotherapy, or hormonal therapy for this cancer prior to surgery (i.e., any neoadjuvant chemotherapy or endocrine therapy is not allowed); patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Planned partial breast radiation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients with known breast cancer (BRCA) mutations; patients who are not tested or whose testing result is not returned at the time of registration are not excluded from registering to this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"40 Years\",\n",
      "          \"min_age_number\": 40,\n",
      "          \"min_age_in_years\": 40\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-00707\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01595061_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients with T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection by standard radical vulvectomy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Platelets >= 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Creatinine =< 1.5 times institutional upper limit of normal (ULN) OR calculated creatinine clearance >= 60 mL/min\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Bilirubin =< 1.5 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Alkaline phosphatase =< 3 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients judged capable of tolerating a radical course of chemoradiation therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must have signed an approved informed consent and authorization permitting release of personal health information\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients with a GOG performance status of 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients with recurrent carcinoma of the vulva regardless of previous treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients who have received prior pelvic radiation or cytotoxic chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients with vulvar melanomas or sarcomas\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with circumstances that will not permit completion of the study or the required follow-up\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Other Female Genital\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-01964\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01349881_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"STEP 0: REGISTRATION (Optional)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients with a primary colon or rectal cancer resection who are potentially eligible for S0820 may be pre-registered at Step 0; patients registered to Step 0 will appear on an institutional patient tracking report; patients registered to Step 0 are not registered to the S0820 protocol; to participate in S0820, patients must be registered to Step 1 after patient is consented and evaluation of eligibility; patients registered to S0820 at Step 0 continuing to Step 1 registration must use the same Southwest Oncology Group (SWOG) patient identification (ID) for registration to S0820 Step 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"STEP 1: REGISTRATION\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have a history of stage 0, I, II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy; adjuvant chemotherapy and radiation therapy (RT) treatment must have been completed at least 30 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients with history of segmental resections are eligible (i.e. right colectomy, extended right colectomy, transverse colectomy, left colectomy, extended left colectomy, sigmoid colectomy, low anterior resection, abdominoperineal resection); the definition of resection does not include endomucosal resection (EMR); patients that have received total proctocolectomy are ineligible\\r\\n* In addition to segmental resections, the following types of procedures are allowed: polypectomy: for Tis (stage 0) or pT1 patients only, resection may consist entirely of polypectomy (without completion of partial colectomy) if ALL of the following criteria are met:\\r\\n** Single specimen, completely removed\\r\\n** Clear margins\\r\\n** None of the following must be present:\\r\\n*** Moderate or poor differentiation\\r\\n*** Lymphovascular invasion\\r\\n*** Perineural invasion\\r\\n* Transanal excision is allowed for pT1 rectal cancer patients with well or moderately differentiated tumors if National Comprehensive Cancer Network (NCCN) criteria for transanal excision are met, as stipulated here:\\r\\n** < 30% circumference of bowel\\r\\n** < 3 cm in size\\r\\n** Margin clear (> 3 mm)\\r\\n** Mobile, nonfixed\\r\\n** Within 8 cm of anal verge\\r\\n** T1 only\\r\\n** Endoscopically removed polyp with cancer\\r\\n** No lymphovascular invasion or perineural invasion\\r\\n** Well to moderately differentiated\\r\\n** No evidence of lymphadenopathy on pretreatment imaging\\r\\n*** When the lesion can be adequately identified in the rectum, transanal endoscopic microsurgery (TEM) may be used; TEM for more proximal lesions may be technically feasible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must be registered between 120 days and 456 days (inclusive) of primary resection; patients must show no evidence of colorectal cancer based on post-operative colonoscopy (performed at least 120 days after the colon or rectal resection date and prior to registration); patients with adenomas detected at the one-year postoperative colonoscopy are eligible if all adenomas have been completely removed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must have a pure tone audiometry evaluation to document air conduction within 30 days prior to registration; patients with hearing loss > 40 decibels (dB) in any of the five tested frequencies (250 Hertz [Hz], 500 Hz, 1,000 Hz, 2,000 Hz, 4,000 Hz) are not eligible; patients with active ear infections should be tested only after the acute phase of infection has resolved; for optimal results, it is recommended that testing be conducted by an audiologist, in a hearing test room, with insert earphones; Note: sites should not order audiometry evaluation until the potential participant has met all other eligibility criteria required for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must have a Zubrod performance status of 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must have the ability to swallow oral medication\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Total white blood cells (WBC) >= 4.0 x 10^3/mcL (within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Platelets >= 100,000/mcL (within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Hemoglobin > 11.0 g/dL (within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"A total WBC >= 3.1 x 10^3/mcL is allowed for non-Hispanic black males (NHBM) and total WBC >= 3.4 x 10^3/mcL for non-Hispanic black females (NHBF) \\r\\n* Exception: If the WBC is lower than the above levels, the patient may be enrolled IF the absolute neutrophil count (ANC) is >= 1.3 for NHBM, >= 1.4 for NHBF, or >= 1.5 for all\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum bilirubin =< 2.0 mg/dL (within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x IULN (institutional upper limit of normal) (within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Serum creatinine =< 1.5 x IULN obtained within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with a prior malignancy or concurrent malignancy that is currently not being treated, whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, are eligible for this trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"SPECIMEN SUBMISSION AND SUBSTUDY CRITERIA\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients must be offered the option to participate in submission of specimens for banking for future translational medicine studies\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients participating through PK sites, must be offered the option to submit blood specimens for population pharmacokinetic analysis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients must be offered the option to participate in the Diet and Lifestyle Substudy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"REGULATORY CRITERIA\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"As part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients must not have cardiovascular risk factors including unstable angina, history of documented myocardial infarction or cerebrovascular accident, coronary artery bypass surgery, or New York Heart Association class III or IV heart failure; patients must not have known uncontrolled hyperlipidemia (defined as low-density lipoprotein cholesterol [LDL-C] >= 190 mg/dL or triglycerides >= 500 mg/dL) within the last 3 years prior to registration or uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must not have a known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, inflammatory bowel disease, biallelic mismatch repair deficiency syndrome (BMMRD), or constitutional mismatch repair deficiency syndrome (CMMRD)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drug (NSAID)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients must not have documented history of gastric/duodenal ulcer within the last 12 months; participant must not currently be on treatment for gastric/duodenal ulcer or be experiencing symptoms at study entry; patients with gastroesophageal reflux disease (GERD) are eligible, however, and these patients may receive over-the-counter histamine-2 (H2) antagonists; proton-pump inhibitors, or other prescription-based treatment for GERD\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients must not be expecting to receive radiation or additional chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Patients must not be receiving or plan to receive concomitant oral or intravenous corticosteroids on a regular basis, nonsteroidal anti-inflammatory drugs (NSAIDs), nor anticoagulants on a regular or predictable intermittent basis; (NSAID use may not exceed 10 days per month); patients may receive daily aspirin for cardiovascular prophylaxis as long as acetylsalicylic acid (ASA) is =< 100 mg per day or =< two 325 mg tablets per week; inhaled steroids (i.e. for asthma or related conditions) are allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Patients must have no significant medical or psychiatric condition that would preclude study completion; tests and exams for this determination should be completed within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Patients must not be pregnant or nursing (due to the status of eflornithine and sulindac as pregnancy class C agents); women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \\\"reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"Individuals must not currently be participating in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only; patients must also agree not to join such a trial while participating in this study\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Colon\",\n",
      "        \"Rectum\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-02067\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01863550_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"STEP I: Patients must be diagnosed with symptomatic standard-risk multiple myeloma (SR-MM) as defined by all of the following (except gene expression profile [GEP]70 status if unknown):\\r\\n* No evidence of t(14;16) by fluorescence in situ hybridization (FISH) testing on bone marrow or not available\\r\\n* No evidence of t(14:20) by FISH testing on bone marrow or not available\\r\\n* No evidence of deletion 17p by FISH testing on bone marrow\\r\\n* FISH should be from within 90 days of registration\\r\\n** NOTE: If the FISH result states that no immunoglobulin heavy chain (IgH) abnormality is present, both t(14;16) and t(14;20) can be considered negative; in addition, if the patient has a t(11;14) or t(4;14) translocation present, they can be considered negative for t(14;16) and t(14;20); if testing for t(14;16) or t(14;20) could not be performed for lack of sufficient material or non-availability of the probe in the test panel, patients can be enrolled on the study\\r\\n* Standard Risk GEP70 signature within the past 90 days (only if GEP has been done and results are available)\\r\\n** NOTE: GEP testing is NOT a requirement for the study; if the test has been done, patients found to have a GEP70 status of high-risk will not be eligible\\r\\n* Serum lactate dehydrogenase (LDH) =< 2 x upper limit of normal (ULN) within the past 28 days\\r\\n* No more than 20% circulating plasma cells on peripheral blood smear differential or 2,000 plasma cells/microliter on white blood cell (WBC) differential of peripheral blood within the past 90 days\\r\\n** NOTE: This is NOT the plasma cell % from the marrow aspirate\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"STEP I: Patients must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization:\\r\\n* >= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis\\r\\n* >= 200 mg/24 hours (hrs) of monoclonal protein on a 24 hour urine protein electrophoresis\\r\\n* Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)\\r\\n* Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"STEP I: Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay are required to be performed within 28 days prior to randomization; a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response\\r\\n* NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable; urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr; please note that if both serum and urine M-components are present, both must be followed in order to evaluate response\\r\\n* NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine; measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL; measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"STEP I: Hemoglobin >= 8 g/dL (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"STEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"STEP I: Absolute neutrophil count >= 1000 cells/mm^3 (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"STEP I: Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"STEP I: Bilirubin =< 1.5 mg/dL (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"STEP I: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 2.5 times the upper limit of normal (obtained within 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"STEP I: Patients must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma; they should not have been exposed to lenalidomide, bortezomib or carfilzomib for treatment of symptomatic myeloma; prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"STEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"STEP I: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (performance status [PS] 3 allowed if secondary to pain)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"STEP I: Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \\u201cin situ\\u201d of the cervix or breast are not excluded)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"STEP I: Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 \\u2013 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide, throughout the entire duration of study treatment, and for 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure; if randomized to Arm B, FCBP must agree to use contraception or abstinence for 30 days after last dose of carfilzomib\\r\\n* A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"STEP I: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; if randomized to Arm B, male subjects must be willing to use condoms while having intercourse, while taking carfilzomib and for 90 days after discontinuation of carfilzomib\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\\r\\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\\r\\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\\r\\n* Not currently prescribed zidovudine or stavudine\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"STEP I: Patient enrolling to this study must agree to register to the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"STEP II: Patients must have complete induction without experiencing progression or patients must have received at least 6 cycles on Arm A and 4 cycles on Arm B but stopped induction therapy due to adverse events\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"STEP II: Step 2 registration must be within 6 weeks of completing step 1 therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"STEP II: Patients must not have received any non-protocol therapy outside of the assigned induction therapy including stem cell transplant\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"STEP II: ECOG performance status 0, 1, or 2 (PS 3 allowed if secondary to pain)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"STEP II: Any adverse event related to step 1 therapy must have resolved to grade 2 or less\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"STEP II: Hemoglobin >= 8 g/dL (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"STEP II: Platelet count >= 75,000 cells/mm^3 (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"STEP II: Absolute neutrophil count >= 1000 cells/mm^3 (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"STEP II: Calculated creatinine clearance >= 30 mL/min (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"STEP II: Bilirubin =< 1.5 mg/dL (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"STEP II: SGPT (ALT) and SGOT (AST) < 2.5 times the upper limit of normal (within 28 days prior to randomization to Step II)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"STEP II: Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 \\u2013 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide, throughout the entire duration of study treatment, and for 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure; if previously randomized to Arm B, FCBPs must also continue to use contraception or abstinence for 30 days after the last dose of carfilzomib\\r\\n* A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"STEP II: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; if previously randomized to Arm B, males must agree to continue use of contraception and agree to not donate sperm for at least 90 days after the last dose of carfilzomib\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"STEP II: Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"STEP I: Patients must not have active, uncontrolled seizure disorder; patients must have had no seizures in the last 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"STEP I: Patients must not have uncontrolled intercurrent illness including uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, uncontrolled cardiac arrhythmia, uncontrolled psychiatric illness or social situation that would limit compliance with the study, or a prior history of Stevens Johnson syndrome\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"STEP I: Patients with monoclonal gammopathy of undetermined significance or asymptomatic multiple myeloma are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"STEP I: Patients must not have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events (CTCAE) 4.0\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"STEP I: Patients must not have active, uncontrolled infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"STEP I: Patients should not have New York Heart Association classification III or IV heart failure or myocardial infarction within the previous 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"STEP I: The following patients will be excluded as this study involves an agent that may have genotoxic, mutagenic and teratogenic effects:\\r\\n* Pregnant women\\r\\n* Nursing women\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 40,\n",
      "            \"description\": \"STEP II: The following patients will be excluded as this study involves an agent that may have genotoxic, mutagenic and teratogenic effects:\\r\\n* Pregnant women\\r\\n* Nursing women\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Multiple Myeloma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-02608\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01767194_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines (i.e., > 2 x upper limit of normal [ULN]), at the time of initial diagnosis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"For the purposes of this study, aggressive multidrug chemotherapy is defined as chemotherapy including 2 or more agents that must include an alkylating agent and a platinum-containing compound; patients must have ONE of the following:\\r\\n* First episode of recurrent disease following completion of aggressive multi-drug frontline therapy\\r\\n* First episode of progressive disease during aggressive multi-drug frontline therapy\\r\\n* Primary resistant/refractory disease (less than partial response by INRC) detected at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (examples include A3973, ANBL0532, ANBL09P1, etc.)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have at least ONE of the following:\\r\\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan obtained within 3 weeks prior to study entry; measurable is defined as >= 10 mm in at least one dimension on spiral/helical CT that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased fludeoxyglucose (FDG) uptake on positron emission tomography (PET) scan\\r\\n* MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site; this site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction\\r\\n* Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma; biopsy is not required for patients who have new site of soft tissue disease (radiographic evidence of disease progression) regardless of whether progression occurs while receiving therapy or after completion of therapy\\r\\n* Note: Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have received frontline therapy (including surgery, chemotherapy, autologous stem cell transplant [SCT] +/- MIBG, immunotherapy, radiotherapy, and retinoids) but may NOT have received second line chemotherapy for resistant/refractory, relapsed disease or progressive disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"At least 14 days must have elapsed since completion of myelosuppressive therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"At least 7 days must have elapsed since the completion of therapy with a non-myelosuppressive biologic agent or retinoid\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients are eligible >= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients are eligible >= 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days of entry on this study; seven days must have elapsed since administration of a short acting myeloid growth factor\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Peripheral absolute neutrophil count (ANC) >= 750/uL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Platelet count >= 75,000/uL (transfusion independent)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Creatinine clearance or estimated radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"A serum creatinine =< upper limit of normal (ULN) based on age/gender as follows:\\r\\n* Age 1 month to < 6 months: 0.4 for males, 0.4 for females\\r\\n* Age 6 months to < 1 year: 0.5 for males, 0.5 for females\\r\\n* Age 1 to < 2 years: 0.6 for males, 0.6 for females\\r\\n* Age 2 to < 6 years: 0.8 for males, 0.8 for females\\r\\n* Age 6 to < 10 years: 1 for males, 1 for females\\r\\n* Age 10 to < 13 years: 1.2 for males, 1.2 for females\\r\\n* Age 13 to < 16 years: 1.5 for males, 1.4 for females\\r\\n* Age >= 16 years: 1.7 for males, 1.4 for females\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x ULN for age AND\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5.0 x ULN for age (=< 225 U/L); for the purpose of this study, the ULN for SGPT is 45 U/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Adequate central nervous system function defined as:\\r\\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\\r\\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\\r\\n* CNS toxicity =< grade 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Shortening fraction of >= 27% by echocardiogram (ECHO) OR\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Ejection fraction >= 50% by ECHO or gated radionuclide study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Adequate coagulation defined as:\\r\\n* Prothrombin time (PT) =< 1.2 x upper limit of normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Adequate pulmonary function defined as:\\r\\n* No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry; normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung of carbon monoxide [DLCO]) are required if there is a clinical indication for determination; for patients who do not have respiratory symptoms, full pulmonary function tests (PFTs) are NOT required\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study; based on the established teratogenic potential of alkylating agents, pregnant women will be excluded from this study; female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study; females of childbearing potential must have a negative pregnancy test to be eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Patients with symptoms of congestive heart failure are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Patients must not have >= grade 2 diarrhea\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Patients must not have uncontrolled infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"Patients with a history of grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of the anti-GD2 therapy are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"0 Years\",\n",
      "          \"min_age_number\": 0,\n",
      "          \"min_age_in_years\": 0\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-03125\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00632853_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Histologically or cytologically confirmed small cell lung cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Limited stage disease patients, with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes\\r\\n* Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible\\r\\n* Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not, are not eligible unless they have a negative thoracentesis\\r\\n* Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray, are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 2 cm with conventional techniques or as >= 1 cm with spiral computed tomography (CT) scan\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients may have received one and only one cycle of chemotherapy prior to enrolling on Cancer and Leukemia Group B (CALGB) 30610, which must have included carboplatin or cisplatin and etoposide; if a patient has had one cycle of cisplatin (or carboplatin)/etoposide prior to registration, the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy; additionally, these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy; registration to CALGB 30610 must take place within 7-21 days after the start of the non-protocol therapy; failing to do all of the above will make the patient NOT eligible for CALGB 30610\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for small cell lung cancer (SCLC)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"No prior mediastinal or thoracic radiotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients with complete surgical resection of disease are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"No patients that are known to be pregnant or nursing\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Granulocytes >= 1,500/ul\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Platelet count >= 100,000/ul\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x upper limit of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.0 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum creatinine =< 1.5 times ULN OR calculated creatinine clearance >= 70 mL/min\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lung\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2009-00470\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01013649_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible\\r\\n* The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major margins\\u2014bile duct, pancreatic parenchyma, and retroperitoneal (uncinate)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"For patients who have not started their chemotherapy prior to registration, the interval between definitive tumor-related surgery and 1st step registration must be between 21-70 days; for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution, the interval between definitive tumor-related surgery and day one of adjuvant chemotherapy must be between 21-77 days\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Zubrod performance status 0 or 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Complete history and physical examination including weight and Zubrod status within 31 days of study entry (or within 31 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Before starting therapy the patient should be able to maintain adequate oral nutrition of >= 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Complete blood count (CBC)/differential obtained within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Platelets >= 100,000/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Hemoglobin (Hgb) >= 8.0 g/dL (transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Post resection serum cancer antigen (CA)19-9 =< 180 units/mL AND prior to any systemic treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Serum total bilirubin =< twice the institutional upper limit of normal (ULN) within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Creatinine levels =< twice the institutional upper limit of normal within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) must be =< 2.5 x institutional ULN within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Negative serum pregnancy test for women of childbearing potential within 14 days of study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Abdominal/pelvic computed tomography (CT) scan with contrast is preferred; abdominal CT alone is acceptable only if insurance restrictions are experienced; chest CT/x-ray (CT of chest preferred) within 31 days of registration on study (or within 31 days prior to day 1 of chemo post-surgery for those patients having started chemotherapy prior to first step registration); patients allergic to intravenous (IV) contrast can have magnetic resonance imaging (MRI) of the abdomen/pelvis instead\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Signed study-specific informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Consultation, agreement, and documentation in the patient\\u2019s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Women of childbearing potential and male participants must practice adequate contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas; patients with tumors that are largely IPMN with a minimal or minor component of invasive carcinoma are not eligible; patients with acinar carcinomas are not eligible; patients with IPMN\\u2019s that contain some secondary (minor) foci of adenocarcinoma are also not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients managed with a total pancreatectomy, a distal pancreatectomy, or central pancreatectomy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients entering on the study after pancreaticoduodenectomy, who have not already started chemotherapy must not have had prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable; for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution, patients must not have received adjuvant chemotherapy with agents other than gemcitabine, nab-paclitaxel, oxaliplatin, fluoropyrimidine, or irinotecan for the current pancreatic cancer; prior chemotherapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patient has been disease free for at least 2 years prior to study entry (or first day of chemotherapy for patients having started chemotherapy prior to first step registration); patients with a previous history of carcinoma in situ are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows per time points indicated below (or per time points indicated below prior to the first day of chemotherapy for patients having started chemotherapy prior to first step registration): \\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\\r\\n* Transmural myocardial infarction within the 3 months of study registration\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Pregnant or lactating women\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist, the patient will be ineligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Pancreas\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01987\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01101451_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):            \\r\\n* Positive capillary-lymphovascular space involvement and one of the following:                \\r\\n** Deep third penetration\\r\\n** Middle third penetration, clinical tumor >= 2 cm\\r\\n** Superficial third penetration, clinical tumor >= 5 cm\\r\\n* Negative capillary-lymphatic space involvement                \\r\\n** Middle or deep third penetration, clinical tumor >= 4 cm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Platelets >= 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Creatinine =< upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Bilirubin =< 1.5 x normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Alkaline phosphate =< 3 x normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Gynecologic Oncology Group (GOG) performance status 0, 1, 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients who have met the pre-entry requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients must have signed an approved informed consent and authorization permitting release of personal health information\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients with tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients with septicemia or severe infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients with intestinal obstruction or gastrointestinal bleeding\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with postoperative fistula\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with cervix cancer who have received any previous radiation or chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients whose circumstances do not permit completion of the study or the required follow-up\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with GOG performance status of 3 or 4\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Cervix\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02037\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02085408_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pre-registration: Diagnostic bone marrow and peripheral blood specimens must be submitted for eligibility testing by multiparameter flow cytometry; testing will be performed by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) Leukemia Translational Studies Laboratory and reported to the institution\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Sexually active males must be strongly advised to use an accepted and effective method of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Total bilirubin =< grade 1\\r\\n* Note: If total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS])\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patient must not have an active, uncontrolled infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"ADDITIONAL INDUCTION ELIGIBILITY CRITERIA:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Newly-diagnosed AML patients according to World Health Organization (WHO) classification who are considered candidates for intensive chemotherapy based upon examination of peripheral blood or bone marrow aspirate specimens or touch preparations of the bone marrow biopsy obtained within two weeks prior to randomization; a bone marrow aspirate is required for enrollment; however, on occasion there is discordance between percentage of myeloblasts on the differential of the peripheral blood or aspirate; the peripheral blood criteria are sufficient for diagnosis; confirmatory immunophenotyping will be performed centrally\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"ECOG performance status (PS) 0-3 (restricted to ECOG PS 0-2 if >= 70 years of age)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must not have blastic transformation of chronic myelogenous leukemia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML\\r\\n* NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis; patients who have received a limited and short-term exposure of ATRA (all trans retinoid acid) while AML-M3 (acute promyelocytic leukemia) was being ruled out, and which has been discontinued, will be eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Total serum bilirubin =< 1.5 times upper limit of normal (ULN) (=< grade 1); if total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients with a serum creatinine > 1 are eligible if they have a calculated glomerular filtration rate (GFR) of >= 60 ml/min (i.e. class I or class II chronic kidney disease ) using the Modification of Diet in Renal Disease (MDRD) formula\\r\\n* Note: Daily creatinine and MDRD formula are only for the 1st induction cycle\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Cardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment\\r\\n* NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if adequate number of circulating blasts (> 10^9/l) from peripheral blood\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients who have received previous treatment for antecedent hematological disorders (AHD) with 5-azacitidine, decitabine, or low dose cytarabine will be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with known human immunodeficiency virus (HIV) infection are excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"HLA typing should be performed at registration, if possible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"CONSOLIDATION CRITERIA:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"NOTE: All patients achieving CR or complete remission with incomplete blood count recovery (CRi) will receive consolidation when fit\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"NOTE: Patients proceeding to transplant are allowed up to one cycle of consolidation treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Consolidation cycle 1 must commence within sixty days of the bone marrow aspirate and biopsy that confirmed the presence of a CR or CRi\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must have achieved a CR or CRi (or morphologic leukemia-free state for those patients proceeding to Arm G transplant)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients must have an ECOG performance status of 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Patients must have resolved any serious infectious complications related to induction\\r\\n* NOTE: Patients with an HLA-matched donor and proceeding to transplant will be allowed up to one cycle of consolidation treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Any significant medical complications related to induction must have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Patients must have a creatinine and AST =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"MAINTENANCE CRITERIA:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"Maintenance should commence within 60 days of recovery of peripheral blood counts after consolidation cycle 2; patients must begin consolidation cycle 2 within 60 days of recovery to be eligible for further therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy and cytogenetic analysis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"Patients must have an ECOG performance status of 0 -2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"Patients must have resolved any serious infectious complications related to consolidation cycle 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"Any significant medical complications related to consolidation cycle 2 must have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"Total serum bilirubin =< 1.5 x ULN\\r\\n* NOTE: if total bilirubin is 2-3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 40,\n",
      "            \"description\": \"Serum creatinine =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 41,\n",
      "            \"description\": \"The absolute neutrophil count (ANC) must be > 1000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 42,\n",
      "            \"description\": \"The platelet count must be > 75,000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 43,\n",
      "            \"description\": \"ALLOGENEIC TRANSPLANTATION:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 44,\n",
      "            \"description\": \"Patients must be > 28 days from the start of induction or re-induction chemotherapy, or from the start of consolidation cycle 1 (if received) and < 90 days following recovery from most recent treatment; and they must have achieved and maintained a response to induction therapy (CR, CRi, or \\u201cmorphologic disease-free state\\u201d)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 45,\n",
      "            \"description\": \"Patients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 46,\n",
      "            \"description\": \"Patients must have a total serum bilirubin =< 1.5 x ULN (grade =< 1) and a serum creatinine =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 47,\n",
      "            \"description\": \"An eligible HLA-identical donor (either related or unrelated) should be available; in sibling donors, low resolution HLA typing (A,B,DR) will be considered sufficient; in the case of unrelated donors, high-resolution class I and II typing (A, B, C, DRB1 and DQ) should be matched at all 10 loci; donors must be willing and able to undergo peripheral blood progenitor mobilization \\r\\n* HLA-identical sibling (6/6): the donor must be determined to be an HLA-identical sibling (6/6) by serologic typing for class (A, B) and low resolution molecular typing for class II (DRB1)\\r\\n* Matched unrelated donor (10/10): high resolution molecular typing at the following loci is required: HLA-A, -B, -C, -DRBL, and \\u2013DQB1\\r\\n* NOTE: for matched donors \\u2013 will allow select 1 antigen mismatched sibling donors and unrelated donors in accordance with site institutional standard, as long as matched at HLA-A, HLA-B, HLA-C, and DRB1, and with advanced discussion/approval by the Study Chair and the bone marrow transplant (BMT) co-chair\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 48,\n",
      "            \"description\": \"Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 49,\n",
      "            \"description\": \"Patients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 50,\n",
      "            \"description\": \"Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 51,\n",
      "            \"description\": \"No known hypersensitivity to Escherichia (E.) coli-derived products\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 52,\n",
      "            \"description\": \"No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 53,\n",
      "            \"description\": \"Creatinine =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 54,\n",
      "            \"description\": \"Bilirubin =< grade 1\\r\\n* If bilirubin is 2-3 mg/dL, but direct bilirubin is normal then patient will be considered eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 55,\n",
      "            \"description\": \"AST =< grade 1\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"60 Years\",\n",
      "          \"min_age_number\": 60,\n",
      "          \"min_age_in_years\": 60\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Myeloid and Monocytic Leukemia\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01992\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00980460_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must be newly diagnosed with histologically-proven hepatoblastoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"In emergency situations when a patient meets all other eligibility criteria and has had baseline required observations, but is too ill to undergo a biopsy safely, the patient may be enrolled on AHEP0731 without a biopsy\\r\\n* Clinical situations in which such emergent treatment may be indicated include, but are not limited to, the following circumstances:\\r\\n** Anatomic or mechanical compromise of critical organ function by tumor (e.g., respiratory distress/failure, abdominal compartment syndrome, urinary obstruction, etc)\\r\\n** Uncorrectable coagulopathy\\r\\n* For a patient to maintain eligibility for AHEP0731 when emergent treatment is given, the following must occur:\\r\\n** The patient must have a clinical diagnosis of hepatoblastoma, including an elevated alpha fetoprotein, and must meet all AHEP0731 eligibility criteria at the time of emergent treatment\\r\\n** Patient must be enrolled on AHEP0731 prior to initiating protocol therapy; a patient will be ineligible if any chemotherapy is administered prior to AHEP0731 enrollment\\r\\n** If the patient receives AHEP0731 chemotherapy PRIOR to undergoing a diagnostic biopsy, pathologic review of material obtained in the future during either biopsy or surgical resection must either confirm the diagnosis of hepatoblastoma or not reveal another pathological diagnosis to be included in the analysis of the study aims\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients will be staged for risk classification and treatment at diagnosis using Children's Oncology Group (COG) staging guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"At the time of study enrollment, the patient\\u2019s treatment regimen must be identified; if the patient\\u2019s primary tumor was resected prior to the day of enrollment and a blood specimen for the determination of serum alpha fetoprotein was not obtained prior to that surgery, the patient will be considered to have alpha fetoprotein of greater than 100 ng/mL for the purpose of treatment assignment; if tumor samples obtained prior to the date of enrollment were not sufficient to determine whether small cell undifferentiated (SCU) histology was present, treatment assignment will be made assuming SCU is not present in the tumor\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"For patients with stage I or II disease, specimens for rapid central review have been submitted and the rapid central review diagnosis and staging must be available to be provided on the AHEP0731 eligibility case report form (CRF)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Organ function requirements are not required for enrolled patients who are stage I, PFH and will not be receiving chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR serum creatinine based on age/gender as follows:\\r\\n* 1 month to < 6 months: 0.4 mg/dL\\r\\n* 6 months to < 1 year: 0.5 mg/dL\\r\\n* 1 to < 2 years: 0.6 mg/dL\\r\\n* 2 to < 6 years: 0.8 mg/dL\\r\\n* 6 to < 10 years: 1 mg/dL\\r\\n* 10 to < 13 years: 1.2 mg/dL\\r\\n* 13 to < 16 years: 1.5 mg/dL (male) or 1.4 mg/dL (female)\\r\\n* >= 16 years: 1.7 mg/dL (male) or 1.4 mg/dL (female)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Total bilirubin < 1.5 x upper limit of normal (ULN) for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 10 x ULN for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) > 750/uL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Platelet count > 75,000/uL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Shortening fraction >= 27% by echocardiogram\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Ejection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]); Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Serum triglyceride level =< 300 mg/dL (=< 3.42 mmol/L)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Serum cholesterol level =< 300 mg/dL (7.75 mmol/L)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Random or fasting blood glucose within the upper normal limits for age; if the initial blood glucose is a random sample that is outside of the normal limits, then a follow-up fasting blood glucose can be obtained and must be within the upper normal limits for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Normal pulmonary function tests (including diffusing capacity of the lungs for carbon monoxide [DLCO]) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen); Note: for patients who do not have respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests (PFTs) are NOT required\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Prothrombin time (PT) < 1.2 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients with stage I or II disease who do not have specimens submitted for rapid central pathology review by day 14 after initial surgical resection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients that have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastoma-directed therapy (e.g., radiation therapy, biologic agents, local therapy [embolization, radiofrequency ablation, laser]) are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients who have received any prior chemotherapy are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients who are currently receiving another investigational drug are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients who are currently receiving other anticancer agents are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients who have previously received a solid organ transplant are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Patients who have an uncontrolled infection are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Females who are pregnant or breast feeding are not eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"Males and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"Patients receiving corticosteroids are not eligible; patients must have been off corticosteroids for 7 days prior to start of chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"Patients who are currently receiving enzyme inducing anticonvulsants are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"Patients must not be receiving any of the following potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors: erythromycin, clarithromycin, azithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, grapefruit juice or St. John\\u2019s wort\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, warfarin and others) are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"Patients who are currently receiving angiotensin-converting enzymes (ACE) inhibitors are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"Patients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"21 Years\",\n",
      "          \"max_age_number\": 21,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 21,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"0 Years\",\n",
      "          \"min_age_number\": 0,\n",
      "          \"min_age_in_years\": 0\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Liver\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01975\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01096368_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must be newly diagnosed with histologically confirmed intracranial ependymoma; patients with classic ependymoma (WHO II) or anaplastic ependymoma (WHO III) are eligible, as are various subtypes described as clear cell, papillary, cellular or a combination of the above\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"There is no minimum performance level; children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor; in the majority of cases, there is neurologic recovery; neurologic recovery is not likely to be impeded by protocol therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"REGULATORY: All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"REGULATORY: All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients with evidence of metastatic disease will be excluded; any evidence of non-contiguous spread beyond the primary site as determined by pre or post-operative magnetic resonance (MR) imaging of brain, pre or post-operative MR imaging of the spine, and post-operative cerebrospinal fluid (CSF) cytology obtained from the lumbar CSF space (the requirement for lumbar CSF examination may be waived if deemed to be medically contraindicated); CSF cytology from a ventriculostomy or permanent ventriculoperitoneal (VP) shunt that reveals the presence of tumor cells is indicative of metastatic disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients with a diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma are NOT eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Pregnant female patients are not eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Post-menarchal females may not participate unless a pregnancy test with a negative result has been obtained\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Lactating females may not participate unless they have agreed not to breastfeed a child while on this study\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"20 Years\",\n",
      "          \"max_age_number\": 20,\n",
      "          \"min_age_unit\": \"Months\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 20,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"13 Months\",\n",
      "          \"min_age_number\": 13,\n",
      "          \"min_age_in_years\": 1.0833333333333333\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02029\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01042522_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients with histologically confirmed ovarian stromal tumor [granulosa cell tumor, ganulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, sex cord tumor with annular tubules]\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have newly diagnosed, stage IIA \\u2013 IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have a Gynecologic Oncology Group (GOG) performance grade of 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients of childbearing potential must have a negative serum pregnancy test and must agree to practice an effective means of birth control\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients in the measureable disease cohort must have at least one \\u201ctarget lesion\\u201d to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as \\u201cnon-target\\u201d lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to Common Terminology Criteria for Adverse Events (CTCAE) grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Platelet greater than or equal to 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Creatinine no greater than the institutional upper limits of normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE grade 1)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less than or equal to 3.0 x ULN (CTCAE grade 1)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Neuropathy (sensory and motor) less than or equal to CTCAE grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"No signs of clinically significant hearing loss\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must have signed an approved informed consent and authorization permitting release of personal health information\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must have pulmonary function sufficient to receive bleomycin, with normal lung expansion, absence of crackles on auscultation, and normal carbon monoxide diffusion (DLCO), defined as greater than 80% predicted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Recovery from effects of recent surgery, radiotherapy, or chemotherapy\\r\\n* Patients must be entered within 8 weeks after surgery performed for either 1) initial diagnosis, staging, and/or cytoreduction, or 2) (if done) management of recurrent disease in a chemonaive patient\\r\\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients who have received any prior cytotoxic chemotherapy or biologics for sex cord-stromal tumors (SCSTs)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients with apparent stage I disease who have not undergone a staging procedure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Woman who are pregnant or breastfeeding\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator can consult the study chair or study co-chairs for uncertainty in this regard\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Ovary\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02000\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT00981656_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically proven diagnosis of carcinoma of the bladder within 105 days prior to registration\\r\\n* Operable patients whose initial tumor is a primary high grade urothelial carcinoma of the bladder exhibiting histologic evidence of invasion into the lamina propria (disease clinical stage T1) or a high grade stage Ta urothelial carcinoma without hydronephrosis; patients who have involvement of the prostatic urethra with urothelial carcinoma and have no evidence of stromal invasion of the prostate remain eligible; if the patient\\u2019s initial tumor was a high grade stage Ta urothelial carcinoma then his/her recurrent tumor must be a high grade stage T1 urothelial carcinoma to be eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have a high grade urothelial carcinoma stage Ta or T1 that has recurred within 540 days after completion of the initial treatment (transurethral resection bladder tumor [TURBT] and intravesical bacillus Calmette-Guerin [BCG] immunotherapy) or on initial presentation with a T1 high grade tumor, the participating urologist judged BCG therapy is contraindicated or unsuitable because the patient is found to be intolerant of BCG therapy or because this patient may be immuno-compromised in ways other than that mentioned in severe, active co-morbidity or because the patient refuses BCG therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"The participating urologist judges that the standard next therapy, based on present urologic guidelines for this patient, is radical cystectomy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"If radiologic evaluation of a lymph node is interpreted as \\u201cpositive\\u201d, this must be evaluated further either by lymphadenectomy or by percutaneous needle biopsy; patients with histologically or cytologically confirmed node metastases will not be eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have an adequately functioning bladder as judged by the participating urologist and radiation oncologist and have undergone a re-staging TURBT by the participating urologist that showed (or was present in the outside pathology specimen) a high grade stage Ta or T1 tumor with uninvolved muscularis propria in the specimen and, if on prostatic urethral biopsy mucosal carcinoma is present, there is no evidence on biopsy in the prostatic stroma of tumor invasion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patient must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy, and a radical cystectomy (if necessary) by the joint agreement of the participating urologist, radiation oncologist, and medical oncologist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Appropriate stage for protocol entry, based upon the following minimum diagnostic workup within 60 days prior to registration:\\r\\n* History/physical examination including weight, performance data, body surface area\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Zubrod performance status =< 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"White blood cell count (WBC) >= 4,000/ml\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,800 cells/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Platelets >= 100,000 cells/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Hemoglobin >= 10.0 g/dL (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"If the patient is to be treated with cisplatin, the serum creatinine should be =< 1.5 mg%\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"If the patient is to be treated with cisplatin, the serum bilirubin of =< 2.0 mg%\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Glomerular filtration rate (GFR) > 25 ml/min (for patients receiving cisplatin, GFR >= 60 ml/min)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Serum pregnancy test for female patients of childbearing potential, =< 72 hours prior to study entry; women of childbearing potential and male participants must practice adequate contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patient must be able to provide study-specific informed consent prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Evidence of tumor-related hydronephrosis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Evidence of distant metastases or histologically or cytologically proven lymph node metastases\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Prior systemic chemotherapy for bladder cancer; prior chemotherapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"A prior or concurrent malignancy of any other site or histology unless the patient has been disease-free for >= 5 years except for non-melanoma skin cancer and/or stage T1a prostate cancer or carcinoma in situ of the uterine cervix or a urothelial carcinoma of the upper urinary tract stage pTa, pTis or pT1 that has not been free of disease after treatment for more than a 2 year period\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients with pN+ or > T1 disease or who have not had a visibly complete TURBT\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients receiving any drugs that have potential nephrotoxicity or ototoxicity (such as an aminoglycoside)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\\r\\n* Transmural myocardial infarction within the last 6 months\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Prior allergic reaction to the study drugs (cisplatin, mitomycin, fluorouracil [5FU]) involved in this protocol\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Urinary Bladder\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-01974\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01515787_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Diagnosis of rectal adenocarcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Radiologically measurable or clinically evaluable disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1 or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"For this patient, the standard treatment recommendation in the absence of a clinical trial would be combined modality, neoadjuvant chemoradiation followed by curative intent surgical resection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Candidate for sphincter-sparing surgical resection prior to initiation of neoadjuvant therapy according to the primary surgeon\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Clinical stage: T2N1, T3N0, T3N1\\r\\n* N2 disease is to be estimated as four or more lymph nodes that are >= 10 mm\\r\\n* Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, computed tomography (CT) or positron emission tomography (PET)/CT scan of the chest/abdomen/pelvis and either a pelvic magnetic resonance imaging (MRI) or an ultrasound (endorectal ultrasound [ERUS]); if a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mm^3 (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Platelet count >= 100,000/mm^3 (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Hemoglobin > 8.0 g/dL (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x upper limit of normal (ULN) (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Creatinine =< 1.5 times ULN (=< 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patient of child-bearing potential is willing to employ adequate contraception; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Provide informed written consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Willing to return to enrolling medical site for all study assessments\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Clinical T4 tumors\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Primary surgeon indicates need for abdominoperineal (APR) at baseline\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Evidence that tumor is adherent to or invading the mesorectal fascia on imaging studies such that the surgeon would not be able to perform an R0 resection (one with negative margins)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Tumor is causing symptomatic bowel obstruction (patients who have had a temporary diverting ostomy are eligible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Chemotherapy within 5 years prior to registration; (hormonal therapy is allowable if the disease free interval is >= 5 years)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Any prior pelvic radiation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Other invasive malignancy =< 5 years prior to registration; exceptions are colonic polyps, non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Any of the following\\r\\n* Pregnant women\\r\\n* Nursing women\\r\\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Co-morbid illnesses or other concurrent disease which, in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Rectum\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-00234\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02883049_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must be enrolled on APEC14B1 and consented to Eligibility Screening on the Part A consent form prior to enrollment on AALL1131\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"White Blood Cell Count (WBC) Criteria\\r\\n* Age 1-9.99 years: WBC >= 50 000/uL \\r\\n* Age 10-30.99 years: Any WBC \\r\\n* Age 1-30.99 years: Any WBC with:\\r\\n** Testicular leukemia\\r\\n** CNS leukemia (CNS3)\\r\\n** Steroid pretreatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia); patients with Down syndrome are also eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Organ function requirements for patients with Ph-like ALL and a predicted TKI-sensitive mutation: patients identified as Ph-like with a TKI-sensitive kinase mutation must have assessment of organ function performed within 3 days of study entry onto the dasatinib arm of AALL1131\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\\r\\n* Age: Maximum Serum Creatinine (mg/dL)\\r\\n* 1 to < 6 months: 0.4 (male) 0.4 (female)\\r\\n* 6 months to < 1 year: 0.5 (male) 0.5 (female)\\r\\n* 1 to < 2 years: 0.6 (male) 0.6 (female)\\r\\n* 2 < 6 years: 0.8 (male) 0.8 (female)\\r\\n* 6 to < 10 years: 1.0 (male) 1.0 (female)\\r\\n* 10 to < 13 years: 1.2 (male) 1.2 (female)\\r\\n* 13 to < 16 years: 1.5 (male) 1.4 (female)\\r\\n* > 16 years: 1.7 (male) 1.4 (female)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Direct bilirubin =< 3 x upper limit of normal (ULN) for age, and\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 10 x upper limit of normal (ULN) for age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Shortening fraction >= 27% by echocardiogram, or ejection fraction >= 50% by gated radionuclide study \\r\\n* Patients must have an electrocardiogram (EKG) fewer than 6 days prior to enrollment on the dasatinib arm; patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry; correct QT interval (QTc) < 450 msec on baseline electrocardiogram as measured by the Friderica or Bazett formula\\r\\n* No major conduction abnormality (unless a cardiac pacemaker is present)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% at sea level if there is clinical indication for determination\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL1131\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients with BCR-ABL1 fusion are not eligible for post-induction therapy on this study but may be eligible to enroll in a successor Children's Oncology Group (COG) Philadelphia positive (Ph+) ALL trial by day 15 Induction\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"DS HR B-ALL patients with Induction failure or BCR-ABL1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Lactating females are not eligible unless they have agreed not to breastfeed their infant\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Eligibility criteria for the Longitudinal, Computerized Assessment of Neurocognitive Functioning study \\r\\n* Patients must be aged 6 to 13 years at time of B-ALL diagnosis, enrolled on AALL1131\\r\\n* Patients must be English-, French- or Spanish-speaking (languages in which the assessment is available)\\r\\n* Patients must have no known history of neurodevelopmental disorder prior to diagnosis of B-ALL (e.g., Down syndrome, Fragile X, William\\u2019s Syndrome, mental retardation)\\r\\n* Patients must have no significant visual impairment that would prevent computer use and recognition of the visual test stimuli\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Eligibility criteria for the National Cancer Institute (NCI) standard risk patients from AALL0932 enrolling on this study at the end of Induction\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Effective March 19, 2018, patients enrolled on AALL0932, without Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 or the HR B-ALL stratum of this study at the end of Induction: \\r\\n* Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day 8 peripheral blood (PB) minimal residual disease (MRD) >= 1% and day 29 bone marrow (BM) MRD < 0.01%\\r\\n* With favorable cytogenetics (ETV6-RUNX1 or double trisomies 4+10), with any day 8 PB MRD and day 29 BM MRD >= 0.01%\\r\\n* Both NCI standard risk (SR) and HR patients without Down syndrome and with testicular disease at diagnosis, who do not meet other VHR criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Effective Amendment 6, patients enrolled on AALL0932, without Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 or the VHR stratum of AALL1131: \\r\\n* Intrachromosomal amplification of chromosome 21 (iAMP21)\\r\\n* Mixed-lineage leukemia (MLL) rearrangement\\r\\n* Hypodiploidy (n < 44 chromosomes and/or a deoxyribonucleic acid [DNA] index < 0.81) \\r\\n* Induction failure (M3 BM at day 29)\\r\\n* Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day 29 BM MRD >= 0.01%\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients enrolled on AALL0932, with Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 but WILL BE eligible to enroll on the DS HR B-ALL stratum of this study at the end of Induction: \\r\\n* Day 29 MRD >= 0.01%\\r\\n* MLL rearrangement\\r\\n* Hypodiploidy (n < 45 chromosomes and/or DNA index < 0.81)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"DS HR B-ALL patients initially enrolled on AALL0932 or this study who have Induction failure (M3 BM day 29) or Philadelphia chromosome (BCR-ABL1) will not be eligible for post-Induction therapy on either trial (AALL0932 or AALL1131)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"All patients and/or their parents or legal guardians must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and NCI requirements for human studies must be met\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"30 Years\",\n",
      "          \"max_age_number\": 30,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 30,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"1 Years\",\n",
      "          \"min_age_number\": 1,\n",
      "          \"min_age_in_years\": 1\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Leukemia, other\",\n",
      "        \"Lymphoid Leukemia\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-03797\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01368588_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence as determined by one of the following combinations:\\r\\n* Gleason score 7-10 + T1c-T2b (palpation) + prostate-specific antigen (PSA) < 50 ng/mL (includes intermediate- and high-risk patients)\\r\\n* Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/mL OR Gleason score 6 + >= 50% (positive) biopsies + PSA < 50 ng/ml\\r\\n* Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/mL\\r\\n* Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are re-biopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Clinically negative lymph nodes as established by imaging (pelvic and/or abdominal computed tomography [CT] or magnetic resonance [MR]), (but not by nodal sampling, or dissection) within 90 days prior to registration\\r\\n* Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 1.5 cm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute)\\r\\n* Equivocal bone scan findings are allowed if plain films (or CT or magnetic resonance imaging [MRI]) are negative for metastasis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Baseline serum PSA value performed with a Food and Drug Administration (FDA)-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Study entry PSA should not be obtained during the following time frames:\\r\\n* 10-day period following prostate biopsy\\r\\n* Following initiation of hormonal therapy\\r\\n* Within 30 days after discontinuation of finasteride\\r\\n* Within 90 days after discontinuation of dutasteride\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Zubrod performance status 0-1 (unless otherwise specified)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mm^3 (within 60 days prior to registration on study)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Platelets >= 100,000/mm^3 (within 60 days prior to registration on study)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Hemoglobin (Hgb) >= 8.0 g/dL (within 60 days prior to registration on study) (Note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patient must be able to provide study specific informed consent prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years (1095 days) not in the pelvis (for example, carcinoma in situ of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed); prior hematological (e.g., leukemia, lymphoma, myeloma) malignancy not allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Previous hormonal therapy, such as LHRH agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is =< 45 days prior to the date of registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Use of finasteride within 30 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Previous or concurrent cytotoxic chemotherapy for prostate cancer; note that prior chemotherapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\\r\\n* Transmural myocardial infarction within the last 6 months\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Prior allergic reaction to the hormones involved in this protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients status post a negative lymph node dissection are not eligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"MALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Prostate\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02674\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01359592_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have biopsy-proven de-novo diffuse large B-cell lymphoma (DLBCL) \\r\\n* Patients with primary mediastinal lymphoma or testicular lymphoma are not eligible\\r\\n* Patients with prior or simultaneous diagnosis of indolent lymphoma are not eligible\\r\\n* Post-transplant lymphoproliferative disorder with DLBCL morphology is ineligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have non-bulky stage I or II disease by Ann Arbor classification\\r\\n* This staging excludes fludeoxyglucose F 18 (FDG)-PET evaluation\\r\\n* Patients who have stage I or II non-bulky disease based on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible\\r\\n* Stage and bulk are assigned using measurements obtained prior to biopsy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have a diagnostic quality contrast-enhanced CT scan of the chest, abdomen, and pelvis AND baseline FDG-PET scan performed within 28 days prior to registration\\r\\n* Low-resolution \\\"localization\\\" CT scans performed as part of a combined PET/CT scan are not adequate for enrollment or response determination on this protocol\\r\\n* If a patient has an allergy to CT contrast, then a non-enhanced CT will be acceptable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma            \\r\\n* Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have either measurable or evaluable limited-stage DLBCL          \\r\\n* Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible; NOTE: if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form\\r\\n* All measurable disease must be assessed within 28 days prior to registration\\r\\n* Patients with non-measurable disease with or without measurable disease must have all non-measurable disease assessed within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have a unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Adequate sections or a paraffin block from the original diagnostic specimen must be submitted for review by the lymphoma pathology group\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must be offered the opportunity to consent to the use of specimens for future research\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"The lymphoma must express the cluster of differentiation (CD)20 antigen by either flow cytometry using anti-CD20 antibodies or by immunoperoxidase staining of paraffin sections; a report providing confirmation of CD20 expression must be submitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must have a complete history and physical examination within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Zubrod performance status 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"The following tests must be performed within 42 days prior to registration either for diagnosis/staging or to obtain baseline values:\\r\\n* White blood cells (WBC)\\r\\n* Hemoglobin\\r\\n* Lactate dehydrogenase (LDH)\\r\\n* Hepatitis B-surface antigen (Ag) and anti-core antibody (Ab)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum creatinine =< 2 x institutional upper limit of normal (IULN), unless due to lymphoma, within 42 day prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must have aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x IULN, unless due to lymphoma, within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Platelet count >= 100,000 cells/mcL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,000 cells/mcL within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Total bilirubin =< 2 x institutional upper limit of normal (IULN) (unless due to Gilbert syndrome) within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients must have a cardiac ejection fraction >= institutional lower limit of normal (ILLN) by multi gated acquisition (MUGA) scan or 2-dimensional (D) echocardiogram (ECHO) within 42 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients must not be known to be human immunodeficiency virus (HIV)-positive\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"No other prior malignancy is allowed except for the following:            \\r\\n* Adequately treated in situ cancers (stage 0)\\r\\n* Adequately treated basal cell or squamous cell skin cancer\\r\\n* Adequately treated stage I or II cancer from which the patient has been in complete remission or\\r\\n* Any other cancer from which the patient has been disease-free for at least 5 years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method during the study period; a woman is considered to be \\\"of reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"SECOND REGISTRATION (STEP 2)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must have completed 3 cycles of R-CHOP with no evidence of disease progression\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Interim PET/CT scans must have been submitted for centralized review\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"If PET-negative based on the returned results from centralized review, patients must be planning to begin further treatment within 35 days of the start of cycle 3 of R-CHOP; if PET-positive based on the returned results from centralized review, it is important for patients to start IFRT as soon as possible after the end of cycle 3 of R-CHOP; they should be planning to initiate IFRT followed by yttrium-90 ibritumomab tiuxetan within 35 days of the start of cycle 3 of R-CHOP\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Non-Hodgkin's Lymphoma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2011-02673\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01674140_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2, for whom standard adjuvant endocrine therapy is planned; estrogen and progesterone receptor positivity must be assessed according to American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guidelines as either estrogen receptor (ER) or progesterone receptor (PR) >= 1% positive nuclear staining; HER-2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using immunohistochemistry (IHC), in situ hybridization (ISH) or both; HER-2 is negative if a single test (or all tests) performed in a tumor specimen show: a) IHC negative (0 or 1+) or b) ISH negative using single probe or dual probe (average HER-2 copy number < 4.0 signals per cell by single probe or HER-2/chromosome enumeration probe [CEP] ratio < 2.0 with an average copy number < 4.0 signals per cell by dual probe); if HER-2 IHC is 2+, evaluation for gene amplification (ISH) must be performed and the ISH must be negative; ISH is not required if IHC is 0 or 1+; HER-2 equivocal is not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must not have metastatic breast cancer (stage IV disease); patients with multifocal, multicentric, and synchronous bilateral, and primary inflammatory breast cancers are allowed\\r\\n* Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant\\r\\n* Multicentric disease is defined as more than one invasive cancer >= 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants\\r\\n* Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other; (NOTE: the tumor with the highest recurrence score should be used)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must be high risk by belonging to one of the following risk groups:\\r\\n* Completion of adjuvant chemotherapy and pathologically negative lymph nodes, and a tumor measuring >= 2 cm in greatest diameter, and an Oncotype DX recurrence score > 25 (completed as standard of care) or a MammaPrint assay (completed as standard of care) in the high-risk category; patients with micrometastases as the only nodal involvement (pN1mi) are eligible, and will be categorized as node-negative \\r\\n* Completion of adjuvant chemotherapy, and pathologically 1-3 positive lymph nodes, and either an Oncotype DX recurrence score > 25, MammaPrint assay in the high-risk category (completed as standard of care), or tumor tissue with pathological grade III following local practice; if Oncotype DX is done, then RS must be > 25, similarly if the MammaPrint assay is performed it has to be high-risk; if the test is not done, but the patient has grade III disease then the patient is eligible and Oncotype DX or MammaPrint does not need to be performed\\r\\n* Completion of adjuvant chemotherapy and pathologically 4 or more positive lymph nodes\\r\\n* Completion of neoadjuvant chemotherapy and 1 or more positive nodes pathologically determined after chemotherapy\\r\\n* NOTE: patients who receive both the neoadjuvant and adjuvant chemotherapy may be registered in the neoadjuvant therapy risk group, provided they meet all the criteria above for that risk group\\r\\n* NOTE: in the lymph node positive groups, at least one metastasis >= 2.0 mm must be present; patients with micrometastases as the only nodal involvement (pN1mi) are eligible and will be categorized as node-negative\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have completed either breast-conserving surgery or total mastectomy, with negative margins and appropriate axillary staging; a negative margin is defined as no evidence of tumor or ductal carcinoma in situ (DCIS) at the line of resection; additional operative procedures may be performed to obtain clear margins\\r\\n* Patients who had breast-conserving surgery must have completed whole breast radiation; use of regional nodal basin radiation will be at the discretion of the investigator according to institutional guidelines\\r\\n* Patients with >= 4 positive lymph nodes must have completed breast/chest wall and nodal basin radiation therapy according to standard of care guidelines before randomization; omission of radiation therapy is not allowed in this high-risk population of patients\\r\\n* Patients must be registered at least 21 days after completion of radiation therapy and must have recovered (=< grade 1) from any of the effects of radiation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have undergone axillary staging by sentinel node biopsy or axillary lymph node dissection (ALND)\\r\\n* For patients with 1-3 positive lymph nodes, sentinel node biopsy alone is allowed provided that the patient completed either whole breast or chest wall radiation and the primary tumor is < 5 cm\\r\\n* All patients with >= 4 positive lymph nodes must have completed ALND (with or without prior sentinel node biopsy)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have completed standard neoadjuvant or adjuvant taxane and/or anthracycline based chemotherapy prior to randomization; completion of chemotherapy will be determined by the treating oncologist, but should include a minimum of 4 cycles (a cycle of weekly paclitaxel is considered 3 doses); patients must be registered within 42 weeks after the last dose of chemotherapy; patients may have started endocrine therapy at any time after the diagnosis of the current breast cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must not be receiving or planning to receive trastuzumab; concurrent bisphosphonate therapy is allowed; patients must not have prior exposure to mechanistic target of rapamycin (serine/threonine kinase) (mTOR) inhibitors (rapamycin, everolimus, temsirolimus, deforolimus); patients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mL (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Hemoglobin >= 9 g/dL (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Platelet count >= 100,000/mL (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome) within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x institutional upper limit of normal (IULN) (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Alkaline phosphatase =< 1.5 x IULN (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum creatinine level =< IULN (obtained within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Fasting cholesterol =< 300 mg/dL and triglycerides =< 2.5 x IULN obtained within 28 days prior to registration; patients may be on lipid lowering agents to reach these values\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients must have a complete history and physical examination within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients must have a performance status of 0-2 by Zubrod criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients must not have any grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients previously diagnosed with diabetes must not have uncontrolled diabetes (defined as a hemoglobin [Hg] A1C > 7% within 28 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients must not have an organ allograft or other history of immune compromise; patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of blinded drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients must not have received immunization with an attenuated live vaccine (e.g., intranasal influenza, measles, mumps, and rubella [MMR], oral polio, varicella, zoster, yellow fever, and Bacillus Calmette\\u2013Guerin [BCG] vaccines) within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients must not have taken within 14 days prior to registration, be taking, nor plan to take while on protocol treatment, strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and/or CYP3A4 inducers\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective non-hormonal contraceptive method; a woman is considered to be of \\\"reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; corresponding procedures for men include castration, vasectomy and barrier contraceptive devices; however, if at any point a previously celibate patient chooses to become heterosexually active during the protocol therapy, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must have pre-treatment blood and tissue specimens submitted for translational medicine as outlined; with patient consent, residuals will be banked for future research\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients (at National Cancer Institute [NCI] Community Oncology Research Program [NCORP] Institutions only) must be offered the opportunity to participate in the S1207-E01 Behavioral and Health Outcomes study (BAHO); NOTE: patients who have already started endocrine therapy are eligible for the BAHO study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\",\n",
      "        \"Breast - Male\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-01995\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01668719_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have newly diagnosed active multiple myeloma (MM); except where otherwise indicated below that assessment is required within 14 days, all tests for establishing baseline disease status must be completed within 28 days prior to registration for patients with no prior therapy, or within 28 days prior to initiation of first Induction course for patients with prior therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"For the Phase II portion only, patients must have high-risk MM based on one or more of the following criteria at the time of initial diagnosis (prior to any chemotherapy):\\r\\n* Poor-risk genomic signature according to the University of Arkansas 70-gene model (available clinically as myeloma prognostic risk score [MyPRS] score, Signal Genetics, Inc) AND/OR\\r\\n* Translocation (14;16), and/or translocation (14;20), and/or deletion (17p) by fluorescence in-situ hybridization (FISH) or cytogenetics AND/OR\\r\\n* Primary plasma cell leukemia (defined by either >= 2,000 plasma cells/mL of peripheral blood, or 20% on a manual differential count) AND/OR\\r\\n* Serum lactate dehydrogenase (LDH) >= 2 x institutional upper limit of normal (IULN) AND/OR\\r\\n* 1q21 amplification by FISH analysis AND/OR\\r\\n* High risk by the SKY92 signature\\r\\n* All tests for establishing high risk status must be completed within 28 days prior to registration for patients with no prior therapy, or within 28 days prior to initiation of first Induction course for patients with prior therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients with non-secretory MM or known amyloidosis are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have measurable disease within 28 days prior to registration (or prior to initiation of first induction course for patients with prior therapy)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients on the Phase I portion may not have received ANY prior chemotherapy; patients on the Phase II portion may have received one prior cycle of any non-investigational chemotherapy; prior chemotherapy must have been completed within 56 days prior to registration and all toxicities must have resolved to =< grade 1; patients on either portion may have received prior treatment with dexamethasone, providing total number of days of treatment was =< 14 days and total treatment dose was =< 360 mg\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only; radiotherapy must be completed at least 14 days prior to registration and all toxicities must have resolved to =< grade 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factor support (within 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Platelet count >= 70,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50%; or >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50% (within 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (within 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 2.5 x IULN (within 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Creatinine clearance (CrCL) >= 30 mL/min, measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients must not have active involvement of the central nervous system (CNS) with MM (by clinical evaluation); patients with documentation of, or clinical signs or symptoms consistent with, CNS involvement of MM must have a lumbar puncture that is negative for CNS involvement of MM; the lumbar puncture must be completed within 14 days prior to registration; patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture prior to registration; note that monitoring of CNS involvement and treatment with intrathecal therapy is recommended during protocol treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\\r\\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\\r\\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\\r\\n* No zidovudine or stavudine as part of cART\\r\\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must have baseline skeletal survey (whole body x-ray) to document lytic lesions, osteopenia or compression fracture\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must have Zubrod performance status =< 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/L within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients must not have POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled >= grade 3 cardiac arrhythmias, uncontrolled hypertension, or uncontrolled diabetes mellitus; patients must have undergone an electrocardiogram (EKG) within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Uncontrolled diabetes: a glycated hemoglobin (Hg A1C) > 7% within 14 days prior to registration; the same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Uncontrolled blood pressure and hypertension: systolic blood pressure (SBP) > 140 mm Hg or diastolic blood pressure (DBP) > 90 mm Hg within 14 days prior to registration; patients are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study); all blood pressure measurements within the 14 days prior to registration and on day 1 of cycle 1 must be SBP =< 140 and DBP =< 90; an exception can be made by a healthcare provider for a patient with a single blood pressure elevation who upon rechecking has a normal blood pressure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients must have history and physical examination within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must not have any psychiatric illness that could potentially interfere with the completion of treatment according to this protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 \\u2013 14 days prior to registration; (Note: that pregnancy testing is also required within 24 hours prior to treatment on cycle 1, day 1); furthermore, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients must be offered participation in banking of specimens for future research; with the patient\\u2019s consent, specimens (serum and bone marrow biopsy core) must be submitted to the repository; patient consent must be obtained before specimens are submitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must be registered to the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program and must be willing and able to comply with the requirements of the Revlimid REMS program\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Multiple Myeloma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-01998\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01781468_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy (excluding stereotactic radiosurgery) > 21 days and =< 24 months prior to enrollment; NOTE: clinical stability will be defined as a stable or improved Karnofsky performance status (KPS) compared to the prior month\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \">= 6 score on the worst fatigue question of the BFI (Brief Fatigue Inventory, question 3); it is not required for the patient to complete the entire BFI to meet this criterion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Undergone surgery (gross total or subtotal resection) or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma patients; Note: radiation must be completed, but chemotherapy is allowed; patients who are currently using Optune device will be eligible to participate in this trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Negative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physician\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Ability to complete questionnaire(s) by themselves or with assistance\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 or 3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Provide informed written consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Willing to return to enrolling institution for follow-up (during the Active Monitoring phase of the study)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Stable dose of corticosteroid >= 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Any of the following:\\r\\n* Pregnant women\\r\\n* Nursing women\\r\\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"History of hypersensitivity to other psychostimulants\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"History of steroid psychosis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Currently taking medications for attention deficit hyperactivity disorder, history of or currently taking medications for severe anxiety disorder, schizophrenia, or substance abuse by patient record and/or self-report\\r\\n* Note: Patients who had childhood attention deficit hyperactivity disorder (ADHD) and no longer require treatment will be eligible to participate\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Currently using any other pharmacologic agents or nonpharmacologic interventions to specifically treat fatigue, including psychostimulants, antidepressants, acupuncture, etc. will be excluded; Note: antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for >= 30 days prior to registration and plans to continue for the duration of the trial; erythropoietin agents to treat anemia are allowed; exercise is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Anticipating surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Uncontrolled hypothyroidism, profound anemia (hemoglobin level of <10 g/dL =< 28 days prior to registration), or untreated clinical depression per physician discretion. Patients with stable, controlled depression or receiving treatment for hypothyroidism will be eligible, if they have been on a stable dose for the past 30 days and plan to continue for the duration of the trial.\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Active or a history of Tourette\\u2019s syndrome or tic disorder\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"History of or active glaucoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"History of intractable epilepsy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Any of the following co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens:\\r\\n* History of myocardial infarction\\r\\n* Unstable angina\\r\\n* Left ventricular hypertrophy\\r\\n* Mitral valve prolapse syndrome\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4); use of the following strong or moderate inhibitors are prohibited =< 7 days prior to registration\\r\\n* Strong inhibitors of CYP3A4:\\r\\n** > 5-fold increase in the plasma area under the curve (AUC) values or more than 80% decrease in clearance\\r\\n** Indinavir (Crixivan)\\r\\n** Nelfinavir (Viracept)\\r\\n** Atazanavir (Reyataz)\\r\\n** Ritonavir (Norvir)\\r\\n** Clarithromycin (Biaxin, Biaxin XL)\\r\\n** Itraconazole (Sporanox)\\r\\n** Ketoconazole (Nizoral)\\r\\n** Nefazodone (Serzone)\\r\\n** Saquinavir (Fortovase, Invirase)\\r\\n** Telithromycin (Ketek)\\r\\n* Moderate Inhibitors of CYP3A4\\r\\n** > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance\\r\\n** Aprepitant (Emend)\\r\\n** Erythromycin (Erythrocin, E.E.S., Ery-Tab, Eryc, EryPed, PCE)\\r\\n** Fluconazole (Diflucan)\\r\\n** Grapefruit juice\\r\\n** Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM)\\r\\n** Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration\\r\\n* Inducers of CYP3A4 \\r\\n** Efavirenz (Sustiva)\\r\\n** Nevirapine (Viramune)\\r\\n** Carbamazepine (Carbatro, Epitol, Equetro, Tegretol, Tegretol-XR)\\r\\n** Modafinil (Provigil)\\r\\n** Phenobarbital (Luminal)\\r\\n** Phenytoin (Dilantin, Phenytek)\\r\\n** Pioglitazone (Acto)\\r\\n** Rifabutin (Mycobutin)\\r\\n** Rifampin (Rifadin)\\r\\n** St. John\\u2019s wort\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-02020\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01805076_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically confirmed diagnosis of breast cancer, clinical stage I-II (T1-3 N0 M0, T0-2 N1 M0); diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded; for patients enrolled after receipt and completion of neoadjuvant chemotherapy, the clinical stage must be determined based on pre-chemotherapy assessment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have either:\\r\\n* Estrogen receptor (ER) negative/progesterone receptor (PR) negative (< 10% by immunohistochemistry [IHC] staining) and HER-2 negative breast cancer OR\\r\\n* ER negative/PR negative (< 10% by IHC staining) and HER-2 positive tumors\\r\\n* HER2 status will be determined per the 2013 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines:\\r\\n** HER2 is considered positive if a) there is IHC 3+ staining or b) positive using either single probe in situ hybridization (ISH) or dual probe ISH\\r\\n** HER2 is considered negative if a) there is IHC 0 or 1+ staining or b) ISH negative using either single probe ISH or dual probe ISH\\r\\n* For patients enrolling after neoadjuvant therapy, the ER, PR, and HER2 markers are based on assessment prior to initiating neoadjuvant treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"No patients with previous ipsilateral or contralateral invasive breast cancer or ductal carcinoma in situ (DCIS)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"No patients with bilateral breast cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"No patients with known deleterious mutations in breast cancer (BRCA) genes\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"No history of receiving endocrine therapy, tamoxifen, and or aromatase inhibitors for therapeutic measures; these agents used previously as chemoprevention are allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients receiving neoadjuvant chemotherapy or recently completed neoadjuvant chemotherapy and will undergo surgery within 6 weeks are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"No patients scheduled to receive partial breast irradiation following breast conserving surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Eligible for BCT based on clinical examination, mammography and, if standard practice at a given institution, ultrasound and/or tomogram; women who cannot be appropriately selected for BCT based on these standard imaging studies, and for whom additional imaging is recommended to clarify local disease extent, will not be eligible for this trial; for patients who have neoadjuvant therapy, eligibility for BCT is determined at completion of therapy; repeat mammogram +/- ultrasound (US) of the affected side only will be required at completion of neoadjuvant chemotherapy to determine eligibility for BCT\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"No patients with multicentric or multifocal disease scheduled to undergo multiple lumpectomies; multifocal disease that can be encompassed in a single operative bed can be enrolled; for patients with multifocal or multicentric disease enrolled after completion of neoadjuvant chemotherapy, histologic confirmation of multifocality/multicentricity must have been completed before initiation of chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Suitable to undergo MRI and receive the contrast agent gadolinium (exclusions follow):\\r\\n* No history of untreatable claustrophobia\\r\\n* No presence of metallic objects or implanted medical devices in body (i.e., cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants)\\r\\n* No history of sickle cell disease\\r\\n* No contraindication to intravenous contrast administration\\r\\n* No known allergy-like reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR); patient may be eligible if willing to undergo pre-treatment as defined by the institution's policy and/or ACR guidance\\r\\n* No findings consistent with renal failure, as determined by glomerular filtration rate (GFR) < 30\\r\\nmL/min/1.73 m^2 based on a serum creatinine level obtained within 28 days prior to registration\\r\\n* Weight lower than that allowable by the MRI table\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"No prior MRI of study breast within the 12 months prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Non-pregnant and non-lactating; patients of child-bearing potential must have a negative pregnancy test within 7 days prior to registration; perimenopausal patients must be amenorrheic > 12 months to be considered not of child-bearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Signed study-specific informed consent prior to registration\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-02045\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01730937_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have an HCC diagnosis (initial, recurrent, progressive and/or refractory to other therapies) by at least one criterion listed below =< 360 days prior to study entry\\r\\n* Pathologically (histologically or cytologically) proven diagnosis of HCC\\r\\n* At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, inferior vena cava [IVC] and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multi-phasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis\\r\\n* For patients whose CURRENT disease is vascular only: enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed previously < 720 days)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have measurable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days PRIOR TO STUDY ENTRY\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Appropriate for protocol entry based upon the following minimum diagnostic workup:\\r\\n* History/physical examination including examination for encephalopathy, ascites, weight, height, and blood pressure within 14 days prior to study entry\\r\\n* Assessment by radiation oncologist and medical oncologist or hepatologist who specializes in treatment of HCC within 28 days prior to study entry\\r\\n* Pre-randomization scan (REQUIRED for all patients): Within 28 days prior to study entry, multiphasic liver CT or multiphasic liver magnetic resonance (MR) scan\\r\\n* Within 28 days prior to study entry CT chest with CT or MR abdomen and CT or MR pelvis, or positron emission tomography (PET) CT chest/abdomen/pelvis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Zubrod performance status 0-2 within 28 days prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 14 days prior to study entry)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Platelets >= 60,000 cells/mm^3 (obtained within 14 days prior to study entry)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) (obtained within 14 days prior to study entry)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 times upper limit of normal (ULN) (obtained within 14 days prior to study entry)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Serum creatinine =< 2 x ULN or creatinine clearance >= 60 mL/min (obtained within 14 days prior to study entry)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must have Barcelona Clinic Liver Cancer (BCLC) stage: intermediate (B) or advanced (C) within 28 days prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Child-Pugh score A within 14 days prior to study entry (using international normalized ratio [INR] from < 28 days is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of radiation therapy (RT) and for at least 28 days following the last dose of sorafenib (whichever is later)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Unsuitable for resection or transplant or radiofrequency ablation (RFA)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Unsuitable for or refractory to transarterial hepatic chemo-embolization (TACE) or drug eluting beads (DEB) for any of the following reasons, as described by Raoul et al (2011):\\r\\n* Technical contraindications: arteriovenous fistula, including surgical portosystemic shunt or spontaneous portosystemic shunt\\r\\n* Severe reduction in portal vein flow: due to tumor portal vein, IVC or atrial invasion or bland portal vein occlusion\\r\\n* Medical contraindications including congestive heart failure, angina, severe peripheral vascular disease\\r\\n* Presence of extrahepatic disease\\r\\n* No response post TACE (or DEB) or progressive HCC despite TACE; prior TACE or DEB is allowed but must be > 28 days from study entry\\r\\n* Serious toxicity following prior TACE (or DEB); prior TACE or DEB must be > 28 days from study entry\\r\\n* Other medical comorbidities making TACE (or DEB) unsafe and/or risky (e.g. combination of relative contraindications including age > 80 years, tumor > 10 cm, > 50% replacement of the liver by HCC, extensive multinodular bilobar HCC, biliary drainage)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patient must be able to provide study-specific informed consent prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Prior invasive malignancy (except non-melanomatous skin cancer and T1 renal cell carcinoma) unless disease free for a minimum of 2 years (note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Prior sorafenib use > 60 days and/or grade 3 or 4 sorafenib related toxicity; note that prior chemotherapy for HCC or a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months PRIOR TO registration\\r\\n* Transmural myocardial infarction within the last 6 months prior to study entry\\r\\n* Unstable ventricular arrhythmia within the last 6 months prior to study entry\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\\r\\n* Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within 28 days prior to study entry\\r\\n* Bleeding within 28 days prior to study entry due to any cause, requiring transfusion\\r\\n* Thrombolytic therapy within 28 days prior to study entry; subcutaneous heparin is permitted\\r\\n* Known bleeding or clotting disorder\\r\\n* Uncontrolled psychotic disorder\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Maximal diameter of any one hepatocellular carcinoma > 15 cm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Total sum of maximum diameters of each definite parenchymal hepatocellular carcinomas within the liver or maximum diameter of a single conglomerate HCC > 20 cm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"More than 5 discrete intrahepatic parenchymal foci of definite HCC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Direct tumor extension into the stomach, duodenum, small bowel or large bowel\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Measurable common or main branch biliary duct involvement with HCC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Prior liver transplant\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Human immunodeficiency virus (HIV) positive with CD4 count < (350) cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= (350) cells/microliter, and no known detectable viral load, at the time of study entry; note also that HIV testing is not required for eligibility for this protocol\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Liver\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-02057\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01872975_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patient must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma); the FNA or core needle biopsy can be performed either by palpation or by image guidance; documentation of axillary nodal positivity by sentinel node biopsy (before neoadjuvant therapy) is not permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have had estrogen receptor (ER) analysis performed on the primary breast tumor before neoadjuvant therapy according to current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing; if negative for ER, assessment of progesterone receptor (PgR) must also be performed according to current ASCO/CAP guideline recommendations for hormone receptor testing\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer; patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"For patients who receive adjuvant chemotherapy after surgery, a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization; (if treatment delays occur, chemotherapy must be completed within 14 weeks); the dose and schedule of the adjuvant chemotherapy are at the investigator's discretion; Note: it is preferred that all intended chemotherapy be administered in the neoadjuvant setting\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients with HER2-positive tumors must have received neoadjuvant anti-HER2 therapy (either with all or with a portion of the neoadjuvant chemotherapy regimen), unless medically contraindicated\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"At the time of definitive surgery, all removed axillary nodes must be histologically free from cancer; acceptable procedures for assessment of axillary nodal status at the time of surgery include:\\r\\n* Axillary node dissection\\r\\n* Sentinel node biopsy alone provided that at least 2 sentinel lymph nodes are removed; removal of at least 3 sentinel lymph nodes and use of dual tracer for lymphatic mapping are strongly recommended or\\r\\n* Sentinel node biopsy followed by axillary node dissection\\r\\nNote: patients are eligible whether there is residual invasive carcinoma in the surgical breast specimen or whether there is evidence of pathologic complete response; patients who are found to be pathologically node-positive at the time of surgery, based on sentinel node biopsy alone, are candidates for A011202, a study developed by the Alliance in Oncology, an National Cancer Institute (NCI) Cooperative Group; if A011202 is open at the investigator's institution, patients should be approached about participating in the A011202 study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients with pathologic staging of ypN0(i+) or ypN0(mol+) are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patient who have undergone either a total mastectomy or a lumpectomy are eligible; (patients who have had a nipple-sparing mastectomy are eligible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"For patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist; additional operative procedures may be performed to obtain clear margins; if tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible; (patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"For patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumor\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 70 days; also, if adjuvant chemotherapy was administered, the interval between the last chemotherapy treatment and randomization must be no more than 70 days\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"The patient must have recovered from surgery with the incision completely healed and no signs of infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of radiation therapy should have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Definitive clinical or radiologic evidence of metastatic disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"T4 tumors including inflammatory breast cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Documentation of axillary nodal positivity before neoadjuvant therapy by sentinel node biopsy alone\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"N2 or N3 disease detected clinically or by imaging\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients with histologically positive axillary nodes post neoadjuvant therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients with microscopic positive margins after definitive surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Synchronous or previous contralateral invasive breast cancer or DCIS; (patients with synchronous and/or previous contralateral LCIS are eligible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy; (patients with synchronous or previous ipsilateral LCIS are eligible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Any radiation therapy for the currently diagnosed breast cancer prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy; patients are eligible if these medications are discontinued prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Prior breast or thoracic radiation therapy (RT) for any condition\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Active collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Pregnancy or lactation at the time of study entry; (Note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2012-03198\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01824836_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria:\\r\\n* >= 60 years of age; or\\r\\n* < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or\\r\\n* < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or\\r\\n* < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or\\r\\n* < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or\\r\\n* Prior radiation castration with amenorrhea for at least 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"NOTE: use of luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide or goserelin) is not allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have estrogen and/or progesterone receptor positive histologically confirmed stage I-III adenocarcinoma of the breast\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have completed planned local therapy (i.e., definitive surgery and radiation therapy) and adjuvant chemotherapy for breast cancer prior to registration; in addition, any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline Patient Reported Outcomes (PRO) instruments (i.e., Health Assessment Questionnaire [HAQ], PROMIS Physical Function, Functional Assessment of Cancer Therapy [FACT] Breast and Endocrine Symptoms [ES], etc.) and collection of optional blood for banking for future research\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"NOTE: concomitant treatment with ongoing trastuzumab (Herceptin) or other targeted/biologic agents is allowed; concomitant treatment with any other type of chemotherapy or hormonal therapy is not allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must not have received prior AI therapy with exemestane, letrozole, or anastrozole as preoperative/adjuvant therapy or for prevention of breast cancer; prior tamoxifen is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Plan to treat with anastrozole for at least 12 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status between 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must be disease-free of other prior invasive malignancies for >= 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; prior early stage breast cancers are also allowed as long as prior treatment did not include aromatase inhibitors\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must not be currently taking (or have taken in the past 6 months) medication for active, chronic conditions, including rheumatoid arthritis, carpal tunnel syndrome, tenosynovitis, systemic lupus erythematosus, gout, fibromyalgia, or severe osteoarthritis involving the hands, wrists, hips, knees, feet or ankles; this includes analgesic medications or medications being taken with the purpose of treating pain or that may have an effect on pain (e.g. anti-depressants for help with pain or neuropathy, corticosteroid shots for arthritis); (Note: patients taking daily low dose aspirin are allowed to participate in this trial)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must not have a prior history of deep vein thrombosis (DVT) or pulmonary embolism in the past 5 years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients must have worst pain rated as no worse than 3 out of 10 on the following question (i.e., a pain score of 0, 1, 2, or 3): \\u201cIn the past week, how much pain have you had on a scale of 0 to 10, where 0 equals no pain and 10 means the worst pain you can imagine; \\\" NOTE: this question regarding patient\\u2019s pain should be completed within one week prior to registration; this question may be asked orally prior to consent up to 7 days prior to registration; the response will be recorded on the registration checklist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-00426\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01220583_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes: \\r\\n* Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma\\r\\n* High-grade adenocarcinoma or high-grade mucoepidermoid carcinoma or salivary duct carcinoma\\r\\n* High-grade acinic cell carcinoma or high-grade (> 30% solid component) adenoid cystic carcinoma\\r\\n* Patients with diagnoses such as \\\"undifferentiated or poorly differentiated carcinoma\\\", \\\"carcinoma-ex pleomorphic adenoma\\\", \\\"carcinoma not otherwise specified (NOS)\\\" and others should be considered for this trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Surgical resection with curative intent within 8 weeks prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup:\\r\\n* History/physical examination within 8 weeks prior to registration\\r\\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Zubrod performance status 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,800 cells/mm^3 (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Platelets >= 100,000 cells/mm^3 (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Serum creatinine < 2.0 mg/dl (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Total bilirubin < 2 x the institutional upper limit of normal (ULN) (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN (within 8 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"All patients must have a Medical Oncology evaluation within 4 weeks prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must be deemed able to comply with the treatment plan and follow-up schedule\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with residual macroscopic disease after surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Prior systemic chemotherapy or radiation therapy for salivary gland malignancy; note that prior chemotherapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\\r\\n* Transmural myocardial infarction within the last 6 months\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, coagulation parameters are not required for entry into this protocol\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol\\r\\n* Pre-existing >= grade 2 neuropathy\\r\\n* Prior organ transplant\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Significant pre-existing hearing loss, as defined by the patient or treating physician\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lip, Oral Cavity and Pharynx\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-00370\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01822496_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm N2 or N3 disease; patients may have invasive mediastinal staging by mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery (VATS)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have measurable disease, i.e., lesions that can be accurately measured in at least 1 dimension (longest dimension in the plane of measurement is to be recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan slice thickness no greater than 5 mm)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"The institution\\u2019s pre-enrollment biomarker screening at a Clinical Laboratory Improvement Amendments (CLIA) certified lab documents presence of known \\u201csensitive\\u201d mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement; either the primary tumor or the metastatic lymph node tissue may be used for testing of mutations\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"The institution\\u2019s pre-enrollment biomarker screening at a CLIA certified lab documents absence of T790M mutation in the EGFR TK domain\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\\r\\n* History/physical examination, including recording of pulse, blood pressure (BP), weight, and body surface area, within 45 days prior to registration\\r\\n* Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to mid-thighs) within 30 days prior to registration; PET/CT must be negative for distant metastasis\\r\\n* CT scan with contrast of the chest and upper abdomen to include liver and adrenals (unless medically contraindicated) within 30 days prior to registration\\r\\n* Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with contrast, if MRI medically contraindicated) within 30 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Zubrod performance status 0-1 within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,000 cells/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Platelets >= 100,000 cells/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 ml/min (by Cockcroft-Gault formula) within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Bilirubin within normal institutional limits within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patient must provide study specific informed consent prior to study entry, including consent for mandatory screening of tissue\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Atelectasis of the entire lung\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Contralateral hilar node involvement\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Exudative, bloody, or cytologically malignant effusions\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\\r\\n* Transmural myocardial infarction within the last 6 months\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Prior allergic reaction to the study drug(s) involved in this protocol\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lung\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-00737\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01901094_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"No inflammatory breast cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"All patients must have had an axillary ultrasound with fine needle aspiration (FNA) or core needle biopsy of axillary lymph nodes documenting axillary metastasis at the time of diagnosis, prior to or at most 14 days after starting neoadjuvant chemotherapy\\r\\n* Note: Biopsy of intramammary nodes does not fulfill eligibility criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have had estrogen receptor, progesterone receptor and HER2 status (by immunohistochemistry [IHC] and/or in situ hybridization [ISH]) evaluated on diagnostic core biopsy prior to start of neoadjuvant chemotherapy\\r\\n* Note: If HER2 status has not been clearly determined (i.e. equivocal/indeterminate), then patients should not be enrolled\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have completed all planned neoadjuvant chemotherapy prior to surgery; sandwich chemotherapy is not allowed (i.e. anthracycline/cytoxan or taxane chemotherapy planned to be given after surgery); patients must have completed at least 4 cycles of neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen without evidence of disease progression in the breast or the lymph nodes\\r\\n* Note: Delays/dose modifications due to toxicities/adverse events are allowed as long as a minimum of 4 cycles of neoadjuvant chemotherapy is administered; more than 4 cycles of neoadjuvant chemotherapy (NAC) may be administered at the discretion of the treating medical oncologist\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients with HER-2 positive tumors must have received neoadjuvant trastuzumab, or trastuzumab + pertuzumab, or other approved anti-HER-2 therapy (either with all or with a portion of the neoadjuvant chemotherapy regimen); therapy must be Food and Drug Administration (FDA)-approved targeted anti-HER2 therapy, but additional therapies are allowed as are non-trastuzumab regimens if administered in the context of an Institutional Review Board (IRB)-approved clinical trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"All patients must have a clinically negative axilla (no bulky adenopathy) on physical examination documented at the completion of neoadjuvant chemotherapy\\r\\n* Note: an ultrasound of the axilla is not required at completion of neoadjuvant chemotherapy; if performed, its findings do NOT impact eligibility\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"No more than 8 weeks of neoadjuvant endocrine therapy prior to the start of neoadjuvant chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"No neoadjuvant radiation therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"No SLN surgery/excisional biopsy for pathological confirmation of axillary status prior to or during neoadjuvant chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"No prior history of ipsilateral breast cancer (invasive disease or ductal carcinoma in situ [DCIS]); lobular carcinoma in situ (LCIS) and benign breast disease is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"No prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or treatment of hidradenitis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"No history of prior or concurrent contralateral invasive breast cancer; benign breast disease; LCIS or DCIS of contralateral breast is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must not be pregnant or nursing\\r\\n* Note: Peri-menopausal women must be amenorrheic for > 12 months to be considered not of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"INTRA-OPERATIVE REGISTRATION/RANDOMIZATION CRITERIA\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be completed within 56 days of the completion of the last dose of neoadjuvant chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"A minimum of 1 sentinel node and a maximum of 8 total nodes (sentinel + non-sentinel) are identified and excised; more than 8 nodes identified by either surgeon or pathologist is NOT allowed\\r\\nNote: Patients who do not have an identifiable sentinel lymph node will not proceed to registration/randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"At least one lymph node (sentinel or non-sentinel) with a metastasis greater than 0.2 mm in greatest dimension identified on intra-operative pathologic assessment\\r\\n* Note: Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as node negative disease (N0i+)\\r\\n* Note: If on final pathology, more than 8 lymph nodes are seen pathologically, then the patient should discontinue study\\r\\n* Axillary lymph node dissection (ALND) is not to be performed prior to registration/randomization\\r\\n* Note: Patients for whom no positive lymph nodes (sentinel or non-sentinel) are found during sentinel lymph node surgery will not proceed to registration/randomization and can be considered for discussion of the NRG NSABP B-51/RTOG 1304 study \\u201cA Randomized Phase III Clinical Trial Evaluating the Role of Post-mastectomy Chest Wall and Regional Nodal XRT and Post-lumpectomy Regional Nodal XRT in Patients with Documented Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy\\u201d\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"POST-OPERATIVE REGISTRATION/RANDOMIZATION CRITERIA\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"For cases where ALND has not been performed and one of the following is true: 1) intra-operative evaluation of sentinel lymph node could not be/was not performed and final pathology identified a positive lymph node (sentinel or non-sentinel) with metastasis greater than 0.2 mm OR 2) lymph node (sentinel or non-sentinel) considered negative on intra-operative evaluation was found to be positive on final pathology (with metastasis greater than 0.2 mm)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be completed within 56 days of the completion of the last dose of neoadjuvant chemotherapy; negative margin (by either breast conservation or mastectomy) on final pathology where negative margin is defined as no tumor on ink\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"At least one lymph node (sentinel or non-sentinel) with a metastasis greater than 0.2 mm in greatest dimension identified on final pathology (for cases where intra-operative evaluation was not performed, or was negative and completion dissection was not performed)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"At least one and no more than 8 lymph nodes (sentinel and non-sentinel) were found by the pathologists to have been actually excised during sentinel lymph node procedure\\r\\nNote: Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as node negative disease (N0i+)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"For those patients who also undergo contralateral breast surgery, if invasive disease is found in the contralateral breast, the patient is not eligible for registration /randomization\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\",\n",
      "        \"Breast - Male\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-00875\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01935934_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have histologically or cytologically confirmed metastatic endometrial cancer; eligible histologies for the experimental cohort are: endometrioid or serous; eligible histologies for the exploratory cohort are: carcinosarcoma, clear cell, mixed, adenosquamous and any other rare sub-type of endometrial cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 10 mm with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam and >= 15 mm in short axis for nodal lesions; patients must have radiographic evidence of disease progression following the most recent line of treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Prior therapy: Eligible subjects must have had 1 line of systemic cytotoxic treatment; this may be adjuvant therapy with documented progression within 12 months of completion, or 1 line of cytotoxic therapy for metastatic disease; NOTE: eligible patients are allowed up to 2 lines of systemic cytotoxic treatment, of which only 1 line is allowed for metastatic disease; the acceptance of progression within 12 months of adjuvant is part inclusion to not require patient to re-challenge with chemotherapy (chemo) if they progressed soon after adjuvant therapy; prior hormonal therapy for metastatic/recurrent disease is also allowed; prior targeted therapy not directed against cMET or vascular endothelial growth factor (VEGF) pathways is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Life expectancy of greater than 3 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Absolute neutrophil count >= 1.5 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Platelets >= 100 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x upper limit of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 X institutional upper limit of normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Creatinine =< 1.5 x ULN OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Hemoglobin >= 90 g/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Serum albumin >= 28 g/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Lipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitis\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Urine protein/creatinine ratio (UPCR) =< 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Women of childbearing potential must have a negative pregnancy test at screening; women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopausal is defined as amenorrhea >= 12 consecutive months; note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; sexually active subjects must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients must consent to analysis on archival tissue; if archival sample is not available, a sufficient tumor biopsy can be performed a minimum of 28 days prior to start of treatment if felt to be clinically reasonable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Ability to understand and the willingness to sign a written informed consent document\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g., cytokines or antibodies) or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before the first dose of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Prior treatment with cabozantinib\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"The subject has received radiation therapy:\\r\\n* To bone metastasis within 14 days before the first dose of study treatment \\r\\n* To any other site(s) within 28 days before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"The subject has received any other type of investigational agent within 28 days before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from related toxicity to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Any other prior malignancy from which the patient has been disease free for less than 3 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients with known brain metastases should be excluded from this clinical trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN =< 7 days before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Therapeutic anticoagulation with warfarin, antiplatelet agents (e.g., clopidogrel), thrombin, or Factor Xa inhibitors is not allowed; therapeutic anticoagulation with low molecular weight heparin (LMWH) is allowed as well as prophylactic anticoagulation using low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and LMWH\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"The subject requires chronic concomitant treatment of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John\\u2019s wort)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"The subject has experienced any of the following:\\r\\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\\r\\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\\r\\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"The subject has tumor in contact with, invading or encasing any major blood vessels\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\\r\\n* Cardiovascular disorders including:\\r\\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\\r\\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment\\r\\n** Any history of congenital long QT syndrome\\r\\n** Any of the following within 6 months before the first dose of study treatment:\\r\\n*** Unstable angina pectoris\\r\\n*** Clinically-significant cardiac arrhythmias\\r\\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\\r\\n*** Myocardial infarction\\r\\n*** Thromboembolic event requiring therapeutic anticoagulation (note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\\r\\n* Any of the following within 28 days before the first dose of study treatment\\r\\n** Intra-abdominal tumor/metastases invading GI mucosa\\r\\n** Active peptic ulcer disease,\\r\\n** Inflammatory bowel disease (including ulcerative colitis and Crohn\\u2019s disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\\r\\n** Malabsorption syndrome\\r\\n* Any of the following within 6 months before the first dose of study treatment:\\r\\n** Abdominal fistula\\r\\n** Gastrointestinal perforation\\r\\n** Bowel obstruction or gastric outlet obstruction\\r\\n** Intra-abdominal abscess; note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"Other clinically significant disorders such as:\\r\\n* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment\\r\\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\\r\\n* History of organ transplant\\r\\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\\r\\n* History of major surgery as follows:\\r\\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\\r\\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\\r\\n*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"The subject is unable to swallow tablets\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 40,\n",
      "            \"description\": \"The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms =< 7 days before the first dose of study treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 41,\n",
      "            \"description\": \"The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 42,\n",
      "            \"description\": \"History of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 43,\n",
      "            \"description\": \"Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 44,\n",
      "            \"description\": \"Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Corpus Uteri\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-00890\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01953588_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Postmenopausal, verified by: \\r\\n* Post bilateral surgical oophorectomy, or\\r\\n* No spontaneous menses >= 1 year or\\r\\n* No menses for < 1 year with follicle-stimulating hormone (FSH) and estradiol levels in postmenopausal range, according to institutional standards\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Clinical T2-T4c, any N, M0 invasive breast cancer, by American Joint Committee on Cancer (AJCC) 7th edition clinical staging, with the goal being surgery to complete excision of the tumor in the breast and the lymph node\\r\\nPrimary tumor must be:\\r\\n* Palpable\\r\\n* Its largest tumor diameter is > 2.0 cm by physical examination or by radiological assessment\\r\\n* Bi-dimensional measurement by tape, ruler or caliper technique must be provided\\r\\n** Note:\\r\\n*** Patients with contralateral ductal carcinoma in situ and/or invasive breast cancer are not eligible\\r\\n*** Patients with multi-focal breast cancer (defined as more than one lesion of invasive breast cancer in the same breast separated from the dominant breast lesion by less than 5 cm of radiologically normal breast tissue) are eligible; if the other lesions have been biopsied (biopsy not required) they must meet the ER/human epidermal growth factor receptor 2 (HER2) eligibility requirements; research biopsies and Ki67 assessment and radiological measures are to be performed on the dominant breast lesion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Invasive breast cancer is estrogen receptor (ER) positive with an Allred score of 6, 7 or 8 by local institution standard protocol; if an Allred score is not reported on the diagnostic pathology report, ER positivity in > 66% cells is eligible; if ER positivity is =< 66%, the staining intensity (weak, intermediate, strong) is needed to calculate the Allred score to determine eligibility\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Invasive breast cancer is HER2 negative; a patient is considered to have HER2 negative breast cancer if one of the following if one of the following applies: \\r\\n* 0 or 1+ by immunohistochemistry (IHC) and in situ hybridization (ISH) not done\\r\\n* 0 or 1+ by IHC or ISH ratio (HER2 gene copy/chromosome 17) < 2\\r\\n* 2+ by IHC and ISH ratio (HER2 gene copy/chromosome 17) < 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Documentation of mammogram and ultrasound (including ductal carcinoma in situ [DCIS] and invasive cancer) of the diseased breast performed within 56 days prior to registration; mammogram for the unaffected contralateral breast is required within 12 months prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) > 1,000/mm^3 (=< 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Platelet count > 100,000/mm^3 (=< 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Total bilirubin < 1.5 x upper limits of normal (ULN) (=< 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Creatinine < 1.5 x upper limits of normal (ULN) (=< 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Serum alanine aminotransferase (ALT) < 2.5 x upper limits of normal (ULN) (=< 14 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Tissue acquisition: patient must agree to provide the required research biopsies at baseline, week 4 and at surgery for integral and integrated biomarker and correlative studies\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Premenopausal status\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d\\u2019orange without erythema)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"An excisional biopsy of this breast cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Hormone replacement therapy of any type, megestrol acetate, or raloxifene within one week prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Tumor ER Allred score between 0-5 or HER2 positive by IHC (3+) or amplified by fluorescence in situ hybridization (FISH) > 2.0\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Surgical axillary staging procedure prior to study entry; Note: fine needle aspiration (FNA) or core needle biopsy of axillary node is permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Clinical or radiographic evidence of metastatic disease; metastatic workup is not required, but is recommended for patients with clinical stage III disease; Note: isolated ipsilateral supraclavicular node involvement is permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Breast implants are contraindicated only if the implant precludes the required research biopsies or interferes with palpating the breast lesion\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entry\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"History of invasive breast cancer or contralateral DCIS\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-01340\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01896999_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by a diagnostic quality computed tomography (CT) scan; patients must use the same imaging modality (CT or PET/CT) throughout the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert\\u2019s syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patient must have no current or prior history of central nervous system (CNS) involvement\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"No history of Steven\\u2019s Johnson\\u2019s syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed\\r\\n* Replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study\\r\\n* Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener\\u2019s Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients must not have grade 2 or greater peripheral sensory neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must not have a serious medical or psychiatric illness likely to interfere with study participation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): ECOG-ACRIN performance status between 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 40,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 41,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 42,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 43,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert\\u2019s syndrome, for which Bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 44,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 45,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 46,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of CNS involvement\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 47,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 48,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): No history of Steven\\u2019s Johnson\\u2019s syndrome, TENs syndrome, or motor neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 49,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:\\r\\n* Long term survival expected were it not for the cHL\\r\\n* HIV viral loads undetectable by standard clinical HIV testing\\r\\n* Willing to adhere to effective combination antiretroviral therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 50,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener\\u2019s Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 51,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 52,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 53,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 54,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a serious medical or psychiatric illness likely to interfere with study participation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 55,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 56,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 57,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agents\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 58,\n",
      "            \"description\": \"RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a history of or evidence of cardiovascular risks including any of the following:\\r\\n* QT interval corrected for heart rate using the Bazett\\u2019s formula QTcB >= 480 msec at baseline \\r\\n* History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration\\r\\n* History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system\\r\\n* Left ventricular ejection fraction (LVEF) =< lower limit of normal on cardiac echocardiogram (echo) or multigated acquisition scan (MUGA)\\r\\n* Intra-cardiac defibrillator\\r\\n* History of abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study\\r\\n* History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible\\r\\n* Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Hodgkin's Lymphoma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-01275\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02004275_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Histologically confirmed diagnosis of symptomatic multiple myeloma; relapsed disease is myeloma that has previously responded to prior therapy (MR or better) and subsequently progressed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patient must have measurable disease or non-measurable disease, defined as one or more of the following holding true:\\r\\n* Measurable disease:\\r\\n** Serum M-protein >= 0.5 g/dL and/or\\r\\n** Urine M-protein >= 200 mg/24 hours and/or\\r\\n** Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free light chain ratio\\r\\n* For non-measurable disease:\\r\\n** Baseline marrow burden of myeloma of at least 30%\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Progression on lenalidomide as part of first line therapy (lenalidomide-refractory disease)\\r\\n* Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment; patients should have received at least 2 cycles of a lenalidomide-based regimen to be evaluable for refractoriness; examples: 1) progression on lenalidomide maintenance therapy after initial induction +/- consolidation; 2) initial response followed by progression on continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Pomalidomide naive disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Proteasome inhibitor naive or sensitive disease; proteasome inhibitor sensitive disease is defined as a PR or better to prior proteasome inhibitor-based therapy that is maintained for >= 60 days from the last dose of the proteasome inhibitor\\r\\n* A patient who receives induction therapy with lenalidomide, bortezomib and dexamethasone and achieves a PR or better but subsequently progresses on continued lenalidomide or lenalidomide-dexamethasone would be eligible provided the progression occurs 60 days or more after discontinuation of the bortezomib; similarly, ixazomib exposure is allowed provided they meet the definition of proteasome inhibitor sensitive disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"1 prior line of systemic therapy for multiple myeloma, where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy); a new line of therapy begins when a planned therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, disease relapse or treatment-related toxicity (e.g. a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen); a new line of therapy also begins when a planned treatment-free interval is interrupted by the need to start treatment due to disease relapse/progression (e.g. a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide, bortezomib and dexamethasone, enjoys an 8-month period off therapy but then experiences disease progression requiring re-initiation of therapy)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant at time of registration, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft versus host disease, and no evidence of active infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"No chemotherapy or radiation therapy within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"No investigational therapy within 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"No major surgery within 28 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"No G-CSF (filgrastim) or GM-CSF (sargramostim) within 7 days of registration or pegfilgrastim within 14 days of registration to meet eligibility criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"No platelet transfusions within 7 days of registration to meet eligibility criteria; Note: red blood cell transfusions are allowed at any time\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\\r\\n* Women of childbearing potential:\\r\\n** Must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlU/ml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide\\r\\n** Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide\\r\\n** Must agree to ongoing pregnancy testing\\r\\n** Must agree to not become pregnant or breast feed a child during treatment on this protocol\\r\\n* Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential, even if they have had a successful vasectomy\\r\\n* Note: All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1.0 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Platelet count >= 50 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Calculated (Calc.) creatinine clearance >= 30 mL/min; calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Total bilirubin < 1.5 x upper limits of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limits of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Note: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients cannot have any of the following:\\r\\n* Central nerve system involvement\\r\\n* Primary refractory multiple myeloma, where primary refractory multiple myeloma is defined as disease that is nonresponsive \\u2013 patients who have never achieved a minimal response (MR) or better \\u2013 with any therapy over the course of their disease; it includes patients who never achieve MR or better in whom there is no significant change in M-protein and no evidence of clinical progression as well as patients who meet criteria for true progressive disease (PD)\\r\\n* Primary or secondary plasma cell leukemia\\r\\n* Light-chain (AL) amyloidosis or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome\\r\\n* Known active hepatitis C based on:\\r\\n** +hepatitis C virus (HCV) antibody (confirmed)\\r\\n** +HCV RNA\\r\\n** Liver disease with history of positive serology\\r\\n** Note: patients with a prior history of hepatitis C that has been successfully eradicated with antiviral therapy are eligible\\r\\n* Known hepatitis B surface antigen positivity\\r\\n* Previous hypersensitivity to any of the components of the study treatment\\r\\n* Prior history of erythema multiforme with thalidomide or lenalidomide treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"=< grade 2 peripheral neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Adequate cardiac function, defined as:\\r\\n* No electrocardiogram (EKG) evidence of acute ischemia\\r\\n* No EKG evidence of active, clinically significant conduction system abnormalities\\r\\n* No EKG evidence of > grade 2 (> 480 ms) corrected QT (QTc) prolongation \\r\\n* Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant\\r\\n* No uncontrolled angina or severe ventricular arrhythmias\\r\\n* No clinically significant pericardial disease\\r\\n* No history of myocardial infarction within 6 months prior to registration\\r\\n* No class 3 or higher New York Heart Association congestive heart failure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 within 14 days prior to registration\\r\\n*Note: Ixazomib is a substrate of CYP3A4 and CYP1A2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\\r\\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\\r\\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to registration\\r\\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration\\r\\n* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patients randomized to Arm 1 may opt to switch to the 3-drug regimen following disease progression; these patients must be re-registered to the study and meet the eligibility criteria below\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patient must have measurable disease or non-measurable disease after progression on pomalidomide + dexamethasone, defined as one or more of the following holding true:\\r\\n* Measurable disease:\\r\\n** Serum M-protein >= 0.5 g/dL and/or\\r\\n** Urine M-protein >= 200 mg/24 hours and/or\\r\\n** Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free light chain ratio\\r\\n* For non-measurable disease:\\r\\n** Marrow burden of myeloma of at least 30%\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): \\r\\n* Women of childbearing potential:\\r\\n** Must have a negative serum or urine pregnancy test within 72 hours prior to re-registration\\r\\n** Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide\\r\\n** Must agree to ongoing pregnancy testing\\r\\n** Must agree to not become pregnant or breast feed a child during treatment on this protocol\\r\\n* Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential, even if they have had a successful vasectomy\\r\\n* Note: All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): ECOG performance status 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Absolute neutrophil count (ANC) >= 1.0 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Platelet count >= 50 x 10^9/L\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Calc. creatinine clearance >= 30 mL/min\\r\\n* Calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Total bilirubin < 1.5 x upper limits of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): AST and ALT < 2.5 x upper limits of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Note: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): =< grade 2 peripheral neuropathy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2\\r\\n* Note: Ixazomib is a substrate of CYP3A4 and CYP1A2\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Multiple Myeloma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-01702\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02003222_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"PRE-REGISTRATION\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing, and the establishment of BCR/ABL status; testing will be performed by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiation Imaging Network (ACRIN) Leukemia Translational Research Laboratory (LTRL) and reported to the institution\\r\\n* NOTE: IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE SUBMITTED TO THE ECOG-ACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW ASSESSMENTS OF MRD CAN BE DONE; IN ADDITION TO ALLOWING THE LTRL TO CONFIRM ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCR/ABL STATUS, IT IS ALSO IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS MULLIGHAN/WILLMAN. WITHOUT ADEQUATE BASELINE SAMPLES, PATIENTS WILL NOT BE ABLE TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL; IF A BONE MARROW ASPIRATE IS NOT AVAILABLE FOR LTRL SUBMISSION AT BASELINE, IT IS IMPERATIVE THAT DR PAIETTA FROM THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WBC AND BLAST COUNT BEFORE BLOOD ONLY IS SUBMITTED\\r\\n* NOTE: Hydroxyurea can be given for up to 5 days prior to initiation of protocol therapy for control of leukocyte count and/or other symptoms or signs; corticosteroids can be given after pre-registration to the protocol and submission of baseline marrow and blood samples for control of leukocyte count and/or other symptoms or signs prior to initiation of protocol therapy if needed; if corticosteroids are given prior to pre-registration, contact the study chair as the patient may still be eligible to participate\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"INDUCTION ELIGIBILITY CRITERIA-STEP 1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"New diagnosis of B lineage ALL must be made upon bone marrow or peripheral blood immunophenotyping; cases with myeloid antigen expression, but unequivocal lymphoid immunophenotype, are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Negativity for the Philadelphia chromosome must be established by conventional cytogenetics, fluorescence in situ hybridization (FISH) and/or polymerase chain reaction (PCR); patients who are negative for the Philadelphia chromosome by conventional cytogenetics must have FISH or PCR performed for BCR/ABL to exclude occult translocations\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if adequate number of circulating blasts from peripheral blood; FISH testing for common B-lineage ALL abnormalities including t(9;22) (BCR/ABL1), t(12;21) (ETS-variant gene 6 [ETV6]/runt-related transcription factor 1 [RUNX1]), t(1;19) (pre-B-cell leukemia homeobox 1 [PBX1]/transcription factor 3 [TCF3]), +4,+10,+17, (centromeric [Cen]4/Cen10/Cen17), t(11q23;var), (myeloid/lymphoid or mixed lineage leukemia [MLL]), deletion (del)(9p) (cyclin-dependent kinase inhibitor 2A [CDKN2A]/Cen9), and t(14;var) (immunoglobulin heavy chain [IGH] is encouraged); if there are few or no circulating blasts and an adequate marrow sample cannot be obtained for cytogenetic analysis, the patient may still enroll on the trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3 (obtained =< 48 hours prior to registration); NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Serum creatinine < 2 mg/dl (obtained =< 48 hours prior to registration); NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\\r\\n* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\\r\\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\\r\\n* Patient must have serum HIV viral load of < 200 copies/mm^3\\r\\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\\r\\n* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine\\r\\n* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patient must not have an antecedent hematologic disorder\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patient must have no history of recent myocardial infarction (within three months), uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patient must not have a history or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia; Parkinson\\u2019s disease, cerebellar disease, organic brain syndrome, psychosis, or other significant CNS abnormalities\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patient must not have an active uncontrolled infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Women must not be pregnant or breast-feeding and must not become pregnant or breastfeed during protocol therapy and for at least 3 months after protocol therapy; woman of childbearing potential must abstain from sexual activity or be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Men who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol-specified therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"ECOG performance score 0-3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patient must have given written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"POST-INDUCTION THERAPY ELIGIBILITY CRITERIA (PRIOR TO INTENSIFICATION-STEP 2)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"ECOG performance status 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients must have achieved a CR or CRi\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Patient must be CNS (cerebrospinal fluid [CSF]) negative for leukemia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients must have resolved any serious infectious complications related to induction\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Any significant medical complications related to induction must have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Serum creatinine =< 2.0 mg/dl (obtained =< 48 hours prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Serum direct bilirubin < 2 mg/dL or serum total bilirubin =< 3 (obtained =< 48 hours prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN) (obtained =< 48 hours prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"Patients must have an ECOG performance status of 0-2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"Patients must have resolved any serious infectious complications related to therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"Any significant medical complications related to therapy must have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert\\u2019s or Meulengracht\\u2019s syndrome); the values must be obtained within 48 hours prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 36,\n",
      "            \"description\": \"Serum creatinine < 1.5 x ULN; the values must be obtained within 48 hours prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 37,\n",
      "            \"description\": \"Bone marrow aspirates must be submitted for centralized minimal residual disease (MRD) assessment performed by the ECOG-ACRIN Leukemia Translational Research Laboratory\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 38,\n",
      "            \"description\": \"MRD results will be reported to the submitting institution\\r\\n* NOTE: FOR MRD ASSESSMENTS, AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION SITE MUST BE SUBMITTED (THE NEEDLE CAN BE RE-DIRECTED THROUGH THE SAME SKIN PUNCTURE SITE); ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE FOR MRD TESTING; DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME ASPIRATION SITE \\r\\n* In B-lineage ALL, MRD levels in peripheral blood or from a dilute marrow aspiration can be 300% lower, on average, than those in bone marrow at a given time point; submitting a first pull from a separate aspiration site will ensure that MRD determinations used in randomization and trial interpretation are accurate\\r\\n** NOTE: failure to submit bone marrow aspirates will result in a major violation at the time of an audit\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 39,\n",
      "            \"description\": \"CRITERIA FOR ALLOGENEIC TRANSPLANTATION\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 40,\n",
      "            \"description\": \"A suitable donor must be identified; there are no restrictions on donor type and can include a matched sibling, a matched or mismatched unrelated donor, a family haplotype matched donor or a cord blood donor (single or double)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 41,\n",
      "            \"description\": \"Patients should meet the eligibility criteria for RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 42,\n",
      "            \"description\": \"Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 43,\n",
      "            \"description\": \"CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have an ECOG performance status of 0-3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 44,\n",
      "            \"description\": \"CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging BM aspirate and biopsy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 45,\n",
      "            \"description\": \"CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have resolved any serious infectious complications related to therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 46,\n",
      "            \"description\": \"CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Any significant medical complications related to therapy must have resolved\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 47,\n",
      "            \"description\": \"Mature B ALL (Burkitt\\u2019s-like leukemia) is excluded from enrollment in this trial; pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 48,\n",
      "            \"description\": \"Patient must not have a concurrent active malignancy for which they are receiving treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 49,\n",
      "            \"description\": \"Patient must not have intercurrent organ damage or medical problems that will jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"70 Years\",\n",
      "          \"max_age_number\": 70,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 70,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"30 Years\",\n",
      "          \"min_age_number\": 30,\n",
      "          \"min_age_in_years\": 30\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lymphoid Leukemia\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-02229\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT01979536_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Newly diagnosed patients with histologically proven ALCL (International Classification of Diseases for Oncology [ICD-0] code: 9714/3)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Disease must be cluster of differentiation (CD)30 positive\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Disease must be anaplastic lymphoma kinase (ALK) positive (defined by local institutional standards)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have stage II, III, or IV disease\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must have a life expectancy of >= 8 weeks\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal (ULN) for age; for the purpose of this study, the ULN for ALT is 45 U/L (within 7 days prior to enrollment)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"If the lab abnormality is thought to be due to the lymphoma the patient is eligible and dose adjustments should be made\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Shortening fraction of >= 27% by echocardiogram, or\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Ejection fraction of >= 50% by radionuclide angiogram\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry > 92% while breathing room air unless current dysfunction is due to the lymphoma in which case the patient is eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients with central nervous system (CNS) disease are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients with disease limited to the skin are not eligible, regardless of how wide-spread\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients with stage I disease are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Previous steroid treatment and/or radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass; emergent steroid treatment and/or radiation treatment should stop once protocol therapy is initiated\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Intrathecal chemotherapy prior to enrollment is allowed for the current diagnosis of ALCL as long as adequate cerebrospinal fluid (CSF) is obtained prior to administration of the intrathecal chemotherapy and subsequently demonstrated to be negative for ALCL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Female patients who are pregnant are not eligible; pregnancy tests must be obtained in girls who are post menarchal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Lactating females are not eligible unless they have agreed not to breastfeed their infants\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Sexually active patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of treatment and for 3 months after stopping treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients with Down syndrome are not eligible due to the amount of methotrexate and potential for side effects\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients with an immunodeficiency that existed prior to diagnosis such as primary immunodeficiency syndromes or organ transplant recipients are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates with narrow therapeutic indices: Patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices including pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; the topical use of these medications (if applicable) is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"CYP3A4 inhibitors: patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, including but not limited to ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, delavirdine, nefazodone, diltiazem, verapamil, and grapefruit juice are not eligible; the topical use of these medications (if applicable), e.g. 2% ketoconazole cream, is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"CYP3A4 inducers: patients chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, ritonavir, and St. John\\u2019s wort are not eligible; the topical use of these medications (if applicable) is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later date\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients who weigh < 10 kg are not eligible\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"21 Years\",\n",
      "          \"max_age_number\": 21,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 21,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"0 Years\",\n",
      "          \"min_age_number\": 0,\n",
      "          \"min_age_in_years\": 0\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Non-Hodgkin's Lymphoma\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-02167\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02054741_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"INCLUSION CRITERIA FOR PHYSICIANS\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Oncology physicians must work at a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) practice site with no plans to leave that NCORP practice site or retire at the time of enrollment into the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"INCLUSION CRITERIA FOR PATIENTS\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration; the treatment regimen is up to the discretion of the treating oncology physician; the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity; patients who will receive monoclonal antibody therapy or other cancer therapies (e.g., tyrosine kinase inhibitors) are eligible if the other agents present a prevalence of toxicity similar to chemotherapy; these therapies can be used in combination with chemotherapy, as a single agent, or in combination with each other\\r\\n* Chemotherapy will be defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) that have a prevalence of grade 3-5 toxicity in older patients similar to chemotherapy (> 50%) will be allowed; a list of allowable agents (single and in combination) meeting this toxicity criteria will be available on the University of Rochester Cancer Center (URCC) NCORP Research Base website as part of the study materials; given the rapidly changing landscape of new drugs for cancer, the study team led by the principal investigator (PI) will update the list accordingly after reviewing the toxicity profile of new therapies; if the potentially eligible participant is to receive an approved drug or regimen not on the list, contacting the URCC NCORP Research Base study team is required for approval prior to participant enrollment\\r\\n* Patients who are receiving approved cancer treatment in combination with radiation are eligible\\r\\n* A patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Plan to be on chemotherapy or other allowable treatment for at least 3 months (minimum 70 days) and be willing to come in for study visits\\r\\n* The plan for treatment should be for at least 3 months at time of study enrollment; the treatment can stop earlier during the study at the discretion of the physician and patient (e.g., due to progression as noted through imaging, toxicity, or patient preference)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Have at least one geriatric assessment domain meet the cut-off score for impairment other than polypharmacy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit; if the participant is found to be impaired on the Blessed-Orientation Memory Concentration Test (BOMC) during screening; they must have a health care proxy or authorized representative to be eligible to enroll\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Participant has adequate understanding of the English language\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"EXCLUSION CRITERIA FOR PATIENTS\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Have surgery planned within 3 months of consent; patients who have previously received surgery are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Presence of symptomatic brain metastases at time of study consent process; patients with history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"70 Years\",\n",
      "          \"min_age_number\": 70,\n",
      "          \"min_age_in_years\": 70\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Multiple\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-01904\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02065687_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma\\r\\n* Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible:\\r\\n** Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Platelets greater than or equal to 100,000/mcl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Creatinine less than 1.4 mg/dl\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Alkaline phosphatase less than or equal to 2.5 x ULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients must be able to swallow and retain orally-administered medication\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must NOT be taking metformin or have been on metformin in the past 6 months\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"FEMALE\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Corpus Uteri\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2013-02284\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02152982_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Histologic documentation: newly diagnosed World Health Organization (WHO) grade IV intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q codeleted; sites submitting GBM with oligodendroglial features will be asked to provide results of 1p/19q codeletion status\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Sufficient tissue available for central pathology review and MGMT methylation status evaluation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients who have had a local MGMT testing that is unmethylated are not allowed to participate\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Tumor MGMT promoter hypermethylation determined by central testing at MD Anderson\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Confirmation by central pathology review of WHO grade IV glioblastoma or gliosarcoma\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1500 cells/mm^3 (within 14 days prior to study registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Platelets >= 100,000 cells/mm^3 (within 14 days prior to study registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Creatinine =< 1.5 x upper limit of normal (ULN) (within 14 days prior to study registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Bilirubin =< 1.5 x ULN (within 14 days prior to study registration; unless patient has Gilbert\\u2019s disease)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to study registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) =< 3 x ULN (within 14 days prior to study registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status =< 2\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Measurable disease or non-measurable disease; extent of resection: patients with complete resection, partial resection, or biopsy are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Progression: patients deemed to have progressive disease based on clinical deterioration after chemoradiation or radiographic progression outside of the radiation field are not eligible; patients deemed to have pseudoprogression are eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Prior treatment:\\r\\n* Must have completed standard radiotherapy and concomitant TMZ therapy as defined and determined by the study oncologist\\r\\n* Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or adjuvant) can be given prior to study registration, including chemotherapy (also including Gliadel/carmustine [BCNU] wafers), biologics, immunotherapy, radiation therapy; the only exception is the Optune device (NovoTTF-100A), which may be started any time after end of radiation therapy up through the initiation of Cycle 1; intent to use Optune must be declared at registration for stratification\\r\\n* No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Not pregnant and not nursing; females of childbearing potential must have negative urine or serum pregnancy test within 7 days of registration but before start of treatment; a female of childbearing potential is a sexually mature female who: \\r\\n* Has not undergone a hysterectomy or bilateral oophorectomy; or \\r\\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Concomitant medications: patients receiving anticoagulation should be on stable dose 2 weeks prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Comorbid conditions: patients are unable to participate due to the following:\\r\\n* Generalized or partial seizure disorder that is uncontrolled at the time of registration; the definition of controlled generalized seizures is patients must be on a stable dose of anti-seizure medication and without generalized seizures for at least 10 days prior to registration; the definition of controlled partial seizures is patients must be on a stable dose of anti-seizure medication for at least 10 days prior to registration; patients with occasional breakthrough partial seizures are allowed at treating physician\\u2019s discretion\\r\\n* Grade 3 or 4 thromboembolic disease within 6 months (mo) of registration\\r\\n* Known history of prolonged QT syndrome\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"No history of major surgery =< 14 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:\\r\\n* >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"No Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Brain and Nervous System\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2014-00616\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02154490_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"SCREENING/PRE-SCREENING REGISTRATION:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the lung confirmed by tumor biopsy and/or fine-needle aspiration; disease must be stage IV SCCA, or recurrent; the primary diagnosis of SCCA should be established using the current World Health Organization (WHO)/International Association for the Study of Lung Cancer (IASLC)-classification of Thoracic Malignancies; the diagnosis is based on hematoxylin and eosin (H&E) stained slides with or without specific defined immunohistochemistry (IHC) characteristic (p40/p63 positive, transcription termination factor [TTF1] negative) if required for diagnosis; mixed histologies are not allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on current treatment; patients will either consent to the screening consent or the pre-screening consent, not both; these criteria are:\\r\\n* Screening at progression on prior treatment: to be eligible for screening at progression, patients must have received at least one line of systemic therapy for any stage of disease (stages I-IV) and must have progressed during or following their most recent line of therapy; for patients whose prior systemic therapy was for stage I-III disease only (i.e. patient has not received any treatment for stage IV or recurrent disease), the prior systemic therapy must have been a platinum-based chemotherapy regimen and disease progression on the platinum-based chemotherapy must have occurred within one year from the last date that patient received that therapy; for patients whose prior therapy was for stage IV or recurrent disease, the patient must have received at least one line of a platinum-based chemotherapy regimen or checkpoint inhibitor therapy (e.g. nivolumab or pembrolizumab)\\r\\n* Pre-screening prior to progression on current treatment: to be eligible for pre-screening, current treatment must be for stage IV or recurrent disease and patient must have received at least one dose of the current regimen; patients must have previously received or currently be receiving a platinum-based chemotherapy regimen or checkpoint inhibitor therapy (e.g. nivolumab or pembrolizumab); patients on first-line platinum-based treatment are eligible upon receiving cycle 1, day 1 infusion; Note: patients will not receive their sub-study assignment until they progress and the S1400 Notice of Progression is submitted\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Patients must have adequate tumor tissue available, defined as >= 20% tumor cells and >= 0.2 mm^3 tumor volume\\r\\n* The local interpreting pathologist must review the specimen\\r\\n* The pathologist must sign the S1400 Local Pathology Review Form confirming tissue adequacy prior to screening/pre-screening registration\\r\\n* Patients must agree to have this tissue submitted to Foundation Medicine for common broad platform Clinical Laboratory Improvement Act (CLIA) biomarker profiling and c-MET IHC; if archival tumor material is exhausted, then a new fresh tumor biopsy that is formalin-fixed and paraffin-embedded (FFPE) must be obtained; a tumor block or FFPE slides 4-5 microns thick must be submitted; bone biopsies are not allowed; if FFPE slides are to be submitted, at least 12 unstained slides plus an H&E stained slide, or 13 unstained slides must be submitted; however it is strongly recommended that 20 FFPE slides be submitted; Note: previous next-generation deoxyribonucleic acid (DNA) sequencing (NGS) will be repeated if done outside this study for sub-study assignment; patients must agree to have any tissue that remains after NGS testing retained for the use of the translational medicine (TM) studies (if such TM studies are defined) within any sub-study the patient is enrolled in\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Patients must not have a known epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion; EGFR/ALK testing is not required prior to registration and is included in the Foundation Medicine Incorporated (FMI) testing for screening/prescreening\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Patients must have Zubrod performance status 0-1 documented within 28 days prior to screening/pre-screening registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must also be offered participation in banking for future use of specimens\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must be willing to provide prior smoking history as required on the S1400 Onstudy Form\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"United States (U.S.) patients who can complete the survey and the interview by telephone or email in English must be offered participation in the S1400GEN survey ancillary study; NOTE: Patients enrolled to S1400 prior to revision #12 are not eligible for the S1400GEN survey ancillary study; study physicians will provide participants with a hard copy of the survey (at the time of informed consent) to improve tracking and comprehension during the interview\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"SUB-STUDY REGISTRATION:\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients whose biomarker profiling results indicate the presence of an EGFR mutation or echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must have progressed (in the opinion of the treating investigator) following the most recent line of therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration; patients must have recovered (=< grade 1) from any side effects of prior therapy; patients must not have received any radiation therapy within 14 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to sub-study registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to sub-study registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registration; patient must not have leptomeningeal disease, spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment and prior to registration, AND (2) patient has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patient must have fully recovered from the effects of prior surgery at least 14 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x IULN\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to sub-study registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must have Zubrod performance status 0-1 documented within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must not have any grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 29,\n",
      "            \"description\": \"Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\\r\\n* Must have undetectable viral load using standard HIV assays in clinical practice\\r\\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\\r\\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)\\r\\n* Must not be newly diagnosed within 12 months prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 30,\n",
      "            \"description\": \"Prestudy history and physical exam must be obtained within 28 days prior to sub-study registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 31,\n",
      "            \"description\": \"No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 32,\n",
      "            \"description\": \"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \\\"reproductive potential\\\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \\\"effective contraception\\\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 33,\n",
      "            \"description\": \"As part of the OPEN registration process the treating institution\\u2019s identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the system\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 34,\n",
      "            \"description\": \"Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 35,\n",
      "            \"description\": \"Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lung\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2014-00627\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02101853_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"First relapse of B-ALL, allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular; extramedullary sites are limited to the CNS and testicles\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"No waiting period for patients who relapse while receiving standard maintenance therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients who relapse on frontline therapy in phases other than maintenance must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Biologic (anti-neoplastic) agent: at least 7 days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Stem cell transplant or rescue: patient has not had a prior stem cell transplant or rescue\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patient has not had prior treatment with blinatumomab\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"With the exception of intrathecal chemotherapy (methotrexate strongly preferred; cytarabine is permissible) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status, patient has not received prior relapse-directed therapy (i.e., this protocol is intended as the INITIAL treatment of first relapse)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\\r\\n* 1 to < 2 years: =< 0.6 mg/dL\\r\\n* 2 to < 6 years: =< 0.8 mg/dL\\r\\n* 6 to < 10 years: =< 1 mg/dL\\r\\n* 10 to < 13 years: =< 1.2 mg/dL\\r\\n* 13 to < 16 years: =< 1.5 mg/dL (males) and =< 1.4 mg/dL (females)\\r\\n* >= 16 years: =< 1.7 mg/dL (males) and =< 1.4 mg/dL (females)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Direct bilirubin < 3.0 mg/dL\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Shortening fraction of >= 27% by echocardiogram, or\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Ejection fraction of >= 50% by radionuclide angiogram\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"All patients and/or their parent or legal guardian must sign a written informed consent\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients with Philadelphia chromosome positive/breakpoint cluster region protein (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1)+ ALL are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients with T-lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (T-LL) are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Patients with B-lymphoblastic lymphoma (B-LL) are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Patients with known optic nerve and/or retinal involvement are not eligible; patients who are presenting with visual disturbances should have an ophthalmologic exam and, if indicated, a magnetic resonance imaging (MRI) to determine optic nerve or retinal involvement\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Patients with known human immunodeficiency virus (HIV) infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Lactating females who plan to breastfeed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients with pre-existing significant central nervous system pathology that would preclude treatment with blinatumomab, including: history of severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination/movement disorder, or autoimmune disease with CNS involvement are not eligible; patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible; (patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients with uncontrolled seizure disorder are not eligible; (patients with seizure disorders that do not require antiepileptic drugs, or are well controlled with stable doses of antiepileptic drugs remain eligible)\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"30 Years\",\n",
      "          \"max_age_number\": 30,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 30,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"1 Years\",\n",
      "          \"min_age_number\": 1,\n",
      "          \"min_age_in_years\": 1\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lymphoid Leukemia\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2014-00631\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02135042_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis\\r\\n* Patients must have detectable pretreatment plasma EBV DNA, determined by the central lab prior to Step 2 registration\\r\\n* For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs within 28 days prior to Step 1 registration: that test result can be used for eligibility without the need for re-testing; to use this test result for eligibility, the central lab must enter the test result through the pathology portal\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:\\r\\n* History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration\\r\\n* Evaluation of tumor extent required within 28 days prior to registration:\\r\\n** Magnetic resonance imaging (MRI) of the nasopharynx and neck; or computed tomography (CT) of the nasopharynx and neck with =< 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement). \\r\\n*** Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous slices with contrast and be read by a radiologist\\r\\n* To rule out distant metastasis, patients must undergo the following imaging within 28 days prior to registration:\\r\\n** A CT scan with contrast of the chest and abdomen (required), and the pelvis (optional), or a total body PET/CT scan (non-contrast PET/CT is acceptable)\\r\\n** A bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Zubrod performance status 0-1 within 21 days prior to registration\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Platelets >= 100,000 cells/mm^3 (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Hemoglobin >= 8.0 g/dl (within 21 days prior to registration) (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x institutional ULN (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Alkaline phosphatase =< 1.5 x institutional ULN (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Serum creatinine =< 1.5 mg/dl or calculated creatinine clearance (CC) >= 50 ml/min determined by 24-hour urine collection or estimated by Cockcroft-Gault formula (within 21 days prior to registration)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patient must provide study specific informed consent prior to study entry, including the mandatory pre-treatment plasma EBV DNA assay\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; however, at least 6-weeks recovery is necessary if the last regimen included nitrosourea or mitomycin\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \">= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Severe, active co-morbidity, defined as follows:\\r\\n* Major medical or psychiatric illness, which in the investigator\\u2019s opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy\\r\\n* Unstable angina and/or uncontrolled congestive heart failure within past 6 months\\r\\n* Myocardial infarction within the last 6 months\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration\\r\\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Prior allergic reaction to the study drug(s) involved in this protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": false,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Patients with undetectable pre-treatment plasma EBV DNA\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Lip, Oral Cavity and Pharynx\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2014-00635\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"trials\",\n",
      "    \"_type\": \"_doc\",\n",
      "    \"_id\": \"NCT02115282_update\",\n",
      "    \"_score\": 1.0,\n",
      "    \"_source\": {\n",
      "      \"eligibility\": {\n",
      "        \"unstructured\": [\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 1,\n",
      "            \"description\": \"Estrogen receptor (ER) and/or progesterone receptor (PR) positive histologically confirmed adenocarcinoma of the breast with staining of >= 1% cells will be considered positive; receptor status may be based on any time during treatment prior to study randomization, and from any site (i.e. primary, recurrent, or metastatic)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 2,\n",
      "            \"description\": \"Patients whose tumors have HER2 immunohistochemistry (IHC) 3+, in situ hybridization (ISH) >= 2.0, or average HER2 copy number >= 6.0 signals per cell are not eligible; receptor status may be based on any time during treatment prior to study randomization, and from any site (i.e. primary, recurrent, or metastatic)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 3,\n",
      "            \"description\": \"Patients must have measurable or non-measurable stage III/locally advanced or metastatic carcinoma of the breast where local therapy with curative intent is not possible; lesions must be evaluated =< 4 weeks prior to study randomization; diagnostic-quality computed tomography (CT) scans with both oral and intravenous (IV) contrast are the expected radiologic method, unless an alternative is approved\\r\\n* NOTE: Where baseline imaging has already been performed =< 6 weeks prior to study randomization, repeat imaging may not be required\\r\\n* NOTE: As of October 16, 2016, accrual of new patients having non-measurable disease has stopped; the planned accrual for this target population has been reached\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 4,\n",
      "            \"description\": \"Pre/peri- and postmenopausal women and all men are eligible for this trial; postmenopausal is defined as:\\r\\n* Age >= 55 years and one year or more of amenorrhea\\r\\n* Age < 55 years and one year or more of amenorrhea, with estradiol < 20 pg/ml\\r\\n* Age < 55 with prior hysterectomy but intact ovaries, with estradiol < 20 pg/ml\\r\\n* Prior bilateral oophorectomy\\r\\n** NOTE: Women who do not fit the criteria for being postmenopausal as above are deemed pre-or peri-menopausal; pre/perimenopausal women and all men can enroll provided they agree to receive concomitant luteinizing hormone-releasing hormone (LHRH) agonist; pre/perimenopausal women must have commenced treatment with LHRH agonist at least 4 weeks prior to randomization; if patients have received alternative LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 5,\n",
      "            \"description\": \"Sexually active males and pre/perimenopausal women must agree to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 3 months after discontinuation of therapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 6,\n",
      "            \"description\": \"Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study =< 2 weeks prior to randomization\\r\\n* A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 7,\n",
      "            \"description\": \"Patients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 8,\n",
      "            \"description\": \"Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\\r\\n* NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 9,\n",
      "            \"description\": \"Patients must meet at least one of the following criteria:\\r\\n* Disease progression any time after non-steroidal AI use in the advanced disease setting\\r\\n* Relapse while on or within =< 12 months of end of adjuvant non-steroidal AI therapy with or without prior endocrine therapy for advanced disease\\r\\n* NOTE: In either setting, treatment with any prior endocrine therapy must be completed >= 2 weeks prior to cycle 1 day 1 (C1D1) of study treatment with the exception of exemestane which is permitted in the advanced disease setting within =< 4 weeks immediately prior to C1D1; prior adjuvant exemestane is allowed if the disease free interval is > 12 months from the discontinuation of exemestane; prior faslodex, everolimus, palbociclib or other cyclin-dependent kinase (CDK) inhibitor (e.g. ribociclib, abemaciclib) use are allowed and must have been completed >= 2 weeks prior to C1D1; failure to adhere to this washout guideline will result in a protocol violation\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 10,\n",
      "            \"description\": \"Patients may have received only one prior chemotherapy regimen for metastatic disease provided treatment was completed >= 3 weeks prior to randomization\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 11,\n",
      "            \"description\": \"Patients may be treated with bone modifying agents such as bisphosphonates or RANK-ligand agents (e.g. denosumab) per American Society of Clinical Oncology (ASCO) guidelines; whenever possible, patients requiring bone modifying agents should start treatment >= 7 days prior to study therapy and should continue the same agent throughout study unless clinically compelled to change\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 12,\n",
      "            \"description\": \"Prior radiotherapy must in general have been completed >= 2 weeks prior to randomization and patients must have recovered from the toxicity of the radiation\\r\\n* NOTE: Patients may receive concurrent radiation therapy to painful sites of bony disease or areas of impending fracture as long as sites of measurable or non-measurable disease outside the radiation therapy port are available to follow\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 13,\n",
      "            \"description\": \"Patients must NOT receive concurrent anti-cancer therapy or investigational agent unless specified in protocol\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 14,\n",
      "            \"description\": \"Patients must NOT be receiving valproic acid, an histone deacetylase (HDAC) inhibitor, and may not have previously received any HDAC inhibitor prior to enrollment (e.g. valproic acid, entinostat, vorinostat) unless discussed with the study chair; patients must not have received prior HDAC therapy for the treatment of their malignancy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 15,\n",
      "            \"description\": \"Patients must have no known allergies to exemestane, entinostat, or medications that have a benzamide structure (e.g., tiapride, remoxipride, clebropride)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 16,\n",
      "            \"description\": \"Patients must NOT suffer from medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, or assessment of response or anticipated toxicities; this includes uncontrolled intercurrent illness including, but not limited to ongoing or active infection\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 17,\n",
      "            \"description\": \"Patients must have recovered from all clinically relevant adverse events to grade 1 or baseline due to previous agents administered (except alopecia)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 18,\n",
      "            \"description\": \"Patients must have adequate hematologic, liver and renal function =< 28 days prior to randomization\\r\\n* NOTE: It is preferred that laboratory values for eligibility be assessed after the last dose of prior treatment, especially in cases where most-recent treatment prior to study entry is chemotherapy\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 19,\n",
      "            \"description\": \"Hemoglobin (HgB) >= 9.0 g/dL (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 20,\n",
      "            \"description\": \"Platelet count >= 100,000/mcL (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 21,\n",
      "            \"description\": \"Absolute neutrophil count >= 1,500/mcL (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 22,\n",
      "            \"description\": \"Creatinine =< 2.0 mg/dL (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 23,\n",
      "            \"description\": \"Total bilirubin < 1.5 x institutional upper limit of normal (=< 3 mg/dL in case of Gilbert\\u2019s syndrome) (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 24,\n",
      "            \"description\": \"Transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x institutional upper limit normal (=< 28 days prior to randomization)\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 25,\n",
      "            \"description\": \"Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 26,\n",
      "            \"description\": \"Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 27,\n",
      "            \"description\": \"Patients must have a life expectancy >= 12 weeks\"\n",
      "          },\n",
      "          {\n",
      "            \"inclusion_indicator\": true,\n",
      "            \"display_order\": 28,\n",
      "            \"description\": \"Patients must be able to swallow tablets\"\n",
      "          }\n",
      "        ],\n",
      "        \"structured\": {\n",
      "          \"max_age\": \"999 Years\",\n",
      "          \"max_age_number\": 999,\n",
      "          \"min_age_unit\": \"Years\",\n",
      "          \"max_age_unit\": \"Years\",\n",
      "          \"max_age_in_years\": 999,\n",
      "          \"gender\": \"BOTH\",\n",
      "          \"min_age\": \"18 Years\",\n",
      "          \"min_age_number\": 18,\n",
      "          \"min_age_in_years\": 18\n",
      "        }\n",
      "      },\n",
      "      \"anatomic_sites\": [\n",
      "        \"Breast - Female\",\n",
      "        \"Breast - Male\"\n",
      "      ],\n",
      "      \"nci_id\": \"NCI-2014-00746\"\n",
      "    }\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "# Importing the trials to test on the patient\n",
    "url = \"https://datawookies.c2labs.com/es/trials/_search\"\n",
    "\n",
    "#Url for connecting to the ELK stack to retrieve the JSON data\n",
    "#url = \"http://20.42.25.27:9200/trials/_doc/NCT00719303_update\"\n",
    "\n",
    "headers = {'accept': '*/*'}\n",
    "\n",
    "data = {\"_source\": [\"nci_id\",\"eligibility\", \"anatomic_sites\"],\"size\":50,\"query\": {\"bool\" : {\"must\" : {\"match_all\" : {}},\"filter\" : {\"geo_distance\" : {\"distance\" : \"50km\",\"sites.org_coordinates\" : \"40,-90\"}}}}}\n",
    "\n",
    "\n",
    "# Getting the JSON data\n",
    "response = requests.get(url, json=data, headers=headers)\n",
    "\n",
    "# Instantiate an empty list so that we can load the trials inclusion criteria descriptions\n",
    "trials = []\n",
    "\n",
    "# The if statement is used to catch data in the case no data is loaded. Status code 200 = data was found\n",
    "# The results variable is the set of descriptions extracted from the original JSON data structure. \n",
    "# We access it by accessing each specific key within the nested dictionaries and when they are assigned to this variabe,\n",
    "# they are still in JSON format\n",
    "if (response.status_code == 200):\n",
    "    results = response.json()['hits']['hits'] \n",
    "    \n",
    "    # Here we extract the values from the descriptions key in the results variable and add each value to a list to make it \n",
    "    # easier to navigate through the data structure\n",
    "    for item in results:\n",
    "        trials.append(item)\n",
    "\n",
    "# This is what prints if there is no data\n",
    "else:\n",
    "\n",
    "    print (\"No Data\")\n",
    "\n",
    "print(json.dumps(trials, indent=2))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "IOPub data rate exceeded.\n",
      "The notebook server will temporarily stop sending output\n",
      "to the client in order to avoid crashing it.\n",
      "To change this limit, set the config variable\n",
      "`--NotebookApp.iopub_data_rate_limit`.\n",
      "\n",
      "Current values:\n",
      "NotebookApp.iopub_data_rate_limit=1000000.0 (bytes/sec)\n",
      "NotebookApp.rate_limit_window=3.0 (secs)\n",
      "\n"
     ]
    }
   ],
   "source": [
    "a_sites = []\n",
    "ids = []\n",
    "all_descriptions = [] \n",
    "for trial in trials:\n",
    "    nci_id = trial['_source']['nci_id']\n",
    "    ids.append(nci_id) \n",
    "    sites = (trial['_source']['anatomic_sites'])\n",
    "    results = trial['_source']['eligibility']['unstructured']\n",
    "    descriptions = []\n",
    "    a_sites.append(sites)\n",
    "    for item in results:\n",
    "        descriptions.append(item.get('description', ''))\n",
    "    all_descriptions.append(descriptions)\n",
    "    print(all_descriptions)\n",
    "id_and_site = dict(zip(ids,sites))\n",
    "#print(id_and_site)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Patients with a histological diagnosis of epithelial ovarian cancer fallopian tube or primary peritoneal carcinoma clinical stage II III or IV at diagnosis', 'Patients with the following histologic epithelial cell types are eligible serous adenocarcinoma endometrioid adenocarcinoma mucinous adenocarcinoma undifferentiated carcinoma clear cell adenocarcinoma mixed epithelial carcinoma transitional cell carcinoma malignant Brenner’s tumor or adenocarcinoma not otherwise specified NOS however the histologic features of the tumor must be compatible with a primary Mullerian epithelial adenocarcinoma', 'Patients must have completed all primary chemotherapy and consolidation therapy if administered at least 6 weeks and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy chemo or biological therapy', 'Patients must have achieved a documented complete response to treatment based on normal cancer antigen CA125 per the institution’s upper limit of normal and computed tomography CT scan or magnetic resonance imaging MRI with contrast ie there must be no clinical evidence of persistent or recurrent disease based on CA125 and CT scan or MRI with contrast', 'Patients must have a Gynecologic Oncology Group GOG performance grade of 0 1 or 2', 'Patients must not be currently enrolled in an ongoing participating for 6 months or longer medically prescribed diet or physical activity regimen', 'Patients must have no other chronic disease that would preclude randomization into a lifestyle intervention trial such diseases include recent myocardial infarction or unstable angina in the previous 6 months chronic hepatitis rheumatoid disease renal or hepatic diseasedysfunction and diabetics receiving insulin or other clinical condition limiting ability to walk recent leg fracture significant osteoarthritis related orthopedic conditions degenerative neurological conditions etc', 'Patients must not have a serious psychiatric illness eg lifetime bipolar disorder schizophrenia or other psychosis serious personality disorder severe major depressive disorder or recent suicide or psychiatric hospitalization previous 12 months or a history of an eating disorder anorexia nervosa or bulimia nervosa', 'Patients must complete all preentry assessments', 'Patients must have signed an approved informed consent and authorization permitting release of personal health information', 'Patients must be willing to provide name and appropriate telephone contact information and be willing to be contacted periodically via telephone by The University of Arizona Cancer Center AZCC staff for completion of individualized lifestyle intervention coaching completion of the Pittsburgh Sleep Quality Index and for clarification of patientcompleted responses if necessary patient must be willing to have Arizona Food Frequency Questionnaire AFFQ Arizona Physical Activity Questionnaire APAQ baseline questionnaire and personal contact information sent to AZCC', 'Patients with GOG performance grade of 3 or 4', 'Patients may not have a history of other invasive malignancies within the last five years with the exception of nonmelanoma skin cancer or stage 1A endometrioid adenocarcinoma of the uterus', 'Patients diagnosed with chronic diseaseillness precluding their participation ie diabetics receiving insulin myocardial infarction or unstable angina within previous 6 months chronic hepatitis rheumatoid disease renal or hepatic diseasedysfunction', 'Patients with a histological diagnosis of clinical stage I epithelial ovarian cancer fallopian tube or primary peritoneal carcinoma', 'Patients who are currently undergoing treatment primary or consolidation for stage II III or IV ovarian fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks ago', 'Patients with a life expectancy of less than one year', 'Patients with body mass index BMI < 20 kgm2', 'Vegan vegetarians', 'Patients enrolled in a weight loss program or who are taking weight loss medications or dietary supplements and are unwilling to discontinue', 'Patients who have participated in a marathon triathlon or other endurancerelated physical activity within the previous 24 months', 'Patients who have had surgery for weight loss\\r\\n Note women will not be excluded if their baseline lifestyle assessment indicates a healthy eating and moderate physical activity with the exception of the exclusion criteria above'], ['Pathologically histologically proven diagnosis of squamous cell carcinoma including variants such as verrucous carcinoma spindle cell carcinoma carcinoma not otherwise specified NOS etc of the headneck oral cavity oropharynx or larynx note hypopharynx primaries are excluded', 'Clinical stage T1 N12 or T24a N02 M0 including no distant metastases based upon the following minimum diagnostic workup\\r\\n General history and physical examination by a radiation oncologist andor medical oncologist within 8 weeks prior to registration\\r\\n Examination by an ear nose and throat ENT or head  neck surgeon within 8 weeks prior to registration a laryngopharyngoscopy mirror andor fiberoptic andor direct procedure is recommended but not required\\r\\n Chest xray at a minimum or chest computed tomography CT scan with or without contrast or CTpositron emission tomography PET of chest with or without contrast within 8 weeks prior to registration', 'Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration with surgical pathology demonstrating one or more of the following “intermediate” risk factors\\r\\n Perineural invasion\\r\\n Lymphovascular invasion\\r\\n Single lymph node > 3 cm or >= 2 lymph nodes all < 6 cm no extracapsular extension\\r\\n Close margins of resection defined as cancer extending to within 5 mm of a surgical margin andor an initially focally positive margin that is subsequently superseded by intraoperative negative margins similarly patients whose tumors had focally positive margins in the main specimen but negative margins from reexcised samples in the region of the positive margin are eligible for questions or ambiguities about an individual case contact Dr Machtay andor Dr Holsinger prior to enrolling the patient\\r\\n Pathologically confirmed T3 or T4a primary tumor for questions or ambiguities about an individual case contact Dr Machtay andor Dr Holsinger prior to enrolling the patient\\r\\n T2 oral cavity cancer with > 5 mm depth of invasion', 'Zubrod performance status 01', 'Absolute granulocyte count AGC >= 1500mm³', 'Platelet count >= 100000mm³', 'Hemoglobin >= 80 gdL note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 80 gdl is acceptable', 'Total bilirubin < 2 x institutional upper limit of normal ULN', 'Aspartate aminotransferase AST or alanine aminotransferase ALT < 3 x institutional ULN', 'Serum creatinine < 2 x institutional ULN or creatinine clearance CC >= 50 mLmin determined by 24hour collection or estimated by CockcroftGault formula', 'Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential', 'The following assessments are required within 2 weeks prior to the start of registration sodium Na potassium K chloride Cl glucose calcium Ca magnesium Mg and albumin note patients with an initial magnesium < 05 mmolL 12 mgdl may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium andor oral magnesium supplementation eg magnesium oxide at the investigator’s discretion', 'Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control', 'Patients must provide study specific informed consent prior to study entry including consent for mandatory tissue submission for EGFR and for oropharyngeal patients HPV analyses', 'Prior invasive malignancy except nonmelanomatous skin cancer unless disease free for a minimum of 3 years noninvasive cancers for example carcinoma in situ of the breast oral cavity or cervix are all permissible are permitted even if diagnosed and treated < 3 years ago patients with simultaneous primaries or bilateral tumors are excluded with the exception of patients with bilateral tonsil cancers or patients with primary tumor T12 nearby lymph nodes N0 metastasis M0 resected differentiated thyroid carcinoma who are eligible', 'Per the operative andor pathology report positive margins defined as tumor present at the cut or inked edge of the tumor nodal extracapsular extension andor gross residual disease after surgery note patients whose tumors had focally positive margins in the main specimen but negative margins from reexcised samples in the region of the positive margin are eligible for questions or ambiguities about an individual case contact Dr Machtay andor Dr Holsinger prior to enrolling the patient', 'Prior systemic chemotherapy or antiEGF therapy for the study cancer note prior chemotherapy or antiEGF therapy for a different cancer is allowable', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within 6 months prior to registration\\r\\n Transmural myocardial infarction within 6 months prior to registration\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration\\r\\n Hepatic insufficiency resulting in clinical jaundice andor coagulation defects note however that laboratory tests for coagulation parameters are not required for entry into this protocol\\r\\n Acquired immune deficiency syndrome AIDS based upon current Centers for Disease Control and Prevention CDC definition note human immunodeficiency virus HIV testing is not required for entry into this protocol protocolspecific requirements may also exclude immunocompromised patients\\r\\n Grade 34 electrolyte abnormalities CTCAE v 4\\r\\n Serum calcium ionized or adjusted for albumin < 7 mgdl 175 mmolL or > 125 mgdl > 31 mmolL despite intervention to normalize levels\\r\\n Glucose < 40 mgdl < 22 mmolL or > 250 mgdl > 14 mmolL\\r\\n Magnesium < 09 mgdl < 04 mmolL or > 3 mgdl > 123 mmolL despite intervention to normalize levels\\r\\n Potassium < 30 mmolL or > 6 mmolL despite intervention to normalize levels\\r\\n Sodium < 130 mmolL or > 155 mmolL despite intervention to normalize levels', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception', 'Prior allergic reaction to cetuximab'], ['PREREGISTRATION INCLUSION CRITERIA', 'United States US and Canadian sites\\r\\n This review is mandatory prior to registration to confirm eligibility patients must be willing to submit tissue samples for mandatory central pathology review submission it should be initiated as soon after surgery as possible', 'Tissue must have been determined to have local 1p9q codeletion and IDH mutation prior to submission for central path review\\r\\n Tumor tissue must show codeletion of chromosomes 1p and 19q for eligibility the 1p19q analysis results will be accepted from the local site as determined by either a locally available or reference laboratory for US must be Clinical Laboratory Improvement Act CLIA certified acceptable methods for determination of 1p19q loss include fluorescent insitu hybridization FISH by genomic sequencing or methylomic analyses US and Canadian sites must send a copy of the official report to the pathology coordinator and quality assurance specialist QAS\\r\\n Tumor must also show evidence of IDH mutation by immunohistochemistry or genomic analyses this should be performed at the local site US performed in a CLIA certified laboratory the site must send a copy of the official report to the pathology coordinator and QAS', 'REGISTRATION INCLUSION CRITERIA', 'Newly diagnosed and =< 3 months from surgical diagnosis patients are also eligible if they have had a prior surgical procedure > 3 months earlier for low grade glioma as long as the patient has not received prior radiation or prior chemotherapy', 'Histological evidence of World Health Organization WHO grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p19q loss and the presence of an either IDH1 or IDH2 both as established by a local or referenced laboratory qualified for the study\\r\\n Note mixed gliomas are eligible regardless of the degree of astrocytic or oligodendrocytic predominance as long as the tumor is also codeleted for 1p and 19q', 'Patients with codeleted low grade gliomas must also be considered “high risk” by exhibiting one or more of the following characteristics\\r\\n Age >= 40 and any surgical therapy\\r\\n Age < 40 with prior and subtotal resection or biopsy ie anything less than gross total resection\\r\\n Documented growth following prior surgery NOTE patients with prior surgery cannot have received prior radiation chemotherapy or targeted therapy\\r\\n Intractable seizures', 'Surgery partial or gross total resection or biopsy must be performed >= 2 weeks prior to registration patient must have recovered adequately from the effects of surgery', 'Absolute neutrophil count ANC >= 1500mm3 obtained =< 21 days prior to registration', 'Platelet PLTs count >= 100000mm3 obtained =< 21 days prior to registration', 'Hemoglobin Hgb > 90 gdL obtained =< 21 days prior to registration', 'Total bilirubin =< 15 x institutional upper limit of normal ULN obtained =< 21 days prior to registration', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 3 x ULN obtained =< 21 days prior to registration', 'Creatinine =< 15 x ULN obtained =< 21 days prior to registration', 'Negative serum or urine pregnancy test done =< 7 days prior to registration for women of childbearing potential only', 'Willingness and ability to personally complete neurocognitive testing without assistance and willingness to complete the QOL testing either personally or with assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS of 0 1 or 2', 'Written informed consent', 'Willingness to return to enrolling institution for followup during the active monitoring phase that is the active treatment and observation portion of the study patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose', 'Willingness to allow the provision of tissue samples for correlative research as long as adequate tissues are available patients will not be excluded from participation in the study if they are willing to allow provision of tissues for the correlative research but there are insufficient quantities of tissue for the correlative analyses eg a patient otherwise eligible and willing who had biopsy only\\r\\nWillingness to allow the provision of blood samples for correlative research patients are not excluded from participation in the study if they are willing to provide the mandatory biospecimens for translationalcorrelative research but for logistical reasons the specimenss were not obtainable or if the volume collected was insufficient', 'The following categories are ineligible\\r\\n Pregnant women\\r\\n Nursing women\\r\\n Men or women of childbearing potential who are unwilling to employ adequate contraception or contraceptive method during this study and 6 months following the completion of chemotherapy treatments', 'History of prior radiation therapy or chemotherapy for glioma note patients who have a history of prior low grade glioma with or without a distant history of prior surgery for that glioma but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the study', 'Comorbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens', 'Concomitant serious immunocompromised status other than that related to concomitant steroids that would compromise the safety of the patient on the study', 'Patients known to be human immunodeficiency virus HIV positive and currently receiving retroviral therapy are not eligible note patients known to be HIV positive but without clinical evidence of an immunocompromised state are eligible for the study', 'Uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illnesssocial situations that would limit compliance with study requirements', 'Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm', 'Other active malignancy within 5 years of registration exceptions nonmelanotic skin cancer or carcinomainsitu of the cervix note if there is a history of prior malignancy the patient is not eligible if they are receiving other specific treatment with the exclusion of hormonal therapy or Her2 inhibitors for their cancer or if they have received prior total body irradiation which included the brain', 'History of myocardial infarction =< 6 months or congestive heart failure requiring use of ongoing maintenance therapy for lifethreatening ventricular arrhythmias', 'Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis'], ['Newly diagnosed previously untreated 1 M0 medulloblastoma with > 15 cm2 residual 2 M+ medulloblastoma patients with diffusely anaplastic medulloblastoma are eligible regardless of Mstage or residual tumor\\r\\n As of amendment  2 enrollment of patients with supratentorial PNET has been discontinued\\r\\n All patients with M4 disease are not eligible', 'A preoperative magnetic resonance imaging MRI scan of the brain with and without contrast is required NOTE computed tomography CT scans are NOT sufficient for study eligibility\\r\\n Postoperative head MRI scan with and without contrast preferably within 72 hours postsurgery for patients who undergo stereotactic biopsy only either a pre or postoperative MRI is sufficient for patients with M2 and M3 disease a postop MRI is strongly encouraged but not mandatory\\r\\n Spinal MRI imaging with and without gadolinium is required within 10 days of surgery if done preoperatively or within 28 days of surgery if done postoperatively for posterior fossa tumors preoperative MRI scans are preferred', 'Lumbar cerebrospinal fluid CSF cytology examination must be obtained preoperatively or within 31 days following surgery the optimal time for obtaining CSF is prior to surgery or 13 weeks following surgery ventricular CSF either pre or postop may be used only if a postoperative spinal tap is contraindicated if a spinal tap is contraindicated and there is no ventricular CSF available then CSF cytology can be waived for patients with supratentorial tumors or if there is documentation of spinal subarachnoid metastases M3 patients who are categorized as M1 must have either an intraoperative positive CSF via lumbar puncture at the end of the procedure or a positive lumbar CSF obtained > 7 days postoperatively', 'Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks', 'No previous chemotherapy or radiation therapy', 'Corticosteroids should not be used during chemotherapy administration as an antiemetic', 'Selected strong inhibitors of cytochrome P450 family 3 subfamily A polypeptide 4 cytochrome P450 3A4 include azole antifungals such as fluconazole voriconazole itraconazole ketoconazole and strong inducers include drugs such as rifampin phenytoin phenobarbitol carbamazepine and St John’s wort the use of these drugs should be avoided with vincristine vincristine sulfate', 'CYP450 3A4 stimulators or inhibitors should be avoided or used with great caution when taking cyclophosphamide aprepitant should also be used with caution with etoposide or vincristine chemotherapy', 'Cisplatin should be used with caution with nephrotoxic drug aminoglycoside should be avoided or used with caution during or shortly after cisplatin administration and concomitant use with amphotericin B should probably also be avoided patients receiving cisplatin and other potentially ototoxic drugs such as aminoglycoside or loop diuretics concomitantly should be closely monitored for signs of ototoxicity\\r\\n Plasma levels of anticonvulsant agents should be monitored and doses adjusted during therapy with cisplatin', 'No other experimental therapy is permitted while on study', 'Creatinine clearance or radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 OR a serum creatinine based on agegender as follows            \\r\\n 08 mgdL 2 to < 6 years of age\\r\\n 10 mgdL 6 to < 10 years of age\\r\\n 12 mgdL 10 to < 13 years of age\\r\\n 15 mgdL male or 14 mgdL female 13 to < 16 years of age\\r\\n 17 mgdL male or 14 mgdL female >= 16 years of age', 'Total bilirubin < 15 x upper limit of normal ULN for age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST or serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 25 x upper limit of normal ULN for age for patients on antiseizure medications SGOT AST or SGPT ALT must be < 5 x ULN', 'Absolute neutrophil count ANC >= 1000uL', 'Platelets >= 100000uL untransfused', 'Hemoglobin >= 8 gdl may be transfused', 'Female patients who are postmenarchal must have a negative pregnancy test lactating female patients must agree not to breastfeed while on this trial males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method', 'All patients andor their parents or legal guardians must sign a written informed consent', 'All institutional Food and Drug Administration FDA and National Cancer Institute NCI requirements for human studies must be met'], ['Participant with histologic confirmation of newly diagnosed squamous cell carcinoma SCC of the head and neck', 'Participant with unilateral or bilateral neck dissection planned for care an N0 neck must be planned to be dissected for the patient to be eligible the N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned', 'Participant with confirmed head and neck SCC\\r\\n CT andor MR imaging has been completed within six 6 weeks prior to enrollment even if the SCC diagnosis has been made via other methods and will be submitted to American College of Radiology Imaging Network ACRIN\\r\\n Simultaneous diagnostic CT with PET will not be excluded but in such cases PET cannot be used as part of the criteria to define the N0 neck as required for entrance to the trial\\r\\n If sites received CT andor MR images from institutions other than their own ACRIN recommends a reread by a local neuroradiologist to ensure compliance with protocol eligibility requirements', 'Participant with at least one neck that is clinically N0 as defined by clinical exam physical exam with CT andor MRI as the gold standard of the N0 neck stages T2 T3 or T4 N0–N3 excluding N2c for bilateral disease based on criteria from the American Joint Commission on Cancer', 'Participant in whom it may be considered a viable clinical option to perform neck dissection when primary cancers are at high risk for neck metastasis see definition above\\r\\n These will include 1 oral cavity cancer 2 oropharynx cancer including base of tongue and tonsil cancers 3 larynx cancer or 4 supraglottic cancer', 'Participant willing to provide a written informed consent', 'Patient who is pregnant andor breastfeeding', 'Patient with sinonasal carcinoma', 'Patient with tumors in the head and neck that are not SCC', 'Patient with salivary gland malignancies', 'Patient with thyroid cancers', 'Patient with advanced skin cancers', 'Patient with nasopharyngeal carcinoma', 'Patient with poorly controlled diabetes defined as fasting glucose level > 200 mgdL optimally participants will have glucose < 150 mgdL despite attempts to improve glucose control by fasting duration and adjustment of medications', 'Patient not a candidate for surgery neck dissection because of an underlying medical condition', 'Patient who weighs more than the weight limit for the PET table'], ['Patients must have a histologically confirmed diagnosis of node positive 13 nodes invasive breast carcinoma with positive estrogen andor progesterone receptor status and negative HER2 status estrogen and progesterone receptor positivity must be assessed according to American Society of Clinical Oncology ASCOCollege of American Pathologists CAP guidelines as either estrogen receptor ER or progesterone receptor PR >= 1 positive nuclear staining HER2 test result negativity must be assessed as per ASCOCAP 2013 guidelines using immunohistochemistry IHC in situ hybridization ISH or both HER2 is negative if a single test or all tests performed in a tumor specimen show a IHC negative 0 or 1+ or b ISH negative using single probe or dual probe average HER2 copy number < 40 signals per cell by single probe or HER2CEP ration < 20 with an average copy number < 40 signals per cell by dual probe if HER2 IHC is 2+ evaluation for gene amplification ISH must be performed and the ISH must be negative ISH is not required if IHC is 0 or 1+ HER2 equivocal is not eligible', 'Patients with multifocal multicentric and synchronous bilateral breast cancers are allowed\\r\\n Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant NOTE the Oncotype DX testing must be completed on the largest lesion\\r\\n Multicentric disease is defined as more than one invasive cancer >= 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants NOTE Oncotype DX testing should be completed on all tumors and the determination for eligibility should be made on the highest recurrence score\\r\\n Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes axillary or intramammary in at least one breast diagnosed within 30 days of each other NOTE the Oncotype DX testing should be completed on both tumors and the tumor with the highest recurrence score should be used', 'Patients will have undergone axillary staging by sentinel node biopsy or axillary lymph nodes dissection ALND patients must have at least one but no more than three known positive lymph nodes pN1a pN1b or pN1c patients with micrometastases as the only nodal involvement pN1mi are not eligible patients with positive sentinel node are not required to undergo full axillary lymph node dissection this is at the discretion of the treating physician axillary node evaluation is to be performed per the standard of care at each institution', 'Patients must not have inflammatory breast cancer and must not have metastatic disease', 'Patients with a prior diagnosis of contralateral ductal carcinoma in situ DCIS are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation prior partial breast irradiation including brachytherapy is not allowed patients with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received radiation to that breast are not eligible', 'Patients must have had either breastconserving surgery with planned radiation therapy or total mastectomy with or without planned postmastectomy radiation patients must have clear margins from both invasive breast cancer and DCIS as per local institutional guidelines lobular carcinoma in situ LCIS at the margins is allowed', 'Registration of patients who have not yet undergone Oncotype DX screening must occur no later than 56 days after definitive surgery for all patients Step 2 Registration must occur within 84 days after definitive surgery if the Oncotype DX Breast Cancer Assay has not been performed patients must be willing to submit tissue samples for testing to determine the Recurrence Score value a representative block or unstained sections from the representative block are sent directly to Genomic Health for Oncotype DX Breast Cancer Assay which will be performed according to the standard commercial process\\r\\n If the Oncotype DX Recurrence Score is already known and is 25 or less the patient must be registered to Step 2 immediately following Step 1 registration if the Oncotype DX Recurrence Score is already known and is greater than 25 the patient is ineligible', 'Patients must have a complete history and physical examination within 28 days prior to registration', 'Patients must have a performance status of 02 by Zubrod criteria', 'Patients must be able to receive taxane andor anthracycline based chemotherapy', 'Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registration', 'Patients must not require chronic treatment with systemic steroids inhaled steroids are allowed or other immunosuppressive agents', 'Patients must not have received an aromatase inhibitor AI or a selective estrogen receptor modulator SERM such as tamoxifen or raloxifene within 5 years prior to registration', 'Patients must not be pregnant or nursing women of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol heshe is responsible for beginning contraceptive measures', 'No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has been diseasefree for 5 years', 'The Quality of Life and Economic Substudy is permanently closed to accrual effective 12112 patients who consented to QOL prior to 12112 should continue to complete QOL forms per their expectation report patients who are able to complete a questionnaire in English must be offered the opportunity to participate in the Quality of Life and Economic Substudy The Quality of Life and Economic Substudy is available to US INSTITUTIONS ONLY patients who are not able to complete a questionnaire in English are registered to S1007 without participating in the Quality of Life and Economic Substudy\\r\\n Patients who consent to participate in the Quality of Life and Economic Substudy and who do not yet know the results of their Oncotype DX screening must agree to complete the S1007 HealthRelated Quality of Life Questionnaire Enrollment between 14 days prior to and 7 days after Step 1 Registration\\r\\n Patients who consent to participate in the Quality of Life and Economic Substudy and who do already know their Oncotype DX Recurrence Score and it is 25 or less will proceed to Step 2 Registration without completing the S1007 HealthRelated Quality of Life Questionnaire Enrollment Form but will complete the S1007 HealthRelated Quality of Life Questionnaire Randomized Study Form', 'Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines for Step 1 registration of patients who have not yet submitted specimens for the Oncotype DX Breast Cancer Assay the appropriate consent form is the Step 1 Consent Form for both Step 1 and Step 2 registration of patients whose Recurrence Score is already known and is 25 or less the appropriate consent form is the Step 2 Consent Form', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system', 'STEP 2 REGISTRATION', 'Recurrence score RS by Oncotype DX must be =< 25', 'Step 2 Registration must take place within 84 days after definitive surgery patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomization', 'Patients randomized to either arm may also coenroll in phase III trials that compare local therapies or compare systemic therapies such as chemotherapy if randomized to Arm I of S1007', 'The Quality of Life and Economic Substudy is permanently closed to accrual effective 12112 patients at US INSTITUTIONS who consent to participate in the Quality of Life and Economic Substudy must agree to complete the S1007 HealthRelated Quality of Life Questionnaire Randomized Study Form after Recurrence Score results and randomized treatment status are known but before treatment has been initiated', 'Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines for all patients the appropriate consent form for this registration is the Step 2 Consent'], ['BALL patients must be enrolled on AALL08B1 or APEC14B1 if open for the classification of newly diagnosed ALL patients prior to treatment and enrollment on AALL0932\\r\\n Note BLLy patients are not eligible for AALL08B1 and can enroll directly onto AALL0932', 'BALL patients must have an initial white blood cell count < 50000uL', 'Patients must have newly diagnosed National Cancer Institute NCI Standard Risk BALL or BLLy Murphy stages I or II patients with Down syndrome are also eligible\\r\\n Note for BLLy patients with tissue available for flow cytometry the criterion for diagnosis should be analogous to BALL for tissue processed by other means ie paraffin blocks the methodology and criteria for immunophenotypic analysis to establish the diagnosis of BLLy defined by the submitting institution will be accepted', 'All patients andor their parents or legal guardians must sign a written informed consent', 'All institutional Food and Drug Administration FDA and NCI requirements for human studies must be met', 'With the exception of steroid pretreatment defined below or the administration of intrathecal cytarabine patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of BALL or BLLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL0932\\r\\n Patients receiving prior steroid therapy may be eligible for AALL0932', 'Patients with central nervous system 3 CNS3 leukemia\\r\\n CNS status must be known prior to enrollment Note the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy except for steroid pretreatment BLLy patients with CNS3 disease are not eligible for this protocol or the COG HR ALL protocol it is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar puncture this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture this is allowed prior to registration systemic chemotherapy must begin within 72 hours of the first dose of intrathecal therapy', 'BALL patients with testicular leukemia are not eligible for AALL0932', 'For BLLy patients the following additional exclusion criteria apply\\r\\n Tlymphoblastic lymphoma\\r\\n Morphologically unclassifiable lymphoma\\r\\n Absence of both Bcell and Tcell phenotype markers in a case submitted as lymphoblastic lymphoma\\r\\n CNS3positive disease or testicular involvement\\r\\n M2 5  25 blasts or M3 > 25 blasts marrow\\r\\n Female patients who are pregnant are ineligible\\r\\n Lactating females are not eligible unless they have agreed not to breastfeed their infants\\r\\n Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\\r\\n Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation'], ['Patients with newly diagnosed biopsy confirmed extracranial nonmetastatic Ewing sarcoma or primitive neuroectodermal tumor PNET of bone or soft tissue are eligible for this study note\\r\\n For the purpose of this study chest wall tumors with ipsilateral pleural effusions ipsilateral positive pleural fluid cytology or ipsilateral pleural based secondary tumor nodules will be considered localized disease\\r\\n Patients with regional node involvement based on clinical suspicion confirmed by pathologic documentation are considered to be nonmetastatic\\r\\n Patients with discontinuous osseous lesions within the same bone are considered to be nonmetastatic\\r\\n Tumors arising in the bony skull extradural are considered to be extracranial', 'Patient eligibility will be based on a diagnosis of Ewing sarcoma or PNET by institutional pathologist', 'No prior chemotherapy or radiation therapy is allowed patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery', 'Creatinine clearance or radioisotope glomerular filtration rate GFR >= 70mLmin173 m2 or serum creatinine based on agegender as follows\\r\\n 1 month to < 6 months 04 mgdL\\r\\n 6 months to < 1 year 05 mgdL\\r\\n 1 to < 2 years 06 mgdL\\r\\n 2 to < 6 years 08 mgdL\\r\\n 6 to < 10 years 1 mgdL\\r\\n 10 to < 13 years 12 mgdL\\r\\n 13 to < 16 years 15 mgdL male 14 mgdL female\\r\\n >= 16 years 17 mgdL male 14 mgdL female', 'Total bilirubin < 15 x upper limit of normal ULN for age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST or serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 25 x upper limit of normal ULN for age', 'Shortening fraction of >= 27 by echocardiogram or ejection fraction of >= 50 by radionuclide angiogram', 'Patients must have no evidence of metastatic disease metastatic disease\\r\\n Are lesions which are discontinuous from the primary tumor are not regional lymph nodes and do not share a body cavity with the primary tumor if there is any doubt whether lesions are metastatic a biopsy of those lesions should be taken\\r\\n Skeletal lesions in adjacent bones transarticular\\r\\n Contralateral pleural effusion and contralateral pleural nodules\\r\\n Distant lymph node involvement\\r\\n Patients with pulmonary nodules are considered to have metastatic disease if the patient has\\r\\n Solitary nodule > 05 cm or multiple nodules of > 03 cm unless biopsied and negative for Ewings\\r\\n Biopsies of solitary nodule =< 05 cm or multiple nodules =< 03 cm are not required but if performed and positive indicate metastatic disease', 'Patients whose tumors arise in the dural and intradural soft tissues of the cranium and spine are not eligible', 'Patients with pathologic diagnoses other than Ewing sarcoma will be excluded', 'Patients diagnosed with Ewing Sarcoma as a second malignant neoplasm are not eligible if they have received chemotherapy or radiation for the treatment of their primary malignancy', 'Pregnant women will not be entered on this study pregnancy tests must be obtained in female patients who are postmenarchal lactating females may not participate unless they have agreed not to breastfeed their infants males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the study treatment', 'All patients andor their parents or legal guardians must sign a written informed consent', 'All institutional Food and Drug Administration FDA and National Cancer Institute NCI requirements for human studies must be met'], ['Patients must have histologically or cytologicallyproven new diagnosis of unresectable stage IIIAIIIB nonsmall cell lung cancer adenocarcinoma bronchioloalveolar cell carcinoma large cell carcinoma squamous cell carcinoma or mixed\\r\\n Per the American Joint Committee on Cancer AJCC 7th edition pleural and pericardial are now considered stage M1a disease when pleural fluid is visible on the computed tomography CT scan or on a chest xray a thoracentesis is required to confirm that the pleural fluid is cytologically negative patients with exudative pleural effusions are excluded regardless of cytology patients with effusions that are minimal ie not visible on chest xray that are too small to safely tap are eligible a small effusion that has positive fludeoxyglucose F 18 FDG uptake on positron emission tomography PET has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excluded', 'Patients must have measurable or nonmeasurable disease documented by CT magnetic resonance imaging MRI or PETCT the CT from a combined PETCT may be used to document only nonmeasurable disease unless the scan is of diagnostic quality measurable disease must be assessed by CT within 28 days prior to registration pleural effusions ascites and laboratory parameters are not acceptable as the only evidence of disease nonmeasurable disease must be assessed within 42 days prior to registration all disease must be assessed and documented on the Baseline Tumor Assessment Form', 'Patients with brain metastases are ineligible all patients must have a pretreatment CT or MRI scan of the brain to evaluate for central nervous system CNS disease within 42 days prior to registration', 'Patients must not have received any prior systemic therapy chemotherapy or other biologic therapy for lung cancer', 'Patients must not have received prior chest radiation therapy for NSCLC', 'Patients must not have had a previous surgical resection however patients may have undergone exploratory thoracotomy mediastinoscopy excisional biopsy or similar surgery for the purpose of determining the diagnosis stage or potential resectability of newly diagnosed lung tumor at least 28 days must have elapsed since thoracic surgery excluding mediastinoscopy or other minor surgeries and patients should have recovered from all associated toxicities at the time of registration patients must not be planning to undergo a minor surgical procedure while on this study', 'Patients must have Zubrod performance status 01', 'Patients must have tumor tissue available for submission to assess gene expression of ERCC1 and XRCC1 patients must also be offered participation in banking for future use of specimens', 'Absolute neutrophil count >= 1500mcl', 'Platelets >= 100000mcl', 'Hemoglobin >= 90 gdl', 'Total bilirubin within institutional upper limit of normal IULN', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST or serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 25 x IULN', 'Patients must not be pregnant or nursing womenmen of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol heshe is responsible for beginning contraceptive measures', 'Patients must have a serum creatinine =< the IULN AND measured or calculated creatinine clearance >= 60 ccmin using the CockroftGault formula', 'Patients must have pulmonary function tests PFTs including forced expiratory volume in 1 second FEV1 within 84 days prior to registration for FEV1 the best value obtained pre or postbronchodilator must be >= 12 literssecond andor >= 50 predicted', 'Patients may not be planning to receive any other investigational agents', 'Patients must not have more than 10 weight loss in the past 6 months', 'Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT888 carboplatin paclitaxel or other agents used in study', 'No other prior malignancy is allowed except for the following adequately treated basal cell or squamous cell skin cancer in situ cervical cancer adequately treated stage I or II cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease free for five years', 'Patient must not have any uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illnesssocial situations that would limit compliance with study requirements', 'Patients must not currently have a > grade 1 symptomatic neuropathysensory National Cancer Institute NCI Common Terminology Criteria for Adverse Events CTCAE version 40', 'Patients must not have a history of seizures', 'Patients must not have any known immune deficiencies patients with immune deficiency are at increased risk of lethal infections when treated with marrowsuppressive therapy therefore known human immunodeficiency virus HIV positive patients receiving combination antiretroviral therapy are excluded from the study', 'Patients must be able to swallow whole capsules', 'Prestudy history and physical must be obtained within 28 days prior to registration', 'All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institution’s identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy the last day of radiation', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients must have undergone restaging tests according to the study calendar and determined to have no evidence of disease progression', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients must have a serum creatinine =< IULN AND measured of calculated creatinine clearance >= 60 ccmin using the CockroftGault formula', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Absolute neutrophil count >= 1500 mcl', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Platelets >= 100000mcl', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Hemoglobin >= 90 gdl', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Total bilirubin =< IULN', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY SGOT AST or SGPT ALT =< 25 x IULN', 'REGISTRATION 2  PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients must have Zubrod performance status 01'], ['Receiving anastrozole 1 mg or letrozole 25 mg orally once a day for >= 21 days prior to registration and plan to continue throughout the duration of study', 'Body mass index BMI between 18 and 35 kgm2', 'Women who have undergone a total mastectomy or breastconserving surgery for primary breast cancer + chemotherapy + radiotherapy', 'Must have BOTH estrogen receptor ER and progesterone receptor PRpositive tumors and BOTH must be >= 26 positive alternatively if ER and PR are determined by Allred score the score needs to be 5 or higher', 'Women who are postmenopausal by surgery radiotherapy or presence of natural amenorrhea >= 12 months', '>= 510 arthralgia in hands wrist knees or hips while being treated with anastrozole or letrozole which is felt by the patient to be caused by their aromatase inhibitor as measured by verbally addressing the following question please rate your pain by picking a number from 0 to 10 0 being none and 10 being as bad as you can imagine that best describes your pain from your aromatase inhibitor breast cancer medication on AVERAGE over the past week\\r\\n Note Patients may or may not be taking nonopioid analgesics', 'Ability to complete questionnaires by themselves or with assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 or 2', 'Willing to provide informed written consent', 'Willing to return to an Alliance enrolling institution for followup', 'Willing to provide blood samples for correlative research purposes', 'Creatinine =< 15 x upper limit of normal ULN =< 365 days prior to registration without medical situations that should change these parameters since they were done', 'Hemoglobin > 11 gdL =< 365 days prior to registration without medical situations that should change these parameters since they were done', 'White blood cell WBC > 30 =< 365 days prior to registration without medical situations that should change these parameters since they were done', 'Platelet count > 100000 =< 365 days prior to registration without medical situations that should change these parameters since they were done', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 15 x ULN =< 365 days prior to registration without medical situations that should change these parameters since they were done', 'Presence of residual or recurrent cancer locally or metastatic', 'Diabetes mellitus or glucose intolerance defined as a fasting glucose > 125 mgdL', 'History of coronary artery disease angina or myocardial infarction', 'Patients on hormonereplacement therapy HRT =< 4 weeks prior to registration this includes the use of vaginal estrogen therapy', 'Known hypersensitivity to any component of testosterone', 'Prolonged systemic corticosteroid treatment except for topical applications eg for rash inhaled sprays eg for obstructive airway diseases eye drops or local insertion eg intraarticular\\r\\n Note Short duration < 2 weeks of systemic corticosteroids is allowed eg for chronic obstructive pulmonary disease but not within 30 days prior to registration', 'Receiving any other investigational agent', 'History of a deep venous thrombosis or a thromboembolism', 'Concurrent use of the aromatase inhibitor exemestane', 'Concurrent radiation therapy or chemotherapy', 'Current or planned use of cyclosporine anticoagulants insulin oral or injectable vitamin D doses over 4000 IUday or tamoxifen'], ['Life expectancy of at least 5 years excluding diagnosis of breast cancer comorbid conditions should be taken into consideration but breast cancer diagnosis is not a consideration', 'Men are excluded from this study', 'Upon clinical exam and preoperative imaging by mammogram + MRI two or three foci of biopsy proven breast cancer separated by >= 2 cm of normal breast tissue foci must include at least one focus of invasive breast carcinoma with another focus of either invasive breast carcinoma or ductal carcinoma in situ DCIS no more than 2 quadrants with biopsy proven breast cancer Note the shortest distance between lesions must be reported on mammogram + MRI and eligibility criteria must be met on both if both are obtained Note patient is eligible for study if lesion is not visualized on all imaging modalities ie any of the lesion s isare visualized on MRI but not on mammogram OR visualized on mammogram but not on MRI ultrasound cannot be used to determine patient eligibility eligibility to be determined by bilateral mammogram + MRI only fine needle aspirate of the second or third lesion to document malignancy is allowed if the first focus is shown to be invasive by core needle biopsy patient may remain on study if upon pathological assessment two or three lesions identified on preoperative imaging represent one contiguous lesion', 'Patients may be registered AFTER surgery and PRIOR TO radiation therapy if either of the criteria is met\\r\\n An area of atypia > 2 cm from the index lesion excised at the time of cancer operation is upgraded to DCIS or invasive carcinoma thereby identifying MIBC OR\\r\\n Patient underwent resection of two or three foci of malignancy by breast conservation surgery with a minimum of one invasive focus of breast cancer and a minimum of 2 cm of normal breast tissue between the lesions on final pathology', 'Bilateral mammogram =< 90 days prior to date of surgery Note for patients undergoing more than 1 breast operation this is the date of the first breast surgery for breast cancer treatment', 'cN0 or cN1 disease', 'Eastern Cooperative Oncology Group ECOG performance status PS of 0 1 or 2', 'Ability to complete questionnaires by themselves or with assistance', 'Ability to provide written informed consent', 'Willing to return to enrolling institution for followup during the Active Monitoring Phase the active treatment and observation portions of the study patients are encouraged to return to the enrolling institution however patients may receive radiation therapy at a different institution other than the enrolling institution', 'Any of the following\\r\\n Pregnant women\\r\\n Nursing women\\r\\n Women of childbearing potential who are unwilling to employ adequate contraception as determined by the treating physician', 'Largest single focus of disease > 5 centimeters by either mammogram or MRI or both Note measurement of the largest single focus should include any satellite lesions within 1 centimeter of the index lesion', 'Surgical axillary staging procedure prior to first definitive breast operation Note fineneedle aspiration FNA or core needle biopsy of axillary node is permitted', 'Clinical or radiographic evidence of metastatic disease', 'Prior history of ipsilateral breast cancer DCIS LCIS lobular cancer in situ or invasive', 'cNX cN2 or cN3 disease', 'Breast implants at time of diagnosis Note patients who have had implants previously removed prior to diagnosis are eligible', 'Comorbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would interfere significantly with wholebreast irradiation such as connective tissue disorders lupus or scleroderma', 'Uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illnesssocial situations that would limit compliance with study requirements', 'Prior or current LCIS DCIS or invasive breast cancer in the opposite breast ie bilateral disease is not allowed', 'Treatment including radiation therapy chemotherapy biotherapy or hormonal therapy for this cancer prior to surgery ie any neoadjuvant chemotherapy or endocrine therapy is not allowed patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapy', 'Planned partial breast radiation', 'Patients with known breast cancer BRCA mutations patients who are not tested or whose testing result is not returned at the time of registration are not excluded from registering to this study', 'Other active malignancy =< 5 years prior to registration EXCEPTIONS nonmelanotic skin cancer or carcinomainsitu of the cervix Note if there is a history of prior malignancy they must not be receiving other specific treatment for their cancer'], ['Patients with locally advanced previously untreated squamous cell carcinoma of the vulva', 'Patients with T2 or T3 primary tumors N03 M0 not amenable to surgical resection by standard radical vulvectomy', 'Absolute neutrophil count ANC >= 1500mcl', 'Platelets >= 100000mcl', 'Creatinine =< 15 times institutional upper limit of normal ULN OR calculated creatinine clearance >= 60 mLmin', 'Bilirubin =< 15 x ULN', 'Aspartate aminotransferase AST and alanine aminotransferase ALT =< 30 x ULN', 'Alkaline phosphatase =< 3 x ULN', 'Patients judged capable of tolerating a radical course of chemoradiation therapy', 'Patients must not be eligible for a higher priority Gynecologic Oncology Group GOG protocol if one exists in general this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population', 'Patients must have signed an approved informed consent and authorization permitting release of personal health information', 'Patients with a GOG performance status of 0 1 or 2', 'Patients with recurrent carcinoma of the vulva regardless of previous treatment', 'Patients who have received prior pelvic radiation or cytotoxic chemotherapy', 'Patients with vulvar melanomas or sarcomas', 'Patients with circumstances that will not permit completion of the study or the required followup', 'Patients with evidence of active septicemia severe infection gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy', 'Patients with a history of other invasive malignancies with the exception of nonmelanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last five years patients are also excluded if their previous cancer treatment contraindicates this protocol therapy'], ['STEP 0 REGISTRATION Optional', 'Patients with a primary colon or rectal cancer resection who are potentially eligible for S0820 may be preregistered at Step 0 patients registered to Step 0 will appear on an institutional patient tracking report patients registered to Step 0 are not registered to the S0820 protocol to participate in S0820 patients must be registered to Step 1 after patient is consented and evaluation of eligibility patients registered to S0820 at Step 0 continuing to Step 1 registration must use the same Southwest Oncology Group SWOG patient identification ID for registration to S0820 Step 1', 'STEP 1 REGISTRATION', 'Patients must have a history of stage 0 I II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy adjuvant chemotherapy and radiation therapy RT treatment must have been completed at least 30 days prior to registration', 'Patients with history of segmental resections are eligible ie right colectomy extended right colectomy transverse colectomy left colectomy extended left colectomy sigmoid colectomy low anterior resection abdominoperineal resection the definition of resection does not include endomucosal resection EMR patients that have received total proctocolectomy are ineligible\\r\\n In addition to segmental resections the following types of procedures are allowed polypectomy for Tis stage 0 or pT1 patients only resection may consist entirely of polypectomy without completion of partial colectomy if ALL of the following criteria are met\\r\\n Single specimen completely removed\\r\\n Clear margins\\r\\n None of the following must be present\\r\\n Moderate or poor differentiation\\r\\n Lymphovascular invasion\\r\\n Perineural invasion\\r\\n Transanal excision is allowed for pT1 rectal cancer patients with well or moderately differentiated tumors if National Comprehensive Cancer Network NCCN criteria for transanal excision are met as stipulated here\\r\\n < 30 circumference of bowel\\r\\n < 3 cm in size\\r\\n Margin clear > 3 mm\\r\\n Mobile nonfixed\\r\\n Within 8 cm of anal verge\\r\\n T1 only\\r\\n Endoscopically removed polyp with cancer\\r\\n No lymphovascular invasion or perineural invasion\\r\\n Well to moderately differentiated\\r\\n No evidence of lymphadenopathy on pretreatment imaging\\r\\n When the lesion can be adequately identified in the rectum transanal endoscopic microsurgery TEM may be used TEM for more proximal lesions may be technically feasible', 'Patients must be registered between 120 days and 456 days inclusive of primary resection patients must show no evidence of colorectal cancer based on postoperative colonoscopy performed at least 120 days after the colon or rectal resection date and prior to registration patients with adenomas detected at the oneyear postoperative colonoscopy are eligible if all adenomas have been completely removed', 'Patients must have a pure tone audiometry evaluation to document air conduction within 30 days prior to registration patients with hearing loss > 40 decibels dB in any of the five tested frequencies 250 Hertz Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz are not eligible patients with active ear infections should be tested only after the acute phase of infection has resolved for optimal results it is recommended that testing be conducted by an audiologist in a hearing test room with insert earphones Note sites should not order audiometry evaluation until the potential participant has met all other eligibility criteria required for this study', 'Patients must have a Zubrod performance status of 01', 'Patients must have the ability to swallow oral medication', 'Total white blood cells WBC >= 40 x 103mcL within 28 days prior to registration', 'Platelets >= 100000mcL within 28 days prior to registration', 'Hemoglobin > 110 gdL within 28 days prior to registration', 'A total WBC >= 31 x 103mcL is allowed for nonHispanic black males NHBM and total WBC >= 34 x 103mcL for nonHispanic black females NHBF \\r\\n Exception If the WBC is lower than the above levels the patient may be enrolled IF the absolute neutrophil count ANC is >= 13 for NHBM >= 14 for NHBF or >= 15 for all', 'Serum bilirubin =< 20 mgdL within 28 days prior to registration', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOT or alanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT =< 2 x IULN institutional upper limit of normal within 28 days prior to registration', 'Serum creatinine =< 15 x IULN obtained within 28 days prior to registration', 'Patients with a prior malignancy or concurrent malignancy that is currently not being treated whose natural history or treatment in the opinion of the treating physician does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial', 'SPECIMEN SUBMISSION AND SUBSTUDY CRITERIA', 'Patients must be offered the option to participate in submission of specimens for banking for future translational medicine studies', 'Patients participating through PK sites must be offered the option to submit blood specimens for population pharmacokinetic analysis', 'Patients must be offered the option to participate in the Diet and Lifestyle Substudy', 'REGULATORY CRITERIA', 'All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'As part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system', 'Patients must not have cardiovascular risk factors including unstable angina history of documented myocardial infarction or cerebrovascular accident coronary artery bypass surgery or New York Heart Association class III or IV heart failure patients must not have known uncontrolled hyperlipidemia defined as lowdensity lipoprotein cholesterol LDLC >= 190 mgdL or triglycerides >= 500 mgdL within the last 3 years prior to registration or uncontrolled high blood pressure systolic blood pressure > 150 mm Hg within 28 days prior to registration', 'Patients must not have a known history of familial adenomatous polyposis hereditary nonpolyposis colorectal cancer inflammatory bowel disease biallelic mismatch repair deficiency syndrome BMMRD or constitutional mismatch repair deficiency syndrome CMMRD', 'Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts patients must not have experienced asthma urticaria or allergictype reactions after taking aspirin or other nonsteroidal antiinflammatory drug NSAID', 'Patients must not have documented history of gastricduodenal ulcer within the last 12 months participant must not currently be on treatment for gastricduodenal ulcer or be experiencing symptoms at study entry patients with gastroesophageal reflux disease GERD are eligible however and these patients may receive overthecounter histamine2 H2 antagonists protonpump inhibitors or other prescriptionbased treatment for GERD', 'Patients must not be expecting to receive radiation or additional chemotherapy', 'Patients must not be receiving or plan to receive concomitant oral or intravenous corticosteroids on a regular basis nonsteroidal antiinflammatory drugs NSAIDs nor anticoagulants on a regular or predictable intermittent basis NSAID use may not exceed 10 days per month patients may receive daily aspirin for cardiovascular prophylaxis as long as acetylsalicylic acid ASA is =< 100 mg per day or =< two 325 mg tablets per week inhaled steroids ie for asthma or related conditions are allowed', 'Patients must have no significant medical or psychiatric condition that would preclude study completion tests and exams for this determination should be completed within 28 days prior to registration', 'Patients must not be pregnant or nursing due to the status of eflornithine and sulindac as pregnancy class C agents womenmen of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol heshe is responsible for beginning contraceptive measures', 'Individuals must not currently be participating in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the followup phase only patients must also agree not to join such a trial while participating in this study'], ['STEP I Patients must be diagnosed with symptomatic standardrisk multiple myeloma SRMM as defined by all of the following except gene expression profile GEP70 status if unknown\\r\\n No evidence of t1416 by fluorescence in situ hybridization FISH testing on bone marrow or not available\\r\\n No evidence of t1420 by FISH testing on bone marrow or not available\\r\\n No evidence of deletion 17p by FISH testing on bone marrow\\r\\n FISH should be from within 90 days of registration\\r\\n NOTE If the FISH result states that no immunoglobulin heavy chain IgH abnormality is present both t1416 and t1420 can be considered negative in addition if the patient has a t1114 or t414 translocation present they can be considered negative for t1416 and t1420 if testing for t1416 or t1420 could not be performed for lack of sufficient material or nonavailability of the probe in the test panel patients can be enrolled on the study\\r\\n Standard Risk GEP70 signature within the past 90 days only if GEP has been done and results are available\\r\\n NOTE GEP testing is NOT a requirement for the study if the test has been done patients found to have a GEP70 status of highrisk will not be eligible\\r\\n Serum lactate dehydrogenase LDH =< 2 x upper limit of normal ULN within the past 28 days\\r\\n No more than 20 circulating plasma cells on peripheral blood smear differential or 2000 plasma cellsmicroliter on white blood cell WBC differential of peripheral blood within the past 90 days\\r\\n NOTE This is NOT the plasma cell  from the marrow aspirate', 'STEP I Patients must have measurable or evaluable disease as defined by having one or more of the following obtained within 28 days prior to randomization\\r\\n >= 1 gdL monoclonal protein Mprotein on serum protein electrophoresis\\r\\n >= 200 mg24 hours hrs of monoclonal protein on a 24 hour urine protein electrophoresis\\r\\n Involved free light chain >= 10 mgdL or >= 100 mgL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio < 026 or > 165\\r\\n Monoclonal bone marrow plasmacytosis >= 30 evaluable disease', 'STEP I Serum protein electrophoresis SPEP urine protein electrophoresis UPEP and serum free light chain FLC assay are required to be performed within 28 days prior to randomization a bone marrow biopsy andor aspirate is required within 28 days if bone marrow is being followed for response\\r\\n NOTE UPEP on a 24hour collection is required no substitute method is acceptable urine must be followed monthly if the baseline urine Mspike is >= 200 mg24 hr please note that if both serum and urine Mcomponents are present both must be followed in order to evaluate response\\r\\n NOTE The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine measurable disease in the serum is defined as having a serum Mspike >= 1 gdL measurable disease in the urine is defined as having a urine Mspike >= 200 mg24 hr', 'STEP I Hemoglobin >= 8 gdL obtained within 28 days prior to randomization', 'STEP I Untransfused platelet count >= 75000 cellsmm3 obtained within 28 days prior to randomization', 'STEP I Absolute neutrophil count >= 1000 cellsmm3 obtained within 28 days prior to randomization', 'STEP I Calculated creatinine clearance >= 30 mLmin obtained within 28 days prior to randomization', 'STEP I Bilirubin =< 15 mgdL obtained within 28 days prior to randomization', 'STEP I Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT and serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST < 25 times the upper limit of normal obtained within 28 days prior to randomization', 'STEP I Patients must have received no more than one cycle 4 weeks or less of prior chemotherapy and no more than 160 mg of prior dexamethasone or equivalent dose of prednisone for treatment of symptomatic myeloma they should not have been exposed to lenalidomide bortezomib or carfilzomib for treatment of symptomatic myeloma prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements', 'STEP I Prior systemic glucocorticoid use for the treatment of nonmalignant disorders is permitted prior or concurrent topical or localized glucocorticoid therapy to treat nonmalignant comorbid disorders is permitted', 'STEP I Eastern Cooperative Oncology Group ECOG performance status 0 1 or 2 performance status PS 3 allowed if secondary to pain', 'STEP I Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anticoagulation as prophylaxis if they are not currently on fulldose anticoagulation', 'STEP I Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy currently treated basal cell squamous cell carcinoma of the skin or carcinoma “in situ” of the cervix or breast are not excluded', 'STEP I Females of childbearing potential FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIUmL within 10 – 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control one highly effective method and one additional effective method AT THE SAME TIME at least 28 days before she starts taking lenalidomide throughout the entire duration of study treatment and for 28 days after the last dose of lenalidomide FCBP must also agree to ongoing pregnancy testing all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure if randomized to Arm B FCBP must agree to use contraception or abstinence for 30 days after last dose of carfilzomib\\r\\n A female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has achieved menarche at some point 2 has not undergone a hysterectomy or bilateral oophorectomy or 3 has not been naturally postmenopausal amenorrhea following cancer therapy does not rule out childbearing potential for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'STEP I Sexually active males must be willing to use a condom even if they have undergone a prior vasectomy while having intercourse while taking lenalidomide and for 28 days after stopping lenalidomide male subjects must also agree to abstain from donating blood semen or sperm during study participation and for at least 28 days after discontinuation from lenalidomide if randomized to Arm B male subjects must be willing to use condoms while having intercourse while taking carfilzomib and for 90 days after discontinuation of carfilzomib', 'STEP I Human immunodeficiency virus HIV infection is not excluded known HIV positive patients must meet the following criteria\\r\\n Cluster of differentiation CD4 cell count >= 350mm3\\r\\n No history of acquired immune deficiency syndrome AIDSrelated illness\\r\\n Not currently prescribed zidovudine or stavudine', 'STEP I Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist', 'STEP II Patients must have complete induction without experiencing progression or patients must have received at least 6 cycles on Arm A and 4 cycles on Arm B but stopped induction therapy due to adverse events', 'STEP II Step 2 registration must be within 6 weeks of completing step 1 therapy', 'STEP II Patients must not have received any nonprotocol therapy outside of the assigned induction therapy including stem cell transplant', 'STEP II ECOG performance status 0 1 or 2 PS 3 allowed if secondary to pain', 'STEP II Any adverse event related to step 1 therapy must have resolved to grade 2 or less', 'STEP II Hemoglobin >= 8 gdL within 28 days prior to randomization to Step II', 'STEP II Platelet count >= 75000 cellsmm3 within 28 days prior to randomization to Step II', 'STEP II Absolute neutrophil count >= 1000 cellsmm3 within 28 days prior to randomization to Step II', 'STEP II Calculated creatinine clearance >= 30 mLmin within 28 days prior to randomization to Step II', 'STEP II Bilirubin =< 15 mgdL within 28 days prior to randomization to Step II', 'STEP II SGPT ALT and SGOT AST < 25 times the upper limit of normal within 28 days prior to randomization to Step II', 'STEP II Females of childbearing potential FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIUmL within 10 – 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control one highly effective method and one additional effective method AT THE SAME TIME at least 28 days before she starts taking lenalidomide throughout the entire duration of study treatment and for 28 days after the last dose of lenalidomide FCBP must also agree to ongoing pregnancy testing all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure if previously randomized to Arm B FCBPs must also continue to use contraception or abstinence for 30 days after the last dose of carfilzomib\\r\\n A female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has achieved menarche at some point 2 has not undergone a hysterectomy or bilateral oophorectomy or 3 has not been naturally postmenopausal amenorrhea following cancer therapy does not rule out childbearing potential for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'STEP II Sexually active males must be willing to use a condom even if they have undergone a prior vasectomy while having intercourse while taking lenalidomide and for 28 days after stopping lenalidomide male subjects must also agree to abstain from donating blood semen or sperm during study participation and for at least 28 days after discontinuation from lenalidomide if previously randomized to Arm B males must agree to continue use of contraception and agree to not donate sperm for at least 90 days after the last dose of carfilzomib', 'STEP II Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist', 'STEP I Patients must not have active uncontrolled seizure disorder patients must have had no seizures in the last 6 months', 'STEP I Patients must not have uncontrolled intercurrent illness including uncontrolled hypertension symptomatic congestive heart failure unstable angina uncontrolled cardiac arrhythmia uncontrolled psychiatric illness or social situation that would limit compliance with the study or a prior history of Stevens Johnson syndrome', 'STEP I Patients with monoclonal gammopathy of undetermined significance or asymptomatic multiple myeloma are not eligible', 'STEP I Patients must not have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events CTCAE 40', 'STEP I Patients must not have active uncontrolled infection', 'STEP I Patients should not have New York Heart Association classification III or IV heart failure or myocardial infarction within the previous 6 months', 'STEP I The following patients will be excluded as this study involves an agent that may have genotoxic mutagenic and teratogenic effects\\r\\n Pregnant women\\r\\n Nursing women', 'STEP II The following patients will be excluded as this study involves an agent that may have genotoxic mutagenic and teratogenic effects\\r\\n Pregnant women\\r\\n Nursing women'], ['Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines ie > 2 x upper limit of normal ULN at the time of initial diagnosis', 'For the purposes of this study aggressive multidrug chemotherapy is defined as chemotherapy including 2 or more agents that must include an alkylating agent and a platinumcontaining compound patients must have ONE of the following\\r\\n First episode of recurrent disease following completion of aggressive multidrug frontline therapy\\r\\n First episode of progressive disease during aggressive multidrug frontline therapy\\r\\n Primary resistantrefractory disease less than partial response by INRC detected at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a highrisk neuroblastoma protocol examples include A3973 ANBL0532 ANBL09P1 etc', 'Patients must have at least ONE of the following\\r\\n Measurable tumor on magnetic resonance imaging MRI computed tomography CT scan obtained within 3 weeks prior to study entry measurable is defined as >= 10 mm in at least one dimension on spiralhelical CT that is metaiodobenzylguanidine MIBG avid or demonstrates increased fludeoxyglucose FDG uptake on positron emission tomography PET scan\\r\\n MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site this site must represent disease recurrence after completion of therapy progressive disease on therapy or refractory disease during induction\\r\\n Patients with resistantrefractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma biopsy is not required for patients who have new site of soft tissue disease radiographic evidence of disease progression regardless of whether progression occurs while receiving therapy or after completion of therapy\\r\\n Note Patients with elevated catecholamines ie > 2 x ULN only or bone marrow disease only are NOT eligible for this study', 'Patients must have a performance status corresponding to Eastern Cooperative Oncology Group ECOG scores of 0 1 or 2 use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age', 'Patients must have received frontline therapy including surgery chemotherapy autologous stem cell transplant SCT + MIBG immunotherapy radiotherapy and retinoids but may NOT have received second line chemotherapy for resistantrefractory relapsed disease or progressive disease', 'At least 14 days must have elapsed since completion of myelosuppressive therapy', 'At least 7 days must have elapsed since the completion of therapy with a nonmyelosuppressive biologic agent or retinoid', 'No interim time prior to study entry is required following prior radiation therapy RT for nontarget lesions however patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma palliative radiation is allowed to sites that will not be used to measure response during this study', 'Patients are eligible >= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met', 'Patients are eligible >= 6 weeks after therapeutic 131IMIBG provided that all other eligibility criteria are met', 'Subjects who have previously received antiGD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior antiGD2 therapy subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads but no other form of antiGD2 monoclonal antibody are eligible', 'Patients must not have received longacting myeloid growth factors eg Neulasta within 14 days of entry on this study seven days must have elapsed since administration of a short acting myeloid growth factor', 'Peripheral absolute neutrophil count ANC >= 750uL', 'Platelet count >= 75000uL transfusion independent', 'Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity', 'Creatinine clearance or estimated radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 or', 'A serum creatinine =< upper limit of normal ULN based on agegender as follows\\r\\n Age 1 month to < 6 months 04 for males 04 for females\\r\\n Age 6 months to < 1 year 05 for males 05 for females\\r\\n Age 1 to < 2 years 06 for males 06 for females\\r\\n Age 2 to < 6 years 08 for males 08 for females\\r\\n Age 6 to < 10 years 1 for males 1 for females\\r\\n Age 10 to < 13 years 12 for males 12 for females\\r\\n Age 13 to < 16 years 15 for males 14 for females\\r\\n Age >= 16 years 17 for males 14 for females', 'Total bilirubin =< 15 x ULN for age AND', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 50 x ULN for age =< 225 UL for the purpose of this study the ULN for SGPT is 45 UL', 'Adequate central nervous system function defined as\\r\\n Patients with a history of central nervous system CNS disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\\r\\n Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\\r\\n CNS toxicity =< grade 2', 'Shortening fraction of >= 27 by echocardiogram ECHO OR', 'Ejection fraction >= 50 by ECHO or gated radionuclide study', 'Adequate coagulation defined as\\r\\n Prothrombin time PT =< 12 x upper limit of normal', 'Adequate pulmonary function defined as\\r\\n No evidence of dyspnea at rest no exercise intolerance no chronic oxygen requirement and room air pulse oximetry > 94 if there is a clinical indication for pulse oximetry normal pulmonary function tests in patients who are capable of cooperating with testing including diffusion capacity of the lung of carbon monoxide DLCO are required if there is a clinical indication for determination for patients who do not have respiratory symptoms full pulmonary function tests PFTs are NOT required', 'Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study based on the established teratogenic potential of alkylating agents pregnant women will be excluded from this study female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study females of childbearing potential must have a negative pregnancy test to be eligible for this study', 'Patients with elevated catecholamines ie > 2 x ULN only or bone marrow disease only are NOT eligible for this study', 'Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible the only exception is for patients known to require 2 mgkg or less of hydrocortisone or an equivalent dose of an alternative corticosteroid as premedication for blood product administration in order to avoid allergic transfusion reactions the use of conventional doses of inhaled steroids for the treatment of asthma is permitted as is the use of physiologic doses of steroids for patients with known adrenal insufficiency', 'Patients must not have received enzymeinducing anticonvulsants including phenytoin phenobarbital valproic acid or carbamazepine for at least 7 days prior to study enrollment patients receiving nonenzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible', 'Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma', 'Patients with symptoms of congestive heart failure are not eligible', 'Patients must not have >= grade 2 diarrhea', 'Patients must not have uncontrolled infection', 'Patients with a history of grade 4 allergic reactions to antiGD2 antibodies or reactions that required discontinuation of the antiGD2 therapy are not eligible', 'Patients with a significant intercurrent illness any ongoing serious medical problem unrelated to cancer or its treatment that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible'], ['Histologically or cytologically confirmed small cell lung cancer', 'Limited stage disease patients with disease restricted to one hemithorax with regional lymph node metastases including ipsilateral hilar ipsilateral and contralateral mediastinal and ipsilateral supraclavicular lymph nodes\\r\\n Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible\\r\\n Patients with pleural effusions that are visible on plain chest radiographs whether cytologically positive or not are not eligible unless they have a negative thoracentesis\\r\\n Patients with cytologically positive pleural or pericardial fluid regardless of the appearance on plain xray are not eligible', 'Patients must have measurable disease which includes lesions that can be accurately measured in at least one dimension longest diameter to be recorded as >= 2 cm with conventional techniques or as >= 1 cm with spiral computed tomography CT scan', 'Patients may have received one and only one cycle of chemotherapy prior to enrolling on Cancer and Leukemia Group B CALGB 30610 which must have included carboplatin or cisplatin and etoposide if a patient has had one cycle of cisplatin or carboplatinetoposide prior to registration the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy additionally these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy registration to CALGB 30610 must take place within 721 days after the start of the nonprotocol therapy failing to do all of the above will make the patient NOT eligible for CALGB 30610', 'No prior radiotherapy or chemotherapy except for the chemotherapy described in the bullet above for small cell lung cancer SCLC', 'No prior mediastinal or thoracic radiotherapy', 'Patients with complete surgical resection of disease are not eligible', 'Eastern Cooperative Oncology Group ECOG performance status PS = 02', 'No patients that are known to be pregnant or nursing', 'Granulocytes >= 1500ul', 'Platelet count >= 100000ul', 'Total bilirubin =< 15 x upper limit of normal ULN', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOT =< 20 x ULN', 'Serum creatinine =< 15 times ULN OR calculated creatinine clearance >= 70 mLmin'], ['Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection ie removal of all gross tumor involving a classic pancreaticoduodenectomy Whipple or a pylorus preserving pancreaticoduodenectomy patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm IPMN are eligible\\r\\n The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved the pathology report must include documentation of the margin status and the size of the tumor the pathology report must also include the status of the three major margins—bile duct pancreatic parenchyma and retroperitoneal uncinate', 'For patients who have not started their chemotherapy prior to registration the interval between definitive tumorrelated surgery and 1st step registration must be between 2170 days for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution the interval between definitive tumorrelated surgery and day one of adjuvant chemotherapy must be between 2177 days', 'Patients will be staged according to the 6th edition American Joint Committee on Cancer AJCC staging system with pathologic stage T13 N01 M0 being eligible', 'Zubrod performance status 0 or 1', 'Complete history and physical examination including weight and Zubrod status within 31 days of study entry or within 31 days prior to day 1 of chemotherapy postsurgery for those patients having started chemotherapy prior to first step registration', 'Before starting therapy the patient should be able to maintain adequate oral nutrition of >= 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting', 'Complete blood count CBCdifferential obtained within 21 days of registration on study or within 21 days prior to day 1 of chemotherapy postsurgery for those patients having started chemotherapy prior to first step registration', 'Absolute neutrophil count ANC >= 1500mm3', 'Platelets >= 100000mm3', 'Hemoglobin Hgb >= 80 gdL transfusion or other intervention to achieve Hgb >= 80 gdl is acceptable', 'Post resection serum cancer antigen CA199 =< 180 unitsmL AND prior to any systemic treatment', 'Serum total bilirubin =< twice the institutional upper limit of normal ULN within 21 days of registration on study or within 21 days prior to day 1 of chemotherapy postsurgery for those patients having started chemotherapy prior to first step registration', 'Creatinine levels =< twice the institutional upper limit of normal within 21 days of registration on study or within 21 days prior to day 1 of chemotherapy postsurgery for those patients having started chemotherapy prior to first step registration', 'Serum glutamic oxaloacetic transaminase SGOT must be =< 25 x institutional ULN within 21 days of registration on study or within 21 days prior to day 1 of chemotherapy postsurgery for those patients having started chemotherapy prior to first step registration', 'Negative serum pregnancy test for women of childbearing potential within 14 days of study registration', 'Abdominalpelvic computed tomography CT scan with contrast is preferred abdominal CT alone is acceptable only if insurance restrictions are experienced chest CTxray CT of chest preferred within 31 days of registration on study or within 31 days prior to day 1 of chemo postsurgery for those patients having started chemotherapy prior to first step registration patients allergic to intravenous IV contrast can have magnetic resonance imaging MRI of the abdomenpelvis instead', 'Signed studyspecific informed consent', 'Consultation agreement and documentation in the patient’s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol', 'Women of childbearing potential and male participants must practice adequate contraception', 'Patients with active human immunodeficiency virus HIV infection are eligible if their cluster of differentiation CD4 count is > 499cu mm and their viral load is < 50 copiesml use of highly active antiretroviral treatment HAART is allowed', 'Patients with nonadenocarcinomas adenosquamous carcinomas islet cell neuroendocrine tumors cystadenomas cystadenocarcinomas carcinoid tumors duodenal carcinomas distal bile duct and ampullary carcinomas patients with tumors that are largely IPMN with a minimal or minor component of invasive carcinoma are not eligible patients with acinar carcinomas are not eligible patients with IPMN’s that contain some secondary minor foci of adenocarcinoma are also not eligible', 'Patients managed with a total pancreatectomy a distal pancreatectomy or central pancreatectomy', 'Patients entering on the study after pancreaticoduodenectomy who have not already started chemotherapy must not have had prior systemic chemotherapy for pancreas cancer note that prior chemotherapy for a different cancer is allowable for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution patients must not have received adjuvant chemotherapy with agents other than gemcitabine nabpaclitaxel oxaliplatin fluoropyrimidine or irinotecan for the current pancreatic cancer prior chemotherapy for a different cancer is allowable', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Previous history of invasive malignancy except nonmelanoma skin cancer unless the patient has been disease free for at least 2 years prior to study entry or first day of chemotherapy for patients having started chemotherapy prior to first step registration patients with a previous history of carcinoma in situ are eligible', 'Severe active comorbidity defined as follows per time points indicated below or per time points indicated below prior to the first day of chemotherapy for patients having started chemotherapy prior to first step registration \\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months\\r\\n Transmural myocardial infarction within the 3 months of study registration\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration', 'Pregnant or lactating women', 'Women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception', 'If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist the patient will be ineligible'], ['Pathologically proven primary cervical cancer IIIA with squamous cell carcinoma adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy', 'Patients with the following characteristics depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed            \\r\\n Positive capillarylymphovascular space involvement and one of the following                \\r\\n Deep third penetration\\r\\n Middle third penetration clinical tumor >= 2 cm\\r\\n Superficial third penetration clinical tumor >= 5 cm\\r\\n Negative capillarylymphatic space involvement                \\r\\n Middle or deep third penetration clinical tumor >= 4 cm', 'Absolute neutrophil count ANC >= 1500mcl', 'Platelets >= 100000mcl', 'Creatinine =< upper limit of normal ULN or calculated creatinine clearance >= 60 mLmin', 'Bilirubin =< 15 x normal', 'Alkaline phosphate =< 3 x normal', 'Serum glutamic oxaloacetic transaminase SGOT =< 3 x normal', 'Gynecologic Oncology Group GOG performance status 0 1 2', 'Patients should not be randomized less than 3 weeks postsurgery but will not be acceptable for randomization more than 8 weeks postsurgery', 'Patients who have met the preentry requirements', 'Patients must have signed an approved informed consent and authorization permitting release of personal health information', 'Patients with tumor in the parametria pelvic lymph nodes or any other extra uterine site or with positive surgical margins', 'Patients with septicemia or severe infection', 'Patients with intestinal obstruction or gastrointestinal bleeding', 'Patients with postoperative fistula', 'Patients with cervix cancer who have received any previous radiation or chemotherapy', 'Patients whose circumstances do not permit completion of the study or the required followup', 'Patients with renal abnormalities requiring modification of radiation field pelvic kidney renal transplant etc', 'Patients with GOG performance status of 3 or 4', 'Patients with a history of other invasive malignancies with the exception of nonmelanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last five years patients are also excluded if their previous cancer treatment contraindicates this protocol therapy'], ['Preregistration Diagnostic bone marrow and peripheral blood specimens must be submitted for eligibility testing by multiparameter flow cytometry testing will be performed by the Eastern Cooperative Oncology Group ECOGAmerican College of Radiology Imaging Network ACRIN Leukemia Translational Studies Laboratory and reported to the institution', 'Sexually active males must be strongly advised to use an accepted and effective method of contraception', 'Aspartate aminotransferase AST alanine aminotransferase ALT =< grade 1', 'Total bilirubin =< grade 1\\r\\n Note If total bilirubin is 2 to 3 mgdL but direct bilirubin is normal then the patient will be considered eligible', 'Patient must not have a concurrent active malignancy for which they are receiving treatment other than myelodysplastic syndromes MDS', 'Patient must not have an active uncontrolled infection', 'ADDITIONAL INDUCTION ELIGIBILITY CRITERIA', 'Newlydiagnosed AML patients according to World Health Organization WHO classification who are considered candidates for intensive chemotherapy based upon examination of peripheral blood or bone marrow aspirate specimens or touch preparations of the bone marrow biopsy obtained within two weeks prior to randomization a bone marrow aspirate is required for enrollment however on occasion there is discordance between percentage of myeloblasts on the differential of the peripheral blood or aspirate the peripheral blood criteria are sufficient for diagnosis confirmatory immunophenotyping will be performed centrally', 'ECOG performance status PS 03 restricted to ECOG PS 02 if >= 70 years of age', 'Patients with acute promyelocytic leukemia APL confirmed either by the presence of t1517q22q21 or promyelocytic leukemia PMLretinoic acid receptor RAR alpha transcripts will be excluded', 'Patients must not have blastic transformation of chronic myelogenous leukemia', 'Patients with secondary AML are eligible for enrollment onto the trial secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities or myelodysplastic syndrome MDS or a myeloproliferative disorder excluding chronic myeloid leukemia or a history of prior chemotherapy or radiation therapy for a disease other than AML\\r\\n NOTE Prior therapy of MDS with decitabine lowdose cytarabine or azacitidine is excluded', 'Patients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis patients who have received a limited and shortterm exposure of ATRA all trans retinoid acid while AMLM3 acute promyelocytic leukemia was being ruled out and which has been discontinued will be eligible', 'Total serum bilirubin =< 15 times upper limit of normal ULN =< grade 1 if total bilirubin is 2 to 3 mgdL but direct bilirubin is normal then the patient will be considered eligible', 'Patients with a serum creatinine > 1 are eligible if they have a calculated glomerular filtration rate GFR of >= 60 mlmin ie class I or class II chronic kidney disease  using the Modification of Diet in Renal Disease MDRD formula\\r\\n Note Daily creatinine and MDRD formula are only for the 1st induction cycle', 'Cardiac ejection fraction >= 45 or within institutional normal limits a nuclear medicine gated blood pool examination is preferred a twodimensional 2D echocardiogram ECHO scan is acceptable if a calculated ejection fraction is obtained and followup measurement of the cardiac ejection fraction will also be performed by echocardiography measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment\\r\\n NOTE when a multi gated acquisition scan MUGA or echocardiogram cannot be obtained due to weekend or holiday then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment', 'Patients with suspected central nervous system CNS involvement should undergo lumbar puncture those with documented CNS involvement will be excluded', 'Cytogenetic analysis must be performed from diagnostic bone marrow preferred or if adequate number of circulating blasts > 109l from peripheral blood', 'Patients who have received previous treatment for antecedent hematological disorders AHD with 5azacitidine decitabine or low dose cytarabine will be excluded', 'Patients with known human immunodeficiency virus HIV infection are excluded', 'HLA typing should be performed at registration if possible', 'Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing', 'CONSOLIDATION CRITERIA', 'NOTE All patients achieving CR or complete remission with incomplete blood count recovery CRi will receive consolidation when fit', 'NOTE Patients proceeding to transplant are allowed up to one cycle of consolidation treatment', 'Consolidation cycle 1 must commence within sixty days of the bone marrow aspirate and biopsy that confirmed the presence of a CR or CRi', 'Patients must have achieved a CR or CRi or morphologic leukemiafree state for those patients proceeding to Arm G transplant', 'Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi', 'Patients must have an ECOG performance status of 02', 'Patients must have resolved any serious infectious complications related to induction\\r\\n NOTE Patients with an HLAmatched donor and proceeding to transplant will be allowed up to one cycle of consolidation treatment', 'Any significant medical complications related to induction must have resolved', 'Patients must have a creatinine and AST =< grade 1', 'MAINTENANCE CRITERIA', 'Maintenance should commence within 60 days of recovery of peripheral blood counts after consolidation cycle 2 patients must begin consolidation cycle 2 within 60 days of recovery to be eligible for further therapy', 'Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi confirmed on restaging bone marrow BM aspirate and biopsy and cytogenetic analysis', 'Patients must have an ECOG performance status of 0 2', 'Patients must have resolved any serious infectious complications related to consolidation cycle 2', 'Any significant medical complications related to consolidation cycle 2 must have resolved', 'Total serum bilirubin =< 15 x ULN\\r\\n NOTE if total bilirubin is 23 mgdL but direct bilirubin is normal then the patient will be considered eligible', 'Serum creatinine =< grade 1', 'The absolute neutrophil count ANC must be > 1000 mm3 prior to starting every cycle of treatment with decitabine decitabine may be delayed for up to 4 weeks between cycles ie may be administered as infrequently as every q 8 weeks while waiting for counts to recover', 'The platelet count must be > 75000 mm3 prior to starting every cycle of treatment with decitabine decitabine may be delayed for up to 4 weeks between cycles ie may be administered as infrequently as every q 8 weeks while waiting for counts to recover', 'ALLOGENEIC TRANSPLANTATION', 'Patients must be > 28 days from the start of induction or reinduction chemotherapy or from the start of consolidation cycle 1 if received and < 90 days following recovery from most recent treatment and they must have achieved and maintained a response to induction therapy CR CRi or “morphologic diseasefree state”', 'Patients must have recovered from the effects of induction reinduction or consolidation chemotherapy all toxicities =< grade I with the exception of reversible electrolyte abnormalities and have no ongoing active infection requiring treatment', 'Patients must have a total serum bilirubin =< 15 x ULN grade =< 1 and a serum creatinine =< grade 1', 'An eligible HLAidentical donor either related or unrelated should be available in sibling donors low resolution HLA typing ABDR will be considered sufficient in the case of unrelated donors highresolution class I and II typing A B C DRB1 and DQ should be matched at all 10 loci donors must be willing and able to undergo peripheral blood progenitor mobilization \\r\\n HLAidentical sibling 66 the donor must be determined to be an HLAidentical sibling 66 by serologic typing for class A B and low resolution molecular typing for class II DRB1\\r\\n Matched unrelated donor 1010 high resolution molecular typing at the following loci is required HLAA B C DRBL and –DQB1\\r\\n NOTE for matched donors – will allow select 1 antigen mismatched sibling donors and unrelated donors in accordance with site institutional standard as long as matched at HLAA HLAB HLAC and DRB1 and with advanced discussionapproval by the Study Chair and the bone marrow transplant BMT cochair', 'Patients must be considered reliable enough to comply with the medication regimen and followup and have social support necessary to allow this compliance', 'Patients must have a cardiac ejection fraction of >= 40 or within institutional normal limits a nuclear medicine gated blood pool examination is preferred a 2D ECHO scan is acceptable if a calculated ejection fraction is obtained and followup measurement of the cardiac ejection fraction will also be performed by echocardiography measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation', 'Diffusion capacity of the lung for carbon monoxide DLCO > 40 with no symptomatic pulmonary disease', 'No known hypersensitivity to Escherichia E coliderived products', 'No human immunodeficiency virus HIV infection patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies', 'Creatinine =< grade 1', 'Bilirubin =< grade 1\\r\\n If bilirubin is 23 mgdL but direct bilirubin is normal then patient will be considered eligible', 'AST =< grade 1'], ['Patients must be newly diagnosed with histologicallyproven hepatoblastoma', 'In emergency situations when a patient meets all other eligibility criteria and has had baseline required observations but is too ill to undergo a biopsy safely the patient may be enrolled on AHEP0731 without a biopsy\\r\\n Clinical situations in which such emergent treatment may be indicated include but are not limited to the following circumstances\\r\\n Anatomic or mechanical compromise of critical organ function by tumor eg respiratory distressfailure abdominal compartment syndrome urinary obstruction etc\\r\\n Uncorrectable coagulopathy\\r\\n For a patient to maintain eligibility for AHEP0731 when emergent treatment is given the following must occur\\r\\n The patient must have a clinical diagnosis of hepatoblastoma including an elevated alpha fetoprotein and must meet all AHEP0731 eligibility criteria at the time of emergent treatment\\r\\n Patient must be enrolled on AHEP0731 prior to initiating protocol therapy a patient will be ineligible if any chemotherapy is administered prior to AHEP0731 enrollment\\r\\n If the patient receives AHEP0731 chemotherapy PRIOR to undergoing a diagnostic biopsy pathologic review of material obtained in the future during either biopsy or surgical resection must either confirm the diagnosis of hepatoblastoma or not reveal another pathological diagnosis to be included in the analysis of the study aims', 'Patients will be staged for risk classification and treatment at diagnosis using Childrens Oncology Group COG staging guidelines', 'At the time of study enrollment the patient’s treatment regimen must be identified if the patient’s primary tumor was resected prior to the day of enrollment and a blood specimen for the determination of serum alpha fetoprotein was not obtained prior to that surgery the patient will be considered to have alpha fetoprotein of greater than 100 ngmL for the purpose of treatment assignment if tumor samples obtained prior to the date of enrollment were not sufficient to determine whether small cell undifferentiated SCU histology was present treatment assignment will be made assuming SCU is not present in the tumor', 'For patients with stage I or II disease specimens for rapid central review have been submitted and the rapid central review diagnosis and staging must be available to be provided on the AHEP0731 eligibility case report form CRF', 'Patients must have a performance status corresponding to Eastern Cooperative Oncology Group ECOG scores 0 1 or 2 use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age', 'Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment', 'Organ function requirements are not required for enrolled patients who are stage I PFH and will not be receiving chemotherapy', 'Creatinine clearance or radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 OR serum creatinine based on agegender as follows\\r\\n 1 month to < 6 months 04 mgdL\\r\\n 6 months to < 1 year 05 mgdL\\r\\n 1 to < 2 years 06 mgdL\\r\\n 2 to < 6 years 08 mgdL\\r\\n 6 to < 10 years 1 mgdL\\r\\n 10 to < 13 years 12 mgdL\\r\\n 13 to < 16 years 15 mgdL male or 14 mgdL female\\r\\n >= 16 years 17 mgdL male or 14 mgdL female', 'Total bilirubin < 15 x upper limit of normal ULN for age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST or serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 10 x ULN for age', 'Absolute neutrophil count ANC > 750uL', 'Platelet count > 75000uL', 'Shortening fraction >= 27 by echocardiogram', 'Ejection fraction >= 47 by radionuclide angiogram multi gated acquisition scan MUGA Note the echocardiogram or MUGA may be done within 28 days prior to enrollment', 'Serum triglyceride level =< 300 mgdL =< 342 mmolL', 'Serum cholesterol level =< 300 mgdL 775 mmolL', 'Random or fasting blood glucose within the upper normal limits for age if the initial blood glucose is a random sample that is outside of the normal limits then a followup fasting blood glucose can be obtained and must be within the upper normal limits for age', 'Normal pulmonary function tests including diffusing capacity of the lungs for carbon monoxide DLCO if there is clinical indication for determination eg dyspnea at rest known requirement for supplemental oxygen Note for patients who do not have respiratory symptoms or requirement for supplemental oxygen pulmonary function tests PFTs are NOT required', 'Patients with seizure disorder may be enrolled if on nonenzyme inducing anticonvulsants and if seizures are well controlled', 'Prothrombin time PT < 12 x ULN', 'All patients andor their parents or legal guardians must sign a written informed consent', 'All institutional Food and Drug Administration FDA and National Cancer Institute NCI requirements for human studies must be met', 'Patients with stage I or II disease who do not have specimens submitted for rapid central pathology review by day 14 after initial surgical resection', 'Patients that have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastomadirected therapy eg radiation therapy biologic agents local therapy embolization radiofrequency ablation laser are not eligible', 'Patients who have received any prior chemotherapy are not eligible', 'Patients who are currently receiving another investigational drug are not eligible', 'Patients who are currently receiving other anticancer agents are not eligible', 'Patients who have previously received a solid organ transplant are not eligible', 'Patients who have an uncontrolled infection are not eligible', 'Females who are pregnant or breast feeding are not eligible for this study', 'Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained', 'Males and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method', 'Patients receiving corticosteroids are not eligible patients must have been off corticosteroids for 7 days prior to start of chemotherapy', 'Patients who are currently receiving enzyme inducing anticonvulsants are not eligible', 'Patients must not be receiving any of the following potent cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 inducers or inhibitors erythromycin clarithromycin azithromycin ketoconazole itraconazole voriconazole posaconazole grapefruit juice or St John’s wort', 'Patients who are currently receiving therapeutic anticoagulants including aspirin low molecular weight heparin warfarin and others are not eligible', 'Patients who are currently receiving angiotensinconverting enzymes ACE inhibitors are not eligible', 'Patients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum patients with history of recent minor surgical procedures vascular catheter placement bone marrow evaluation laparoscopic surgery liver tumor biopsy will be eligible'], ['Patients must be newly diagnosed with histologically confirmed intracranial ependymoma patients with classic ependymoma WHO II or anaplastic ependymoma WHO III are eligible as are various subtypes described as clear cell papillary cellular or a combination of the above', 'There is no minimum performance level children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor in the majority of cases there is neurologic recovery neurologic recovery is not likely to be impeded by protocol therapy', 'REGULATORY All patients andor their parents or legal guardians must sign a written informed consent', 'REGULATORY All institutional Food and Drug Administration FDA and National Cancer Institute NCI requirements for human studies must be met', 'Patients with evidence of metastatic disease will be excluded any evidence of noncontiguous spread beyond the primary site as determined by pre or postoperative magnetic resonance MR imaging of brain pre or postoperative MR imaging of the spine and postoperative cerebrospinal fluid CSF cytology obtained from the lumbar CSF space the requirement for lumbar CSF examination may be waived if deemed to be medically contraindicated CSF cytology from a ventriculostomy or permanent ventriculoperitoneal VP shunt that reveals the presence of tumor cells is indicative of metastatic disease', 'Patients with a diagnosis of spinal cord ependymoma myxopapillary ependymoma subependymoma ependymoblastoma or mixed glioma are NOT eligible', 'No prior treatment other than surgical intervention and corticosteroids patients are allowed to have had more than one attempt at resection prior to enrollment', 'Pregnant female patients are not eligible for this study', 'Postmenarchal females may not participate unless a pregnancy test with a negative result has been obtained', 'Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method', 'Lactating females may not participate unless they have agreed not to breastfeed a child while on this study'], ['Patients with histologically confirmed ovarian stromal tumor granulosa cell tumor ganulosa celltheca cell tumor SertoliLeydig cell tumor androblastoma steroid lipid cell tumor gynandroblastoma unclassified sex cordstromal tumor sex cord tumor with annular tubules', 'Patients must have newly diagnosed stage IIA – IV disease and must be entered within eight weeks from surgery they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors RECIST criteria or they may have no measurable residual disease OR they must have biopsyproven recurrent disease of any stage and have never received cytotoxic chemotherapy', 'Patients must have a Gynecologic Oncology Group GOG performance grade of 0 1 or 2', 'Patients of childbearing potential must have a negative serum pregnancy test and must agree to practice an effective means of birth control', 'Patients in the measureable disease cohort must have at least one “target lesion” to be used to assess response on this protocol as defined by RECIST 11 tumors within a previously irradiated field will be designated as “nontarget” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy', 'Absolute neutrophil count ANC greater than or equal to 1500mcl equivalent to Common Terminology Criteria for Adverse Events CTCAE grade 1', 'Platelet greater than or equal to 100000mcl', 'Creatinine no greater than the institutional upper limits of normal', 'Bilirubin less than or equal to 15 x upper limit of normal ULN CTCAE grade 1', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST less than or equal to 30 x ULN CTCAE grade 1', 'Alkaline phosphatase less than or equal to 25 x ULN CTCAE grade 1', 'Neuropathy sensory and motor less than or equal to CTCAE grade 1', 'No signs of clinically significant hearing loss', 'Patients must have signed an approved informed consent and authorization permitting release of personal health information', 'Patients must have pulmonary function sufficient to receive bleomycin with normal lung expansion absence of crackles on auscultation and normal carbon monoxide diffusion DLCO defined as greater than 80 predicted', 'Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization', 'Recovery from effects of recent surgery radiotherapy or chemotherapy\\r\\n Patients must be entered within 8 weeks after surgery performed for either 1 initial diagnosis staging andor cytoreduction or 2 if done management of recurrent disease in a chemonaive patient\\r\\n Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration continuation of hormone replacement therapy is permitted', 'Patients who have received any prior cytotoxic chemotherapy or biologics for sex cordstromal tumors SCSTs', 'Patients with apparent stage I disease who have not undergone a staging procedure', 'Patients with a history of other invasive malignancies with the exception of nonmelanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last five years', 'Woman who are pregnant or breastfeeding', 'Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator can consult the study chair or study cochairs for uncertainty in this regard'], ['Pathologically proven diagnosis of carcinoma of the bladder within 105 days prior to registration\\r\\n Operable patients whose initial tumor is a primary high grade urothelial carcinoma of the bladder exhibiting histologic evidence of invasion into the lamina propria disease clinical stage T1 or a high grade stage Ta urothelial carcinoma without hydronephrosis patients who have involvement of the prostatic urethra with urothelial carcinoma and have no evidence of stromal invasion of the prostate remain eligible if the patient’s initial tumor was a high grade stage Ta urothelial carcinoma then hisher recurrent tumor must be a high grade stage T1 urothelial carcinoma to be eligible', 'Patients must have a high grade urothelial carcinoma stage Ta or T1 that has recurred within 540 days after completion of the initial treatment transurethral resection bladder tumor TURBT and intravesical bacillus CalmetteGuerin BCG immunotherapy or on initial presentation with a T1 high grade tumor the participating urologist judged BCG therapy is contraindicated or unsuitable because the patient is found to be intolerant of BCG therapy or because this patient may be immunocompromised in ways other than that mentioned in severe active comorbidity or because the patient refuses BCG therapy', 'The participating urologist judges that the standard next therapy based on present urologic guidelines for this patient is radical cystectomy', 'If radiologic evaluation of a lymph node is interpreted as “positive” this must be evaluated further either by lymphadenectomy or by percutaneous needle biopsy patients with histologically or cytologically confirmed node metastases will not be eligible', 'Patients must have an adequately functioning bladder as judged by the participating urologist and radiation oncologist and have undergone a restaging TURBT by the participating urologist that showed or was present in the outside pathology specimen a high grade stage Ta or T1 tumor with uninvolved muscularis propria in the specimen and if on prostatic urethral biopsy mucosal carcinoma is present there is no evidence on biopsy in the prostatic stroma of tumor invasion', 'Patient must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy and a radical cystectomy if necessary by the joint agreement of the participating urologist radiation oncologist and medical oncologist', 'Appropriate stage for protocol entry based upon the following minimum diagnostic workup within 60 days prior to registration\\r\\n Historyphysical examination including weight performance data body surface area', 'Zubrod performance status =< 1', 'White blood cell count WBC >= 4000ml', 'Absolute neutrophil count ANC >= 1800 cellsmm3', 'Platelets >= 100000 cellsmm3', 'Hemoglobin >= 100 gdL Note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 100 gdl is acceptable', 'If the patient is to be treated with cisplatin the serum creatinine should be =< 15 mg', 'If the patient is to be treated with cisplatin the serum bilirubin of =< 20 mg', 'Glomerular filtration rate GFR > 25 mlmin for patients receiving cisplatin GFR >= 60 mlmin', 'Serum pregnancy test for female patients of childbearing potential =< 72 hours prior to study entry women of childbearing potential and male participants must practice adequate contraception', 'Patient must be able to provide studyspecific informed consent prior to study entry', 'Evidence of tumorrelated hydronephrosis', 'Evidence of distant metastases or histologically or cytologically proven lymph node metastases', 'Prior systemic chemotherapy for bladder cancer prior chemotherapy for a different cancer is allowable', 'A prior or concurrent malignancy of any other site or histology unless the patient has been diseasefree for >= 5 years except for nonmelanoma skin cancer andor stage T1a prostate cancer or carcinoma in situ of the uterine cervix or a urothelial carcinoma of the upper urinary tract stage pTa pTis or pT1 that has not been free of disease after treatment for more than a 2 year period', 'Patients with pN+ or > T1 disease or who have not had a visibly complete TURBT', 'Patients receiving any drugs that have potential nephrotoxicity or ototoxicity such as an aminoglycoside', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months\\r\\n Transmural myocardial infarction within the last 6 months\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n Hepatic insufficiency resulting in clinical jaundice andor coagulation defects note however that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol\\r\\n Acquired immune deficiency syndrome AIDS based upon the current Centers for Disease Control and Prevention CDC definition note however that human immunodeficiency virus HIV testing is not required for entry into this protocol protocolspecific requirements may also exclude immunocompromised patients', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception this exclusion is necessary because the treatment involved in this study may be significantly teratogenic', 'Prior allergic reaction to the study drugs cisplatin mitomycin fluorouracil 5FU involved in this protocol'], ['Diagnosis of rectal adenocarcinoma', 'Radiologically measurable or clinically evaluable disease', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 or 2', 'For this patient the standard treatment recommendation in the absence of a clinical trial would be combined modality neoadjuvant chemoradiation followed by curative intent surgical resection', 'Candidate for sphinctersparing surgical resection prior to initiation of neoadjuvant therapy according to the primary surgeon', 'Clinical stage T2N1 T3N0 T3N1\\r\\n N2 disease is to be estimated as four or more lymph nodes that are >= 10 mm\\r\\n Clinical staging should be estimated based on the combination of the following assessments physical exam by the primary surgeon computed tomography CT or positron emission tomography PETCT scan of the chestabdomenpelvis and either a pelvic magnetic resonance imaging MRI or an ultrasound endorectal ultrasound ERUS if a pelvic MRI is performed it is acceptable to perform CT of the chestabdomen omitting CT imaging of the pelvis', 'Absolute neutrophil count ANC >= 1500mm3 =< 28 days prior to registration', 'Platelet count >= 100000mm3 =< 28 days prior to registration', 'Hemoglobin > 80 gdL =< 28 days prior to registration', 'Total bilirubin =< 15 x upper limit of normal ULN =< 28 days prior to registration', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 3 x ULN =< 28 days prior to registration', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 3 x ULN =< 28 days prior to registration', 'Creatinine =< 15 times ULN =< 28 days prior to registration', 'Negative pregnancy test done =< 7 days prior to registration for women of childbearing potential only', 'Patient of childbearing potential is willing to employ adequate contraception appropriate methods of birth control include abstinence oral contraceptives implantable hormonal contraceptives or double barrier method diaphragm plus condom', 'Provide informed written consent', 'Willing to return to enrolling medical site for all study assessments', 'Clinical T4 tumors', 'Primary surgeon indicates need for abdominoperineal APR at baseline', 'Evidence that tumor is adherent to or invading the mesorectal fascia on imaging studies such that the surgeon would not be able to perform an R0 resection one with negative margins', 'Tumor is causing symptomatic bowel obstruction patients who have had a temporary diverting ostomy are eligible', 'Chemotherapy within 5 years prior to registration hormonal therapy is allowable if the disease free interval is >= 5 years', 'Any prior pelvic radiation', 'Other invasive malignancy =< 5 years prior to registration exceptions are colonic polyps nonmelanoma skin cancer ductal carcinoma in situ bladder carcinoma in situ or carcinomainsitu of the cervix', 'Any of the following\\r\\n Pregnant women\\r\\n Nursing women\\r\\n Men or women of childbearing potential who are unwilling to employ adequate contraception', 'Comorbid illnesses or other concurrent disease which in the judgment of the clinician obtaining informed consent would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens'], ['Patients must be enrolled on APEC14B1 and consented to Eligibility Screening on the Part A consent form prior to enrollment on AALL1131', 'White Blood Cell Count WBC Criteria\\r\\n Age 1999 years WBC >= 50 000uL \\r\\n Age 103099 years Any WBC \\r\\n Age 13099 years Any WBC with\\r\\n Testicular leukemia\\r\\n CNS leukemia CNS3\\r\\n Steroid pretreatment', 'Patients must have newly diagnosed B lymphoblastic leukemia 2008 World Health Organization WHO classification also termed Bprecursor acute lymphoblastic leukemia patients with Down syndrome are also eligible', 'Organ function requirements for patients with Phlike ALL and a predicted TKIsensitive mutation patients identified as Phlike with a TKIsensitive kinase mutation must have assessment of organ function performed within 3 days of study entry onto the dasatinib arm of AALL1131', 'Creatinine clearance or radioisotope glomerular filtration rate GFR > 70mLmin173 m2 or a serum creatinine based on agegender as follows\\r\\n Age Maximum Serum Creatinine mgdL\\r\\n 1 to < 6 months 04 male 04 female\\r\\n 6 months to < 1 year 05 male 05 female\\r\\n 1 to < 2 years 06 male 06 female\\r\\n 2 < 6 years 08 male 08 female\\r\\n 6 to < 10 years 10 male 10 female\\r\\n 10 to < 13 years 12 male 12 female\\r\\n 13 to < 16 years 15 male 14 female\\r\\n > 16 years 17 male 14 female', 'Direct bilirubin =< 3 x upper limit of normal ULN for age and', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 10 x upper limit of normal ULN for age', 'Shortening fraction >= 27 by echocardiogram or ejection fraction >= 50 by gated radionuclide study \\r\\n Patients must have an electrocardiogram EKG fewer than 6 days prior to enrollment on the dasatinib arm patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry correct QT interval QTc < 450 msec on baseline electrocardiogram as measured by the Friderica or Bazett formula\\r\\n No major conduction abnormality unless a cardiac pacemaker is present', 'No evidence of dyspnea at rest no exercise intolerance and a pulse oximetry > 94 at sea level if there is clinical indication for determination', 'Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled however drugs that induce CYP3A45 carbamazepine oxcarbazepine phenytoin primidone phenobarbital should be avoided', 'With the exception of steroid pretreatment or the administration of intrathecal cytarabine patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of BALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131 patients cannot have secondary BALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy patients receiving prior steroid therapy may be eligible for AALL1131', 'Patients with BCRABL1 fusion are not eligible for postinduction therapy on this study but may be eligible to enroll in a successor Childrens Oncology Group COG Philadelphia positive Ph+ ALL trial by day 15 Induction', 'DS HR BALL patients with Induction failure or BCRABL1', 'Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs', 'Lactating females are not eligible unless they have agreed not to breastfeed their infant', 'Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained', 'Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation', 'Eligibility criteria for the Longitudinal Computerized Assessment of Neurocognitive Functioning study \\r\\n Patients must be aged 6 to 13 years at time of BALL diagnosis enrolled on AALL1131\\r\\n Patients must be English French or Spanishspeaking languages in which the assessment is available\\r\\n Patients must have no known history of neurodevelopmental disorder prior to diagnosis of BALL eg Down syndrome Fragile X William’s Syndrome mental retardation\\r\\n Patients must have no significant visual impairment that would prevent computer use and recognition of the visual test stimuli', 'Eligibility criteria for the National Cancer Institute NCI standard risk patients from AALL0932 enrolling on this study at the end of Induction', 'Effective March 19 2018 patients enrolled on AALL0932 without Down syndrome meeting the following criteria will NOT be eligible to continue on AALL0932 or the HR BALL stratum of this study at the end of Induction \\r\\n Without favorable cytogenetics no ETV6RUNX1 or double trisomies 4+10 with day 8 peripheral blood PB minimal residual disease MRD >= 1 and day 29 bone marrow BM MRD < 001\\r\\n With favorable cytogenetics ETV6RUNX1 or double trisomies 4+10 with any day 8 PB MRD and day 29 BM MRD >= 001\\r\\n Both NCI standard risk SR and HR patients without Down syndrome and with testicular disease at diagnosis who do not meet other VHR criteria', 'Effective Amendment 6 patients enrolled on AALL0932 without Down syndrome meeting the following criteria will NOT be eligible to continue on AALL0932 or the VHR stratum of AALL1131 \\r\\n Intrachromosomal amplification of chromosome 21 iAMP21\\r\\n Mixedlineage leukemia MLL rearrangement\\r\\n Hypodiploidy n < 44 chromosomes andor a deoxyribonucleic acid DNA index < 081 \\r\\n Induction failure M3 BM at day 29\\r\\n Without favorable cytogenetics no ETV6RUNX1 or double trisomies 4+10 with day 29 BM MRD >= 001', 'Patients enrolled on AALL0932 with Down syndrome meeting the following criteria will NOT be eligible to continue on AALL0932 but WILL BE eligible to enroll on the DS HR BALL stratum of this study at the end of Induction \\r\\n Day 29 MRD >= 001\\r\\n MLL rearrangement\\r\\n Hypodiploidy n < 45 chromosomes andor DNA index < 081', 'DS HR BALL patients initially enrolled on AALL0932 or this study who have Induction failure M3 BM day 29 or Philadelphia chromosome BCRABL1 will not be eligible for postInduction therapy on either trial AALL0932 or AALL1131', 'All patients andor their parents or legal guardians must sign a written informed consent', 'All institutional Food and Drug Administration FDA and NCI requirements for human studies must be met'], ['Pathologically histologically or cytologically proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to highrisk for recurrence as determined by one of the following combinations\\r\\n Gleason score 710 + T1cT2b palpation + prostatespecific antigen PSA < 50 ngmL includes intermediate and highrisk patients\\r\\n Gleason score 6 + T2cT4 palpation + PSA < 50 ngmL OR Gleason score 6 + >= 50 positive biopsies + PSA < 50 ngml\\r\\n Gleason score 6 + T1cT2b palpation + PSA > 20 ngmL\\r\\n Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are rebiopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure', 'Historyphysical examination to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen within 90 days prior to registration', 'Clinically negative lymph nodes as established by imaging pelvic andor abdominal computed tomography CT or magnetic resonance MR but not by nodal sampling or dissection within 90 days prior to registration\\r\\n Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 15 cm', 'No evidence of bone metastases M0 on bone scan within 120 days prior to registration sodium fluoride NaF positron emission tomography PETCT is an acceptable substitute\\r\\n Equivocal bone scan findings are allowed if plain films or CT or magnetic resonance imaging MRI are negative for metastasis', 'Baseline serum PSA value performed with a Food and Drug Administration FDAapproved assay eg Abbott Hybritech within 120 days prior to registration', 'Study entry PSA should not be obtained during the following time frames\\r\\n 10day period following prostate biopsy\\r\\n Following initiation of hormonal therapy\\r\\n Within 30 days after discontinuation of finasteride\\r\\n Within 90 days after discontinuation of dutasteride', 'Zubrod performance status 01 unless otherwise specified', 'Absolute neutrophil count ANC >= 1500mm3 within 60 days prior to registration on study', 'Platelets >= 100000mm3 within 60 days prior to registration on study', 'Hemoglobin Hgb >= 80 gdL within 60 days prior to registration on study Note the use of transfusion or other intervention to achieve Hgb >= 80 gdL is acceptable', 'Patient must be able to provide study specific informed consent prior to study entry', 'Prior invasive except nonmelanoma skin cancer malignancy unless diseasefree for a minimum of 3 years 1095 days not in the pelvis for example carcinoma in situ of the oral cavity is permissible however patients with prior history of bladder cancer are not allowed prior hematological eg leukemia lymphoma myeloma malignancy not allowed', 'Previous radical surgery prostatectomy or cryosurgery for prostate cancer', 'Previous pelvic irradiation prostate brachytherapy or bilateral orchiectomy', 'Previous hormonal therapy such as LHRH agonists eg leuprolide goserelin buserelin triptorelin or LHRH antagonist eg degarelix antiandrogens eg flutamide bicalutamide cyproterone acetate estrogens eg diethylstilbestrol DES or surgical castration orchiectomy', 'Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation both LHRH agonist and oral antiandrogen is =< 45 days prior to the date of registration', 'Use of finasteride within 30 days prior to registration', 'Use of dutasteride or dutasteridetamsulosin Jalyn within 90 days prior to registration', 'Previous or concurrent cytotoxic chemotherapy for prostate cancer note that prior chemotherapy for a different cancer is allowable', 'Prior radiotherapy including brachytherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months\\r\\n Transmural myocardial infarction within the last 6 months\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n Hepatic insufficiency resulting in clinical jaundice andor coagulation defects or severe liver dysfunction\\r\\n Acquired immune deficiency syndrome AIDS based upon current Centers for Disease Control and Prevention CDC definition note however that human immunodeficiency virus HIV testing is not required for entry into this protocol the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive protocolspecific requirements may also exclude immunocompromised patients', 'Patients who are sexually active and not willingable to use medically acceptable forms of contraception this exclusion is necessary because the treatment involved in this study may be significantly teratogenic', 'Prior allergic reaction to the hormones involved in this protocol', 'Patients status post a negative lymph node dissection are not eligible'], ['Patients must have biopsyproven denovo diffuse large Bcell lymphoma DLBCL \\r\\n Patients with primary mediastinal lymphoma or testicular lymphoma are not eligible\\r\\n Patients with prior or simultaneous diagnosis of indolent lymphoma are not eligible\\r\\n Posttransplant lymphoproliferative disorder with DLBCL morphology is ineligible', 'Patients must have nonbulky stage I or II disease by Ann Arbor classification\\r\\n This staging excludes fludeoxyglucose F 18 FDGPET evaluation\\r\\n Patients who have stage I or II nonbulky disease based on diagnostic CT scan but are upstaged to stage III or IV based on FDGPET evaluation are also eligible\\r\\n Stage and bulk are assigned using measurements obtained prior to biopsy', 'Patients must have a diagnostic quality contrastenhanced CT scan of the chest abdomen and pelvis AND baseline FDGPET scan performed within 28 days prior to registration\\r\\n Lowresolution localization CT scans performed as part of a combined PETCT scan are not adequate for enrollment or response determination on this protocol\\r\\n If a patient has an allergy to CT contrast then a nonenhanced CT will be acceptable', 'Patients must not have clinical evidence of central nervous system CNS involvement by lymphoma            \\r\\n Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registration', 'Patients must have either measurable or evaluable limitedstage DLBCL          \\r\\n Patients rendered free of measurable or evaluable disease by virtue of biopsy resection are also eligible NOTE if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form\\r\\n All measurable disease must be assessed within 28 days prior to registration\\r\\n Patients with nonmeasurable disease with or without measurable disease must have all nonmeasurable disease assessed within 42 days prior to registration', 'Patients must have a unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration', 'Adequate sections or a paraffin block from the original diagnostic specimen must be submitted for review by the lymphoma pathology group', 'Patients must be offered the opportunity to consent to the use of specimens for future research', 'The lymphoma must express the cluster of differentiation CD20 antigen by either flow cytometry using antiCD20 antibodies or by immunoperoxidase staining of paraffin sections a report providing confirmation of CD20 expression must be submitted', 'Patients must not have received prior chemotherapy radiotherapy or antibody therapy for lymphoma', 'Patients must have a complete history and physical examination within 28 days prior to registration', 'Zubrod performance status 02', 'The following tests must be performed within 42 days prior to registration either for diagnosisstaging or to obtain baseline values\\r\\n White blood cells WBC\\r\\n Hemoglobin\\r\\n Lactate dehydrogenase LDH\\r\\n Hepatitis Bsurface antigen Ag and anticore antibody Ab', 'Serum creatinine =< 2 x institutional upper limit of normal IULN unless due to lymphoma within 42 day prior to registration', 'Patients must have aspartate aminotransferase ASTalanine aminotransferase ALT =< 5 x IULN unless due to lymphoma within 42 days prior to registration', 'Platelet count >= 100000 cellsmcL', 'Absolute neutrophil count ANC >= 1000 cellsmcL within 42 days prior to registration', 'Total bilirubin =< 2 x institutional upper limit of normal IULN unless due to Gilbert syndrome within 42 days prior to registration', 'Patients must have a cardiac ejection fraction >= institutional lower limit of normal ILLN by multi gated acquisition MUGA scan or 2dimensional D echocardiogram ECHO within 42 days prior to registration', 'Patients must not be known to be human immunodeficiency virus HIVpositive', 'No other prior malignancy is allowed except for the following            \\r\\n Adequately treated in situ cancers stage 0\\r\\n Adequately treated basal cell or squamous cell skin cancer\\r\\n Adequately treated stage I or II cancer from which the patient has been in complete remission or\\r\\n Any other cancer from which the patient has been diseasefree for at least 5 years', 'Patients must not be pregnant or nursing womenmen of reproductive potential must have agreed to use an effective contraceptive method during the study period a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol heshe is responsible for beginning contraceptive measures', 'Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system', 'SECOND REGISTRATION STEP 2', 'Patients must have completed 3 cycles of RCHOP with no evidence of disease progression', 'Interim PETCT scans must have been submitted for centralized review', 'If PETnegative based on the returned results from centralized review patients must be planning to begin further treatment within 35 days of the start of cycle 3 of RCHOP if PETpositive based on the returned results from centralized review it is important for patients to start IFRT as soon as possible after the end of cycle 3 of RCHOP they should be planning to initiate IFRT followed by yttrium90 ibritumomab tiuxetan within 35 days of the start of cycle 3 of RCHOP'], ['Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen andor progesterone receptor status and negative HER2 for whom standard adjuvant endocrine therapy is planned estrogen and progesterone receptor positivity must be assessed according to American Society of Clinical Oncology ASCOCollege of American Pathologist CAP guidelines as either estrogen receptor ER or progesterone receptor PR >= 1 positive nuclear staining HER2 test result negativity must be assessed as per ASCOCAP 2013 guidelines using immunohistochemistry IHC in situ hybridization ISH or both HER2 is negative if a single test or all tests performed in a tumor specimen show a IHC negative 0 or 1+ or b ISH negative using single probe or dual probe average HER2 copy number < 40 signals per cell by single probe or HER2chromosome enumeration probe CEP ratio < 20 with an average copy number < 40 signals per cell by dual probe if HER2 IHC is 2+ evaluation for gene amplification ISH must be performed and the ISH must be negative ISH is not required if IHC is 0 or 1+ HER2 equivocal is not eligible', 'Patients must not have metastatic breast cancer stage IV disease patients with multifocal multicentric and synchronous bilateral and primary inflammatory breast cancers are allowed\\r\\n Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant\\r\\n Multicentric disease is defined as more than one invasive cancer >= 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants\\r\\n Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes axillary or intramammary in at least one breast diagnosed within 30 days of each other NOTE the tumor with the highest recurrence score should be used', 'Patients must be high risk by belonging to one of the following risk groups\\r\\n Completion of adjuvant chemotherapy and pathologically negative lymph nodes and a tumor measuring >= 2 cm in greatest diameter and an Oncotype DX recurrence score > 25 completed as standard of care or a MammaPrint assay completed as standard of care in the highrisk category patients with micrometastases as the only nodal involvement pN1mi are eligible and will be categorized as nodenegative \\r\\n Completion of adjuvant chemotherapy and pathologically 13 positive lymph nodes and either an Oncotype DX recurrence score > 25 MammaPrint assay in the highrisk category completed as standard of care or tumor tissue with pathological grade III following local practice if Oncotype DX is done then RS must be > 25 similarly if the MammaPrint assay is performed it has to be highrisk if the test is not done but the patient has grade III disease then the patient is eligible and Oncotype DX or MammaPrint does not need to be performed\\r\\n Completion of adjuvant chemotherapy and pathologically 4 or more positive lymph nodes\\r\\n Completion of neoadjuvant chemotherapy and 1 or more positive nodes pathologically determined after chemotherapy\\r\\n NOTE patients who receive both the neoadjuvant and adjuvant chemotherapy may be registered in the neoadjuvant therapy risk group provided they meet all the criteria above for that risk group\\r\\n NOTE in the lymph node positive groups at least one metastasis >= 20 mm must be present patients with micrometastases as the only nodal involvement pN1mi are eligible and will be categorized as nodenegative', 'Patients must have completed either breastconserving surgery or total mastectomy with negative margins and appropriate axillary staging a negative margin is defined as no evidence of tumor or ductal carcinoma in situ DCIS at the line of resection additional operative procedures may be performed to obtain clear margins\\r\\n Patients who had breastconserving surgery must have completed whole breast radiation use of regional nodal basin radiation will be at the discretion of the investigator according to institutional guidelines\\r\\n Patients with >= 4 positive lymph nodes must have completed breastchest wall and nodal basin radiation therapy according to standard of care guidelines before randomization omission of radiation therapy is not allowed in this highrisk population of patients\\r\\n Patients must be registered at least 21 days after completion of radiation therapy and must have recovered =< grade 1 from any of the effects of radiation', 'Patients must have undergone axillary staging by sentinel node biopsy or axillary lymph node dissection ALND\\r\\n For patients with 13 positive lymph nodes sentinel node biopsy alone is allowed provided that the patient completed either whole breast or chest wall radiation and the primary tumor is < 5 cm\\r\\n All patients with >= 4 positive lymph nodes must have completed ALND with or without prior sentinel node biopsy', 'Patients must have completed standard neoadjuvant or adjuvant taxane andor anthracycline based chemotherapy prior to randomization completion of chemotherapy will be determined by the treating oncologist but should include a minimum of 4 cycles a cycle of weekly paclitaxel is considered 3 doses patients must be registered within 42 weeks after the last dose of chemotherapy patients may have started endocrine therapy at any time after the diagnosis of the current breast cancer', 'Patients must not be receiving or planning to receive trastuzumab concurrent bisphosphonate therapy is allowed patients must not have prior exposure to mechanistic target of rapamycin serinethreonine kinase mTOR inhibitors rapamycin everolimus temsirolimus deforolimus patients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the study', 'Absolute neutrophil count ANC >= 1500mL obtained within 28 days prior to registration', 'Hemoglobin >= 9 gdL obtained within 28 days prior to registration', 'Platelet count >= 100000mL obtained within 28 days prior to registration', 'Bilirubin =< 15 mgdL or =< 30 mgdL if due to Gilberts syndrome within 28 days prior to registration', 'Alanine aminotransferase ALT and aspartate aminotransferase AST =< 15 x institutional upper limit of normal IULN obtained within 28 days prior to registration', 'Alkaline phosphatase =< 15 x IULN obtained within 28 days prior to registration', 'Serum creatinine level =< IULN obtained within 28 days prior to registration', 'Fasting cholesterol =< 300 mgdL and triglycerides =< 25 x IULN obtained within 28 days prior to registration patients may be on lipid lowering agents to reach these values', 'Patients must have a complete history and physical examination within 28 days prior to registration', 'Patients must have a performance status of 02 by Zubrod criteria', 'Patients must not have any grade IIIIV cardiac disease as defined by the New York Heart Association Criteria ie patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort unstable angina pectoris myocardial infarction within 6 months or serious uncontrolled cardiac arrhythmia', 'Patients previously diagnosed with diabetes must not have uncontrolled diabetes defined as a hemoglobin Hg A1C > 7 within 28 days prior to registration', 'Patients must not have an organ allograft or other history of immune compromise patients must not be receiving chronic systemic treatment with corticosteroids or other immunosuppressive agent topical or inhaled corticosteroids are allowed', 'Patients known to be human immunodeficiency virus HIV positive may be enrolled if baseline cluster of differentiation CD4 count is > 500 cellsmm3 AND not taking antiretroviral therapy patients with known hepatitis are not eligible unless there is a known negative hepatitis panel exception previous history of hepatitis A infection that is not currently active is allowed patients must not have any known uncontrolled underlying pulmonary disease', 'Patients must be able to take oral medications patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of blinded drug eg ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection', 'Patients must not have received immunization with an attenuated live vaccine eg intranasal influenza measles mumps and rubella MMR oral polio varicella zoster yellow fever and Bacillus Calmette–Guerin BCG vaccines within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment', 'Patients must not have taken within 14 days prior to registration be taking nor plan to take while on protocol treatment strong cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 inhibitors andor CYP3A4 inducers', 'No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has been diseasefree for 5 years', 'Patients must not be pregnant or nursing womenmen of reproductive potential must have agreed to use an effective nonhormonal contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation corresponding procedures for men include castration vasectomy and barrier contraceptive devices however if at any point a previously celibate patient chooses to become heterosexually active during the protocol therapy heshe is responsible for beginning contraceptive measures', 'Patients must have pretreatment blood and tissue specimens submitted for translational medicine as outlined with patient consent residuals will be banked for future research', 'Patients at National Cancer Institute NCI Community Oncology Research Program NCORP Institutions only must be offered the opportunity to participate in the S1207E01 Behavioral and Health Outcomes study BAHO NOTE patients who have already started endocrine therapy are eligible for the BAHO study', 'Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system'], ['Patients must have newly diagnosed active multiple myeloma MM except where otherwise indicated below that assessment is required within 14 days all tests for establishing baseline disease status must be completed within 28 days prior to registration for patients with no prior therapy or within 28 days prior to initiation of first Induction course for patients with prior therapy', 'For the Phase II portion only patients must have highrisk MM based on one or more of the following criteria at the time of initial diagnosis prior to any chemotherapy\\r\\n Poorrisk genomic signature according to the University of Arkansas 70gene model available clinically as myeloma prognostic risk score MyPRS score Signal Genetics Inc ANDOR\\r\\n Translocation 1416 andor translocation 1420 andor deletion 17p by fluorescence insitu hybridization FISH or cytogenetics ANDOR\\r\\n Primary plasma cell leukemia defined by either >= 2000 plasma cellsmL of peripheral blood or 20 on a manual differential count ANDOR\\r\\n Serum lactate dehydrogenase LDH >= 2 x institutional upper limit of normal IULN ANDOR\\r\\n 1q21 amplification by FISH analysis ANDOR\\r\\n High risk by the SKY92 signature\\r\\n All tests for establishing high risk status must be completed within 28 days prior to registration for patients with no prior therapy or within 28 days prior to initiation of first Induction course for patients with prior therapy', 'Patients with nonsecretory MM or known amyloidosis are not eligible', 'Patients must have measurable disease within 28 days prior to registration or prior to initiation of first induction course for patients with prior therapy', 'Patients on the Phase I portion may not have received ANY prior chemotherapy patients on the Phase II portion may have received one prior cycle of any noninvestigational chemotherapy prior chemotherapy must have been completed within 56 days prior to registration and all toxicities must have resolved to =< grade 1 patients on either portion may have received prior treatment with dexamethasone providing total number of days of treatment was =< 14 days and total treatment dose was =< 360 mg', 'Patients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only radiotherapy must be completed at least 14 days prior to registration and all toxicities must have resolved to =< grade 1', 'Absolute neutrophil count ANC >= 1000 cellsmm3 without growth factor support within 14 days prior to registration', 'Platelet count >= 70000 cellsmm3 for patients who have bone marrow plasmacytosis < 50 or >= 50000 cellsmm3 for patients who have bone marrow plasmacytosis of >= 50 within 14 days prior to registration', 'Total bilirubin =< 15 x institutional upper limit of normal IULN within 14 days prior to registration', 'Serum glutamic oxaloacetic transaminase SGOTaspartate aminotransferase AST and serum glutamate pyruvate transaminase SGPTalanine aminotransferase ALT =< 25 x IULN within 14 days prior to registration', 'Creatinine clearance CrCL >= 30 mLmin measured by a 24hour urine collection or estimated by the Cockcroft and Gault formula within 14 days prior to registration', 'Patients must not have active involvement of the central nervous system CNS with MM by clinical evaluation patients with documentation of or clinical signs or symptoms consistent with CNS involvement of MM must have a lumbar puncture that is negative for CNS involvement of MM the lumbar puncture must be completed within 14 days prior to registration patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture prior to registration note that monitoring of CNS involvement and treatment with intrathecal therapy is recommended during protocol treatment', 'Patients who are known to be human immunodeficiency virus positive HIV+ are eligible providing they meet all of the following additional criteria within 28 days prior to registration\\r\\n Cluster of differentiation CD4 cells >= 500mm3\\r\\n Viral load of < 50 copies HIV messenger ribonucleic acid mRNAmm3 if on combination antiretroviral therapy cART or < 25000 copies HIV mRNA if not on cART\\r\\n No zidovudine or stavudine as part of cART\\r\\n Patients who are HIV+ and do not meet all of these criteria are not eligible for this study', 'Patients must have baseline skeletal survey whole body xray to document lytic lesions osteopenia or compression fracture', 'Patients must have Zubrod performance status =< 2', 'Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800000 IUL within 28 days prior to registration', 'Patients must not have POEMS syndrome plasma cell dyscrasia with polyneuropathy organomegaly endocrinopathy monoclonal protein and skin changes', 'Patients must not have clinically significant illness including uncontrolled active infection requiring intravenous antibiotics New York Heart Association NYHA class III or class IV heart failure unstable angina pectoris myocardial infarction within the past 6 months uncontrolled >= grade 3 cardiac arrhythmias uncontrolled hypertension or uncontrolled diabetes mellitus patients must have undergone an electrocardiogram EKG within 28 days prior to registration', 'Uncontrolled diabetes a glycated hemoglobin Hg A1C > 7 within 14 days prior to registration the same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months', 'Uncontrolled blood pressure and hypertension systolic blood pressure SBP > 140 mm Hg or diastolic blood pressure DBP > 90 mm Hg within 14 days prior to registration patients are permitted to be receiving multiple antihypertensive medications unless otherwise indicated in the study all blood pressure measurements within the 14 days prior to registration and on day 1 of cycle 1 must be SBP =< 140 and DBP =< 90 an exception can be made by a healthcare provider for a patient with a single blood pressure elevation who upon rechecking has a normal blood pressure', 'Patients must have history and physical examination within 28 days prior to registration', 'Patients must not have any psychiatric illness that could potentially interfere with the completion of treatment according to this protocol', 'Females of childbearing potential FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIUmL within 10 – 14 days prior to registration Note that pregnancy testing is also required within 24 hours prior to treatment on cycle 1 day 1 furthermore they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control one highly effective method and one additional effective method AT THE SAME TIME at least 28 days before starting lenalidomide FCBP must also agree to ongoing pregnancy testing men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy a FCBP is a sexually mature woman who 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'No other prior malignancy is allowed except for the following adequately treated basal cell or squamous cell skin cancer in situ cervical cancer adequately treated stage I or II cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease free for five years', 'Patients must be offered participation in banking of specimens for future research with the patient’s consent specimens serum and bone marrow biopsy core must be submitted to the repository patient consent must be obtained before specimens are submitted', 'Patients must be registered to the mandatory Revlimid Risk Evaluation and Mitigation Strategy REMS program and must be willing and able to comply with the requirements of the Revlimid REMS program', 'Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system'], ['Diagnosed with glioblastoma gliosarcoma small cell or large cell glioblastoma glioblastoma with oligo features glioblastoma with primitive neuroectodermal tumorlike components GBMPNET features anaplastic astrocytoma anaplastic oligodendroglioma or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy excluding stereotactic radiosurgery > 21 days and =< 24 months prior to enrollment NOTE clinical stability will be defined as a stable or improved Karnofsky performance status KPS compared to the prior month', '>= 6 score on the worst fatigue question of the BFI Brief Fatigue Inventory question 3 it is not required for the patient to complete the entire BFI to meet this criterion', 'Undergone surgery gross total or subtotal resection or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma gliosarcoma small cell or large cell glioblastoma glioblastoma with oligo features glioblastoma with primitive neuroectodermal tumorlike components GBMPNET features anaplastic astrocytoma anaplastic oligodendroglioma or anaplastic oligoastrocytoma patients Note radiation must be completed but chemotherapy is allowed patients who are currently using Optune device will be eligible to participate in this trial', 'Negative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physician', 'Ability to complete questionnaires by themselves or with assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS of 0 1 2 or 3', 'Provide informed written consent', 'Willing to return to enrolling institution for followup during the Active Monitoring phase of the study', 'Stable dose of corticosteroid >= 14 days prior to registration', 'Any of the following\\r\\n Pregnant women\\r\\n Nursing women\\r\\n Men or women of childbearing potential who are unwilling to employ adequate contraception', 'History of hypersensitivity to other psychostimulants', 'History of steroid psychosis', 'Currently taking medications for attention deficit hyperactivity disorder history of or currently taking medications for severe anxiety disorder schizophrenia or substance abuse by patient record andor selfreport\\r\\n Note Patients who had childhood attention deficit hyperactivity disorder ADHD and no longer require treatment will be eligible to participate', 'Currently using any other pharmacologic agents or nonpharmacologic interventions to specifically treat fatigue including psychostimulants antidepressants acupuncture etc will be excluded Note antidepressants used to treat items other than fatigue such as hot flashes or depression are allowed if the patient has been on a stable dose for >= 30 days prior to registration and plans to continue for the duration of the trial erythropoietin agents to treat anemia are allowed exercise is allowed', 'Anticipating surgery', 'Uncontrolled hypothyroidism profound anemia hemoglobin level of <10 gdL =< 28 days prior to registration or untreated clinical depression per physician discretion Patients with stable controlled depression or receiving treatment for hypothyroidism will be eligible if they have been on a stable dose for the past 30 days and plan to continue for the duration of the trial', 'Active or a history of Tourette’s syndrome or tic disorder', 'History of or active glaucoma', 'History of intractable epilepsy', 'Any of the following comorbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\\r\\n History of myocardial infarction\\r\\n Unstable angina\\r\\n Left ventricular hypertrophy\\r\\n Mitral valve prolapse syndrome', 'Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 use of the following strong or moderate inhibitors are prohibited =< 7 days prior to registration\\r\\n Strong inhibitors of CYP3A4\\r\\n > 5fold increase in the plasma area under the curve AUC values or more than 80 decrease in clearance\\r\\n Indinavir Crixivan\\r\\n Nelfinavir Viracept\\r\\n Atazanavir Reyataz\\r\\n Ritonavir Norvir\\r\\n Clarithromycin Biaxin Biaxin XL\\r\\n Itraconazole Sporanox\\r\\n Ketoconazole Nizoral\\r\\n Nefazodone Serzone\\r\\n Saquinavir Fortovase Invirase\\r\\n Telithromycin Ketek\\r\\n Moderate Inhibitors of CYP3A4\\r\\n > 2fold increase in the plasma AUC values or 5080 decrease in clearance\\r\\n Aprepitant Emend\\r\\n Erythromycin Erythrocin EES EryTab Eryc EryPed PCE\\r\\n Fluconazole Diflucan\\r\\n Grapefruit juice\\r\\n Verapamil Calan Calan SR CoveraHS Isoptin SR Verelan Verelan PM\\r\\n Diltiazem Cardizem Cardizem CD Cardizem LA Cardizem SR Cartia XT Dilacor XR Diltia XT Taztia XT Tiazac', 'Receiving any medications or substances that are inducers of CYP3A4 use of the following inducers are prohibited =< 7 days prior to registration\\r\\n Inducers of CYP3A4 \\r\\n Efavirenz Sustiva\\r\\n Nevirapine Viramune\\r\\n Carbamazepine Carbatro Epitol Equetro Tegretol TegretolXR\\r\\n Modafinil Provigil\\r\\n Phenobarbital Luminal\\r\\n Phenytoin Dilantin Phenytek\\r\\n Pioglitazone Acto\\r\\n Rifabutin Mycobutin\\r\\n Rifampin Rifadin\\r\\n St John’s wort'], ['Pathologically confirmed diagnosis of breast cancer clinical stage III T13 N0 M0 T02 N1 M0 diagnosis must be by needle biopsy patients diagnosed by surgical excision are excluded for patients enrolled after receipt and completion of neoadjuvant chemotherapy the clinical stage must be determined based on prechemotherapy assessment', 'Patients must have either\\r\\n Estrogen receptor ER negativeprogesterone receptor PR negative < 10 by immunohistochemistry IHC staining and HER2 negative breast cancer OR\\r\\n ER negativePR negative < 10 by IHC staining and HER2 positive tumors\\r\\n HER2 status will be determined per the 2013 American Society of Clinical Oncology ASCO College of American Pathologists CAP guidelines\\r\\n HER2 is considered positive if a there is IHC 3+ staining or b positive using either single probe in situ hybridization ISH or dual probe ISH\\r\\n HER2 is considered negative if a there is IHC 0 or 1+ staining or b ISH negative using either single probe ISH or dual probe ISH\\r\\n For patients enrolling after neoadjuvant therapy the ER PR and HER2 markers are based on assessment prior to initiating neoadjuvant treatment', 'No patients with previous ipsilateral or contralateral invasive breast cancer or ductal carcinoma in situ DCIS', 'No patients with bilateral breast cancer', 'No patients with known deleterious mutations in breast cancer BRCA genes', 'No history of receiving endocrine therapy tamoxifen and or aromatase inhibitors for therapeutic measures these agents used previously as chemoprevention are allowed', 'Patients receiving neoadjuvant chemotherapy or recently completed neoadjuvant chemotherapy and will undergo surgery within 6 weeks are eligible', 'No patients scheduled to receive partial breast irradiation following breast conserving surgery', 'Eligible for BCT based on clinical examination mammography and if standard practice at a given institution ultrasound andor tomogram women who cannot be appropriately selected for BCT based on these standard imaging studies and for whom additional imaging is recommended to clarify local disease extent will not be eligible for this trial for patients who have neoadjuvant therapy eligibility for BCT is determined at completion of therapy repeat mammogram + ultrasound US of the affected side only will be required at completion of neoadjuvant chemotherapy to determine eligibility for BCT', 'No patients with multicentric or multifocal disease scheduled to undergo multiple lumpectomies multifocal disease that can be encompassed in a single operative bed can be enrolled for patients with multifocal or multicentric disease enrolled after completion of neoadjuvant chemotherapy histologic confirmation of multifocalitymulticentricity must have been completed before initiation of chemotherapy', 'Suitable to undergo MRI and receive the contrast agent gadolinium exclusions follow\\r\\n No history of untreatable claustrophobia\\r\\n No presence of metallic objects or implanted medical devices in body ie cardiac pacemaker aneurysm clips surgical clips prostheses artificial hearts valves with steel parts metal fragments shrapnel tattoos near the eye or steel implants\\r\\n No history of sickle cell disease\\r\\n No contraindication to intravenous contrast administration\\r\\n No known allergylike reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology ACR patient may be eligible if willing to undergo pretreatment as defined by the institutions policy andor ACR guidance\\r\\n No findings consistent with renal failure as determined by glomerular filtration rate GFR < 30\\r\\nmLmin173 m2 based on a serum creatinine level obtained within 28 days prior to registration\\r\\n Weight lower than that allowable by the MRI table', 'No prior MRI of study breast within the 12 months prior to registration', 'Nonpregnant and nonlactating patients of childbearing potential must have a negative pregnancy test within 7 days prior to registration perimenopausal patients must be amenorrheic > 12 months to be considered not of childbearing potential', 'Signed studyspecific informed consent prior to registration'], ['Patients must have an HCC diagnosis initial recurrent progressive andor refractory to other therapies by at least one criterion listed below =< 360 days prior to study entry\\r\\n Pathologically histologically or cytologically proven diagnosis of HCC\\r\\n At least one solid liver lesion or vascular tumor thrombosis involving portal vein inferior vena cava IVC andor hepatic vein > 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography CT or magnetic resonance imaging MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis\\r\\n For patients whose CURRENT disease is vascular only enhancing vascular thrombosis involving portal vein IVC andor hepatic vein demonstrating early arterial enhancement and delayed washout on multiphasic CT or MRI in a patient with known HCC diagnosed previously < 720 days', 'Patients must have measurable hepatic disease andor presence of vascular tumor thrombosis involving portal vein IVC andor hepatic vein which may not be measurable as per Response Evaluation Criteria in Solid Tumors RECIST on liver CT or MRI within 28 days PRIOR TO STUDY ENTRY', 'Appropriate for protocol entry based upon the following minimum diagnostic workup\\r\\n Historyphysical examination including examination for encephalopathy ascites weight height and blood pressure within 14 days prior to study entry\\r\\n Assessment by radiation oncologist and medical oncologist or hepatologist who specializes in treatment of HCC within 28 days prior to study entry\\r\\n Prerandomization scan REQUIRED for all patients Within 28 days prior to study entry multiphasic liver CT or multiphasic liver magnetic resonance MR scan\\r\\n Within 28 days prior to study entry CT chest with CT or MR abdomen and CT or MR pelvis or positron emission tomography PET CT chestabdomenpelvis', 'Zubrod performance status 02 within 28 days prior to study entry', 'Absolute neutrophil count ANC >= 1500 cellsmm3 obtained within 14 days prior to study entry', 'Platelets >= 60000 cellsmm3 obtained within 14 days prior to study entry', 'Hemoglobin >= 80 gdl Note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 80 gdl is acceptable obtained within 14 days prior to study entry', 'Aspartate aminotransferase AST and alanine aminotransferase ALT < 6 times upper limit of normal ULN obtained within 14 days prior to study entry', 'Serum creatinine =< 2 x ULN or creatinine clearance >= 60 mLmin obtained within 14 days prior to study entry', 'Patients must have Barcelona Clinic Liver Cancer BCLC stage intermediate B or advanced C within 28 days prior to study entry', 'ChildPugh score A within 14 days prior to study entry using international normalized ratio INR from < 28 days is acceptable', 'Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of radiation therapy RT and for at least 28 days following the last dose of sorafenib whichever is later', 'Unsuitable for resection or transplant or radiofrequency ablation RFA', 'Unsuitable for or refractory to transarterial hepatic chemoembolization TACE or drug eluting beads DEB for any of the following reasons as described by Raoul et al 2011\\r\\n Technical contraindications arteriovenous fistula including surgical portosystemic shunt or spontaneous portosystemic shunt\\r\\n Severe reduction in portal vein flow due to tumor portal vein IVC or atrial invasion or bland portal vein occlusion\\r\\n Medical contraindications including congestive heart failure angina severe peripheral vascular disease\\r\\n Presence of extrahepatic disease\\r\\n No response post TACE or DEB or progressive HCC despite TACE prior TACE or DEB is allowed but must be > 28 days from study entry\\r\\n Serious toxicity following prior TACE or DEB prior TACE or DEB must be > 28 days from study entry\\r\\n Other medical comorbidities making TACE or DEB unsafe andor risky eg combination of relative contraindications including age > 80 years tumor > 10 cm > 50 replacement of the liver by HCC extensive multinodular bilobar HCC biliary drainage', 'Patients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteria', 'Patient must be able to provide studyspecific informed consent prior to study entry', 'Prior invasive malignancy except nonmelanomatous skin cancer and T1 renal cell carcinoma unless disease free for a minimum of 2 years note that carcinoma in situ of the breast oral cavity or cervix are all permissible', 'Prior sorafenib use > 60 days andor grade 3 or 4 sorafenib related toxicity note that prior chemotherapy for HCC or a different cancer is allowable', 'Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields', 'Prior selective internal radiotherapyhepatic arterial yttrium therapy at any time', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months PRIOR TO registration\\r\\n Transmural myocardial infarction within the last 6 months prior to study entry\\r\\n Unstable ventricular arrhythmia within the last 6 months prior to study entry\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\\r\\n Hepatic insufficiency resulting in clinical jaundice encephalopathy andor variceal bleed within 28 days prior to study entry\\r\\n Bleeding within 28 days prior to study entry due to any cause requiring transfusion\\r\\n Thrombolytic therapy within 28 days prior to study entry subcutaneous heparin is permitted\\r\\n Known bleeding or clotting disorder\\r\\n Uncontrolled psychotic disorder', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception this exclusion is necessary because the treatment involved in this study may be significantly teratogenic', 'Maximal diameter of any one hepatocellular carcinoma > 15 cm', 'Total sum of maximum diameters of each definite parenchymal hepatocellular carcinomas within the liver or maximum diameter of a single conglomerate HCC > 20 cm', 'More than 5 discrete intrahepatic parenchymal foci of definite HCC', 'Direct tumor extension into the stomach duodenum small bowel or large bowel', 'Measurable common or main branch biliary duct involvement with HCC', 'Extrahepatic metastases or malignant nodes that enhance with typical features of HCC > 30 cm in sum of maximal diameters eg presence of one 34 cm metastatic lymph node or two 2 cm lung lesions note that benign nonenhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted even if the sum of enlarged nodes is > 20 cm', 'Prior liver transplant', 'Human immunodeficiency virus HIV positive with CD4 count < 350 cellsmicroliter note that patients who are HIV positive are eligible provided they are under treatment with highly active antiretroviral therapy HAART and have a CD4 count >= 350 cellsmicroliter and no known detectable viral load at the time of study entry note also that HIV testing is not required for eligibility for this protocol'], ['The patient must have signed and dated an Institutional Review Board IRBapproved consent form that conforms to federal and institutional guidelines', 'The patient must have an Eastern Cooperative Oncology Group ECOG performance status of 0 or 1', 'Patient must have clinically T13 N1 breast cancer at the time of diagnosis before neoadjuvant therapy clinical axillary nodal involvement can be assessed by palpation ultrasound CT scan magnetic resonance imaging MRI positron emission tomography PET scan or PETCT scan', 'Patient must have had pathologic confirmation of axillary nodal involvement at presentation before neoadjuvant therapy based on either a positive fine needle aspirate FNA demonstrating malignant cells or positive core needle biopsy demonstrating invasive adenocarcinoma the FNA or core needle biopsy can be performed either by palpation or by image guidance documentation of axillary nodal positivity by sentinel node biopsy before neoadjuvant therapy is not permitted', 'Patients must have had estrogen receptor ER analysis performed on the primary breast tumor before neoadjuvant therapy according to current American Society of Clinical Oncology ASCOCollege of American Pathologists CAP guideline recommendations for hormone receptor testing if negative for ER assessment of progesterone receptor PgR must also be performed according to current ASCOCAP guideline recommendations for hormone receptor testing', 'Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCOCAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer patients who have a primary tumor that is either HER2positive or HER2negative are eligible', 'Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline andor taxanebased regimen', 'For patients who receive adjuvant chemotherapy after surgery a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization if treatment delays occur chemotherapy must be completed within 14 weeks the dose and schedule of the adjuvant chemotherapy are at the investigators discretion Note it is preferred that all intended chemotherapy be administered in the neoadjuvant setting', 'Patients with HER2positive tumors must have received neoadjuvant antiHER2 therapy either with all or with a portion of the neoadjuvant chemotherapy regimen unless medically contraindicated', 'At the time of definitive surgery all removed axillary nodes must be histologically free from cancer acceptable procedures for assessment of axillary nodal status at the time of surgery include\\r\\n Axillary node dissection\\r\\n Sentinel node biopsy alone provided that at least 2 sentinel lymph nodes are removed removal of at least 3 sentinel lymph nodes and use of dual tracer for lymphatic mapping are strongly recommended or\\r\\n Sentinel node biopsy followed by axillary node dissection\\r\\nNote patients are eligible whether there is residual invasive carcinoma in the surgical breast specimen or whether there is evidence of pathologic complete response patients who are found to be pathologically nodepositive at the time of surgery based on sentinel node biopsy alone are candidates for A011202 a study developed by the Alliance in Oncology an National Cancer Institute NCI Cooperative Group if A011202 is open at the investigators institution patients should be approached about participating in the A011202 study', 'Patients with pathologic staging of ypN0i+ or ypN0mol+ are eligible', 'Patient who have undergone either a total mastectomy or a lumpectomy are eligible patients who have had a nipplesparing mastectomy are eligible', 'For patients who undergo lumpectomy the margins of the resected specimen or reexcision must be histologically free of invasive tumor and DCIS as determined by the local pathologist additional operative procedures may be performed to obtain clear margins if tumor is still present at the resected margin after reexcisions the patient must undergo total mastectomy to be eligible patients with margins positive for lobular carcinoma in situ LCIS are eligible without additional resection', 'For patients who undergo mastectomy the margins must be histologically free of residual microscopic or gross tumor', 'The interval between the last surgery for breast cancer including reexcision of margins and randomization must be no more than 70 days also if adjuvant chemotherapy was administered the interval between the last chemotherapy treatment and randomization must be no more than 70 days', 'The patient must have recovered from surgery with the incision completely healed and no signs of infection', 'If adjuvant chemotherapy was administered chemotherapyrelated toxicity that may interfere with delivery of radiation therapy should have resolved', 'Definitive clinical or radiologic evidence of metastatic disease', 'T4 tumors including inflammatory breast cancer', 'Documentation of axillary nodal positivity before neoadjuvant therapy by sentinel node biopsy alone', 'N2 or N3 disease detected clinically or by imaging', 'Patients with histologically positive axillary nodes post neoadjuvant therapy', 'Patients with microscopic positive margins after definitive surgery', 'Synchronous or previous contralateral invasive breast cancer or DCIS patients with synchronous andor previous contralateral LCIS are eligible', 'Any prior history not including the index cancer of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy patients with synchronous or previous ipsilateral LCIS are eligible', 'History of nonbreast malignancies except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin within 5 years prior to randomization', 'Any radiation therapy for the currently diagnosed breast cancer prior to randomization', 'Any continued use of sex hormonal therapy eg birth control pills ovarian hormone replacement therapy patients are eligible if these medications are discontinued prior to randomization', 'Prior breast or thoracic radiation therapy RT for any condition', 'Active collagen vascular disease specifically dermatomyositis with a creatinine phosphokinase CPK level above normal or with an active skin rash systemic lupus erythematosus or scleroderma', 'Pregnancy or lactation at the time of study entry Note pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential', 'Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required followup', 'Psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude the patient from meeting the study requirements'], ['Patients must be postmenopausal postmenopausal will be defined as women meeting any of the following criteria\\r\\n >= 60 years of age or\\r\\n < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterusovaries are intact or\\r\\n < 60 years of age and the last menstrual period 612 months prior to day 1 if intact uterusovaries and meets biochemical criteria for menopause folliclestimulating hormone FSH and estradiol within institutional standard for postmenopausal status or\\r\\n < 60 years of age without a uterus and meets biochemical criteria for menopause FSH and estradiol within institutional standards for postmenopausal status or\\r\\n < 60 years of age and history of bilateral oophorectomy surgery must have been completed at least 4 weeks prior to day 1 or\\r\\n Prior radiation castration with amenorrhea for at least 6 months', 'NOTE use of luteinizing hormonereleasing hormone LHRH agonists eg leuprolide or goserelin is not allowed', 'Patients must have estrogen andor progesterone receptor positive histologically confirmed stage IIII adenocarcinoma of the breast', 'Patients must have completed planned local therapy ie definitive surgery and radiation therapy and adjuvant chemotherapy for breast cancer prior to registration in addition any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline Patient Reported Outcomes PRO instruments ie Health Assessment Questionnaire HAQ PROMIS Physical Function Functional Assessment of Cancer Therapy FACT Breast and Endocrine Symptoms ES etc and collection of optional blood for banking for future research', 'NOTE concomitant treatment with ongoing trastuzumab Herceptin or other targetedbiologic agents is allowed concomitant treatment with any other type of chemotherapy or hormonal therapy is not allowed', 'Patients must not have received prior AI therapy with exemestane letrozole or anastrozole as preoperativeadjuvant therapy or for prevention of breast cancer prior tamoxifen is allowed', 'Plan to treat with anastrozole for at least 12 months', 'Eastern Cooperative Oncology Group ECOG performance status between 02', 'Patients must be diseasefree of other prior invasive malignancies for >= 5 years with the exception of curativelytreated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior early stage breast cancers are also allowed as long as prior treatment did not include aromatase inhibitors', 'Patients must not be currently taking or have taken in the past 6 months medication for active chronic conditions including rheumatoid arthritis carpal tunnel syndrome tenosynovitis systemic lupus erythematosus gout fibromyalgia or severe osteoarthritis involving the hands wrists hips knees feet or ankles this includes analgesic medications or medications being taken with the purpose of treating pain or that may have an effect on pain eg antidepressants for help with pain or neuropathy corticosteroid shots for arthritis Note patients taking daily low dose aspirin are allowed to participate in this trial', 'Patients must not have a prior history of deep vein thrombosis DVT or pulmonary embolism in the past 5 years', 'Patients must have worst pain rated as no worse than 3 out of 10 on the following question ie a pain score of 0 1 2 or 3 “In the past week how much pain have you had on a scale of 0 to 10 where 0 equals no pain and 10 means the worst pain you can imagine  NOTE this question regarding patient’s pain should be completed within one week prior to registration this question may be asked orally prior to consent up to 7 days prior to registration the response will be recorded on the registration checklist', 'Patients must have adequate hepatic hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician'], ['Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes \\r\\n Intermediategrade adenocarcinoma or intermediategrade mucoepidermoid carcinoma\\r\\n Highgrade adenocarcinoma or highgrade mucoepidermoid carcinoma or salivary duct carcinoma\\r\\n Highgrade acinic cell carcinoma or highgrade > 30 solid component adenoid cystic carcinoma\\r\\n Patients with diagnoses such as undifferentiated or poorly differentiated carcinoma carcinomaex pleomorphic adenoma carcinoma not otherwise specified NOS and others should be considered for this trial', 'Surgical resection with curative intent within 8 weeks prior to registration', 'Pathologic stage T34 or N13 or T12 N0 with a close =< 1 mm or microscopically positive surgical margin American Joint Committee on Cancer AJCC 7th edition patients must be free of distant metastases based upon the following minimum diagnostic workup\\r\\n Historyphysical examination within 8 weeks prior to registration\\r\\n Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration at a minimum contrast computed tomography CT imaging of the chest is required positron emission tomography PETCT is acceptable', 'Zubrod performance status 01', 'Absolute neutrophil count ANC >= 1800 cellsmm3 within 8 weeks prior to registration', 'Platelets >= 100000 cellsmm3 within 8 weeks prior to registration', 'Hemoglobin >= 80 gdl Note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 80 gdl is acceptable within 8 weeks prior to registration', 'Serum creatinine < 20 mgdl within 8 weeks prior to registration', 'Total bilirubin < 2 x the institutional upper limit of normal ULN within 8 weeks prior to registration', 'Aspartate aminotransferase AST or alanine aminotransferase ALT < 3 x the institutional ULN within 8 weeks prior to registration', 'Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential', 'Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment', 'All patients must have a Medical Oncology evaluation within 4 weeks prior to registration', 'Patients must be deemed able to comply with the treatment plan and followup schedule', 'Patients must provide study specific informed consent prior to study entry including consent for mandatory tissue submission for central review', 'Patients with residual macroscopic disease after surgery', 'Prior invasive malignancy except nonmelanomatous skin cancer unless disease free for a minimum of 3 years for example carcinoma in situ of the breast oral cavity or cervix are all permissible', 'Prior systemic chemotherapy or radiation therapy for salivary gland malignancy note that prior chemotherapy for a different cancer is allowable', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months\\r\\n Transmural myocardial infarction within the last 6 months\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\\r\\n Hepatic insufficiency resulting in clinical jaundice andor coagulation defects note however coagulation parameters are not required for entry into this protocol\\r\\n Acquired immune deficiency syndrome AIDS based upon current Centers for Disease Control CDC definition note however that human immunodeficiency virus HIV testing is not required for entry into this protocol\\r\\n Preexisting >= grade 2 neuropathy\\r\\n Prior organ transplant', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception', 'Significant preexisting hearing loss as defined by the patient or treating physician'], ['Histologically or cytologically confirmed newly diagnosed nonsquamous NSCLC', 'Unresectable stage IIIA or IIIB disease patients must be surgically staged to confirm N2 or N3 disease patients may have invasive mediastinal staging by mediastinoscopy mediastinotomy endobronchial ultrasound transbronchial aspiration EBUSTBNA endoscopic ultrasound EUS or videoassisted thoracoscopic surgery VATS', 'Patients with any tumor T with node N2 or N3 are eligible patients with T3 N1N3 disease are eligible if deemed unresectable patients with T4 any N are eligible', 'Patients must have measurable disease ie lesions that can be accurately measured in at least 1 dimension longest dimension in the plane of measurement is to be recorded with a minimum size of 10 mm by computed tomography CT scan CT scan slice thickness no greater than 5 mm', 'Patients with a pleural effusion which is a transudate cytologically negative and nonbloody are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy', 'If a pleural effusion can be seen on the chest CT but not on chest xray and is too small to tap the patient will be eligible patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible', 'The institution’s preenrollment biomarker screening at a Clinical Laboratory Improvement Amendments CLIA certified lab documents presence of known “sensitive” mutations in epidermal growth factor receptor tyrosine kinase EGFR TK domain exon 19 deletion L858 andor EML4anaplastic lymphoma kinase ALK fusion arrangement either the primary tumor or the metastatic lymph node tissue may be used for testing of mutations', 'The institution’s preenrollment biomarker screening at a CLIA certified lab documents absence of T790M mutation in the EGFR TK domain', 'Appropriate stage for protocol entry including no distant metastases based upon the following minimum diagnostic workup\\r\\n Historyphysical examination including recording of pulse blood pressure BP weight and body surface area within 45 days prior to registration\\r\\n Whole body fludeoxyglucosepositron emission tomography FDGPETCT orbits to midthighs within 30 days prior to registration PETCT must be negative for distant metastasis\\r\\n CT scan with contrast of the chest and upper abdomen to include liver and adrenals unless medically contraindicated within 30 days prior to registration\\r\\n Magnetic resonance imaging MRI of the brain with contrast or CT scan with contrast if MRI medically contraindicated within 30 days prior to registration', 'Zubrod performance status 01 within 14 days prior to registration', 'Absolute neutrophil count ANC >= 1000 cellsmm3', 'Platelets >= 100000 cellsmm3', 'Hemoglobin >= 80 gdl Note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 80 gdl is acceptable', 'Serum creatinine < 15 mgdL or calculated creatinine clearance >= 50 mlmin by CockcroftGault formula within 14 days prior to registration', 'Aspartate aminotransferase ASTalanine aminotransferase ALT =< 25 x upper limit of normal ULN within 14 days prior to registration', 'Bilirubin within normal institutional limits within 14 days prior to registration', 'Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential', 'Patient must provide study specific informed consent prior to study entry including consent for mandatory screening of tissue', 'Prior invasive malignancy except nonmelanomatous skin cancer unless disease free for a minimum of 730 days 2 years for example carcinoma in situ of the breast oral cavity or cervix are all permissible', 'Prior systemic chemotherapy for the study cancer note that prior chemotherapy for a different cancer is allowable', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Atelectasis of the entire lung', 'Contralateral hilar node involvement', 'Exudative bloody or cytologically malignant effusions', 'Severe active comorbidity defined as follows\\r\\n Unstable angina andor congestive heart failure requiring hospitalization within the last 6 months\\r\\n Transmural myocardial infarction within the last 6 months\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration hepatic insufficiency resulting in clinical jaundice andor coagulation defects\\r\\n Acquired immune deficiency syndrome AIDS based upon current Centers for Disease Control and Prevention CDC definition note however that human immunodeficiency virus HIV testing is not required for entry into this protocol protocolspecific requirements may also exclude immunocompromised patients', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception', 'Prior allergic reaction to the study drugs involved in this protocol'], ['Clinical stage T13 N1 M0 breast cancer at diagnosis prior to the start of neoadjuvant chemotherapy by American Joint Committee on Cancer AJCC staging 7th edition', 'No inflammatory breast cancer', 'No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix', 'All patients must have had an axillary ultrasound with fine needle aspiration FNA or core needle biopsy of axillary lymph nodes documenting axillary metastasis at the time of diagnosis prior to or at most 14 days after starting neoadjuvant chemotherapy\\r\\n Note Biopsy of intramammary nodes does not fulfill eligibility criteria', 'Patients must have had estrogen receptor progesterone receptor and HER2 status by immunohistochemistry IHC andor in situ hybridization ISH evaluated on diagnostic core biopsy prior to start of neoadjuvant chemotherapy\\r\\n Note If HER2 status has not been clearly determined ie equivocalindeterminate then patients should not be enrolled', 'Patients must have completed all planned neoadjuvant chemotherapy prior to surgery sandwich chemotherapy is not allowed ie anthracyclinecytoxan or taxane chemotherapy planned to be given after surgery patients must have completed at least 4 cycles of neoadjuvant chemotherapy consisting of an anthracycline andor taxanebased regimen without evidence of disease progression in the breast or the lymph nodes\\r\\n Note Delaysdose modifications due to toxicitiesadverse events are allowed as long as a minimum of 4 cycles of neoadjuvant chemotherapy is administered more than 4 cycles of neoadjuvant chemotherapy NAC may be administered at the discretion of the treating medical oncologist', 'Patients with HER2 positive tumors must have received neoadjuvant trastuzumab or trastuzumab + pertuzumab or other approved antiHER2 therapy either with all or with a portion of the neoadjuvant chemotherapy regimen therapy must be Food and Drug Administration FDAapproved targeted antiHER2 therapy but additional therapies are allowed as are nontrastuzumab regimens if administered in the context of an Institutional Review Board IRBapproved clinical trial', 'All patients must have a clinically negative axilla no bulky adenopathy on physical examination documented at the completion of neoadjuvant chemotherapy\\r\\n Note an ultrasound of the axilla is not required at completion of neoadjuvant chemotherapy if performed its findings do NOT impact eligibility', 'No more than 8 weeks of neoadjuvant endocrine therapy prior to the start of neoadjuvant chemotherapy', 'No neoadjuvant radiation therapy', 'No SLN surgeryexcisional biopsy for pathological confirmation of axillary status prior to or during neoadjuvant chemotherapy', 'No prior history of ipsilateral breast cancer invasive disease or ductal carcinoma in situ DCIS lobular carcinoma in situ LCIS and benign breast disease is allowed', 'No prior ipsilateral axillary surgery such as excisional biopsy of lymph nodes or treatment of hidradenitis', 'No history of prior or concurrent contralateral invasive breast cancer benign breast disease LCIS or DCIS of contralateral breast is allowed', 'Patients must not be pregnant or nursing\\r\\n Note Perimenopausal women must be amenorrheic for > 12 months to be considered not of childbearing potential', 'Eastern Cooperative Oncology Group ECOG Zubrod performance status 01', 'INTRAOPERATIVE REGISTRATIONRANDOMIZATION CRITERIA', 'Breast surgery lumpectomy or mastectomy and sentinel lymph node surgery must be completed within 56 days of the completion of the last dose of neoadjuvant chemotherapy', 'A minimum of 1 sentinel node and a maximum of 8 total nodes sentinel + nonsentinel are identified and excised more than 8 nodes identified by either surgeon or pathologist is NOT allowed\\r\\nNote Patients who do not have an identifiable sentinel lymph node will not proceed to registrationrandomization', 'At least one lymph node sentinel or nonsentinel with a metastasis greater than 02 mm in greatest dimension identified on intraoperative pathologic assessment\\r\\n Note Isolated tumor cells metastases less than or equal to 02 mm will be treated as node negative disease N0i+\\r\\n Note If on final pathology more than 8 lymph nodes are seen pathologically then the patient should discontinue study\\r\\n Axillary lymph node dissection ALND is not to be performed prior to registrationrandomization\\r\\n Note Patients for whom no positive lymph nodes sentinel or nonsentinel are found during sentinel lymph node surgery will not proceed to registrationrandomization and can be considered for discussion of the NRG NSABP B51RTOG 1304 study “A Randomized Phase III Clinical Trial Evaluating the Role of Postmastectomy Chest Wall and Regional Nodal XRT and Postlumpectomy Regional Nodal XRT in Patients with Documented Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy”', 'POSTOPERATIVE REGISTRATIONRANDOMIZATION CRITERIA', 'For cases where ALND has not been performed and one of the following is true 1 intraoperative evaluation of sentinel lymph node could not bewas not performed and final pathology identified a positive lymph node sentinel or nonsentinel with metastasis greater than 02 mm OR 2 lymph node sentinel or nonsentinel considered negative on intraoperative evaluation was found to be positive on final pathology with metastasis greater than 02 mm', 'Breast surgery lumpectomy or mastectomy and sentinel lymph node surgery must be completed within 56 days of the completion of the last dose of neoadjuvant chemotherapy negative margin by either breast conservation or mastectomy on final pathology where negative margin is defined as no tumor on ink', 'At least one lymph node sentinel or nonsentinel with a metastasis greater than 02 mm in greatest dimension identified on final pathology for cases where intraoperative evaluation was not performed or was negative and completion dissection was not performed', 'At least one and no more than 8 lymph nodes sentinel and nonsentinel were found by the pathologists to have been actually excised during sentinel lymph node procedure\\r\\nNote Isolated tumor cells metastases less than or equal to 02 mm will be treated as node negative disease N0i+', 'For those patients who also undergo contralateral breast surgery if invasive disease is found in the contralateral breast the patient is not eligible for registration randomization'], ['Patients must have histologically or cytologically confirmed metastatic endometrial cancer eligible histologies for the experimental cohort are endometrioid or serous eligible histologies for the exploratory cohort are carcinosarcoma clear cell mixed adenosquamous and any other rare subtype of endometrial cancer', 'Patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions as >= 10 mm with computed tomography CT scan magnetic resonance imaging MRI or calipers by clinical exam and >= 15 mm in short axis for nodal lesions patients must have radiographic evidence of disease progression following the most recent line of treatment', 'Prior therapy Eligible subjects must have had 1 line of systemic cytotoxic treatment this may be adjuvant therapy with documented progression within 12 months of completion or 1 line of cytotoxic therapy for metastatic disease NOTE eligible patients are allowed up to 2 lines of systemic cytotoxic treatment of which only 1 line is allowed for metastatic disease the acceptance of progression within 12 months of adjuvant is part inclusion to not require patient to rechallenge with chemotherapy chemo if they progressed soon after adjuvant therapy prior hormonal therapy for metastaticrecurrent disease is also allowed prior targeted therapy not directed against cMET or vascular endothelial growth factor VEGF pathways is allowed', 'Eastern Cooperative Oncology Group ECOG performance status =< 2 Karnofsky >= 60', 'Life expectancy of greater than 3 months', 'Absolute neutrophil count >= 15 x 109L', 'Platelets >= 100 x 109L', 'Total bilirubin =< 15 x upper limit of normal ULN', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOTalanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT =< 30 X institutional upper limit of normal', 'Creatinine =< 15 x ULN OR creatinine clearance >= 50 mLmin173 m2 for patients with creatinine levels above institutional normal', 'Hemoglobin >= 90 gL', 'Serum albumin >= 28 gL', 'Lipase < 20 x ULN no radiologicclinical evidence of pancreatitis', 'Urine proteincreatinine ratio UPCR =< 1', 'Serum phosphorus calcium magnesium and potassium >= lower limit of normal LLN', 'Women of childbearing potential must have a negative pregnancy test at screening women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization hysterectomy bilateral tubal ligation or bilateral oophorectomy or are not postmenopausal postmenopausal is defined as amenorrhea >= 12 consecutive months note women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy antiestrogens ovarian suppression or any other reversible reason', 'Women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation should a woman become pregnant or suspect she is pregnant while she is participating in this study she should inform her treating physician immediately sexually active subjects must agree to use medically accepted barrier methods of contraception eg male or female condom during the course of the study and for 4 months after the last dose of study drugs even if oral contraceptives are also used all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drugs', 'Patients must consent to analysis on archival tissue if archival sample is not available a sufficient tumor biopsy can be performed a minimum of 28 days prior to start of treatment if felt to be clinically reasonable', 'Ability to understand and the willingness to sign a written informed consent document', 'Patients who have had chemotherapy including investigational cytotoxic chemotherapy biologic agents eg cytokines or antibodies or radiotherapy within 4 weeks 6 weeks for nitrosoureas or mitomycin C before the first dose of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier', 'Prior treatment with cabozantinib', 'The subject has received radiation therapy\\r\\n To bone metastasis within 14 days before the first dose of study treatment \\r\\n To any other sites within 28 days before the first dose of study treatment', 'The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment', 'The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy including investigational kinase inhibitors or hormones within 14 days or five halflives of the compound or active metabolites whichever is longer before the first dose of study treatment', 'The subject has received any other type of investigational agent within 28 days before the first dose of study treatment', 'The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events CTCAE =< grade 1 from related toxicity to all prior therapies except alopecia and other nonclinically significant adverse events AEs', 'Any other prior malignancy from which the patient has been disease free for less than 3 years with the exception of adequately treated and cured basal or squamous cell skin cancer superficial bladder cancer carcinoma in situ of any site or any other cancer', 'Patients with known brain metastases should be excluded from this clinical trial', 'The subject has prothrombin time PTinternational normalized ratio INR or partial thromboplastin time PTT test >= 13 x the laboratory ULN =< 7 days before the first dose of study treatment', 'Therapeutic anticoagulation with warfarin antiplatelet agents eg clopidogrel thrombin or Factor Xa inhibitors is not allowed therapeutic anticoagulation with low molecular weight heparin LMWH is allowed as well as prophylactic anticoagulation using low dose aspirin =< 81 mgday lowdose warfarin =< 1 mgday and LMWH', 'The subject requires chronic concomitant treatment of strong CYP3A4 inducers eg dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentine phenobarbital and St John’s wort', 'The subject has experienced any of the following\\r\\n Clinicallysignificant gastrointestinal bleeding within 6 months before the first dose of study treatment\\r\\n Hemoptysis of >= 05 teaspoon 25 mL of red blood within 3 months before the first dose of study treatment\\r\\n Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment', 'The subject has tumor in contact with invading or encasing any major blood vessels', 'The subject has evidence of tumor invading the gastrointestinal GI tract esophagus stomach small or large bowel rectum or anus or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib', 'The subject has uncontrolled significant intercurrent or recent illness including but not limited to the following conditions\\r\\n Cardiovascular disorders including\\r\\n Congestive heart failure CHF New York Heart Association NYHA class III moderate or class IV severe at the time of screening\\r\\n Concurrent uncontrolled hypertension defined as sustained blood pressure BP > 140 mmHg systolic or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment\\r\\n Any history of congenital long QT syndrome\\r\\n Any of the following within 6 months before the first dose of study treatment\\r\\n Unstable angina pectoris\\r\\n Clinicallysignificant cardiac arrhythmias\\r\\n Stroke including transient ischemic attack TIA or other ischemic event\\r\\n Myocardial infarction\\r\\n Thromboembolic event requiring therapeutic anticoagulation note subjects with a venous filter eg vena cava filter are not eligible for this study', 'Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including\\r\\n Any of the following within 28 days before the first dose of study treatment\\r\\n Intraabdominal tumormetastases invading GI mucosa\\r\\n Active peptic ulcer disease\\r\\n Inflammatory bowel disease including ulcerative colitis and Crohn’s disease diverticulitis cholecystitis symptomatic cholangitis or appendicitis\\r\\n Malabsorption syndrome\\r\\n Any of the following within 6 months before the first dose of study treatment\\r\\n Abdominal fistula\\r\\n Gastrointestinal perforation\\r\\n Bowel obstruction or gastric outlet obstruction\\r\\n Intraabdominal abscess note complete resolution of an intraabdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment', 'Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy PEG tube placement within 3 months before the first dose of study therapy', 'Other clinically significant disorders such as\\r\\n Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment\\r\\n Serious nonhealing woundulcerbone fracture within 28 days before the first dose of study treatment\\r\\n History of organ transplant\\r\\n Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\\r\\n History of major surgery as follows\\r\\n Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\\r\\n Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\\r\\n In addition complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery', 'The subject is unable to swallow tablets', 'The subject has a corrected QT interval calculated by the Fridericia formula QTcF > 500 ms =< 7 days before the first dose of study treatment', 'The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee', 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184', 'Pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with XL184', 'Known human immunodeficiency virus HIVpositive patients on combination antiretroviral therapy are ineligible'], ['Eastern Cooperative Oncology Group ECOG performance status 02', 'Postmenopausal verified by \\r\\n Post bilateral surgical oophorectomy or\\r\\n No spontaneous menses >= 1 year or\\r\\n No menses for < 1 year with folliclestimulating hormone FSH and estradiol levels in postmenopausal range according to institutional standards', 'Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy', 'Clinical T2T4c any N M0 invasive breast cancer by American Joint Committee on Cancer AJCC 7th edition clinical staging with the goal being surgery to complete excision of the tumor in the breast and the lymph node\\r\\nPrimary tumor must be\\r\\n Palpable\\r\\n Its largest tumor diameter is > 20 cm by physical examination or by radiological assessment\\r\\n Bidimensional measurement by tape ruler or caliper technique must be provided\\r\\n Note\\r\\n Patients with contralateral ductal carcinoma in situ andor invasive breast cancer are not eligible\\r\\n Patients with multifocal breast cancer defined as more than one lesion of invasive breast cancer in the same breast separated from the dominant breast lesion by less than 5 cm of radiologically normal breast tissue are eligible if the other lesions have been biopsied biopsy not required they must meet the ERhuman epidermal growth factor receptor 2 HER2 eligibility requirements research biopsies and Ki67 assessment and radiological measures are to be performed on the dominant breast lesion', 'Invasive breast cancer is estrogen receptor ER positive with an Allred score of 6 7 or 8 by local institution standard protocol if an Allred score is not reported on the diagnostic pathology report ER positivity in > 66 cells is eligible if ER positivity is =< 66 the staining intensity weak intermediate strong is needed to calculate the Allred score to determine eligibility', 'Invasive breast cancer is HER2 negative a patient is considered to have HER2 negative breast cancer if one of the following if one of the following applies \\r\\n 0 or 1+ by immunohistochemistry IHC and in situ hybridization ISH not done\\r\\n 0 or 1+ by IHC or ISH ratio HER2 gene copychromosome 17 < 2\\r\\n 2+ by IHC and ISH ratio HER2 gene copychromosome 17 < 2', 'Documentation of mammogram and ultrasound including ductal carcinoma in situ DCIS and invasive cancer of the diseased breast performed within 56 days prior to registration mammogram for the unaffected contralateral breast is required within 12 months prior to registration', 'Absolute neutrophil count ANC > 1000mm3 =< 14 days prior to registration', 'Platelet count > 100000mm3 =< 14 days prior to registration', 'Total bilirubin < 15 x upper limits of normal ULN =< 14 days prior to registration', 'Creatinine < 15 x upper limits of normal ULN =< 14 days prior to registration', 'Serum alanine aminotransferase ALT < 25 x upper limits of normal ULN =< 14 days prior to registration', 'Tissue acquisition patient must agree to provide the required research biopsies at baseline week 4 and at surgery for integral and integrated biomarker and correlative studies', 'Premenopausal status', 'Inflammatory breast cancer defined as clinically significant erythema of the breast andor documented dermal lymphatic invasion not direct skin invasion by tumor or peau d’orange without erythema', 'An excisional biopsy of this breast cancer', 'Hormone replacement therapy of any type megestrol acetate or raloxifene within one week prior to registration', 'Tumor ER Allred score between 05 or HER2 positive by IHC 3+ or amplified by fluorescence in situ hybridization FISH > 20', 'Surgical axillary staging procedure prior to study entry Note fine needle aspiration FNA or core needle biopsy of axillary node is permitted', 'Clinical or radiographic evidence of metastatic disease metastatic workup is not required but is recommended for patients with clinical stage III disease Note isolated ipsilateral supraclavicular node involvement is permitted', 'Breast implants are contraindicated only if the implant precludes the required research biopsies or interferes with palpating the breast lesion', 'Treatment for this cancer including surgery radiation therapy chemotherapy biotherapy hormonal therapy or investigational agent prior to study entry', 'History of invasive breast cancer or contralateral DCIS'], ['PHASE I ARMS A B C D E F G H I X Y Z', 'Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma cHL a biopsy at any relapse is acceptable other histologies including lymphocyte predominant LP HL are not permitted', 'Patients must have relapsed after first line chemotherapy may have relapsed after autologous or allogeneic stem cell transplant or have primary refractory disease no upper limit for number of prior therapies if status post allogeneic stem cell transplant no active graft versus host disease', 'Patients may have received prior brentuximab vedotin but must not have received brentuximab vedotin within 6 months prior to registration and must not have relapsed within 6 months of receiving previous brentuximab vedotin patients may not have received prior nivolumab or PD1PDL1 axis agents patients in the nivolumabbrentuximab cohorts ONLY D E F Y may have received prior ipilimumab', 'Patients may have received other prior activating immunotherapies ie checkpoint inhibitors but must not have received them within 6 months prior to registration and there must be no serious unresolved complication of therapy at the time of registration for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents except prior brentuximab vedotin', 'Eastern Cooperative Oncology Group ECOGAmerican College of Radiology Imaging Network ACRIN performance status between 02', 'Patients must have measurable disease baseline measurements and evaluations must be obtained within 4 weeks of registration to the study abnormal positron emission tomography PET scans will not constitute evaluable disease unless verified by a diagnostic quality computed tomography CT scan patients must use the same imaging modality CT or PETCT throughout the study', 'Women must not be pregnant or breastfeeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'Women of childbearing potential WOCBP and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug for female patients and for 7 months after the last dose of study drug for male patients who are sexually active with WOCBP should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she or the participating partner should inform the treating physician immediately', 'Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92 while breathing room air', 'Patients must have forced expiratory volume in 1 second FEV1forced vital capacity FVC > 60 by pulmonary function test PFT unless due to large mediastinal mass from HL carbon monoxide diffusion capacity DLCO FEV1 and FVC all > 50 predicted value all pulmonary function tests must be obtained within one month prior to registration', 'Absolute neutrophil count ANC >= 1500mcL 15 x 109L obtained within 2 weeks prior to registration', 'Platelets >= 75000mcL 75 x 109L obtained within 2 weeks prior to registration', 'Aspartate aminotransferase ASTalanine aminotransferase ALT =< 25 x upper limit of normal ULN obtained within 2 weeks prior to registration', 'Bilirubin =< 2 x upper limit of normal ULN unless documented Gilbert’s syndrome for which bilirubin =< 3 x upper limit of normal ULN is permitted obtained within 2 weeks prior to registration', 'Calculated creatinine clearance by CockcroftGault formula >= 30 mlmin obtained within 2 weeks prior to registration', 'No evidence of prior malignancy except adequately treated nonmelanoma skin cancer in situ cervical carcinoma or any surgically or radiationcured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response', 'Patient must have no current or prior history of central nervous system CNS involvement', 'All prior therapy must have been completed at least 21 days prior to enrollment no concomitant anti lymphoma therapy including systemic corticosteroids for the purpose of treatment of lymphoma are allowed topical steroids are allowed', 'No history of Steven’s Johnson’s syndrome toxic epidermal necrolysis TENs syndrome or motor neuropathy', 'Human immunodeficiency virus HIV positive patients are allowed on this study if they have a CD4 count > 400 and are on a stable antiviral regimen patients with poorly controlled HIV or other chronic active viral infections will be excluded', 'Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids or other systemic immunosuppressants including oral steroids ie prednisone dexamethasone or continuous use of topical steroid creams or ointments or ophthalmologic steroids a history of occasional but not continuous use of steroid inhalers is allowed\\r\\n Replacement doses of steroids for patients with adrenal insufficiency are allowed patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if in the judgment of the treating physician investigator the patient is not likely to require resumption of treatment with these classes of drugs during the study\\r\\n Exclusion from this study also includes patients with a history of symptomatic autoimmune disease eg rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus Sjogrens syndrome autoimmune vasculitis eg Wegener’s Granulomatosis motor neuropathy considered of autoimmune origin eg GuillainBarre syndrome and Myasthenia Gravis other CNS autoimmune disease eg Multiple sclerosis patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible', 'Patients must not have grade 2 or greater peripheral sensory neuropathy', 'Patients must not have New York Heart Association NYHA class III or IV heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia', 'Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab', 'Patients must not have a serious medical or psychiatric illness likely to interfere with study participation', 'Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration', 'Routine vaccinations including seasonal influenza should be given at least 2 weeks prior to study treatment vaccines are not prohibited on study but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment', 'Patients registering to Arms D E F G H I X Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months', 'RANDOMIZED PHASE II ARMS K AND L Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma cHL a biopsy at any relapse is acceptable other histologies including lymphocyte predominant LP HL are not permitted', 'RANDOMIZED PHASE II ARMS K AND L Patients must have relapsed after first line chemotherapy may have relapsed after autologous stem cell transplant or have primary refractory disease no upper limit for number of prior therapies patient must not have received a prior allogeneic stem cell transplant', 'RANDOMIZED PHASE II ARMS K AND L Patients may have received prior brentuximab vedotin but must not have received brentuximab vedotin within 6 months prior to registration and must not have relapsed within 6 months of receiving previous brentuximab vedotin patients may not have received prior nivolumab or PD1PDL1 axis agents patients may not have received prior ipilimumab', 'RANDOMIZED PHASE II ARMS K AND L Patients may not have received other prior activating immunotherapies ie checkpoint inhibitor therapies for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents except prior brentuximab vedotin', 'RANDOMIZED PHASE II ARMS K AND L ECOGACRIN performance status between 02', 'RANDOMIZED PHASE II ARMS K AND L Patients must have measurable disease baseline measurements and evaluations must be obtained within 4 weeks of registration to the study abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan patients must use the same imaging modality CT or PETCT throughout the study', 'RANDOMIZED PHASE II ARMS K AND L Women must not be pregnant or breastfeeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'RANDOMIZED PHASE II ARMS K AND L Women of childbearing potential WOCBP and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug for female patients and for 7 months after the last dose of study drug for male patients who are sexually active with WOCBP should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she or the participating partner should inform the treating physician immediately', 'RANDOMIZED PHASE II ARMS K AND L Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92 while breathing room air', 'RANDOMIZED PHASE II ARMS K AND L Patients must have FEV1FVC > 60 by pulmonary function test PFT unless due to large mediastinal mass from HL carbon monoxide diffusion capacity DLCO FEV1 and FVC all > 50 predicted value all pulmonary function tests must be obtained within one month prior to registration', 'RANDOMIZED PHASE II ARMS K AND L ANC >= 1500mcL 15 x 09L obtained within 2 weeks prior to registration', 'RANDOMIZED PHASE II ARMS K AND L Platelets >= 75000mcL 75 x 109L obtained within 2 weeks prior to registration', 'RANDOMIZED PHASE II ARMS K AND L ASTALT =< 25 x upper limit of normal ULN obtained within 2 weeks prior to registration', 'RANDOMIZED PHASE II ARMS K AND L Bilirubin =< 2 x upper limit of normal ULN unless documented Gilbert’s syndrome for which Bilirubin =< 3 x upper limit of normal ULN is permitted obtained within 2 weeks prior to registration', 'RANDOMIZED PHASE II ARMS K AND L Calculated creatinine clearance by CockcroftGault formula >= 30 mlmin obtained within 2 weeks prior to registration', 'RANDOMIZED PHASE II ARMS K AND L No evidence of prior malignancy except adequately treated nonmelanoma skin cancer in situ cervical carcinoma or any surgically or radiationcured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response', 'RANDOMIZED PHASE II ARMS K AND L Patient must have no current or prior history of CNS involvement', 'RANDOMIZED PHASE II ARMS K AND L All prior therapy must have been completed at least 21 days prior to enrollment 6 weeks for nitrosoureas or mitomycin C no concomitant anti lymphoma therapy including systemic corticosteroids for the purpose of treatment of lymphoma are allowed topical steroids are allowed', 'RANDOMIZED PHASE II ARMS K AND L No history of Steven’s Johnson’s syndrome TENs syndrome or motor neuropathy', 'RANDOMIZED PHASE II ARMS K AND L HIV positive patients are eligible provided they meet the other protocol criteria including the following\\r\\n Long term survival expected were it not for the cHL\\r\\n HIV viral loads undetectable by standard clinical HIV testing\\r\\n Willing to adhere to effective combination antiretroviral therapy', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids or other systemic immunosuppressants including oral steroids ie prednisone dexamethasone or continuous use of topical steroid creams or ointments or ophthalmologic steroids a history of occasional but not continuous use of steroid inhalers is allowed replacement doses of steroids for patients with adrenal insufficiency are allowed patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if in the judgment of the treating physician investigator the patient is not likely to require resumption of treatment with these classes of drugs during the study exclusion from this study also includes patients with a history of symptomatic autoimmune disease eg rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus Sjogrens syndrome autoimmune vasculitis eg Wegener’s Granulomatosis motor neuropathy considered of autoimmune origin eg GuillainBarre syndrome and Myasthenia Gravis other CNS autoimmune disease eg Multiple sclerosis patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have grade 2 or greater peripheral sensory neuropathy', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have NYHA class III or IV heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have a serious medical or psychiatric illness likely to interfere with study participation', 'RANDOMIZED PHASE II ARMS K AND L Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration', 'RANDOMIZED PHASE II ARMS K AND L Routine vaccinations including seasonal influenza should be given at least 2 weeks prior to study treatment vaccines are not prohibited on study but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment', 'RANDOMIZED PHASE II ARMS K AND L Patients must not currently be smoking tobacco or other agents', 'RANDOMIZED PHASE II ARMS K AND L Patients must not have a history of or evidence of cardiovascular risks including any of the following\\r\\n QT interval corrected for heart rate using the Bazett’s formula QTcB >= 480 msec at baseline \\r\\n History of acute coronary syndromes including myocardial infarction or unstable angina coronary angioplasty or stenting within the past 24 weeks prior to registration\\r\\n History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association NYHA functional classification system\\r\\n Left ventricular ejection fraction LVEF =< lower limit of normal on cardiac echocardiogram echo or multigated acquisition scan MUGA\\r\\n Intracardiac defibrillator\\r\\n History of abnormal cardiac valve morphology >= grade 2 documented by ECHO subjects with grade 1 abnormalities ie mild regurgitationstenosis can be entered on study subjects with moderate valvular thickening should not be entered on study\\r\\n History or evidence of current clinically significant uncontrolled cardiac arrhythmias clarification subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible\\r\\n Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg andor diastolic > 90 mm Hg which cannot be controlled by antihypertensive therapy'], ['Histologically confirmed diagnosis of symptomatic multiple myeloma relapsed disease is myeloma that has previously responded to prior therapy MR or better and subsequently progressed', 'Patient must have measurable disease or nonmeasurable disease defined as one or more of the following holding true\\r\\n Measurable disease\\r\\n Serum Mprotein >= 05 gdL andor\\r\\n Urine Mprotein >= 200 mg24 hours andor\\r\\n Involved serum free light chain level >= 10 mgdL AND an abnormal serum free light chain ratio\\r\\n For nonmeasurable disease\\r\\n Baseline marrow burden of myeloma of at least 30', 'Progression on lenalidomide as part of first line therapy lenalidomiderefractory disease\\r\\n Lenalidomiderefractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomidebased treatment patients should have received at least 2 cycles of a lenalidomidebased regimen to be evaluable for refractoriness examples 1 progression on lenalidomide maintenance therapy after initial induction + consolidation 2 initial response followed by progression on continuous lenalidomidedexamethasone + elotuzumab or daratumumab', 'Pomalidomide naive disease', 'Proteasome inhibitor naive or sensitive disease proteasome inhibitor sensitive disease is defined as a PR or better to prior proteasome inhibitorbased therapy that is maintained for >= 60 days from the last dose of the proteasome inhibitor\\r\\n A patient who receives induction therapy with lenalidomide bortezomib and dexamethasone and achieves a PR or better but subsequently progresses on continued lenalidomide or lenalidomidedexamethasone would be eligible provided the progression occurs 60 days or more after discontinuation of the bortezomib similarly ixazomib exposure is allowed provided they meet the definition of proteasome inhibitor sensitive disease', '1 prior line of systemic therapy for multiple myeloma where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy as well as a planned series of treatment regimens administered in a sequential manner eg lenalidomide bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy a new line of therapy begins when a planned therapy is modified to include other treatment agents alone or in combination as a result of disease progression disease relapse or treatmentrelated toxicity eg a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen a new line of therapy also begins when a planned treatmentfree interval is interrupted by the need to start treatment due to disease relapseprogression eg a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide bortezomib and dexamethasone enjoys an 8month period off therapy but then experiences disease progression requiring reinitiation of therapy', 'Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant at time of registration is not on immunosuppressive therapy to treatprevent graftversushost disease has no evidence of active graft versus host disease and no evidence of active infection', 'No chemotherapy or radiation therapy within 14 days prior to registration', 'No investigational therapy within 14 days prior to registration', 'No major surgery within 28 days prior to registration', 'No GCSF filgrastim or GMCSF sargramostim within 7 days of registration or pegfilgrastim within 14 days of registration to meet eligibility criteria', 'No platelet transfusions within 7 days of registration to meet eligibility criteria Note red blood cell transfusions are allowed at any time', 'A female of childbearing potential is a sexually mature female who 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months\\r\\n Women of childbearing potential\\r\\n Must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlUml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide\\r\\n Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control one highly effective method and one additional effective barrier method AT THE SAME TIME before starting pomalidomide\\r\\n Must agree to ongoing pregnancy testing\\r\\n Must agree to not become pregnant or breast feed a child during treatment on this protocol\\r\\n Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy\\r\\n Note All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure', 'Eastern Cooperative Oncology Group ECOG performance status 02', 'Absolute neutrophil count ANC >= 10 x 109L', 'Platelet count >= 50 x 109L', 'Calculated Calc creatinine clearance >= 30 mLmin calculated utilizing the CockcroftGault formula or 24hour urine collection', 'Total bilirubin < 15 x upper limits of normal ULN', 'Aspartate aminotransferase AST and alanine aminotransferase ALT < 25 x upper limits of normal ULN', 'Note GCSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria', 'Patients cannot have any of the following\\r\\n Central nerve system involvement\\r\\n Primary refractory multiple myeloma where primary refractory multiple myeloma is defined as disease that is nonresponsive – patients who have never achieved a minimal response MR or better – with any therapy over the course of their disease it includes patients who never achieve MR or better in whom there is no significant change in Mprotein and no evidence of clinical progression as well as patients who meet criteria for true progressive disease PD\\r\\n Primary or secondary plasma cell leukemia\\r\\n Lightchain AL amyloidosis or polyneuropathy organomegaly endocrinopathy monoclonal gammopathy and skin changes POEMS syndrome\\r\\n Known active hepatitis C based on\\r\\n +hepatitis C virus HCV antibody confirmed\\r\\n +HCV RNA\\r\\n Liver disease with history of positive serology\\r\\n Note patients with a prior history of hepatitis C that has been successfully eradicated with antiviral therapy are eligible\\r\\n Known hepatitis B surface antigen positivity\\r\\n Previous hypersensitivity to any of the components of the study treatment\\r\\n Prior history of erythema multiforme with thalidomide or lenalidomide treatment', '=< grade 2 peripheral neuropathy', 'Adequate cardiac function defined as\\r\\n No electrocardiogram EKG evidence of acute ischemia\\r\\n No EKG evidence of active clinically significant conduction system abnormalities\\r\\n No EKG evidence of > grade 2 > 480 ms corrected QT QTc prolongation \\r\\n Prior to study entry any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant\\r\\n No uncontrolled angina or severe ventricular arrhythmias\\r\\n No clinically significant pericardial disease\\r\\n No history of myocardial infarction within 6 months prior to registration\\r\\n No class 3 or higher New York Heart Association congestive heart failure', 'No strong inducers of cytochrome P450 CYP 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 within 14 days prior to registration\\r\\nNote Ixazomib is a substrate of CYP3A4 and CYP1A2', 'Patients with human immunodeficiency virus HIV infection are eligible provided they meet the following\\r\\n No history of acquired immunodeficiency syndrome AIDSdefining conditions or other HIV related illness\\r\\n Cluster of differentiation CD4+ cells nadirs > 350mm3 within 28 days prior to registration\\r\\n Treatment sensitive HIV and if on antiHIV therapy HIV viral load < 50 copiesmm3 within 28 days prior to registration\\r\\n Note HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their antiretroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Patients randomized to Arm 1 may opt to switch to the 3drug regimen following disease progression these patients must be reregistered to the study and meet the eligibility criteria below', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Patient must have measurable disease or nonmeasurable disease after progression on pomalidomide + dexamethasone defined as one or more of the following holding true\\r\\n Measurable disease\\r\\n Serum Mprotein >= 05 gdL andor\\r\\n Urine Mprotein >= 200 mg24 hours andor\\r\\n Involved serum free light chain level >= 10 mgdL AND an abnormal serum free light chain ratio\\r\\n For nonmeasurable disease\\r\\n Marrow burden of myeloma of at least 30', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 \\r\\n Women of childbearing potential\\r\\n Must have a negative serum or urine pregnancy test within 72 hours prior to reregistration\\r\\n Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control one highly effective method and one additional effective barrier method AT THE SAME TIME before starting pomalidomide\\r\\n Must agree to ongoing pregnancy testing\\r\\n Must agree to not become pregnant or breast feed a child during treatment on this protocol\\r\\n Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy\\r\\n Note All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 ECOG performance status 02', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Absolute neutrophil count ANC >= 10 x 109L', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Platelet count >= 50 x 109L', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Calc creatinine clearance >= 30 mLmin\\r\\n Calculated utilizing the CockcroftGault formula or 24hour urine collection', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Total bilirubin < 15 x upper limits of normal ULN', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 AST and ALT < 25 x upper limits of normal ULN', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Note GCSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 =< grade 2 peripheral neuropathy', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 No strong inducers of cytochrome P450 CYP 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2\\r\\n Note Ixazomib is a substrate of CYP3A4 and CYP1A2'], ['PREREGISTRATION', 'Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing and the establishment of BCRABL status testing will be performed by the Eastern Cooperative Oncology Group ECOGAmerican College of Radiation Imaging Network ACRIN Leukemia Translational Research Laboratory LTRL and reported to the institution\\r\\n NOTE IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE SUBMITTED TO THE ECOGACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW ASSESSMENTS OF MRD CAN BE DONE IN ADDITION TO ALLOWING THE LTRL TO CONFIRM ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCRABL STATUS IT IS ALSO IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS MULLIGHANWILLMAN WITHOUT ADEQUATE BASELINE SAMPLES PATIENTS WILL NOT BE ABLE TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL IF A BONE MARROW ASPIRATE IS NOT AVAILABLE FOR LTRL SUBMISSION AT BASELINE IT IS IMPERATIVE THAT DR PAIETTA FROM THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WBC AND BLAST COUNT BEFORE BLOOD ONLY IS SUBMITTED\\r\\n NOTE Hydroxyurea can be given for up to 5 days prior to initiation of protocol therapy for control of leukocyte count andor other symptoms or signs corticosteroids can be given after preregistration to the protocol and submission of baseline marrow and blood samples for control of leukocyte count andor other symptoms or signs prior to initiation of protocol therapy if needed if corticosteroids are given prior to preregistration contact the study chair as the patient may still be eligible to participate', 'INDUCTION ELIGIBILITY CRITERIASTEP 1', 'New diagnosis of B lineage ALL must be made upon bone marrow or peripheral blood immunophenotyping cases with myeloid antigen expression but unequivocal lymphoid immunophenotype are eligible', 'Negativity for the Philadelphia chromosome must be established by conventional cytogenetics fluorescence in situ hybridization FISH andor polymerase chain reaction PCR patients who are negative for the Philadelphia chromosome by conventional cytogenetics must have FISH or PCR performed for BCRABL to exclude occult translocations', 'Cytogenetic analysis must be performed from diagnostic bone marrow preferred or if adequate number of circulating blasts from peripheral blood FISH testing for common Blineage ALL abnormalities including t922 BCRABL1 t1221 ETSvariant gene 6 ETV6runtrelated transcription factor 1 RUNX1 t119 preBcell leukemia homeobox 1 PBX1transcription factor 3 TCF3 +4+10+17 centromeric Cen4Cen10Cen17 t11q23var myeloidlymphoid or mixed lineage leukemia MLL deletion del9p cyclindependent kinase inhibitor 2A CDKN2ACen9 and t14var immunoglobulin heavy chain IGH is encouraged if there are few or no circulating blasts and an adequate marrow sample cannot be obtained for cytogenetic analysis the patient may still enroll on the trial', 'Serum direct bilirubin < 2 mgdl or serum total bilirubin =< 3 obtained =< 48 hours prior to registration NOTE the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration', 'Serum creatinine < 2 mgdl obtained =< 48 hours prior to registration NOTE the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration', 'Patient should be human leukocyte antigen HLA typed A B C DR and DQ during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet', 'Patients with known human immunodeficiency virus HIV infection are eligible if they meet all of the following criteria\\r\\n No history of acquired immune deficiency syndrome AIDSrelated complications other than a history of low CD4+ Tcell count < 200mm3 prior to initiation of combination antiretroviral therapy on study CD4+ Tcell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\\r\\n Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\\r\\n Patient must have serum HIV viral load of < 200 copiesmm3\\r\\n Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\\r\\n Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat stavudine or on regimens containing stavudine or zidovudine\\r\\n It is recommended to utilize a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarateemtricitabine or dolutegravir combined with tenofovir alafenamideemtricitabine', 'Patient must not have an antecedent hematologic disorder', 'Patient must have no history of recent myocardial infarction within three months uncontrolled congestive heart failure or uncontrolled cardiac arrhythmia', 'Patient must not have a history or presence of clinically relevant central nervous system CNS pathology such as epilepsy seizure paresis aphasia stroke severe brain injuries dementia Parkinson’s disease cerebellar disease organic brain syndrome psychosis or other significant CNS abnormalities', 'Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan MUGA or echocardiogram within 4 weeks prior to registration resting ejection fraction >= 40 or >= 5 increase with exercise shortening fraction by echocardiogram >= 24 or to within the normal range of values for the institution', 'Patient must not have an active uncontrolled infection', 'Women must not be pregnant or breastfeeding and must not become pregnant or breastfeed during protocol therapy and for at least 3 months after protocol therapy woman of childbearing potential must abstain from sexual activity or be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocolspecified therapy all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'Men who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocolspecified therapy men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocolspecified therapy', 'ECOG performance score 03', 'Patient must have given written informed consent', 'POSTINDUCTION THERAPY ELIGIBILITY CRITERIA PRIOR TO INTENSIFICATIONSTEP 2', 'ECOG performance status 02', 'Patients must have achieved a CR or CRi', 'Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi', 'Patient must be CNS cerebrospinal fluid CSF negative for leukemia', 'Patients must have resolved any serious infectious complications related to induction', 'Any significant medical complications related to induction must have resolved', 'Serum creatinine =< 20 mgdl obtained =< 48 hours prior to registration', 'Serum direct bilirubin < 2 mgdL or serum total bilirubin =< 3 obtained =< 48 hours prior to registration', 'Aspartate aminotransferase AST and alanine aminotransferase ALT < 3 x upper limit of normal ULN obtained =< 48 hours prior to registration', 'RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMABSTEP 3', 'Patients must have an ECOG performance status of 02', 'Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi confirmed on restaging bone marrow BM aspirate and biopsy', 'Patients must have resolved any serious infectious complications related to therapy', 'Any significant medical complications related to therapy must have resolved', 'Direct or total bilirubin < 15 x ULN unless related to Gilbert’s or Meulengracht’s syndrome the values must be obtained within 48 hours prior to randomization', 'Serum creatinine < 15 x ULN the values must be obtained within 48 hours prior to randomization', 'Bone marrow aspirates must be submitted for centralized minimal residual disease MRD assessment performed by the ECOGACRIN Leukemia Translational Research Laboratory', 'MRD results will be reported to the submitting institution\\r\\n NOTE FOR MRD ASSESSMENTS AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION SITE MUST BE SUBMITTED THE NEEDLE CAN BE REDIRECTED THROUGH THE SAME SKIN PUNCTURE SITE ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE FOR MRD TESTING DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME ASPIRATION SITE \\r\\n In Blineage ALL MRD levels in peripheral blood or from a dilute marrow aspiration can be 300 lower on average than those in bone marrow at a given time point submitting a first pull from a separate aspiration site will ensure that MRD determinations used in randomization and trial interpretation are accurate\\r\\n NOTE failure to submit bone marrow aspirates will result in a major violation at the time of an audit', 'CRITERIA FOR ALLOGENEIC TRANSPLANTATION', 'A suitable donor must be identified there are no restrictions on donor type and can include a matched sibling a matched or mismatched unrelated donor a family haplotype matched donor or a cord blood donor single or double', 'Patients should meet the eligibility criteria for RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMABSTEP 3', 'Patients must be considered reliable enough to comply with the medication regimen and followup and have social support necessary to allow this compliance', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients must have an ECOG performance status of 03', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi confirmed on restaging BM aspirate and biopsy', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients must have resolved any serious infectious complications related to therapy', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Any significant medical complications related to therapy must have resolved', 'Mature B ALL Burkitt’slike leukemia is excluded from enrollment in this trial prestudy bone marrow biopsy and aspirate must be completed =< 1 week prior to registration', 'Patient must not have a concurrent active malignancy for which they are receiving treatment', 'Patient must not have intercurrent organ damage or medical problems that will jeopardize the outcome of therapy ie psychiatric disorder drug abuse pregnancy'], ['Newly diagnosed patients with histologically proven ALCL International Classification of Diseases for Oncology ICD0 code 97143', 'Disease must be cluster of differentiation CD30 positive', 'Disease must be anaplastic lymphoma kinase ALK positive defined by local institutional standards', 'Patients must have stage II III or IV disease', 'Patients must have a life expectancy of >= 8 weeks', 'Total bilirubin =< 15 x upper limit of normal ULN for age within 7 days prior to enrollment', 'Alanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT < 25 x upper limit of normal ULN for age for the purpose of this study the ULN for ALT is 45 UL within 7 days prior to enrollment', 'If the lab abnormality is thought to be due to the lymphoma the patient is eligible and dose adjustments should be made', 'Shortening fraction of >= 27 by echocardiogram or', 'Ejection fraction of >= 50 by radionuclide angiogram', 'Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest no exercise intolerance due to pulmonary insufficiency and a pulse oximetry > 92 while breathing room air unless current dysfunction is due to the lymphoma in which case the patient is eligible', 'Patients with central nervous system CNS disease are not eligible', 'Patients with disease limited to the skin are not eligible regardless of how widespread', 'Patients with stage I disease are not eligible', 'Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible', 'Previous steroid treatment andor radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass emergent steroid treatment andor radiation treatment should stop once protocol therapy is initiated', 'Intrathecal chemotherapy prior to enrollment is allowed for the current diagnosis of ALCL as long as adequate cerebrospinal fluid CSF is obtained prior to administration of the intrathecal chemotherapy and subsequently demonstrated to be negative for ALCL', 'Female patients who are pregnant are not eligible pregnancy tests must be obtained in girls who are post menarchal', 'Lactating females are not eligible unless they have agreed not to breastfeed their infants', 'Sexually active patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of treatment and for 3 months after stopping treatment', 'Patients with Down syndrome are not eligible due to the amount of methotrexate and potential for side effects', 'Patients with an immunodeficiency that existed prior to diagnosis such as primary immunodeficiency syndromes or organ transplant recipients are not eligible', 'Cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 substrates with narrow therapeutic indices Patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices including pimozide aripiprazole triazolam ergotamine and halofantrine are not eligible the topical use of these medications if applicable is allowed', 'CYP3A4 inhibitors patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment including but not limited to ketoconazole itraconazole clarithromycin erythromycin ritonavir indinavir nelfinavir saquinavir delavirdine nefazodone diltiazem verapamil and grapefruit juice are not eligible the topical use of these medications if applicable eg 2 ketoconazole cream is allowed', 'CYP3A4 inducers patients chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment including but not limited to carbamazepine phenobarbital phenytoin rifabutin rifampin ritonavir and St John’s wort are not eligible the topical use of these medications if applicable is allowed', 'Patients that are known to be positive for human immunodeficiency virus HIV are not eligible note inclusion of HIV positive patients will be considered at a later date', 'Patients who weigh < 10 kg are not eligible'], ['INCLUSION CRITERIA FOR PHYSICIANS', 'Oncology physicians must work at a National Cancer Institute NCI Community Oncology Research Program NCORP practice site with no plans to leave that NCORP practice site or retire at the time of enrollment into the study', 'INCLUSION CRITERIA FOR PATIENTS', 'Diagnosis of an advanced solid tumor malignancy advanced cancer or lymphoma in most situations this would be a stage IV cancer patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated clinical staging without pathological confirmation of advanced disease is allowed', 'Plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration the treatment regimen is up to the discretion of the treating oncology physician the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity patients who will receive monoclonal antibody therapy or other cancer therapies eg tyrosine kinase inhibitors are eligible if the other agents present a prevalence of toxicity similar to chemotherapy these therapies can be used in combination with chemotherapy as a single agent or in combination with each other\\r\\n Chemotherapy will be defined as cytotoxic drugs in addition agents eg monoclonal antibodies and targeted agents that have a prevalence of grade 35 toxicity in older patients similar to chemotherapy > 50 will be allowed a list of allowable agents single and in combination meeting this toxicity criteria will be available on the University of Rochester Cancer Center URCC NCORP Research Base website as part of the study materials given the rapidly changing landscape of new drugs for cancer the study team led by the principal investigator PI will update the list accordingly after reviewing the toxicity profile of new therapies if the potentially eligible participant is to receive an approved drug or regimen not on the list contacting the URCC NCORP Research Base study team is required for approval prior to participant enrollment\\r\\n Patients who are receiving approved cancer treatment in combination with radiation are eligible\\r\\n A patient may also be enrolled on a treatment trial and participate in this study if all other inclusion and exclusion criteria are met', 'Plan to be on chemotherapy or other allowable treatment for at least 3 months minimum 70 days and be willing to come in for study visits\\r\\n The plan for treatment should be for at least 3 months at time of study enrollment the treatment can stop earlier during the study at the discretion of the physician and patient eg due to progression as noted through imaging toxicity or patient preference', 'Have at least one geriatric assessment domain meet the cutoff score for impairment other than polypharmacy', 'Able to provide informed consent or if the oncology physician determines the patient to not have decisionmaking capacity a patientdesignated health care proxy or authorized representative per institutional policies must sign consent by the baseline visit if the participant is found to be impaired on the BlessedOrientation Memory Concentration Test BOMC during screening they must have a health care proxy or authorized representative to be eligible to enroll', 'Participant has adequate understanding of the English language', 'EXCLUSION CRITERIA FOR PATIENTS', 'Have surgery planned within 3 months of consent patients who have previously received surgery are eligible', 'Presence of symptomatic brain metastases at time of study consent process patients with history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment'], ['Patients must have measurable stage III measurable stage IVA stage IVB with or without measurable disease or recurrent with or without measurable disease endometrial carcinoma\\r\\n Histologic confirmation of the original primary tumor is required patients with the following histologic epithelial cell types are eligible\\r\\n Endometrioid adenocarcinoma serous adenocarcinoma undifferentiated carcinoma clear cell adenocarcinoma mixed epithelial carcinoma adenocarcinoma not otherwise specified NOS', 'Measurable disease is defined by Response Evaluation Criteria in Solid Tumors RECIST version 11 measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded each lesion must be >= 10 mm when measured by computed tomography CT magnetic resonance imaging MRI or caliper measurement by clinical exam or >= 20 mm when measured by chest xray lymph nodes must be >= 15 mm in short axis when measured by CT or MRI', 'Patients must have a Gynecologic Oncology Group GOG performance status of 0 1 or 2', 'Absolute neutrophil count ANC greater than or equal to 1500mcl', 'Platelets greater than or equal to 100000mcl', 'Creatinine less than 14 mgdl', 'Bilirubin less than or equal to 15 x institutionallaboratory upper limit of normal ULN', 'Aspartate aminotransferase AST and alanine aminotransferase ALT less than or equal to 3 x ULN', 'Alkaline phosphatase less than or equal to 25 x ULN', 'Patients must NOT have received prior chemotherapy or targeted therapy including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma', 'Patients may have received prior radiation therapy for treatment of endometrial carcinoma prior radiation therapy may have included pelvic radiation therapy extended field pelvicparaaortic radiation therapy andor intravaginal brachytherapy all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy', 'Patients may have received prior hormonal therapy for treatment of endometrial carcinoma all hormonal therapy must be discontinued at least one week prior to the first date of study therapy', 'Patients must be able to swallow and retain orallyadministered medication', 'Patients must have signed an approved informed consent and authorization permitting release of personal health information individuals with impaired decisionmaking capacity are not eligible to participate on the study', 'Patients must NOT be taking metformin or have been on metformin in the past 6 months', 'Patients with a history of other invasive malignancies with the exception of nonmelanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years', 'Uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illnesssocial situations that would limit compliance with study requirements', 'Patients who are pregnant or nursing if patients are of reproductive age and have not undergone hysterectomy they must use an effective contraceptive method for the duration of this study', 'Any condition associated with increased risk of metforminassociated lactic acidosis eg congestive heart failure defined as New York Heart Association NYHA class III or IV functional status history of acidosis of any type habitual intake of 3 or more alcoholic beverages per day'], ['Histologic documentation newly diagnosed World Health Organization WHO grade IV intracranial glioblastoma or gliosarcoma GBM with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q codeleted sites submitting GBM with oligodendroglial features will be asked to provide results of 1p19q codeletion status', 'Sufficient tissue available for central pathology review and MGMT methylation status evaluation', 'Patients who have had a local MGMT testing that is unmethylated are not allowed to participate', 'Tumor MGMT promoter hypermethylation determined by central testing at MD Anderson', 'Confirmation by central pathology review of WHO grade IV glioblastoma or gliosarcoma', 'Absolute neutrophil count ANC >= 1500 cellsmm3 within 14 days prior to study registration', 'Platelets >= 100000 cellsmm3 within 14 days prior to study registration', 'Creatinine =< 15 x upper limit of normal ULN within 14 days prior to study registration', 'Bilirubin =< 15 x ULN within 14 days prior to study registration unless patient has Gilbert’s disease', 'Alanine aminotransferase ALT =< 3 x ULN within 14 days prior to study registration', 'Aspartate aminotransferase AST =< 3 x ULN within 14 days prior to study registration', 'Eastern Cooperative Oncology Group ECOG performance status =< 2', 'Measurable disease or nonmeasurable disease extent of resection patients with complete resection partial resection or biopsy are eligible', 'Progression patients deemed to have progressive disease based on clinical deterioration after chemoradiation or radiographic progression outside of the radiation field are not eligible patients deemed to have pseudoprogression are eligible', 'Prior treatment\\r\\n Must have completed standard radiotherapy and concomitant TMZ therapy as defined and determined by the study oncologist\\r\\n Besides concomitant TMZ with radiation no other therapy neoadjuvant or adjuvant can be given prior to study registration including chemotherapy also including Gliadelcarmustine BCNU wafers biologics immunotherapy radiation therapy the only exception is the Optune device NovoTTF100A which may be started any time after end of radiation therapy up through the initiation of Cycle 1 intent to use Optune must be declared at registration for stratification\\r\\n No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation', 'Not pregnant and not nursing females of childbearing potential must have negative urine or serum pregnancy test within 7 days of registration but before start of treatment a female of childbearing potential is a sexually mature female who \\r\\n Has not undergone a hysterectomy or bilateral oophorectomy or \\r\\n Has not been naturally postmenopausal for at least 12 consecutive months ie has had menses at any time in the preceding 12 consecutive months', 'Concomitant medications patients receiving anticoagulation should be on stable dose 2 weeks prior to registration', 'Comorbid conditions patients are unable to participate due to the following\\r\\n Generalized or partial seizure disorder that is uncontrolled at the time of registration the definition of controlled generalized seizures is patients must be on a stable dose of antiseizure medication and without generalized seizures for at least 10 days prior to registration the definition of controlled partial seizures is patients must be on a stable dose of antiseizure medication for at least 10 days prior to registration patients with occasional breakthrough partial seizures are allowed at treating physician’s discretion\\r\\n Grade 3 or 4 thromboembolic disease within 6 months mo of registration\\r\\n Known history of prolonged QT syndrome', 'No history of major surgery =< 14 days prior to registration', 'Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT888 as defined below\\r\\n >= 100 gdL hemoglobin Hb with no blood transfusion in the past 28 days', 'No Patients with treatmentrelated acute myeloid leukemia AML tAMLmyelodysplastic syndrome MDS or with features suggestive of AMLMDS'], ['SCREENINGPRESCREENING REGISTRATION', 'Patients must have pathologically proven squamous cell carcinoma SCCA cancer of the lung confirmed by tumor biopsy andor fineneedle aspiration disease must be stage IV SCCA or recurrent the primary diagnosis of SCCA should be established using the current World Health Organization WHOInternational Association for the Study of Lung Cancer IASLCclassification of Thoracic Malignancies the diagnosis is based on hematoxylin and eosin HE stained slides with or without specific defined immunohistochemistry IHC characteristic p40p63 positive transcription termination factor TTF1 negative if required for diagnosis mixed histologies are not allowed', 'Patients must either be eligible to be screened at progression on prior treatment or to be prescreened prior to progression on current treatment patients will either consent to the screening consent or the prescreening consent not both these criteria are\\r\\n Screening at progression on prior treatment to be eligible for screening at progression patients must have received at least one line of systemic therapy for any stage of disease stages IIV and must have progressed during or following their most recent line of therapy for patients whose prior systemic therapy was for stage IIII disease only ie patient has not received any treatment for stage IV or recurrent disease the prior systemic therapy must have been a platinumbased chemotherapy regimen and disease progression on the platinumbased chemotherapy must have occurred within one year from the last date that patient received that therapy for patients whose prior therapy was for stage IV or recurrent disease the patient must have received at least one line of a platinumbased chemotherapy regimen or checkpoint inhibitor therapy eg nivolumab or pembrolizumab\\r\\n Prescreening prior to progression on current treatment to be eligible for prescreening current treatment must be for stage IV or recurrent disease and patient must have received at least one dose of the current regimen patients must have previously received or currently be receiving a platinumbased chemotherapy regimen or checkpoint inhibitor therapy eg nivolumab or pembrolizumab patients on firstline platinumbased treatment are eligible upon receiving cycle 1 day 1 infusion Note patients will not receive their substudy assignment until they progress and the S1400 Notice of Progression is submitted', 'Patients must have adequate tumor tissue available defined as >= 20 tumor cells and >= 02 mm3 tumor volume\\r\\n The local interpreting pathologist must review the specimen\\r\\n The pathologist must sign the S1400 Local Pathology Review Form confirming tissue adequacy prior to screeningprescreening registration\\r\\n Patients must agree to have this tissue submitted to Foundation Medicine for common broad platform Clinical Laboratory Improvement Act CLIA biomarker profiling and cMET IHC if archival tumor material is exhausted then a new fresh tumor biopsy that is formalinfixed and paraffinembedded FFPE must be obtained a tumor block or FFPE slides 45 microns thick must be submitted bone biopsies are not allowed if FFPE slides are to be submitted at least 12 unstained slides plus an HE stained slide or 13 unstained slides must be submitted however it is strongly recommended that 20 FFPE slides be submitted Note previous nextgeneration deoxyribonucleic acid DNA sequencing NGS will be repeated if done outside this study for substudy assignment patients must agree to have any tissue that remains after NGS testing retained for the use of the translational medicine TM studies if such TM studies are defined within any substudy the patient is enrolled in', 'Patients must not have a known epidermal growth factor receptor EGFR mutation or anaplastic lymphoma kinase ALK fusion EGFRALK testing is not required prior to registration and is included in the Foundation Medicine Incorporated FMI testing for screeningprescreening', 'Patients must have Zubrod performance status 01 documented within 28 days prior to screeningprescreening registration', 'Patients must also be offered participation in banking for future use of specimens', 'Patients must be willing to provide prior smoking history as required on the S1400 Onstudy Form', 'As a part of the Oncology Patient Enrollment Network OPEN registration process the treating institutions identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered in the system', 'Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines', 'United States US patients who can complete the survey and the interview by telephone or email in English must be offered participation in the S1400GEN survey ancillary study NOTE Patients enrolled to S1400 prior to revision 12 are not eligible for the S1400GEN survey ancillary study study physicians will provide participants with a hard copy of the survey at the time of informed consent to improve tracking and comprehension during the interview', 'SUBSTUDY REGISTRATION', 'Patients whose biomarker profiling results indicate the presence of an EGFR mutation or echinoderm microtubuleassociated proteinlike 4 EML4ALK fusion are not eligible', 'Patients must have progressed in the opinion of the treating investigator following the most recent line of therapy', 'Patients must not have received any prior systemic therapy systemic chemotherapy immunotherapy or investigational drug within 21 days prior to substudy registration patients must have recovered =< grade 1 from any side effects of prior therapy patients must not have received any radiation therapy within 14 days prior to substudy registration', 'Patients must have measurable disease documented by computed tomography CT or magnetic resonance imaging MRI the CT from a combined positron emission tomography PETCT may be used to document only nonmeasurable disease unless it is of diagnostic quality measurable disease must be assessed within 28 days prior to substudy registration pleural effusions ascites and laboratory parameters are not acceptable as the only evidence of disease nonmeasurable disease must be assessed within 42 days prior to substudy registration all disease must be assessed and documented on the Baseline Tumor Assessment Form patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease in the opinion of the treating investigator prior to registration', 'Patients must have a CT or MRI scan of the brain to evaluate for central nervous system CNS disease within 42 days prior to substudy registration patient must not have leptomeningeal disease spinal cord compression or brain metastases unless 1 metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment and prior to registration AND 2 patient has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to substudy registration', 'Patient must have fully recovered from the effects of prior surgery at least 14 days prior to substudy registration', 'Patients must not be planning to receive any concurrent chemotherapy immunotherapy biologic or hormonal therapy for cancer treatment concurrent use of hormones for noncancerrelated conditions eg insulin for diabetes and hormone replacement therapy is acceptable', 'Absolute neutrophil count ANC >= 1500mcl obtained within 28 days prior to substudy registration', 'Platelet count >= 100000 mcl obtained within 28 days prior to substudy registration', 'Hemoglobin >= 9 gdL obtained within 28 days prior to substudy registration', 'Serum bilirubin =< institutional upper limit of normal IULN within 28 days prior to substudy registration for patients with liver metastases bilirubin must be =< 5 x IULN', 'Either alanine aminotransferase ALT or aspartate aminotransferase AST =< 2 x IULN within 28 days prior to substudy registration if both ALT and AST are done both must be =< 2 IULN for patients with liver metastases either ALT or AST must be =< 5 x IULN if both ALT and AST are done both must be =< 5 x IULN', 'Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50 mLmin using the following CockcroftGault Formula within 28 days prior to substudy registration', 'Patients must have Zubrod performance status 01 documented within 28 days prior to substudy registration', 'Patients must not have any grade IIIIV cardiac disease as defined by the New York Heart Association Criteria ie patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort unstable angina pectoris and myocardial infarction within 6 months or serious uncontrolled cardiac arrhythmia', 'Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection', 'Patients with a known history of human immunodeficiency virus HIV seropositivity\\r\\n Must have undetectable viral load using standard HIV assays in clinical practice\\r\\n Must have cluster of differentiation CD4 count >= 400mcL\\r\\n Must not require prophylaxis for any opportunistic infections ie fungal Mycobacterium avium complex mAC or pneumocystis jiroveci pneumonia PCP prophylaxis\\r\\n Must not be newly diagnosed within 12 months prior to substudy registration', 'Prestudy history and physical exam must be obtained within 28 days prior to substudy registration', 'No other prior malignancy is allowed except for the following adequately treated basal cell or squamous cell skin cancer in situ cervical cancer adequately treated stage I or II cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease free for five years', 'Patients must not be pregnant or nursing womenmen of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a sideeffect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol heshe is responsible for beginning contraceptive measures', 'As part of the OPEN registration process the treating institution’s identity is provided in order to ensure that the current within 365 days date of institutional review board approval for this study has been entered into the system', 'Patients with impaired decisionmaking capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study eg tracking pill consumption and reporting adverse events to the investigator', 'Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines'], ['First relapse of BALL allowable sites of disease include isolated bone marrow combined bone marrow and CNS andor testicular and isolated CNS andor testicular extramedullary sites are limited to the CNS and testicles', 'No waiting period for patients who relapse while receiving standard maintenance therapy', 'Patients who relapse on frontline therapy in phases other than maintenance must have fully recovered from the acute toxic effects of all prior chemotherapy immunotherapy or radiotherapy prior to entering this study', 'Cytotoxic therapy at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea which is permitted up to 24 hours prior to the start of protocol therapy or maintenance chemotherapy or intrathecal chemotherapy methotrexate strongly preferred administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status', 'Biologic antineoplastic agent at least 7 days since the completion of therapy with a biologic agent for agents that have known adverse events occurring beyond 7 days after administration this period must be extended beyond the time during which adverse events are known to occur', 'Stem cell transplant or rescue patient has not had a prior stem cell transplant or rescue', 'Patient has not had prior treatment with blinatumomab', 'With the exception of intrathecal chemotherapy methotrexate strongly preferred cytarabine is permissible administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status patient has not received prior relapsedirected therapy ie this protocol is intended as the INITIAL treatment of first relapse', 'Patients must have a performance status corresponding to Eastern Cooperative Oncology Group ECOG scores of 0 1 or 2 use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age', 'Creatinine clearance or radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 or a serum creatinine based on agegender as follows\\r\\n 1 to < 2 years =< 06 mgdL\\r\\n 2 to < 6 years =< 08 mgdL\\r\\n 6 to < 10 years =< 1 mgdL\\r\\n 10 to < 13 years =< 12 mgdL\\r\\n 13 to < 16 years =< 15 mgdL males and =< 14 mgdL females\\r\\n >= 16 years =< 17 mgdL males and =< 14 mgdL females', 'Direct bilirubin < 30 mgdL', 'Shortening fraction of >= 27 by echocardiogram or', 'Ejection fraction of >= 50 by radionuclide angiogram', 'All patients andor their parent or legal guardian must sign a written informed consent', 'All institutional Food and Drug Administration FDA and National Cancer Institute NCI requirements for human studies must be met', 'Patients with Philadelphia chromosome positivebreakpoint cluster region protein BCRAbelson murine leukemia viral oncogene homolog 1 ABL1+ ALL are not eligible', 'Patients with Burkitt leukemialymphoma or mature Bcell leukemia are not eligible', 'Patients with Tlymphoblastic leukemia TALLlymphoblastic lymphoma TLL are not eligible', 'Patients with Blymphoblastic lymphoma BLL are not eligible', 'Patients with known optic nerve andor retinal involvement are not eligible patients who are presenting with visual disturbances should have an ophthalmologic exam and if indicated a magnetic resonance imaging MRI to determine optic nerve or retinal involvement', 'Patients known to have one of the following concomitant genetic syndromes Down syndrome Bloom syndrome ataxiatelangiectasia Fanconi anemia Kostmann syndrome Shwachman syndrome or any other known bone marrow failure syndrome', 'Patients with known human immunodeficiency virus HIV infection', 'Patients with known allergy to mitoxantrone cytarabine or both etoposide and etoposide phosphate Etopophos', 'Lactating females who plan to breastfeed', 'Patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs a pregnancy test is required for female patients of childbearing potential', 'Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation', 'Patients with preexisting significant central nervous system pathology that would preclude treatment with blinatumomab including history of severe brain injury dementia cerebellar disease organic brain syndrome psychosis coordinationmovement disorder or autoimmune disease with CNS involvement are not eligible patients with a history of cerebrovascular ischemiahemorrhage with residual deficits are not eligible patients with a history of cerebrovascular ischemiahemorrhage remain eligible provided all neurologic deficits have resolved', 'Patients with uncontrolled seizure disorder are not eligible patients with seizure disorders that do not require antiepileptic drugs or are well controlled with stable doses of antiepileptic drugs remain eligible'], ['Biopsy proven from primary lesion andor lymph nodes diagnosis of cancer of the nasopharynx', 'Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis\\r\\n Patients must have detectable pretreatment plasma EBV DNA determined by the central lab prior to Step 2 registration\\r\\n For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs within 28 days prior to Step 1 registration that test result can be used for eligibility without the need for retesting to use this test result for eligibility the central lab must enter the test result through the pathology portal', 'Stage IIIVB disease American Joint Committee on Cancer AJCC 7th edition ed with no evidence of distant metastasis based upon the following minimum diagnostic workup\\r\\n Historyphysical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear Nose Throat specialist ENT which must include an endoscopic evaluation a complete list of current medications and assessment of weight and weight loss in the past 6 months within 21 days prior to registration\\r\\n Evaluation of tumor extent required within 28 days prior to registration\\r\\n Magnetic resonance imaging MRI of the nasopharynx and neck or computed tomography CT of the nasopharynx and neck with =< 3 mm contiguous slices with contrast and bone windows to evaluate base of skull involvement \\r\\n Note If a treatment planning CT scan is used it must be with =< 3 mm contiguous slices with contrast and be read by a radiologist\\r\\n To rule out distant metastasis patients must undergo the following imaging within 28 days prior to registration\\r\\n A CT scan with contrast of the chest and abdomen required and the pelvis optional or a total body PETCT scan noncontrast PETCT is acceptable\\r\\n A bone scan only when there is suspicion of bone metastases a PETCT scan can substitute for the bone scan', 'Zubrod performance status 01 within 21 days prior to registration', 'Absolute neutrophil count ANC >= 1500 cellsmm3 within 21 days prior to registration', 'Platelets >= 100000 cellsmm3 within 21 days prior to registration', 'Hemoglobin >= 80 gdl within 21 days prior to registration Note the use of transfusion or other intervention to achieve hemoglobin Hgb >= 80 gdl is acceptable', 'Total bilirubin =< 15 x institutional upper limit of normal ULN within 21 days prior to registration', 'Aspartate aminotransferase AST or alanine aminotransferase ALT =< 15 x institutional ULN within 21 days prior to registration', 'Alkaline phosphatase =< 15 x institutional ULN within 21 days prior to registration', 'Serum creatinine =< 15 mgdl or calculated creatinine clearance CC >= 50 mlmin determined by 24hour urine collection or estimated by CockcroftGault formula within 21 days prior to registration', 'Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential', 'Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment', 'Patient must provide study specific informed consent prior to study entry including the mandatory pretreatment plasma EBV DNA assay', 'Prior invasive malignancy except node negative nonmelanomatous skin cancer unless disease free for a minimum of 1095 days 3 years for example carcinoma in situ of the breast oral cavity or cervix are all permissible', 'Prior systemic chemotherapy for the study cancer note that prior chemotherapy for a different cancer is allowable however at least 6weeks recovery is necessary if the last regimen included nitrosourea or mitomycin', 'Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields', 'Patients with hearing loss assessed to be primarily sensorineural in nature requiring a hearing aid or intervention ie interfering in a clinically significant way with activities of daily living a conductive hearing loss that is tumorrelated is allowed', '>= Grade 2 peripheral sensory neuropathy CTCAE v 40', 'Severe active comorbidity defined as follows\\r\\n Major medical or psychiatric illness which in the investigator’s opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy\\r\\n Unstable angina andor uncontrolled congestive heart failure within past 6 months\\r\\n Myocardial infarction within the last 6 months\\r\\n Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible\\r\\n Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration\\r\\n Acquired immune deficiency syndrome AIDS based upon current Centers for Disease Control and Prevention CDC definition note however that human immunodeficiency virus HIV testing is not required for entry into this protocol', 'Pregnancy or women of childbearing potential and men who are sexually active and not willingable to use medically acceptable forms of contraception', 'Prior allergic reaction to the study drugs involved in this protocol', 'Patients with undetectable pretreatment plasma EBV DNA'], ['Estrogen receptor ER andor progesterone receptor PR positive histologically confirmed adenocarcinoma of the breast with staining of >= 1 cells will be considered positive receptor status may be based on any time during treatment prior to study randomization and from any site ie primary recurrent or metastatic', 'Patients whose tumors have HER2 immunohistochemistry IHC 3+ in situ hybridization ISH >= 20 or average HER2 copy number >= 60 signals per cell are not eligible receptor status may be based on any time during treatment prior to study randomization and from any site ie primary recurrent or metastatic', 'Patients must have measurable or nonmeasurable stage IIIlocally advanced or metastatic carcinoma of the breast where local therapy with curative intent is not possible lesions must be evaluated =< 4 weeks prior to study randomization diagnosticquality computed tomography CT scans with both oral and intravenous IV contrast are the expected radiologic method unless an alternative is approved\\r\\n NOTE Where baseline imaging has already been performed =< 6 weeks prior to study randomization repeat imaging may not be required\\r\\n NOTE As of October 16 2016 accrual of new patients having nonmeasurable disease has stopped the planned accrual for this target population has been reached', 'Preperi and postmenopausal women and all men are eligible for this trial postmenopausal is defined as\\r\\n Age >= 55 years and one year or more of amenorrhea\\r\\n Age < 55 years and one year or more of amenorrhea with estradiol < 20 pgml\\r\\n Age < 55 with prior hysterectomy but intact ovaries with estradiol < 20 pgml\\r\\n Prior bilateral oophorectomy\\r\\n NOTE Women who do not fit the criteria for being postmenopausal as above are deemed preor perimenopausal preperimenopausal women and all men can enroll provided they agree to receive concomitant luteinizing hormonereleasing hormone LHRH agonist preperimenopausal women must have commenced treatment with LHRH agonist at least 4 weeks prior to randomization if patients have received alternative LHRH agonist prior to study entry they must switch to goserelin for the duration of the trial', 'Sexually active males and preperimenopausal women must agree to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 3 months after discontinuation of therapy', 'Women must not be pregnant or breastfeeding all females of childbearing potential must have a blood test or urine study =< 2 weeks prior to randomization\\r\\n A female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months ie has had menses at any time in the preceding 24 consecutive months', 'Patients must not have known central nervous system metastasis or a history of central nervous system CNS metastases patients with leptomeningeal disease are not eligible', 'Patients must be diseasefree of prior invasive malignancies for > 5 years with the exception of curativelytreated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\\r\\n NOTE If there is a history of prior malignancy patients must not be receiving other specific treatment for that cancer', 'Patients must meet at least one of the following criteria\\r\\n Disease progression any time after nonsteroidal AI use in the advanced disease setting\\r\\n Relapse while on or within =< 12 months of end of adjuvant nonsteroidal AI therapy with or without prior endocrine therapy for advanced disease\\r\\n NOTE In either setting treatment with any prior endocrine therapy must be completed >= 2 weeks prior to cycle 1 day 1 C1D1 of study treatment with the exception of exemestane which is permitted in the advanced disease setting within =< 4 weeks immediately prior to C1D1 prior adjuvant exemestane is allowed if the disease free interval is > 12 months from the discontinuation of exemestane prior faslodex everolimus palbociclib or other cyclindependent kinase CDK inhibitor eg ribociclib abemaciclib use are allowed and must have been completed >= 2 weeks prior to C1D1 failure to adhere to this washout guideline will result in a protocol violation', 'Patients may have received only one prior chemotherapy regimen for metastatic disease provided treatment was completed >= 3 weeks prior to randomization', 'Patients may be treated with bone modifying agents such as bisphosphonates or RANKligand agents eg denosumab per American Society of Clinical Oncology ASCO guidelines whenever possible patients requiring bone modifying agents should start treatment >= 7 days prior to study therapy and should continue the same agent throughout study unless clinically compelled to change', 'Prior radiotherapy must in general have been completed >= 2 weeks prior to randomization and patients must have recovered from the toxicity of the radiation\\r\\n NOTE Patients may receive concurrent radiation therapy to painful sites of bony disease or areas of impending fracture as long as sites of measurable or nonmeasurable disease outside the radiation therapy port are available to follow', 'Patients must NOT receive concurrent anticancer therapy or investigational agent unless specified in protocol', 'Patients must NOT be receiving valproic acid an histone deacetylase HDAC inhibitor and may not have previously received any HDAC inhibitor prior to enrollment eg valproic acid entinostat vorinostat unless discussed with the study chair patients must not have received prior HDAC therapy for the treatment of their malignancy', 'Patients must have no known allergies to exemestane entinostat or medications that have a benzamide structure eg tiapride remoxipride clebropride', 'Patients must NOT suffer from medical or psychiatric conditions that would interfere with protocol compliance the ability to provide informed consent or assessment of response or anticipated toxicities this includes uncontrolled intercurrent illness including but not limited to ongoing or active infection', 'Patients must have recovered from all clinically relevant adverse events to grade 1 or baseline due to previous agents administered except alopecia', 'Patients must have adequate hematologic liver and renal function =< 28 days prior to randomization\\r\\n NOTE It is preferred that laboratory values for eligibility be assessed after the last dose of prior treatment especially in cases where mostrecent treatment prior to study entry is chemotherapy', 'Hemoglobin HgB >= 90 gdL =< 28 days prior to randomization', 'Platelet count >= 100000mcL =< 28 days prior to randomization', 'Absolute neutrophil count >= 1500mcL =< 28 days prior to randomization', 'Creatinine =< 20 mgdL =< 28 days prior to randomization', 'Total bilirubin < 15 x institutional upper limit of normal =< 3 mgdL in case of Gilbert’s syndrome =< 28 days prior to randomization', 'Transaminases alanine aminotransferase ALT aspartate aminotransferase AST =< 25 x institutional upper limit normal =< 28 days prior to randomization', 'Known human immunodeficiency virus HIVpositive patients should have a cluster of differentiation CD4 count > 250mm3', 'Patients must have Eastern Cooperative Oncology Group ECOG performance status 01', 'Patients must have a life expectancy >= 12 weeks', 'Patients must be able to swallow tablets']]\n"
     ]
    }
   ],
   "source": [
    "# Remove the punctuation from each description so when we use fuzzy matching it will be more accurate. If we compare\n",
    "# bob to bob, they are dissimilar by the comma, so this can help with accuracy, and help reducing the number of tokens if\n",
    "# we wanted to break down this data structure even further\n",
    "punctuation = '''!()-[]{};:'\"\\,./?@#$%^&*_~'''\n",
    "all_desc_no_punc = []\n",
    "\n",
    "for trial in all_descriptions:\n",
    "    \n",
    "    descriptions = []\n",
    "    \n",
    "    for desc in trial:\n",
    "    \n",
    "        desc_np = ''\n",
    "\n",
    "        for ch in desc:\n",
    "\n",
    "            if ch not in punctuation:\n",
    "                desc_np = desc_np + ch\n",
    "\n",
    "        descriptions.append(desc_np)\n",
    "        \n",
    "    all_desc_no_punc.append(descriptions)\n",
    "\n",
    "print(all_desc_no_punc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Patients histological diagnosis epithelial ovarian cancer fallopian tube primary peritoneal carcinoma clinical stage II III IV diagnosis', 'Patients following histologic epithelial cell types eligible serous adenocarcinoma endometrioid adenocarcinoma mucinous adenocarcinoma undifferentiated carcinoma clear cell adenocarcinoma mixed epithelial carcinoma transitional cell carcinoma malignant Brenner’s tumor adenocarcinoma specified NOS histologic features tumor compatible primary Mullerian epithelial adenocarcinoma', 'Patients completed primary chemotherapy consolidation therapy administered 6 weeks 6 months 2 weeks prior enrollment complete remission consolidation therapy defined chemotherapy biological therapy patient completed courses primary chemotherapy documented complete remission prior initiation chemotherapy chemo biological therapy', 'Patients achieved documented complete response treatment based normal cancer antigen CA125 institution’s upper limit normal computed tomography CT scan magnetic resonance imaging MRI contrast clinical evidence persistent recurrent disease based CA125 CT scan MRI contrast', 'Patients Gynecologic Oncology Group GOG performance grade 0 1 2', 'Patients currently enrolled ongoing participating 6 months longer medically prescribed diet physical activity regimen', 'Patients chronic disease preclude randomization lifestyle intervention trial diseases include recent myocardial infarction unstable angina previous 6 months chronic hepatitis rheumatoid disease renal hepatic diseasedysfunction diabetics receiving insulin clinical condition limiting ability walk recent leg fracture significant osteoarthritis related orthopedic conditions degenerative neurological conditions', 'Patients psychiatric illness lifetime bipolar disorder schizophrenia psychosis personality disorder severe major depressive disorder recent suicide psychiatric hospitalization previous 12 months history eating disorder anorexia nervosa bulimia nervosa', 'Patients complete preentry assessments', 'Patients signed approved informed consent authorization permitting release personal health information', 'Patients willing provide appropriate telephone contact information willing contacted periodically telephone The University Arizona Cancer Center AZCC staff completion individualized lifestyle intervention coaching completion Pittsburgh Sleep Quality Index clarification patientcompleted responses necessary patient willing Arizona Food Frequency Questionnaire AFFQ Arizona Physical Activity Questionnaire APAQ baseline questionnaire personal contact information sent AZCC', 'Patients GOG performance grade 3 4', 'Patients history invasive malignancies years exception nonmelanoma skin cancer stage 1A endometrioid adenocarcinoma uterus', 'Patients diagnosed chronic diseaseillness precluding participation diabetics receiving insulin myocardial infarction unstable angina previous 6 months chronic hepatitis rheumatoid disease renal hepatic diseasedysfunction', 'Patients histological diagnosis clinical stage I epithelial ovarian cancer fallopian tube primary peritoneal carcinoma', 'Patients currently undergoing treatment primary consolidation stage II III IV ovarian fallopian tube primary peritoneal cancer completed treatment weeks ago', 'Patients life expectancy year', 'Patients body mass index BMI < 20 kgm2', 'Vegan vegetarians', 'Patients enrolled weight loss program taking weight loss medications dietary supplements unwilling discontinue', 'Patients participated marathon triathlon endurancerelated physical activity previous 24 months', 'Patients surgery weight loss Note women excluded baseline lifestyle assessment indicates healthy eating moderate physical activity exception exclusion criteria'], ['Pathologically histologically proven diagnosis squamous cell carcinoma including variants verrucous carcinoma spindle cell carcinoma carcinoma specified NOS headneck oral cavity oropharynx larynx note hypopharynx primaries excluded', 'Clinical stage T1 N12 T24a N02 M0 including distant metastases based following minimum diagnostic workup General history physical examination radiation oncologist andor medical oncologist 8 weeks prior registration Examination ear nose throat ENT head neck surgeon 8 weeks prior registration laryngopharyngoscopy mirror andor fiberoptic andor direct procedure recommended required Chest xray minimum chest computed tomography CT scan contrast CTpositron emission tomography PET chest contrast 8 weeks prior registration', 'Gross total resection primary tumor curative intent completed 7 weeks registration surgical pathology demonstrating following “intermediate” risk factors Perineural invasion Lymphovascular invasion Single lymph node > 3 cm >= 2 lymph nodes < 6 cm extracapsular extension Close margins resection defined cancer extending 5 mm surgical margin andor initially focally positive margin subsequently superseded intraoperative negative margins similarly patients tumors focally positive margins main specimen negative margins reexcised samples region positive margin eligible questions ambiguities individual case contact Dr Machtay andor Dr Holsinger prior enrolling patient Pathologically confirmed T3 T4a primary tumor questions ambiguities individual case contact Dr Machtay andor Dr Holsinger prior enrolling patient T2 oral cavity cancer > 5 mm depth invasion', 'Zubrod performance status 01', 'Absolute granulocyte count AGC >= 1500mm³', 'Platelet count >= 100000mm³', 'Hemoglobin >= 80 gdL note use transfusion intervention achieve hemoglobin Hgb >= 80 gdl acceptable', 'Total bilirubin < 2 x institutional upper limit normal ULN', 'Aspartate aminotransferase AST alanine aminotransferase ALT < 3 x institutional ULN', 'Serum creatinine < 2 x institutional ULN creatinine clearance CC >= 50 mLmin determined 24hour collection estimated CockcroftGault formula', 'Negative serum pregnancy test 2 weeks prior registration women childbearing potential', 'The following assessments required 2 weeks prior start registration sodium Na potassium K chloride Cl glucose calcium Ca magnesium Mg albumin note patients initial magnesium < 05 mmolL 12 mgdl receive corrective magnesium supplementation continue receive prophylactic weekly infusion magnesium andor oral magnesium supplementation magnesium oxide investigator’s discretion', 'Women childbearing potential male participants sexually active agree use medically effective means birth control', 'Patients provide study specific informed consent prior study entry including consent mandatory tissue submission EGFR oropharyngeal patients HPV analyses', 'Prior invasive malignancy nonmelanomatous skin cancer disease free minimum 3 years noninvasive cancers example carcinoma situ breast oral cavity cervix permissible permitted diagnosed treated < 3 years ago patients simultaneous primaries bilateral tumors excluded exception patients bilateral tonsil cancers patients primary tumor T12 nearby lymph nodes N0 metastasis M0 resected differentiated thyroid carcinoma eligible', 'Per operative andor pathology report positive margins defined tumor present cut inked edge tumor nodal extracapsular extension andor gross residual disease surgery note patients tumors focally positive margins main specimen negative margins reexcised samples region positive margin eligible questions ambiguities individual case contact Dr Machtay andor Dr Holsinger prior enrolling patient', 'Prior systemic chemotherapy antiEGF therapy study cancer note prior chemotherapy antiEGF therapy different cancer allowable', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months prior registration Transmural myocardial infarction 6 months prior registration Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration Idiopathic pulmonary fibrosis severe interstitial lung disease requires oxygen therapy thought require oxygen therapy 1 year prior registration Hepatic insufficiency resulting clinical jaundice andor coagulation defects note laboratory tests coagulation parameters required entry protocol Acquired immune deficiency syndrome AIDS based current Centers Disease Control Prevention CDC definition note human immunodeficiency virus HIV testing required entry protocol protocolspecific requirements exclude immunocompromised patients Grade 34 electrolyte abnormalities CTCAE v 4 Serum calcium ionized adjusted albumin < 7 mgdl 175 mmolL > 125 mgdl > 31 mmolL despite intervention normalize levels Glucose < 40 mgdl < 22 mmolL > 250 mgdl > 14 mmolL Magnesium < 09 mgdl < 04 mmolL > 3 mgdl > 123 mmolL despite intervention normalize levels Potassium < 30 mmolL > 6 mmolL despite intervention normalize levels Sodium < 130 mmolL > 155 mmolL despite intervention normalize levels', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception', 'Prior allergic reaction cetuximab'], ['PREREGISTRATION INCLUSION CRITERIA', 'United States US Canadian sites This review mandatory prior registration confirm eligibility patients willing submit tissue samples mandatory central pathology review submission initiated soon surgery possible', 'Tissue determined local 1p9q codeletion IDH mutation prior submission central path review Tumor tissue codeletion chromosomes 1p 19q eligibility 1p19q analysis results accepted local site determined locally available reference laboratory US Clinical Laboratory Improvement Act CLIA certified acceptable methods determination 1p19q loss include fluorescent insitu hybridization FISH genomic sequencing methylomic analyses US Canadian sites send copy official report pathology coordinator quality assurance specialist QAS Tumor evidence IDH mutation immunohistochemistry genomic analyses performed local site US performed CLIA certified laboratory site send copy official report pathology coordinator QAS', 'REGISTRATION INCLUSION CRITERIA', 'Newly diagnosed =< 3 months surgical diagnosis patients eligible prior surgical procedure > 3 months earlier low grade glioma long patient received prior radiation prior chemotherapy', 'Histological evidence World Health Organization WHO grade III anaplastic glioma WHO grade II low grade glioma locally diagnosed combined 1p19q loss presence IDH1 IDH2 established local referenced laboratory qualified study Note mixed gliomas eligible regardless degree astrocytic oligodendrocytic predominance long tumor codeleted 1p 19q', 'Patients codeleted low grade gliomas considered “high risk” exhibiting following characteristics Age >= 40 surgical therapy Age < 40 prior subtotal resection biopsy gross total resection Documented growth following prior surgery NOTE patients prior surgery received prior radiation chemotherapy targeted therapy Intractable seizures', 'Surgery partial gross total resection biopsy performed >= 2 weeks prior registration patient recovered adequately effects surgery', 'Absolute neutrophil count ANC >= 1500mm3 obtained =< 21 days prior registration', 'Platelet PLTs count >= 100000mm3 obtained =< 21 days prior registration', 'Hemoglobin Hgb > 90 gdL obtained =< 21 days prior registration', 'Total bilirubin =< 15 x institutional upper limit normal ULN obtained =< 21 days prior registration', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 3 x ULN obtained =< 21 days prior registration', 'Creatinine =< 15 x ULN obtained =< 21 days prior registration', 'Negative serum urine pregnancy test =< 7 days prior registration women childbearing potential', 'Willingness ability personally complete neurocognitive testing assistance willingness complete QOL testing personally assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 2', 'Written informed consent', 'Willingness return enrolling institution followup active monitoring phase active treatment observation portion study patients formally transferred active approved site participating study need return enrolling institution purpose', 'Willingness allow provision tissue samples correlative research long adequate tissues available patients excluded participation study willing allow provision tissues correlative research insufficient quantities tissue correlative analyses patient eligible willing biopsy Willingness allow provision blood samples correlative research patients excluded participation study willing provide mandatory biospecimens translationalcorrelative research logistical reasons specimenss obtainable volume collected insufficient', 'The following categories ineligible Pregnant women Nursing women Men women childbearing potential unwilling employ adequate contraception contraceptive method study 6 months following completion chemotherapy treatments', 'History prior radiation therapy chemotherapy glioma note patients history prior low grade glioma distant history prior surgery glioma received prior chemotherapy radiation therapy glioma eligible study', 'Comorbid systemic illnesses severe concurrent disease judgment investigator patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribed regimens', 'Concomitant immunocompromised status related concomitant steroids compromise safety patient study', 'Patients known human immunodeficiency virus HIV positive currently receiving retroviral therapy eligible note patients known HIV positive clinical evidence immunocompromised state eligible study', 'Uncontrolled intercurrent illness including limited ongoing active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia psychiatric illnesssocial situations limit compliance study requirements', 'Receiving investigational agent considered treatment primary neoplasm', 'Other active malignancy 5 years registration exceptions nonmelanotic skin cancer carcinomainsitu cervix note history prior malignancy patient eligible receiving specific treatment exclusion hormonal therapy Her2 inhibitors cancer received prior total body irradiation included brain', 'History myocardial infarction =< 6 months congestive heart failure requiring use ongoing maintenance therapy lifethreatening ventricular arrhythmias', 'Recent history hepatitis infection treating physician determined patient significant risk reactivation hepatitis'], ['Newly diagnosed previously untreated 1 M0 medulloblastoma > 15 cm2 residual 2 M+ medulloblastoma patients diffusely anaplastic medulloblastoma eligible regardless Mstage residual tumor As amendment 2 enrollment patients supratentorial PNET discontinued All patients M4 disease eligible', 'A preoperative magnetic resonance imaging MRI scan brain contrast required NOTE computed tomography CT scans NOT sufficient study eligibility Postoperative head MRI scan contrast preferably 72 hours postsurgery patients undergo stereotactic biopsy pre postoperative MRI sufficient patients M2 M3 disease postop MRI strongly encouraged mandatory Spinal MRI imaging gadolinium required 10 days surgery preoperatively 28 days surgery postoperatively posterior fossa tumors preoperative MRI scans preferred', 'Lumbar cerebrospinal fluid CSF cytology examination obtained preoperatively 31 days following surgery optimal time obtaining CSF prior surgery 13 weeks following surgery ventricular CSF pre postop postoperative spinal tap contraindicated spinal tap contraindicated ventricular CSF available CSF cytology waived patients supratentorial tumors documentation spinal subarachnoid metastases M3 patients categorized M1 intraoperative positive CSF lumbar puncture end procedure positive lumbar CSF obtained > 7 days postoperatively', 'Patients Karnofsky performance level >= 30 patients > 16 years age Lansky performance scale >= 30 patients =< 16 years age life expectancy > 8 weeks', 'No previous chemotherapy radiation therapy', 'Corticosteroids chemotherapy administration antiemetic', 'Selected strong inhibitors cytochrome P450 family 3 subfamily A polypeptide 4 cytochrome P450 3A4 include azole antifungals fluconazole voriconazole itraconazole ketoconazole strong inducers include drugs rifampin phenytoin phenobarbitol carbamazepine St John’s wort use drugs avoided vincristine vincristine sulfate', 'CYP450 3A4 stimulators inhibitors avoided great caution taking cyclophosphamide aprepitant caution etoposide vincristine chemotherapy', 'Cisplatin caution nephrotoxic drug aminoglycoside avoided caution shortly cisplatin administration concomitant use amphotericin B probably avoided patients receiving cisplatin potentially ototoxic drugs aminoglycoside loop diuretics concomitantly closely monitored signs ototoxicity Plasma levels anticonvulsant agents monitored doses adjusted therapy cisplatin', 'No experimental therapy permitted study', 'Creatinine clearance radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 OR serum creatinine based agegender follows 08 mgdL 2 < 6 years age 10 mgdL 6 < 10 years age 12 mgdL 10 < 13 years age 15 mgdL male 14 mgdL female 13 < 16 years age 17 mgdL male 14 mgdL female >= 16 years age', 'Total bilirubin < 15 x upper limit normal ULN age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 25 x upper limit normal ULN age patients antiseizure medications SGOT AST SGPT ALT < 5 x ULN', 'Absolute neutrophil count ANC >= 1000uL', 'Platelets >= 100000uL untransfused', 'Hemoglobin >= 8 gdl transfused', 'Female patients postmenarchal negative pregnancy test lactating female patients agree breastfeed trial males females reproductive potential participate agreed use effective contraceptive method', 'All patients andor parents legal guardians sign written informed consent', 'All institutional Food Drug Administration FDA National Cancer Institute NCI requirements human studies met'], ['Participant histologic confirmation newly diagnosed squamous cell carcinoma SCC head neck', 'Participant unilateral bilateral neck dissection planned care N0 neck planned dissected patient eligible N0 neck ipsilateral head neck tumor contralateral N0 neck bilateral neck dissection planned', 'Participant confirmed head neck SCC CT andor MR imaging completed 6 weeks prior enrollment SCC diagnosis methods submitted American College Radiology Imaging Network ACRIN Simultaneous diagnostic CT PET excluded cases PET criteria define N0 neck required entrance trial If sites received CT andor MR images institutions ACRIN recommends reread local neuroradiologist ensure compliance protocol eligibility requirements', 'Participant neck clinically N0 defined clinical exam physical exam CT andor MRI gold standard N0 neck stages T2 T3 T4 N0–N3 excluding N2c bilateral disease based criteria American Joint Commission Cancer', 'Participant considered viable clinical option perform neck dissection primary cancers high risk neck metastasis definition These include 1 oral cavity cancer 2 oropharynx cancer including base tongue tonsil cancers 3 larynx cancer 4 supraglottic cancer', 'Participant willing provide written informed consent', 'Patient pregnant andor breastfeeding', 'Patient sinonasal carcinoma', 'Patient tumors head neck SCC', 'Patient salivary gland malignancies', 'Patient thyroid cancers', 'Patient advanced skin cancers', 'Patient nasopharyngeal carcinoma', 'Patient poorly controlled diabetes defined fasting glucose level > 200 mgdL optimally participants glucose < 150 mgdL despite attempts improve glucose control fasting duration adjustment medications', 'Patient candidate surgery neck dissection underlying medical condition', 'Patient weighs weight limit PET table'], ['Patients histologically confirmed diagnosis node positive 13 nodes invasive breast carcinoma positive estrogen andor progesterone receptor status negative HER2 status estrogen progesterone receptor positivity assessed according American Society Clinical Oncology ASCOCollege American Pathologists CAP guidelines estrogen receptor ER progesterone receptor PR >= 1 positive nuclear staining HER2 test result negativity assessed ASCOCAP 2013 guidelines immunohistochemistry IHC situ hybridization ISH HER2 negative single test tests performed tumor specimen IHC negative 0 1+ b ISH negative single probe dual probe average HER2 copy number < 40 signals cell single probe HER2CEP ration < 20 average copy number < 40 signals cell dual probe HER2 IHC 2+ evaluation gene amplification ISH performed ISH negative ISH required IHC 0 1+ HER2 equivocal eligible', 'Patients multifocal multicentric synchronous bilateral breast cancers allowed Multifocal disease defined invasive cancer < 2 cm largest lesion breast quadrant NOTE Oncotype DX testing completed largest lesion Multicentric disease defined invasive cancer >= 2 cm largest lesion breast quadrant lesion different quadrants NOTE Oncotype DX testing completed tumors determination eligibility highest recurrence score Synchronous bilateral disease defined invasive breast cancer positive lymph nodes axillary intramammary breast diagnosed 30 days NOTE Oncotype DX testing completed tumors tumor highest recurrence score', 'Patients undergone axillary staging sentinel node biopsy axillary lymph nodes dissection ALND patients known positive lymph nodes pN1a pN1b pN1c patients micrometastases nodal involvement pN1mi eligible patients positive sentinel node required undergo axillary lymph node dissection discretion treating physician axillary node evaluation performed standard care institution', 'Patients inflammatory breast cancer metastatic disease', 'Patients prior diagnosis contralateral ductal carcinoma situ DCIS eligible underwent mastectomy lumpectomy breast radiation prior partial breast irradiation including brachytherapy allowed patients prior diagnosis ipsilateral DCIS invasive breast cancer received radiation breast eligible', 'Patients breastconserving surgery planned radiation therapy total mastectomy planned postmastectomy radiation patients clear margins invasive breast cancer DCIS local institutional guidelines lobular carcinoma situ LCIS margins allowed', 'Registration patients undergone Oncotype DX screening occur later 56 days definitive surgery patients Step 2 Registration occur 84 days definitive surgery Oncotype DX Breast Cancer Assay performed patients willing submit tissue samples testing determine Recurrence Score value representative block unstained sections representative block sent directly Genomic Health Oncotype DX Breast Cancer Assay performed according standard commercial process If Oncotype DX Recurrence Score known 25 patient registered Step 2 immediately following Step 1 registration Oncotype DX Recurrence Score known greater 25 patient ineligible', 'Patients complete history physical examination 28 days prior registration', 'Patients performance status 02 Zubrod criteria', 'Patients able receive taxane andor anthracycline based chemotherapy', 'Patients begun chemotherapy endocrine therapy breast cancer prior registration', 'Patients require chronic treatment systemic steroids inhaled steroids allowed immunosuppressive agents', 'Patients received aromatase inhibitor AI selective estrogen receptor modulator SERM tamoxifen raloxifene 5 years prior registration', 'Patients pregnant nursing women reproductive potential agreed use effective contraceptive method woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation point previously celibate patient chooses heterosexually active time period use contraceptive measures outlined protocol heshe responsible beginning contraceptive measures', 'No prior malignancy allowed adequately treated basal cell squamous cell skin cancer situ cervical cancer cancer patient diseasefree 5 years', 'The Quality Life Economic Substudy permanently closed accrual effective 12112 patients consented QOL prior 12112 continue complete QOL forms expectation report patients able complete questionnaire English offered opportunity participate Quality Life Economic Substudy The Quality Life Economic Substudy available US INSTITUTIONS ONLY patients able complete questionnaire English registered S1007 participating Quality Life Economic Substudy Patients consent participate Quality Life Economic Substudy know results Oncotype DX screening agree complete S1007 HealthRelated Quality Life Questionnaire Enrollment 14 days prior 7 days Step 1 Registration Patients consent participate Quality Life Economic Substudy know Oncotype DX Recurrence Score 25 proceed Step 2 Registration completing S1007 HealthRelated Quality Life Questionnaire Enrollment Form complete S1007 HealthRelated Quality Life Questionnaire Randomized Study Form', 'Patients legally authorized representative informed investigational nature study sign written informed consent accordance institutional federal guidelines Step 1 registration patients submitted specimens Oncotype DX Breast Cancer Assay appropriate consent form Step 1 Consent Form Step 1 Step 2 registration patients Recurrence Score known 25 appropriate consent form Step 2 Consent Form', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered', 'STEP 2 REGISTRATION', 'Recurrence score RS Oncotype DX =< 25', 'Step 2 Registration place 84 days definitive surgery patients begun chemotherapy endocrine therapy breast cancer prior randomization', 'Patients randomized arm coenroll phase III trials compare local therapies compare systemic therapies chemotherapy randomized Arm I S1007', 'The Quality Life Economic Substudy permanently closed accrual effective 12112 patients US INSTITUTIONS consent participate Quality Life Economic Substudy agree complete S1007 HealthRelated Quality Life Questionnaire Randomized Study Form Recurrence Score results randomized treatment status known treatment initiated', 'Patients legally authorized representative informed investigational nature study sign written informed consent accordance institutional federal guidelines patients appropriate consent form registration Step 2 Consent'], ['BALL patients enrolled AALL08B1 APEC14B1 open classification newly diagnosed ALL patients prior treatment enrollment AALL0932 Note BLLy patients eligible AALL08B1 enroll directly AALL0932', 'BALL patients initial white blood cell count < 50000uL', 'Patients newly diagnosed National Cancer Institute NCI Standard Risk BALL BLLy Murphy stages I II patients Down syndrome eligible Note BLLy patients tissue available flow cytometry criterion diagnosis analogous BALL tissue processed means paraffin blocks methodology criteria immunophenotypic analysis establish diagnosis BLLy defined submitting institution accepted', 'All patients andor parents legal guardians sign written informed consent', 'All institutional Food Drug Administration FDA NCI requirements human studies met', 'With exception steroid pretreatment defined administration intrathecal cytarabine patients received prior cytotoxic chemotherapy current diagnosis BALL BLLy cancer diagnosed prior initiation protocol therapy AALL0932 Patients receiving prior steroid therapy eligible AALL0932', 'Patients central nervous 3 CNS3 leukemia CNS status known prior enrollment Note CNS status determined based sample obtained prior administration systemic intrathecal chemotherapy steroid pretreatment BLLy patients CNS3 disease eligible protocol COG HR ALL protocol recommended intrathecal cytarabine administered time diagnostic lumbar puncture usually time diagnostic bone marrow venous line placement avoid second lumbar puncture allowed prior registration systemic chemotherapy begin 72 hours dose intrathecal therapy', 'BALL patients testicular leukemia eligible AALL0932', 'For BLLy patients following additional exclusion criteria apply Tlymphoblastic lymphoma Morphologically unclassifiable lymphoma Absence Bcell Tcell phenotype markers case submitted lymphoblastic lymphoma CNS3positive disease testicular involvement M2 5 25 blasts M3 > 25 blasts marrow Female patients pregnant ineligible Lactating females eligible agreed breastfeed infants Female patients childbearing potential eligible negative pregnancy test result obtained Sexually active patients reproductive potential eligible agreed use effective contraceptive method duration study participation'], ['Patients newly diagnosed biopsy confirmed extracranial nonmetastatic Ewing sarcoma primitive neuroectodermal tumor PNET bone soft tissue eligible study note For purpose study chest wall tumors ipsilateral pleural effusions ipsilateral positive pleural fluid cytology ipsilateral pleural based secondary tumor nodules considered localized disease Patients regional node involvement based clinical suspicion confirmed pathologic documentation considered nonmetastatic Patients discontinuous osseous lesions bone considered nonmetastatic Tumors arising bony skull extradural considered extracranial', 'Patient eligibility based diagnosis Ewing sarcoma PNET institutional pathologist', 'No prior chemotherapy radiation therapy allowed patients biopsy primary tumor attempt complete partial resection patients eligible unplanned excision attempted accomplished long adequate imaging obtained prior surgery', 'Creatinine clearance radioisotope glomerular filtration rate GFR >= 70mLmin173 m2 serum creatinine based agegender follows 1 month < 6 months 04 mgdL 6 months < 1 year 05 mgdL 1 < 2 years 06 mgdL 2 < 6 years 08 mgdL 6 < 10 years 1 mgdL 10 < 13 years 12 mgdL 13 < 16 years 15 mgdL male 14 mgdL female >= 16 years 17 mgdL male 14 mgdL female', 'Total bilirubin < 15 x upper limit normal ULN age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 25 x upper limit normal ULN age', 'Shortening fraction >= 27 echocardiogram ejection fraction >= 50 radionuclide angiogram', 'Patients evidence metastatic disease metastatic disease Are lesions discontinuous primary tumor regional lymph nodes share body cavity primary tumor doubt lesions metastatic biopsy lesions taken Skeletal lesions adjacent bones transarticular Contralateral pleural effusion contralateral pleural nodules Distant lymph node involvement Patients pulmonary nodules considered metastatic disease patient Solitary nodule > 05 cm multiple nodules > 03 cm biopsied negative Ewings Biopsies solitary nodule =< 05 cm multiple nodules =< 03 cm required performed positive indicate metastatic disease', 'Patients tumors arise dural intradural soft tissues cranium spine eligible', 'Patients pathologic diagnoses Ewing sarcoma excluded', 'Patients diagnosed Ewing Sarcoma second malignant neoplasm eligible received chemotherapy radiation treatment primary malignancy', 'Pregnant women entered study pregnancy tests obtained female patients postmenarchal lactating females participate agreed breastfeed infants males females reproductive potential participate agreed use effective contraceptive method duration study treatment', 'All patients andor parents legal guardians sign written informed consent', 'All institutional Food Drug Administration FDA National Cancer Institute NCI requirements human studies met'], ['Patients histologically cytologicallyproven new diagnosis unresectable stage IIIAIIIB nonsmall cell lung cancer adenocarcinoma bronchioloalveolar cell carcinoma large cell carcinoma squamous cell carcinoma mixed Per American Joint Committee Cancer AJCC 7th edition pleural pericardial considered stage M1a disease pleural fluid visible computed tomography CT scan chest xray thoracentesis required confirm pleural fluid cytologically negative patients exudative pleural effusions excluded regardless cytology patients effusions minimal visible chest xray small safely tap eligible small effusion positive fludeoxyglucose F 18 FDG uptake positron emission tomography PET proven malignant standard care diagnostic procedures patient excluded', 'Patients measurable nonmeasurable disease documented CT magnetic resonance imaging MRI PETCT CT combined PETCT document nonmeasurable disease scan diagnostic quality measurable disease assessed CT 28 days prior registration pleural effusions ascites laboratory parameters acceptable evidence disease nonmeasurable disease assessed 42 days prior registration disease assessed documented Baseline Tumor Assessment Form', 'Patients brain metastases ineligible patients pretreatment CT MRI scan brain evaluate central nervous CNS disease 42 days prior registration', 'Patients received prior systemic therapy chemotherapy biologic therapy lung cancer', 'Patients received prior chest radiation therapy NSCLC', 'Patients previous surgical resection patients undergone exploratory thoracotomy mediastinoscopy excisional biopsy similar surgery purpose determining diagnosis stage potential resectability newly diagnosed lung tumor 28 days elapsed thoracic surgery excluding mediastinoscopy minor surgeries patients recovered associated toxicities time registration patients planning undergo minor surgical procedure study', 'Patients Zubrod performance status 01', 'Patients tumor tissue available submission assess gene expression ERCC1 XRCC1 patients offered participation banking future use specimens', 'Absolute neutrophil count >= 1500mcl', 'Platelets >= 100000mcl', 'Hemoglobin >= 90 gdl', 'Total bilirubin institutional upper limit normal IULN', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 25 x IULN', 'Patients pregnant nursing womenmen reproductive potential agreed use effective contraceptive method woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation point previously celibate patient chooses heterosexually active time period use contraceptive measures outlined protocol heshe responsible beginning contraceptive measures', 'Patients serum creatinine =< IULN AND measured calculated creatinine clearance >= 60 ccmin CockroftGault formula', 'Patients pulmonary function tests PFTs including forced expiratory volume 1 second FEV1 84 days prior registration FEV1 best value obtained pre postbronchodilator >= 12 literssecond andor >= 50 predicted', 'Patients planning receive investigational agents', 'Patients 10 weight loss past 6 months', 'Patients history allergic reactions attributed compounds similar chemical biologic composition ABT888 carboplatin paclitaxel agents study', 'No prior malignancy allowed following adequately treated basal cell squamous cell skin cancer situ cervical cancer adequately treated stage I II cancer patient currently complete remission cancer patient disease free years', 'Patient uncontrolled intercurrent illness including limited ongoing active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia psychiatric illnesssocial situations limit compliance study requirements', 'Patients currently > grade 1 symptomatic neuropathysensory National Cancer Institute NCI Common Terminology Criteria Adverse Events CTCAE version 40', 'Patients history seizures', 'Patients known immune deficiencies patients immune deficiency increased risk lethal infections treated marrowsuppressive therapy known human immunodeficiency virus HIV positive patients receiving combination antiretroviral therapy excluded study', 'Patients able swallow capsules', 'Prestudy history physical obtained 28 days prior registration', 'All patients informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'As Oncology Patient Enrollment Network OPEN registration process treating institution’s identity provided order ensure current 365 days date institutional review board approval study entered', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients completed chemoradiotherapy protocol weeks weeks elapsed day induction therapy day radiation', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients undergone restaging tests according study calendar determined evidence disease progression', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients serum creatinine =< IULN AND measured calculated creatinine clearance >= 60 ccmin CockroftGault formula', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Absolute neutrophil count >= 1500 mcl', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Platelets >= 100000mcl', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Hemoglobin >= 90 gdl', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Total bilirubin =< IULN', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY SGOT AST SGPT ALT =< 25 x IULN', 'REGISTRATION 2 PRIOR TO CONSOLIDATION CHEMOTHERAPY Patients Zubrod performance status 01'], ['Receiving anastrozole 1 mg letrozole 25 mg orally day >= 21 days prior registration plan continue duration study', 'Body mass index BMI 18 35 kgm2', 'Women undergone total mastectomy breastconserving surgery primary breast cancer + chemotherapy + radiotherapy', 'Must BOTH estrogen receptor ER progesterone receptor PRpositive tumors BOTH >= 26 positive alternatively ER PR determined Allred score score needs 5 higher', 'Women postmenopausal surgery radiotherapy presence natural amenorrhea >= 12 months', '>= 510 arthralgia hands wrist knees hips treated anastrozole letrozole felt patient caused aromatase inhibitor measured verbally addressing following question rate pain picking number 0 10 0 10 bad imagine best describes pain aromatase inhibitor breast cancer medication AVERAGE past week Note Patients taking nonopioid analgesics', 'Ability complete questionnaires assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 2', 'Willing provide informed written consent', 'Willing return Alliance enrolling institution followup', 'Willing provide blood samples correlative research purposes', 'Creatinine =< 15 x upper limit normal ULN =< 365 days prior registration medical situations change parameters', 'Hemoglobin > 11 gdL =< 365 days prior registration medical situations change parameters', 'White blood cell WBC > 30 =< 365 days prior registration medical situations change parameters', 'Platelet count > 100000 =< 365 days prior registration medical situations change parameters', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 15 x ULN =< 365 days prior registration medical situations change parameters', 'Presence residual recurrent cancer locally metastatic', 'Diabetes mellitus glucose intolerance defined fasting glucose > 125 mgdL', 'History coronary artery disease angina myocardial infarction', 'Patients hormonereplacement therapy HRT =< 4 weeks prior registration includes use vaginal estrogen therapy', 'Known hypersensitivity component testosterone', 'Prolonged systemic corticosteroid treatment topical applications rash inhaled sprays obstructive airway diseases eye drops local insertion intraarticular Note Short duration < 2 weeks systemic corticosteroids allowed chronic obstructive pulmonary disease 30 days prior registration', 'Receiving investigational agent', 'History deep venous thrombosis thromboembolism', 'Concurrent use aromatase inhibitor exemestane', 'Concurrent radiation therapy chemotherapy', 'Current planned use cyclosporine anticoagulants insulin oral injectable vitamin D doses 4000 IUday tamoxifen'], ['Life expectancy 5 years excluding diagnosis breast cancer comorbid conditions taken consideration breast cancer diagnosis consideration', 'Men excluded study', 'Upon clinical exam preoperative imaging mammogram + MRI foci biopsy proven breast cancer separated >= 2 cm normal breast tissue foci include focus invasive breast carcinoma focus invasive breast carcinoma ductal carcinoma situ DCIS 2 quadrants biopsy proven breast cancer Note shortest distance lesions reported mammogram + MRI eligibility criteria met obtained Note patient eligible study lesion visualized imaging modalities lesion s isare visualized MRI mammogram OR visualized mammogram MRI ultrasound determine patient eligibility eligibility determined bilateral mammogram + MRI fine needle aspirate second lesion document malignancy allowed focus shown invasive core needle biopsy patient remain study pathological assessment lesions identified preoperative imaging represent contiguous lesion', 'Patients registered AFTER surgery PRIOR TO radiation therapy criteria met An area atypia > 2 cm index lesion excised time cancer operation upgraded DCIS invasive carcinoma identifying MIBC OR Patient underwent resection foci malignancy breast conservation surgery minimum invasive focus breast cancer minimum 2 cm normal breast tissue lesions final pathology', 'Bilateral mammogram =< 90 days prior date surgery Note patients undergoing 1 breast operation date breast surgery breast cancer treatment', 'cN0 cN1 disease', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 2', 'Ability complete questionnaires assistance', 'Ability provide written informed consent', 'Willing return enrolling institution followup Active Monitoring Phase active treatment observation portions study patients encouraged return enrolling institution patients receive radiation therapy different institution enrolling institution', 'Any following Pregnant women Nursing women Women childbearing potential unwilling employ adequate contraception determined treating physician', 'Largest single focus disease > 5 centimeters mammogram MRI Note measurement largest single focus include satellite lesions 1 centimeter index lesion', 'Surgical axillary staging procedure prior definitive breast operation Note fineneedle aspiration FNA core needle biopsy axillary node permitted', 'Clinical radiographic evidence metastatic disease', 'Prior history ipsilateral breast cancer DCIS LCIS lobular cancer situ invasive', 'cNX cN2 cN3 disease', 'Breast implants time diagnosis Note patients implants previously removed prior diagnosis eligible', 'Comorbid systemic illnesses severe concurrent disease judgment investigator interfere significantly wholebreast irradiation connective tissue disorders lupus scleroderma', 'Uncontrolled intercurrent illness including limited ongoing active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia psychiatric illnesssocial situations limit compliance study requirements', 'Prior current LCIS DCIS invasive breast cancer opposite breast bilateral disease allowed', 'Treatment including radiation therapy chemotherapy biotherapy hormonal therapy cancer prior surgery neoadjuvant chemotherapy endocrine therapy allowed patients undergo surgical resection breast conservation treated adjuvant systemic therapy eligible enroll prior start radiotherapy', 'Planned partial breast radiation', 'Patients known breast cancer BRCA mutations patients tested testing result returned time registration excluded registering study', 'Other active malignancy =< 5 years prior registration EXCEPTIONS nonmelanotic skin cancer carcinomainsitu cervix Note history prior malignancy receiving specific treatment cancer'], ['Patients locally advanced previously untreated squamous cell carcinoma vulva', 'Patients T2 T3 primary tumors N03 M0 amenable surgical resection standard radical vulvectomy', 'Absolute neutrophil count ANC >= 1500mcl', 'Platelets >= 100000mcl', 'Creatinine =< 15 times institutional upper limit normal ULN OR calculated creatinine clearance >= 60 mLmin', 'Bilirubin =< 15 x ULN', 'Aspartate aminotransferase AST alanine aminotransferase ALT =< 30 x ULN', 'Alkaline phosphatase =< 3 x ULN', 'Patients judged capable tolerating radical course chemoradiation therapy', 'Patients eligible higher priority Gynecologic Oncology Group GOG protocol exists general refer active GOG Phase III protocol Rare Tumor protocol patient population', 'Patients signed approved informed consent authorization permitting release personal health information', 'Patients GOG performance status 0 1 2', 'Patients recurrent carcinoma vulva regardless previous treatment', 'Patients received prior pelvic radiation cytotoxic chemotherapy', 'Patients vulvar melanomas sarcomas', 'Patients circumstances permit completion study required followup', 'Patients evidence active septicemia severe infection gastrointestinal bleeding severe gastrointestinal symptoms requiring medical surgical therapy', 'Patients history invasive malignancies exception nonmelanoma skin cancer excluded evidence malignancy present years patients excluded previous cancer treatment contraindicates protocol therapy'], ['STEP 0 REGISTRATION Optional', 'Patients primary colon rectal cancer resection potentially eligible S0820 preregistered Step 0 patients registered Step 0 appear institutional patient tracking report patients registered Step 0 registered S0820 protocol participate S0820 patients registered Step 1 patient consented evaluation eligibility patients registered S0820 Step 0 continuing Step 1 registration use Southwest Oncology Group SWOG patient identification ID registration S0820 Step 1', 'STEP 1 REGISTRATION', 'Patients history stage 0 I II III colon rectal adenocarcinoma treated standard care resection combination radiation chemotherapy adjuvant chemotherapy radiation therapy RT treatment completed 30 days prior registration', 'Patients history segmental resections eligible right colectomy extended right colectomy transverse colectomy left colectomy extended left colectomy sigmoid colectomy low anterior resection abdominoperineal resection definition resection include endomucosal resection EMR patients received total proctocolectomy ineligible In addition segmental resections following types procedures allowed polypectomy Tis stage 0 pT1 patients resection consist entirely polypectomy completion partial colectomy ALL following criteria met Single specimen completely removed Clear margins None following present Moderate poor differentiation Lymphovascular invasion Perineural invasion Transanal excision allowed pT1 rectal cancer patients moderately differentiated tumors National Comprehensive Cancer Network NCCN criteria transanal excision met stipulated < 30 circumference bowel < 3 cm size Margin clear > 3 mm Mobile nonfixed Within 8 cm anal verge T1 Endoscopically removed polyp cancer No lymphovascular invasion perineural invasion Well moderately differentiated No evidence lymphadenopathy pretreatment imaging When lesion adequately identified rectum transanal endoscopic microsurgery TEM TEM proximal lesions technically feasible', 'Patients registered 120 days 456 days inclusive primary resection patients evidence colorectal cancer based postoperative colonoscopy performed 120 days colon rectal resection date prior registration patients adenomas detected oneyear postoperative colonoscopy eligible adenomas completely removed', 'Patients pure tone audiometry evaluation document air conduction 30 days prior registration patients hearing loss > 40 decibels dB tested frequencies 250 Hertz Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz eligible patients active ear infections tested acute phase infection resolved optimal results recommended testing conducted audiologist hearing test room insert earphones Note sites order audiometry evaluation potential participant met eligibility criteria required study', 'Patients Zubrod performance status 01', 'Patients ability swallow oral medication', 'Total white blood cells WBC >= 40 x 103mcL 28 days prior registration', 'Platelets >= 100000mcL 28 days prior registration', 'Hemoglobin > 110 gdL 28 days prior registration', 'A total WBC >= 31 x 103mcL allowed nonHispanic black males NHBM total WBC >= 34 x 103mcL nonHispanic black females NHBF Exception If WBC lower levels patient enrolled IF absolute neutrophil count ANC >= 13 NHBM >= 14 NHBF >= 15', 'Serum bilirubin =< 20 mgdL 28 days prior registration', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOT alanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT =< 2 x IULN institutional upper limit normal 28 days prior registration', 'Serum creatinine =< 15 x IULN obtained 28 days prior registration', 'Patients prior malignancy concurrent malignancy currently treated natural history treatment opinion treating physician potential interfere safety efficacy assessment investigational regimen eligible trial', 'SPECIMEN SUBMISSION AND SUBSTUDY CRITERIA', 'Patients offered option participate submission specimens banking future translational medicine studies', 'Patients participating PK sites offered option submit blood specimens population pharmacokinetic analysis', 'Patients offered option participate Diet Lifestyle Substudy', 'REGULATORY CRITERIA', 'All patients informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered', 'Patients cardiovascular risk factors including unstable angina history documented myocardial infarction cerebrovascular accident coronary artery bypass surgery New York Heart Association class III IV heart failure patients known uncontrolled hyperlipidemia defined lowdensity lipoprotein cholesterol LDLC >= 190 mgdL triglycerides >= 500 mgdL 3 years prior registration uncontrolled high blood pressure systolic blood pressure > 150 mm Hg 28 days prior registration', 'Patients known history familial adenomatous polyposis hereditary nonpolyposis colorectal cancer inflammatory bowel disease biallelic mismatch repair deficiency syndrome BMMRD constitutional mismatch repair deficiency syndrome CMMRD', 'Patients known hypersensitivity eflornithine sulindac excipients byproducts patients experienced asthma urticaria allergictype reactions taking aspirin nonsteroidal antiinflammatory drug NSAID', 'Patients documented history gastricduodenal ulcer 12 months participant currently treatment gastricduodenal ulcer experiencing symptoms study entry patients gastroesophageal reflux disease GERD eligible patients receive overthecounter histamine2 H2 antagonists protonpump inhibitors prescriptionbased treatment GERD', 'Patients expecting receive radiation additional chemotherapy', 'Patients receiving plan receive concomitant oral intravenous corticosteroids regular basis nonsteroidal antiinflammatory drugs NSAIDs anticoagulants regular predictable intermittent basis NSAID use exceed 10 days month patients receive daily aspirin cardiovascular prophylaxis long acetylsalicylic acid ASA =< 100 mg day =< 325 mg tablets week inhaled steroids asthma related conditions allowed', 'Patients significant medical psychiatric condition preclude study completion tests exams determination completed 28 days prior registration', 'Patients pregnant nursing status eflornithine sulindac pregnancy class C agents womenmen reproductive potential agreed use effective contraceptive method woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation point previously celibate patient chooses heterosexually active time period use contraceptive measures outlined protocol heshe responsible beginning contraceptive measures', 'Individuals currently participating clinical trial treatment prevention cancer longer receiving intervention followup phase patients agree join trial participating study'], ['STEP I Patients diagnosed symptomatic standardrisk multiple myeloma SRMM defined following gene expression profile GEP70 status unknown No evidence t1416 fluorescence situ hybridization FISH testing bone marrow available No evidence t1420 FISH testing bone marrow available No evidence deletion 17p FISH testing bone marrow FISH 90 days registration NOTE If FISH result states immunoglobulin heavy chain IgH abnormality present t1416 t1420 considered negative addition patient t1114 t414 translocation present considered negative t1416 t1420 testing t1416 t1420 performed lack sufficient material nonavailability probe test panel patients enrolled study Standard Risk GEP70 signature past 90 days GEP results available NOTE GEP testing NOT requirement study test patients GEP70 status highrisk eligible Serum lactate dehydrogenase LDH =< 2 x upper limit normal ULN past 28 days No 20 circulating plasma cells peripheral blood smear differential 2000 plasma cellsmicroliter white blood cell WBC differential peripheral blood past 90 days NOTE This NOT plasma cell marrow aspirate', 'STEP I Patients measurable evaluable disease defined having following obtained 28 days prior randomization >= 1 gdL monoclonal protein Mprotein serum protein electrophoresis >= 200 mg24 hours hrs monoclonal protein 24 hour urine protein electrophoresis Involved free light chain >= 10 mgdL >= 100 mgL AND abnormal serum immunoglobulin kappa lambda free light chain ratio < 026 > 165 Monoclonal bone marrow plasmacytosis >= 30 evaluable disease', 'STEP I Serum protein electrophoresis SPEP urine protein electrophoresis UPEP serum free light chain FLC assay required performed 28 days prior randomization bone marrow biopsy andor aspirate required 28 days bone marrow followed response NOTE UPEP 24hour collection required substitute method acceptable urine followed monthly baseline urine Mspike >= 200 mg24 hr note serum urine Mcomponents present followed order evaluate response NOTE The serum free light chain test required patient measurable disease serum urine measurable disease serum defined having serum Mspike >= 1 gdL measurable disease urine defined having urine Mspike >= 200 mg24 hr', 'STEP I Hemoglobin >= 8 gdL obtained 28 days prior randomization', 'STEP I Untransfused platelet count >= 75000 cellsmm3 obtained 28 days prior randomization', 'STEP I Absolute neutrophil count >= 1000 cellsmm3 obtained 28 days prior randomization', 'STEP I Calculated creatinine clearance >= 30 mLmin obtained 28 days prior randomization', 'STEP I Bilirubin =< 15 mgdL obtained 28 days prior randomization', 'STEP I Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST < 25 times upper limit normal obtained 28 days prior randomization', 'STEP I Patients received cycle 4 weeks prior chemotherapy 160 mg prior dexamethasone equivalent dose prednisone treatment symptomatic myeloma exposed lenalidomide bortezomib carfilzomib treatment symptomatic myeloma prior radiation therapy symptomatic lesions allowed provided residual toxicity related radiation blood counts meet study requirements', 'STEP I Prior systemic glucocorticoid use treatment nonmalignant disorders permitted prior concurrent topical localized glucocorticoid therapy treat nonmalignant comorbid disorders permitted', 'STEP I Eastern Cooperative Oncology Group ECOG performance status 0 1 2 performance status PS 3 allowed secondary pain', 'STEP I Patients history current previous deep vein thrombosis pulmonary embolism willing form anticoagulation prophylaxis currently fulldose anticoagulation', 'STEP I Patients history prior malignancy eligible provided treated curative intent require active therapy currently treated basal cell squamous cell carcinoma skin carcinoma “in situ” cervix breast excluded', 'STEP I Females childbearing potential FCBP negative serum urine pregnancy test sensitivity 50 mIUmL 10 – 14 days prior 24 hours starting lenalidomide commit continued abstinence heterosexual intercourse begin TWO acceptable methods birth control highly effective method additional effective method AT THE SAME TIME 28 days starts taking lenalidomide entire duration study treatment 28 days dose lenalidomide FCBP agree ongoing pregnancy testing patients counseled minimum 28 days pregnancy precautions risks fetal exposure randomized Arm B FCBP agree use contraception abstinence 30 days dose carfilzomib A female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria 1 achieved menarche point 2 undergone hysterectomy bilateral oophorectomy 3 naturally postmenopausal amenorrhea following cancer therapy rule childbearing potential 24 consecutive months menses time preceding 24 consecutive months', 'STEP I Sexually active males willing use condom undergone prior vasectomy having intercourse taking lenalidomide 28 days stopping lenalidomide male subjects agree abstain donating blood semen sperm study participation 28 days discontinuation lenalidomide randomized Arm B male subjects willing use condoms having intercourse taking carfilzomib 90 days discontinuation carfilzomib', 'STEP I Human immunodeficiency virus HIV infection excluded known HIV positive patients meet following criteria Cluster differentiation CD4 cell count >= 350mm3 No history acquired immune deficiency syndrome AIDSrelated illness Not currently prescribed zidovudine stavudine', 'STEP I Patient enrolling study agree register mandatory RevAssist program willing able comply requirements RevAssist', 'STEP II Patients complete induction experiencing progression patients received 6 cycles Arm A 4 cycles Arm B stopped induction therapy adverse events', 'STEP II Step 2 registration 6 weeks completing step 1 therapy', 'STEP II Patients received nonprotocol therapy outside assigned induction therapy including stem cell transplant', 'STEP II ECOG performance status 0 1 2 PS 3 allowed secondary pain', 'STEP II Any adverse event related step 1 therapy resolved grade 2', 'STEP II Hemoglobin >= 8 gdL 28 days prior randomization Step II', 'STEP II Platelet count >= 75000 cellsmm3 28 days prior randomization Step II', 'STEP II Absolute neutrophil count >= 1000 cellsmm3 28 days prior randomization Step II', 'STEP II Calculated creatinine clearance >= 30 mLmin 28 days prior randomization Step II', 'STEP II Bilirubin =< 15 mgdL 28 days prior randomization Step II', 'STEP II SGPT ALT SGOT AST < 25 times upper limit normal 28 days prior randomization Step II', 'STEP II Females childbearing potential FCBP negative serum urine pregnancy test sensitivity 50 mIUmL 10 – 14 days prior 24 hours starting lenalidomide commit continued abstinence heterosexual intercourse begin TWO acceptable methods birth control highly effective method additional effective method AT THE SAME TIME 28 days starts taking lenalidomide entire duration study treatment 28 days dose lenalidomide FCBP agree ongoing pregnancy testing patients counseled minimum 28 days pregnancy precautions risks fetal exposure previously randomized Arm B FCBPs continue use contraception abstinence 30 days dose carfilzomib A female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria 1 achieved menarche point 2 undergone hysterectomy bilateral oophorectomy 3 naturally postmenopausal amenorrhea following cancer therapy rule childbearing potential 24 consecutive months menses time preceding 24 consecutive months', 'STEP II Sexually active males willing use condom undergone prior vasectomy having intercourse taking lenalidomide 28 days stopping lenalidomide male subjects agree abstain donating blood semen sperm study participation 28 days discontinuation lenalidomide previously randomized Arm B males agree continue use contraception agree donate sperm 90 days dose carfilzomib', 'STEP II Patient enrolling study agree register mandatory RevAssist program willing able comply requirements RevAssist', 'STEP I Patients active uncontrolled seizure disorder patients seizures 6 months', 'STEP I Patients uncontrolled intercurrent illness including uncontrolled hypertension symptomatic congestive heart failure unstable angina uncontrolled cardiac arrhythmia uncontrolled psychiatric illness social situation limit compliance study prior history Stevens Johnson syndrome', 'STEP I Patients monoclonal gammopathy undetermined significance asymptomatic multiple myeloma eligible', 'STEP I Patients grade 2 higher peripheral neuropathy Common Terminology Criteria Adverse Events CTCAE 40', 'STEP I Patients active uncontrolled infection', 'STEP I Patients New York Heart Association classification III IV heart failure myocardial infarction previous 6 months', 'STEP I The following patients excluded study involves agent genotoxic mutagenic teratogenic effects Pregnant women Nursing women', 'STEP II The following patients excluded study involves agent genotoxic mutagenic teratogenic effects Pregnant women Nursing women'], ['Patients histologic verification neuroblastoma ganglioneuroblastoma demonstration neuroblastoma cells bone marrow elevated urinary catecholamines > 2 x upper limit normal ULN time initial diagnosis', 'For purposes study aggressive multidrug chemotherapy defined chemotherapy including 2 agents include alkylating agent platinumcontaining compound patients ONE following First episode recurrent disease following completion aggressive multidrug frontline therapy First episode progressive disease aggressive multidrug frontline therapy Primary resistantrefractory disease partial response INRC detected conclusion 4 cycles aggressive multidrug induction chemotherapy according highrisk neuroblastoma protocol examples include A3973 ANBL0532 ANBL09P1', 'Patients ONE following Measurable tumor magnetic resonance imaging MRI computed tomography CT scan obtained 3 weeks prior study entry measurable defined >= 10 mm dimension spiralhelical CT metaiodobenzylguanidine MIBG avid demonstrates increased fludeoxyglucose FDG uptake positron emission tomography PET scan MIBG scan obtained 3 weeks prior study entry positive uptake minimum site site represent disease recurrence completion therapy progressive disease therapy refractory disease induction Patients resistantrefractory soft tissue disease MIBG avid demonstrate increased FDG uptake PET scan undergo biopsy document presence viable neuroblastoma biopsy required patients new site soft tissue disease radiographic evidence disease progression regardless progression occurs receiving therapy completion therapy Note Patients elevated catecholamines > 2 x ULN bone marrow disease NOT eligible study', 'Patients performance status corresponding Eastern Cooperative Oncology Group ECOG scores 0 1 2 use Karnofsky patients > 16 years age Lansky patients =< 16 years age', 'Patients received frontline therapy including surgery chemotherapy autologous stem cell transplant SCT + MIBG immunotherapy radiotherapy retinoids NOT received second line chemotherapy resistantrefractory relapsed disease progressive disease', 'At 14 days elapsed completion myelosuppressive therapy', 'At 7 days elapsed completion therapy nonmyelosuppressive biologic agent retinoid', 'No interim time prior study entry required following prior radiation therapy RT nontarget lesions patients received radiation minimum 4 weeks prior study entry site lesion identified target lesion measure tumor response lesions previously radiated target lesions radiographic evidence progression site following radiation biopsy following radiation shows viable neuroblastoma palliative radiation allowed sites measure response study', 'Patients eligible >= 6 weeks autologous stem cell transplants stem cell infusions long hematologic eligibility criteria met', 'Patients eligible >= 6 weeks therapeutic 131IMIBG provided eligibility criteria met', 'Subjects previously received antiGD2 monoclonal antibodies biologic therapy tumor imaging eligible progressive disease receiving prior antiGD2 therapy subjects received autologous marrow infusions autologous stem cell infusions purged monoclonal antibody linked beads form antiGD2 monoclonal antibody eligible', 'Patients received longacting myeloid growth factors Neulasta 14 days entry study seven days elapsed administration short acting myeloid growth factor', 'Peripheral absolute neutrophil count ANC >= 750uL', 'Platelet count >= 75000uL transfusion independent', 'Patients known bone marrow involvement neuroblastoma eligible provided minimum ANC platelet count criteria met evaluable hematological toxicity', 'Creatinine clearance estimated radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2', 'A serum creatinine =< upper limit normal ULN based agegender follows Age 1 month < 6 months 04 males 04 females Age 6 months < 1 year 05 males 05 females Age 1 < 2 years 06 males 06 females Age 2 < 6 years 08 males 08 females Age 6 < 10 years 1 males 1 females Age 10 < 13 years 12 males 12 females Age 13 < 16 years 15 males 14 females Age >= 16 years 17 males 14 females', 'Total bilirubin =< 15 x ULN age AND', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 50 x ULN age =< 225 UL purpose study ULN SGPT 45 UL', 'Adequate central nervous function defined Patients history central nervous CNS disease clinical radiological evidence CNS disease time study enrollment Patients seizure disorders enrolled seizures controlled anticonvulsants CNS toxicity =< grade 2', 'Shortening fraction >= 27 echocardiogram ECHO OR', 'Ejection fraction >= 50 ECHO gated radionuclide study', 'Adequate coagulation defined Prothrombin time PT =< 12 x upper limit normal', 'Adequate pulmonary function defined No evidence dyspnea rest exercise intolerance chronic oxygen requirement room air pulse oximetry > 94 clinical indication pulse oximetry normal pulmonary function tests patients capable cooperating testing including diffusion capacity lung carbon monoxide DLCO required clinical indication determination patients respiratory symptoms pulmonary function tests PFTs NOT required', 'Men women childbearing potential partners agree use adequate contraception enrolled study based established teratogenic potential alkylating agents pregnant women excluded study female patients lactating agree stop breastfeeding excluded study females childbearing potential negative pregnancy test eligible study', 'Patients elevated catecholamines > 2 x ULN bone marrow disease NOT eligible study', 'Patients pharmacologic doses systemic steroids 7 days prior enrollment patients require likely require pharmacologic doses systemic corticosteroids receiving treatment study ineligible exception patients known require 2 mgkg hydrocortisone equivalent dose alternative corticosteroid premedication blood product administration order avoid allergic transfusion reactions use conventional doses inhaled steroids treatment asthma permitted use physiologic doses steroids patients known adrenal insufficiency', 'Patients received enzymeinducing anticonvulsants including phenytoin phenobarbital valproic acid carbamazepine 7 days prior study enrollment patients receiving nonenzyme inducing anticonvulsants gabapentin levetiracetam eligible', 'Patients diagnosed myelodysplastic syndrome malignancy neuroblastoma', 'Patients symptoms congestive heart failure eligible', 'Patients >= grade 2 diarrhea', 'Patients uncontrolled infection', 'Patients history grade 4 allergic reactions antiGD2 antibodies reactions required discontinuation antiGD2 therapy eligible', 'Patients significant intercurrent illness ongoing medical problem unrelated cancer treatment covered detailed exclusion criteria expected interfere action study agents significantly increase severity toxicities experienced study treatment eligible'], ['Histologically cytologically confirmed small cell lung cancer', 'Limited stage disease patients disease restricted hemithorax regional lymph node metastases including ipsilateral hilar ipsilateral contralateral mediastinal ipsilateral supraclavicular lymph nodes Patients disease involvement contralateral hilar supraclavicular lymph nodes eligible Patients pleural effusions visible plain chest radiographs cytologically positive eligible negative thoracentesis Patients cytologically positive pleural pericardial fluid regardless appearance plain xray eligible', 'Patients measurable disease includes lesions accurately measured dimension longest diameter recorded >= 2 cm conventional techniques >= 1 cm spiral computed tomography CT scan', 'Patients received cycle chemotherapy prior enrolling Cancer Leukemia Group B CALGB 30610 included carboplatin cisplatin etoposide patient cycle cisplatin carboplatinetoposide prior registration patient prior registration tests prior starting cycle chemotherapy additionally patients met eligibility criteria prior receiving cycle chemotherapy registration CALGB 30610 place 721 days start nonprotocol therapy failing patient NOT eligible CALGB 30610', 'No prior radiotherapy chemotherapy chemotherapy described bullet small cell lung cancer SCLC', 'No prior mediastinal thoracic radiotherapy', 'Patients complete surgical resection disease eligible', 'Eastern Cooperative Oncology Group ECOG performance status PS = 02', 'No patients known pregnant nursing', 'Granulocytes >= 1500ul', 'Platelet count >= 100000ul', 'Total bilirubin =< 15 x upper limit normal ULN', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOT =< 20 x ULN', 'Serum creatinine =< 15 times ULN OR calculated creatinine clearance >= 70 mLmin'], ['Histologic proof primary head pancreas invasive adenocarcinoma managed potentially curative resection removal gross tumor involving classic pancreaticoduodenectomy Whipple pylorus preserving pancreaticoduodenectomy patients invasive adenocarcinoma contains component intraductal papillary mucinous neoplasm IPMN eligible The operating surgeon document operative note complete gross excision primary tumor achieved pathology report include documentation margin status size tumor pathology report include status major margins—bile duct pancreatic parenchyma retroperitoneal uncinate', 'For patients started chemotherapy prior registration interval definitive tumorrelated surgery 1st step registration 2170 days patients entering study received 3 months adjuvant chemotherapy treating institution interval definitive tumorrelated surgery day adjuvant chemotherapy 2177 days', 'Patients staged according 6th edition American Joint Committee Cancer AJCC staging pathologic stage T13 N01 M0 eligible', 'Zubrod performance status 0 1', 'Complete history physical examination including weight Zubrod status 31 days study entry 31 days prior day 1 chemotherapy postsurgery patients having started chemotherapy prior step registration', 'Before starting therapy patient able maintain adequate oral nutrition >= 1500 calories estimated caloric intake day free significant nausea vomiting', 'Complete blood count CBCdifferential obtained 21 days registration study 21 days prior day 1 chemotherapy postsurgery patients having started chemotherapy prior step registration', 'Absolute neutrophil count ANC >= 1500mm3', 'Platelets >= 100000mm3', 'Hemoglobin Hgb >= 80 gdL transfusion intervention achieve Hgb >= 80 gdl acceptable', 'Post resection serum cancer antigen CA199 =< 180 unitsmL AND prior systemic treatment', 'Serum total bilirubin =< twice institutional upper limit normal ULN 21 days registration study 21 days prior day 1 chemotherapy postsurgery patients having started chemotherapy prior step registration', 'Creatinine levels =< twice institutional upper limit normal 21 days registration study 21 days prior day 1 chemotherapy postsurgery patients having started chemotherapy prior step registration', 'Serum glutamic oxaloacetic transaminase SGOT =< 25 x institutional ULN 21 days registration study 21 days prior day 1 chemotherapy postsurgery patients having started chemotherapy prior step registration', 'Negative serum pregnancy test women childbearing potential 14 days study registration', 'Abdominalpelvic computed tomography CT scan contrast preferred abdominal CT acceptable insurance restrictions experienced chest CTxray CT chest preferred 31 days registration study 31 days prior day 1 chemo postsurgery patients having started chemotherapy prior step registration patients allergic intravenous IV contrast magnetic resonance imaging MRI abdomenpelvis instead', 'Signed studyspecific informed consent', 'Consultation agreement documentation patient’s chart radiation oncologist patient suitable receive radiotherapy protocol', 'Women childbearing potential male participants practice adequate contraception', 'Patients active human immunodeficiency virus HIV infection eligible cluster differentiation CD4 count > 499cu mm viral load < 50 copiesml use highly active antiretroviral treatment HAART allowed', 'Patients nonadenocarcinomas adenosquamous carcinomas islet cell neuroendocrine tumors cystadenomas cystadenocarcinomas carcinoid tumors duodenal carcinomas distal bile duct ampullary carcinomas patients tumors largely IPMN minimal minor component invasive carcinoma eligible patients acinar carcinomas eligible patients IPMN’s contain secondary minor foci adenocarcinoma eligible', 'Patients managed total pancreatectomy distal pancreatectomy central pancreatectomy', 'Patients entering study pancreaticoduodenectomy started chemotherapy prior systemic chemotherapy pancreas cancer note prior chemotherapy different cancer allowable patients entering study received 3 months adjuvant chemotherapy treating institution patients received adjuvant chemotherapy agents gemcitabine nabpaclitaxel oxaliplatin fluoropyrimidine irinotecan current pancreatic cancer prior chemotherapy different cancer allowable', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Previous history invasive malignancy nonmelanoma skin cancer patient disease free 2 years prior study entry day chemotherapy patients having started chemotherapy prior step registration patients previous history carcinoma situ eligible', 'Severe active comorbidity defined follows time points indicated time points indicated prior day chemotherapy patients having started chemotherapy prior step registration Unstable angina andor congestive heart failure requiring hospitalization 6 months Transmural myocardial infarction 3 months study registration Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration', 'Pregnant lactating women', 'Women childbearing potential men sexually active willingable use medically acceptable forms contraception', 'If surgical margin status determined consultation operating surgeon institutional pathologist patient ineligible'], ['Pathologically proven primary cervical cancer IIIA squamous cell carcinoma adenosquamous carcinoma adenocarcinoma initially treated standard radical hysterectomy pelvic lymphadenectomy', 'Patients following characteristics depth stromal invasion lymphovascular space involvement pathologically confirmed Positive capillarylymphovascular space involvement following Deep penetration Middle penetration clinical tumor >= 2 cm Superficial penetration clinical tumor >= 5 cm Negative capillarylymphatic space involvement Middle deep penetration clinical tumor >= 4 cm', 'Absolute neutrophil count ANC >= 1500mcl', 'Platelets >= 100000mcl', 'Creatinine =< upper limit normal ULN calculated creatinine clearance >= 60 mLmin', 'Bilirubin =< 15 x normal', 'Alkaline phosphate =< 3 x normal', 'Serum glutamic oxaloacetic transaminase SGOT =< 3 x normal', 'Gynecologic Oncology Group GOG performance status 0 1 2', 'Patients randomized 3 weeks postsurgery acceptable randomization 8 weeks postsurgery', 'Patients met preentry requirements', 'Patients signed approved informed consent authorization permitting release personal health information', 'Patients tumor parametria pelvic lymph nodes extra uterine site positive surgical margins', 'Patients septicemia severe infection', 'Patients intestinal obstruction gastrointestinal bleeding', 'Patients postoperative fistula', 'Patients cervix cancer received previous radiation chemotherapy', 'Patients circumstances permit completion study required followup', 'Patients renal abnormalities requiring modification radiation field pelvic kidney renal transplant', 'Patients GOG performance status 3 4', 'Patients history invasive malignancies exception nonmelanoma skin cancer excluded evidence malignancy present years patients excluded previous cancer treatment contraindicates protocol therapy'], ['Preregistration Diagnostic bone marrow peripheral blood specimens submitted eligibility testing multiparameter flow cytometry testing performed Eastern Cooperative Oncology Group ECOGAmerican College Radiology Imaging Network ACRIN Leukemia Translational Studies Laboratory reported institution', 'Sexually active males strongly advised use accepted effective method contraception', 'Aspartate aminotransferase AST alanine aminotransferase ALT =< grade 1', 'Total bilirubin =< grade 1 Note If total bilirubin 2 3 mgdL direct bilirubin normal patient considered eligible', 'Patient concurrent active malignancy receiving treatment myelodysplastic syndromes MDS', 'Patient active uncontrolled infection', 'ADDITIONAL INDUCTION ELIGIBILITY CRITERIA', 'Newlydiagnosed AML patients according World Health Organization WHO classification considered candidates intensive chemotherapy based examination peripheral blood bone marrow aspirate specimens touch preparations bone marrow biopsy obtained weeks prior randomization bone marrow aspirate required enrollment occasion discordance percentage myeloblasts differential peripheral blood aspirate peripheral blood criteria sufficient diagnosis confirmatory immunophenotyping performed centrally', 'ECOG performance status PS 03 restricted ECOG PS 02 >= 70 years age', 'Patients acute promyelocytic leukemia APL confirmed presence t1517q22q21 promyelocytic leukemia PMLretinoic acid receptor RAR alpha transcripts excluded', 'Patients blastic transformation chronic myelogenous leukemia', 'Patients secondary AML eligible enrollment trial secondary AML defined AML developed person history antecedent blood count abnormalities myelodysplastic syndrome MDS myeloproliferative disorder excluding chronic myeloid leukemia history prior chemotherapy radiation therapy disease AML NOTE Prior therapy MDS decitabine lowdose cytarabine azacitidine excluded', 'Patients received prior chemotherapy AML exception hydroxyurea increased blast count leukapheresis leukocytosis patients received limited shortterm exposure ATRA trans retinoid acid AMLM3 acute promyelocytic leukemia ruled discontinued eligible', 'Total serum bilirubin =< 15 times upper limit normal ULN =< grade 1 total bilirubin 2 3 mgdL direct bilirubin normal patient considered eligible', 'Patients serum creatinine > 1 eligible calculated glomerular filtration rate GFR >= 60 mlmin class I class II chronic kidney disease Modification Diet Renal Disease MDRD formula Note Daily creatinine MDRD formula 1st induction cycle', 'Cardiac ejection fraction >= 45 institutional normal limits nuclear medicine gated blood pool examination preferred twodimensional 2D echocardiogram ECHO scan acceptable calculated ejection fraction obtained followup measurement cardiac ejection fraction performed echocardiography measurement cardiac ejection fraction weeks prior receiving treatment NOTE multi gated acquisition scan MUGA echocardiogram obtained weekend holiday patients enrolled provided history significant cardiovascular disease measurement cardiac ejection fraction performed 5 days study enrollment', 'Patients suspected central nervous CNS involvement undergo lumbar puncture documented CNS involvement excluded', 'Cytogenetic analysis performed diagnostic bone marrow preferred adequate number circulating blasts > 109l peripheral blood', 'Patients received previous treatment antecedent hematological disorders AHD 5azacitidine decitabine low dose cytarabine excluded', 'Patients known human immunodeficiency virus HIV infection excluded', 'HLA typing performed registration possible', 'Diagnostic bone marrow peripheral blood specimens submitted immunophenotyping selected molecular testing', 'CONSOLIDATION CRITERIA', 'NOTE All patients achieving CR complete remission incomplete blood count recovery CRi receive consolidation fit', 'NOTE Patients proceeding transplant allowed cycle consolidation treatment', 'Consolidation cycle 1 commence days bone marrow aspirate biopsy confirmed presence CR CRi', 'Patients achieved CR CRi morphologic leukemiafree state patients proceeding Arm G transplant', 'Patients achieved CR CRi maintained peripheral blood evidence CR CRi', 'Patients ECOG performance status 02', 'Patients resolved infectious complications related induction NOTE Patients HLAmatched donor proceeding transplant allowed cycle consolidation treatment', 'Any significant medical complications related induction resolved', 'Patients creatinine AST =< grade 1', 'MAINTENANCE CRITERIA', 'Maintenance commence 60 days recovery peripheral blood counts consolidation cycle 2 patients begin consolidation cycle 2 60 days recovery eligible therapy', 'Patients maintained peripheral blood evidence remission CR CRi confirmed restaging bone marrow BM aspirate biopsy cytogenetic analysis', 'Patients ECOG performance status 0 2', 'Patients resolved infectious complications related consolidation cycle 2', 'Any significant medical complications related consolidation cycle 2 resolved', 'Total serum bilirubin =< 15 x ULN NOTE total bilirubin 23 mgdL direct bilirubin normal patient considered eligible', 'Serum creatinine =< grade 1', 'The absolute neutrophil count ANC > 1000 mm3 prior starting cycle treatment decitabine decitabine delayed 4 weeks cycles administered infrequently q 8 weeks waiting counts recover', 'The platelet count > 75000 mm3 prior starting cycle treatment decitabine decitabine delayed 4 weeks cycles administered infrequently q 8 weeks waiting counts recover', 'ALLOGENEIC TRANSPLANTATION', 'Patients > 28 days start induction reinduction chemotherapy start consolidation cycle 1 received < 90 days following recovery recent treatment achieved maintained response induction therapy CR CRi “morphologic diseasefree state”', 'Patients recovered effects induction reinduction consolidation chemotherapy toxicities =< grade I exception reversible electrolyte abnormalities ongoing active infection requiring treatment', 'Patients total serum bilirubin =< 15 x ULN grade =< 1 serum creatinine =< grade 1', 'An eligible HLAidentical donor related unrelated available sibling donors low resolution HLA typing ABDR considered sufficient case unrelated donors highresolution class I II typing A B C DRB1 DQ matched 10 loci donors willing able undergo peripheral blood progenitor mobilization HLAidentical sibling 66 donor determined HLAidentical sibling 66 serologic typing class A B low resolution molecular typing class II DRB1 Matched unrelated donor 1010 high resolution molecular typing following loci required HLAA B C DRBL –DQB1 NOTE matched donors – allow select 1 antigen mismatched sibling donors unrelated donors accordance site institutional standard long matched HLAA HLAB HLAC DRB1 advanced discussionapproval Study Chair bone marrow transplant BMT cochair', 'Patients considered reliable comply medication regimen followup social support necessary allow compliance', 'Patients cardiac ejection fraction >= 40 institutional normal limits nuclear medicine gated blood pool examination preferred 2D ECHO scan acceptable calculated ejection fraction obtained followup measurement cardiac ejection fraction performed echocardiography measurement cardiac ejection fraction weeks prior allogeneic transplantation', 'Diffusion capacity lung carbon monoxide DLCO > 40 symptomatic pulmonary disease', 'No known hypersensitivity Escherichia E coliderived products', 'No human immunodeficiency virus HIV infection patients immune dysfunction significantly higher risk toxicities intensive immunosuppressive therapies', 'Creatinine =< grade 1', 'Bilirubin =< grade 1 If bilirubin 23 mgdL direct bilirubin normal patient considered eligible', 'AST =< grade 1'], ['Patients newly diagnosed histologicallyproven hepatoblastoma', 'In emergency situations patient meets eligibility criteria baseline required observations ill undergo biopsy safely patient enrolled AHEP0731 biopsy Clinical situations emergent treatment indicated include limited following circumstances Anatomic mechanical compromise critical organ function tumor respiratory distressfailure abdominal compartment syndrome urinary obstruction Uncorrectable coagulopathy For patient maintain eligibility AHEP0731 emergent treatment given following occur The patient clinical diagnosis hepatoblastoma including elevated alpha fetoprotein meet AHEP0731 eligibility criteria time emergent treatment Patient enrolled AHEP0731 prior initiating protocol therapy patient ineligible chemotherapy administered prior AHEP0731 enrollment If patient receives AHEP0731 chemotherapy PRIOR undergoing diagnostic biopsy pathologic review material obtained future biopsy surgical resection confirm diagnosis hepatoblastoma reveal pathological diagnosis included analysis study aims', 'Patients staged risk classification treatment diagnosis Childrens Oncology Group COG staging guidelines', 'At time study enrollment patient’s treatment regimen identified patient’s primary tumor resected prior day enrollment blood specimen determination serum alpha fetoprotein obtained prior surgery patient considered alpha fetoprotein greater 100 ngmL purpose treatment assignment tumor samples obtained prior date enrollment sufficient determine small cell undifferentiated SCU histology present treatment assignment assuming SCU present tumor', 'For patients stage I II disease specimens rapid central review submitted rapid central review diagnosis staging available provided AHEP0731 eligibility case report form CRF', 'Patients performance status corresponding Eastern Cooperative Oncology Group ECOG scores 0 1 2 use Karnofsky patients > 16 years age Lansky patients =< 16 years age', 'Patients surgical resection sites hepatoblastoma prior enrollment', 'Organ function requirements required enrolled patients stage I PFH receiving chemotherapy', 'Creatinine clearance radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 OR serum creatinine based agegender follows 1 month < 6 months 04 mgdL 6 months < 1 year 05 mgdL 1 < 2 years 06 mgdL 2 < 6 years 08 mgdL 6 < 10 years 1 mgdL 10 < 13 years 12 mgdL 13 < 16 years 15 mgdL male 14 mgdL female >= 16 years 17 mgdL male 14 mgdL female', 'Total bilirubin < 15 x upper limit normal ULN age', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT < 10 x ULN age', 'Absolute neutrophil count ANC > 750uL', 'Platelet count > 75000uL', 'Shortening fraction >= 27 echocardiogram', 'Ejection fraction >= 47 radionuclide angiogram multi gated acquisition scan MUGA Note echocardiogram MUGA 28 days prior enrollment', 'Serum triglyceride level =< 300 mgdL =< 342 mmolL', 'Serum cholesterol level =< 300 mgdL 775 mmolL', 'Random fasting blood glucose upper normal limits age initial blood glucose random sample outside normal limits followup fasting blood glucose obtained upper normal limits age', 'Normal pulmonary function tests including diffusing capacity lungs carbon monoxide DLCO clinical indication determination dyspnea rest known requirement supplemental oxygen Note patients respiratory symptoms requirement supplemental oxygen pulmonary function tests PFTs NOT required', 'Patients seizure disorder enrolled nonenzyme inducing anticonvulsants seizures controlled', 'Prothrombin time PT < 12 x ULN', 'All patients andor parents legal guardians sign written informed consent', 'All institutional Food Drug Administration FDA National Cancer Institute NCI requirements human studies met', 'Patients stage I II disease specimens submitted rapid central pathology review day 14 initial surgical resection', 'Patients previously treated chemotherapy hepatoblastoma hepatoblastomadirected therapy radiation therapy biologic agents local therapy embolization radiofrequency ablation laser eligible', 'Patients received prior chemotherapy eligible', 'Patients currently receiving investigational drug eligible', 'Patients currently receiving anticancer agents eligible', 'Patients previously received solid organ transplant eligible', 'Patients uncontrolled infection eligible', 'Females pregnant breast feeding eligible study', 'Female patients childbearing potential eligible negative pregnancy test result obtained', 'Males females reproductive potential eligible agreed use effective contraceptive method', 'Patients receiving corticosteroids eligible patients corticosteroids 7 days prior start chemotherapy', 'Patients currently receiving enzyme inducing anticonvulsants eligible', 'Patients receiving following potent cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 inducers inhibitors erythromycin clarithromycin azithromycin ketoconazole itraconazole voriconazole posaconazole grapefruit juice St John’s wort', 'Patients currently receiving therapeutic anticoagulants including aspirin low molecular weight heparin warfarin eligible', 'Patients currently receiving angiotensinconverting enzymes ACE inhibitors eligible', 'Patients major surgery 6 weeks prior enrollment high risk stratum patients history recent minor surgical procedures vascular catheter placement bone marrow evaluation laparoscopic surgery liver tumor biopsy eligible'], ['Patients newly diagnosed histologically confirmed intracranial ependymoma patients classic ependymoma WHO II anaplastic ependymoma WHO III eligible subtypes described clear cell papillary cellular combination', 'There minimum performance level children ependymoma suffer neurologic sequelae result tumor surgical measures taken establish diagnosis resect tumor majority cases neurologic recovery neurologic recovery likely impeded protocol therapy', 'REGULATORY All patients andor parents legal guardians sign written informed consent', 'REGULATORY All institutional Food Drug Administration FDA National Cancer Institute NCI requirements human studies met', 'Patients evidence metastatic disease excluded evidence noncontiguous spread primary site determined pre postoperative magnetic resonance MR imaging brain pre postoperative MR imaging spine postoperative cerebrospinal fluid CSF cytology obtained lumbar CSF space requirement lumbar CSF examination waived deemed medically contraindicated CSF cytology ventriculostomy permanent ventriculoperitoneal VP shunt reveals presence tumor cells indicative metastatic disease', 'Patients diagnosis spinal cord ependymoma myxopapillary ependymoma subependymoma ependymoblastoma mixed glioma NOT eligible', 'No prior treatment surgical intervention corticosteroids patients allowed attempt resection prior enrollment', 'Pregnant female patients eligible study', 'Postmenarchal females participate pregnancy test negative result obtained', 'Males females reproductive potential participate agreed use effective contraceptive method', 'Lactating females participate agreed breastfeed child study'], ['Patients histologically confirmed ovarian stromal tumor granulosa cell tumor ganulosa celltheca cell tumor SertoliLeydig cell tumor androblastoma steroid lipid cell tumor gynandroblastoma unclassified sex cordstromal tumor sex cord tumor annular tubules', 'Patients newly diagnosed stage IIA – IV disease entered weeks surgery measurable residual disease Response Evaluation Criteria In Solid Tumors RECIST criteria measurable residual disease OR biopsyproven recurrent disease stage received cytotoxic chemotherapy', 'Patients Gynecologic Oncology Group GOG performance grade 0 1 2', 'Patients childbearing potential negative serum pregnancy test agree practice effective means birth control', 'Patients measureable disease cohort “target lesion” assess response protocol defined RECIST 11 tumors previously irradiated field designated “nontarget” lesions progression documented biopsy obtained confirm persistence 90 days following completion radiation therapy', 'Absolute neutrophil count ANC greater equal 1500mcl equivalent Common Terminology Criteria Adverse Events CTCAE grade 1', 'Platelet greater equal 100000mcl', 'Creatinine greater institutional upper limits normal', 'Bilirubin equal 15 x upper limit normal ULN CTCAE grade 1', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST equal 30 x ULN CTCAE grade 1', 'Alkaline phosphatase equal 25 x ULN CTCAE grade 1', 'Neuropathy sensory motor equal CTCAE grade 1', 'No signs clinically significant hearing loss', 'Patients signed approved informed consent authorization permitting release personal health information', 'Patients pulmonary function sufficient receive bleomycin normal lung expansion absence crackles auscultation normal carbon monoxide diffusion DLCO defined greater 80 predicted', 'Patients history hypersensitivity reactions prior chemotherapy administered previous cancer diagnoses eligible participate study hypersensitivity reaction consisted anaphylaxis amenable desensitization', 'Recovery effects recent surgery radiotherapy chemotherapy Patients entered 8 weeks surgery performed 1 initial diagnosis staging andor cytoreduction 2 management recurrent disease chemonaive patient Any hormonal therapy directed malignant tumor discontinued week prior registration continuation hormone replacement therapy permitted', 'Patients received prior cytotoxic chemotherapy biologics sex cordstromal tumors SCSTs', 'Patients apparent stage I disease undergone staging procedure', 'Patients history invasive malignancies exception nonmelanoma skin cancer excluded evidence malignancy present years', 'Woman pregnant breastfeeding', 'Patients medical history conditions previously specified opinion investigator exclude participation study investigator consult study chair study cochairs uncertainty regard'], ['Pathologically proven diagnosis carcinoma bladder 105 days prior registration Operable patients initial tumor primary high grade urothelial carcinoma bladder exhibiting histologic evidence invasion lamina propria disease clinical stage T1 high grade stage Ta urothelial carcinoma hydronephrosis patients involvement prostatic urethra urothelial carcinoma evidence stromal invasion prostate remain eligible patient’s initial tumor high grade stage Ta urothelial carcinoma hisher recurrent tumor high grade stage T1 urothelial carcinoma eligible', 'Patients high grade urothelial carcinoma stage Ta T1 recurred 540 days completion initial treatment transurethral resection bladder tumor TURBT intravesical bacillus CalmetteGuerin BCG immunotherapy initial presentation T1 high grade tumor participating urologist judged BCG therapy contraindicated unsuitable patient intolerant BCG therapy patient immunocompromised ways mentioned severe active comorbidity patient refuses BCG therapy', 'The participating urologist judges standard therapy based present urologic guidelines patient radical cystectomy', 'If radiologic evaluation lymph node interpreted “positive” evaluated lymphadenectomy percutaneous needle biopsy patients histologically cytologically confirmed node metastases eligible', 'Patients adequately functioning bladder judged participating urologist radiation oncologist undergone restaging TURBT participating urologist showed present outside pathology specimen high grade stage Ta T1 tumor uninvolved muscularis propria specimen prostatic urethral biopsy mucosal carcinoma present evidence biopsy prostatic stroma tumor invasion', 'Patient considered able tolerate systemic chemotherapy combined pelvic radiation therapy radical cystectomy necessary joint agreement participating urologist radiation oncologist medical oncologist', 'Appropriate stage protocol entry based following minimum diagnostic workup 60 days prior registration Historyphysical examination including weight performance data body surface area', 'Zubrod performance status =< 1', 'White blood cell count WBC >= 4000ml', 'Absolute neutrophil count ANC >= 1800 cellsmm3', 'Platelets >= 100000 cellsmm3', 'Hemoglobin >= 100 gdL Note use transfusion intervention achieve hemoglobin Hgb >= 100 gdl acceptable', 'If patient treated cisplatin serum creatinine =< 15 mg', 'If patient treated cisplatin serum bilirubin =< 20 mg', 'Glomerular filtration rate GFR > 25 mlmin patients receiving cisplatin GFR >= 60 mlmin', 'Serum pregnancy test female patients childbearing potential =< 72 hours prior study entry women childbearing potential male participants practice adequate contraception', 'Patient able provide studyspecific informed consent prior study entry', 'Evidence tumorrelated hydronephrosis', 'Evidence distant metastases histologically cytologically proven lymph node metastases', 'Prior systemic chemotherapy bladder cancer prior chemotherapy different cancer allowable', 'A prior concurrent malignancy site histology patient diseasefree >= 5 years nonmelanoma skin cancer andor stage T1a prostate cancer carcinoma situ uterine cervix urothelial carcinoma upper urinary tract stage pTa pTis pT1 free disease treatment 2 year period', 'Patients pN+ > T1 disease visibly complete TURBT', 'Patients receiving drugs potential nephrotoxicity ototoxicity aminoglycoside', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months Transmural myocardial infarction 6 months Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration Hepatic insufficiency resulting clinical jaundice andor coagulation defects note laboratory tests liver function coagulation parameters required entry protocol Acquired immune deficiency syndrome AIDS based current Centers Disease Control Prevention CDC definition note human immunodeficiency virus HIV testing required entry protocol protocolspecific requirements exclude immunocompromised patients', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception exclusion necessary treatment involved study significantly teratogenic', 'Prior allergic reaction study drugs cisplatin mitomycin fluorouracil 5FU involved protocol'], ['Diagnosis rectal adenocarcinoma', 'Radiologically measurable clinically evaluable disease', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 2', 'For patient standard treatment recommendation absence clinical trial combined modality neoadjuvant chemoradiation followed curative intent surgical resection', 'Candidate sphinctersparing surgical resection prior initiation neoadjuvant therapy according primary surgeon', 'Clinical stage T2N1 T3N0 T3N1 N2 disease estimated lymph nodes >= 10 mm Clinical staging estimated based combination following assessments physical exam primary surgeon computed tomography CT positron emission tomography PETCT scan chestabdomenpelvis pelvic magnetic resonance imaging MRI ultrasound endorectal ultrasound ERUS pelvic MRI performed acceptable perform CT chestabdomen omitting CT imaging pelvis', 'Absolute neutrophil count ANC >= 1500mm3 =< 28 days prior registration', 'Platelet count >= 100000mm3 =< 28 days prior registration', 'Hemoglobin > 80 gdL =< 28 days prior registration', 'Total bilirubin =< 15 x upper limit normal ULN =< 28 days prior registration', 'Serum glutamic oxaloacetic transaminase SGOT aspartate aminotransferase AST =< 3 x ULN =< 28 days prior registration', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 3 x ULN =< 28 days prior registration', 'Creatinine =< 15 times ULN =< 28 days prior registration', 'Negative pregnancy test =< 7 days prior registration women childbearing potential', 'Patient childbearing potential willing employ adequate contraception appropriate methods birth control include abstinence oral contraceptives implantable hormonal contraceptives double barrier method diaphragm plus condom', 'Provide informed written consent', 'Willing return enrolling medical site study assessments', 'Clinical T4 tumors', 'Primary surgeon indicates need abdominoperineal APR baseline', 'Evidence tumor adherent invading mesorectal fascia imaging studies surgeon able perform R0 resection negative margins', 'Tumor causing symptomatic bowel obstruction patients temporary diverting ostomy eligible', 'Chemotherapy 5 years prior registration hormonal therapy allowable disease free interval >= 5 years', 'Any prior pelvic radiation', 'Other invasive malignancy =< 5 years prior registration exceptions colonic polyps nonmelanoma skin cancer ductal carcinoma situ bladder carcinoma situ carcinomainsitu cervix', 'Any following Pregnant women Nursing women Men women childbearing potential unwilling employ adequate contraception', 'Comorbid illnesses concurrent disease judgment clinician obtaining informed consent patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribed regimens'], ['Patients enrolled APEC14B1 consented Eligibility Screening Part A consent form prior enrollment AALL1131', 'White Blood Cell Count WBC Criteria Age 1999 years WBC >= 50 000uL Age 103099 years Any WBC Age 13099 years Any WBC Testicular leukemia CNS leukemia CNS3 Steroid pretreatment', 'Patients newly diagnosed B lymphoblastic leukemia 2008 World Health Organization WHO classification termed Bprecursor acute lymphoblastic leukemia patients Down syndrome eligible', 'Organ function requirements patients Phlike ALL predicted TKIsensitive mutation patients identified Phlike TKIsensitive kinase mutation assessment organ function performed 3 days study entry dasatinib arm AALL1131', 'Creatinine clearance radioisotope glomerular filtration rate GFR > 70mLmin173 m2 serum creatinine based agegender follows Age Maximum Serum Creatinine mgdL 1 < 6 months 04 male 04 female 6 months < 1 year 05 male 05 female 1 < 2 years 06 male 06 female 2 < 6 years 08 male 08 female 6 < 10 years 10 male 10 female 10 < 13 years 12 male 12 female 13 < 16 years 15 male 14 female > 16 years 17 male 14 female', 'Direct bilirubin =< 3 x upper limit normal ULN age', 'Serum glutamate pyruvate transaminase SGPT alanine aminotransferase ALT =< 10 x upper limit normal ULN age', 'Shortening fraction >= 27 echocardiogram ejection fraction >= 50 gated radionuclide study Patients electrocardiogram EKG fewer 6 days prior enrollment dasatinib arm patients cardiac assessments echocardiogram radionuclide scan beginning induction need repeated prior study entry correct QT interval QTc < 450 msec baseline electrocardiogram measured Friderica Bazett formula No major conduction abnormality cardiac pacemaker present', 'No evidence dyspnea rest exercise intolerance pulse oximetry > 94 sea level clinical indication determination', 'Patients seizure disorder enrolled anticonvulsants controlled drugs induce CYP3A45 carbamazepine oxcarbazepine phenytoin primidone phenobarbital avoided', 'With exception steroid pretreatment administration intrathecal cytarabine patients received prior cytotoxic chemotherapy current diagnosis BALL cancer diagnosed prior initiation protocol therapy AALL1131 patients secondary BALL developed treatment prior malignancy cytotoxic chemotherapy patients receiving prior steroid therapy eligible AALL1131', 'Patients BCRABL1 fusion eligible postinduction therapy study eligible enroll successor Childrens Oncology Group COG Philadelphia positive Ph+ ALL trial day 15 Induction', 'DS HR BALL patients Induction failure BCRABL1', 'Female patients pregnant ineligible fetal toxicities teratogenic effects noted study drugs', 'Lactating females eligible agreed breastfeed infant', 'Female patients childbearing potential eligible negative pregnancy test result obtained', 'Sexually active patients reproductive potential eligible agreed use effective contraceptive method duration study participation', 'Eligibility criteria Longitudinal Computerized Assessment Neurocognitive Functioning study Patients aged 6 13 years time BALL diagnosis enrolled AALL1131 Patients English French Spanishspeaking languages assessment available Patients known history neurodevelopmental disorder prior diagnosis BALL Down syndrome Fragile X William’s Syndrome mental retardation Patients significant visual impairment prevent use recognition visual test stimuli', 'Eligibility criteria National Cancer Institute NCI standard risk patients AALL0932 enrolling study end Induction', 'Effective March 19 2018 patients enrolled AALL0932 Down syndrome meeting following criteria NOT eligible continue AALL0932 HR BALL stratum study end Induction Without favorable cytogenetics ETV6RUNX1 double trisomies 4+10 day 8 peripheral blood PB minimal residual disease MRD >= 1 day 29 bone marrow BM MRD < 001 With favorable cytogenetics ETV6RUNX1 double trisomies 4+10 day 8 PB MRD day 29 BM MRD >= 001 Both NCI standard risk SR HR patients Down syndrome testicular disease diagnosis meet VHR criteria', 'Effective Amendment 6 patients enrolled AALL0932 Down syndrome meeting following criteria NOT eligible continue AALL0932 VHR stratum AALL1131 Intrachromosomal amplification chromosome 21 iAMP21 Mixedlineage leukemia MLL rearrangement Hypodiploidy n < 44 chromosomes andor deoxyribonucleic acid DNA index < 081 Induction failure M3 BM day 29 Without favorable cytogenetics ETV6RUNX1 double trisomies 4+10 day 29 BM MRD >= 001', 'Patients enrolled AALL0932 Down syndrome meeting following criteria NOT eligible continue AALL0932 WILL BE eligible enroll DS HR BALL stratum study end Induction Day 29 MRD >= 001 MLL rearrangement Hypodiploidy n < 45 chromosomes andor DNA index < 081', 'DS HR BALL patients initially enrolled AALL0932 study Induction failure M3 BM day 29 Philadelphia chromosome BCRABL1 eligible postInduction therapy trial AALL0932 AALL1131', 'All patients andor parents legal guardians sign written informed consent', 'All institutional Food Drug Administration FDA NCI requirements human studies met'], ['Pathologically histologically cytologically proven diagnosis prostatic adenocarcinoma 180 days registration moderate highrisk recurrence determined following combinations Gleason score 710 + T1cT2b palpation + prostatespecific antigen PSA < 50 ngmL includes intermediate highrisk patients Gleason score 6 + T2cT4 palpation + PSA < 50 ngmL OR Gleason score 6 + >= 50 positive biopsies + PSA < 50 ngml Gleason score 6 + T1cT2b palpation + PSA > 20 ngmL Patients previously diagnosed low risk prostate cancer undergoing active surveillance rebiopsied unfavorable intermediate risk disease favorable high risk disease according protocol criteria eligible enrollment 180 days repeat biopsy procedure', 'Historyphysical examination include minimum digital rectal examination prostate examination skeletal abdomen 90 days prior registration', 'Clinically negative lymph nodes established imaging pelvic andor abdominal computed tomography CT magnetic resonance MR nodal sampling dissection 90 days prior registration Patients lymph nodes equivocal questionable imaging eligible nodes =< 15 cm', 'No evidence bone metastases M0 bone scan 120 days prior registration sodium fluoride NaF positron emission tomography PETCT acceptable substitute Equivocal bone scan findings allowed plain films CT magnetic resonance imaging MRI negative metastasis', 'Baseline serum PSA value performed Food Drug Administration FDAapproved assay Abbott Hybritech 120 days prior registration', 'Study entry PSA obtained following time frames 10day period following prostate biopsy Following initiation hormonal therapy Within 30 days discontinuation finasteride Within 90 days discontinuation dutasteride', 'Zubrod performance status 01 specified', 'Absolute neutrophil count ANC >= 1500mm3 60 days prior registration study', 'Platelets >= 100000mm3 60 days prior registration study', 'Hemoglobin Hgb >= 80 gdL 60 days prior registration study Note use transfusion intervention achieve Hgb >= 80 gdL acceptable', 'Patient able provide study specific informed consent prior study entry', 'Prior invasive nonmelanoma skin cancer malignancy diseasefree minimum 3 years 1095 days pelvis example carcinoma situ oral cavity permissible patients prior history bladder cancer allowed prior hematological leukemia lymphoma myeloma malignancy allowed', 'Previous radical surgery prostatectomy cryosurgery prostate cancer', 'Previous pelvic irradiation prostate brachytherapy bilateral orchiectomy', 'Previous hormonal therapy LHRH agonists leuprolide goserelin buserelin triptorelin LHRH antagonist degarelix antiandrogens flutamide bicalutamide cyproterone acetate estrogens diethylstilbestrol DES surgical castration orchiectomy', 'Prior pharmacologic androgen ablation prostate cancer allowed onset androgen ablation LHRH agonist oral antiandrogen =< 45 days prior date registration', 'Use finasteride 30 days prior registration', 'Use dutasteride dutasteridetamsulosin Jalyn 90 days prior registration', 'Previous concurrent cytotoxic chemotherapy prostate cancer note prior chemotherapy different cancer allowable', 'Prior radiotherapy including brachytherapy region study cancer result overlap radiation therapy fields', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months Transmural myocardial infarction 6 months Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration Hepatic insufficiency resulting clinical jaundice andor coagulation defects severe liver dysfunction Acquired immune deficiency syndrome AIDS based current Centers Disease Control Prevention CDC definition note human immunodeficiency virus HIV testing required entry protocol need exclude patients AIDS protocol necessary treatments involved protocol significantly immunosuppressive protocolspecific requirements exclude immunocompromised patients', 'Patients sexually active willingable use medically acceptable forms contraception exclusion necessary treatment involved study significantly teratogenic', 'Prior allergic reaction hormones involved protocol', 'Patients status post negative lymph node dissection eligible'], ['Patients biopsyproven denovo diffuse large Bcell lymphoma DLBCL Patients primary mediastinal lymphoma testicular lymphoma eligible Patients prior simultaneous diagnosis indolent lymphoma eligible Posttransplant lymphoproliferative disorder DLBCL morphology ineligible', 'Patients nonbulky stage I II disease Ann Arbor classification This staging excludes fludeoxyglucose F 18 FDGPET evaluation Patients stage I II nonbulky disease based diagnostic CT scan upstaged stage III IV based FDGPET evaluation eligible Stage bulk assigned measurements obtained prior biopsy', 'Patients diagnostic quality contrastenhanced CT scan chest abdomen pelvis AND baseline FDGPET scan performed 28 days prior registration Lowresolution localization CT scans performed combined PETCT scan adequate enrollment response determination protocol If patient allergy CT contrast nonenhanced CT acceptable', 'Patients clinical evidence central nervous CNS involvement lymphoma Any laboratory radiographic tests performed assess CNS involvement negative performed 42 days prior registration', 'Patients measurable evaluable limitedstage DLBCL Patients rendered free measurable evaluable disease virtue biopsy resection eligible NOTE patient measurable disease documented Lymphoma Baseline Tumor Assessment Form All measurable disease assessed 28 days prior registration Patients nonmeasurable disease measurable disease nonmeasurable disease assessed 42 days prior registration', 'Patients unilateral bilateral bone marrow biopsy performed 42 days prior registration', 'Adequate sections paraffin block original diagnostic specimen submitted review lymphoma pathology group', 'Patients offered opportunity consent use specimens future research', 'The lymphoma express cluster differentiation CD20 antigen flow cytometry antiCD20 antibodies immunoperoxidase staining paraffin sections report providing confirmation CD20 expression submitted', 'Patients received prior chemotherapy radiotherapy antibody therapy lymphoma', 'Patients complete history physical examination 28 days prior registration', 'Zubrod performance status 02', 'The following tests performed 42 days prior registration diagnosisstaging obtain baseline values White blood cells WBC Hemoglobin Lactate dehydrogenase LDH Hepatitis Bsurface antigen Ag anticore antibody Ab', 'Serum creatinine =< 2 x institutional upper limit normal IULN lymphoma 42 day prior registration', 'Patients aspartate aminotransferase ASTalanine aminotransferase ALT =< 5 x IULN lymphoma 42 days prior registration', 'Platelet count >= 100000 cellsmcL', 'Absolute neutrophil count ANC >= 1000 cellsmcL 42 days prior registration', 'Total bilirubin =< 2 x institutional upper limit normal IULN Gilbert syndrome 42 days prior registration', 'Patients cardiac ejection fraction >= institutional lower limit normal ILLN multi gated acquisition MUGA scan 2dimensional D echocardiogram ECHO 42 days prior registration', 'Patients known human immunodeficiency virus HIVpositive', 'No prior malignancy allowed following Adequately treated situ cancers stage 0 Adequately treated basal cell squamous cell skin cancer Adequately treated stage I II cancer patient complete remission Any cancer patient diseasefree 5 years', 'Patients pregnant nursing womenmen reproductive potential agreed use effective contraceptive method study period woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation point previously celibate patient chooses heterosexually active time period use contraceptive measures outlined protocol heshe responsible beginning contraceptive measures', 'Patients legally authorized representative informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered', 'SECOND REGISTRATION STEP 2', 'Patients completed 3 cycles RCHOP evidence disease progression', 'Interim PETCT scans submitted centralized review', 'If PETnegative based returned results centralized review patients planning begin treatment 35 days start cycle 3 RCHOP PETpositive based returned results centralized review important patients start IFRT soon possible end cycle 3 RCHOP planning initiate IFRT followed yttrium90 ibritumomab tiuxetan 35 days start cycle 3 RCHOP'], ['Patients histologically confirmed diagnosis invasive breast carcinoma positive estrogen andor progesterone receptor status negative HER2 standard adjuvant endocrine therapy planned estrogen progesterone receptor positivity assessed according American Society Clinical Oncology ASCOCollege American Pathologist CAP guidelines estrogen receptor ER progesterone receptor PR >= 1 positive nuclear staining HER2 test result negativity assessed ASCOCAP 2013 guidelines immunohistochemistry IHC situ hybridization ISH HER2 negative single test tests performed tumor specimen IHC negative 0 1+ b ISH negative single probe dual probe average HER2 copy number < 40 signals cell single probe HER2chromosome enumeration probe CEP ratio < 20 average copy number < 40 signals cell dual probe HER2 IHC 2+ evaluation gene amplification ISH performed ISH negative ISH required IHC 0 1+ HER2 equivocal eligible', 'Patients metastatic breast cancer stage IV disease patients multifocal multicentric synchronous bilateral primary inflammatory breast cancers allowed Multifocal disease defined invasive cancer < 2 cm largest lesion breast quadrant Multicentric disease defined invasive cancer >= 2 cm largest lesion breast quadrant lesion different quadrants Synchronous bilateral disease defined invasive breast cancer positive lymph nodes axillary intramammary breast diagnosed 30 days NOTE tumor highest recurrence score', 'Patients high risk belonging following risk groups Completion adjuvant chemotherapy pathologically negative lymph nodes tumor measuring >= 2 cm greatest diameter Oncotype DX recurrence score > 25 completed standard care MammaPrint assay completed standard care highrisk category patients micrometastases nodal involvement pN1mi eligible categorized nodenegative Completion adjuvant chemotherapy pathologically 13 positive lymph nodes Oncotype DX recurrence score > 25 MammaPrint assay highrisk category completed standard care tumor tissue pathological grade III following local practice Oncotype DX RS > 25 similarly MammaPrint assay performed highrisk test patient grade III disease patient eligible Oncotype DX MammaPrint need performed Completion adjuvant chemotherapy pathologically 4 positive lymph nodes Completion neoadjuvant chemotherapy 1 positive nodes pathologically determined chemotherapy NOTE patients receive neoadjuvant adjuvant chemotherapy registered neoadjuvant therapy risk group provided meet criteria risk group NOTE lymph node positive groups metastasis >= 20 mm present patients micrometastases nodal involvement pN1mi eligible categorized nodenegative', 'Patients completed breastconserving surgery total mastectomy negative margins appropriate axillary staging negative margin defined evidence tumor ductal carcinoma situ DCIS line resection additional operative procedures performed obtain clear margins Patients breastconserving surgery completed breast radiation use regional nodal basin radiation discretion investigator according institutional guidelines Patients >= 4 positive lymph nodes completed breastchest wall nodal basin radiation therapy according standard care guidelines randomization omission radiation therapy allowed highrisk population patients Patients registered 21 days completion radiation therapy recovered =< grade 1 effects radiation', 'Patients undergone axillary staging sentinel node biopsy axillary lymph node dissection ALND For patients 13 positive lymph nodes sentinel node biopsy allowed provided patient completed breast chest wall radiation primary tumor < 5 cm All patients >= 4 positive lymph nodes completed ALND prior sentinel node biopsy', 'Patients completed standard neoadjuvant adjuvant taxane andor anthracycline based chemotherapy prior randomization completion chemotherapy determined treating oncologist include minimum 4 cycles cycle weekly paclitaxel considered 3 doses patients registered 42 weeks dose chemotherapy patients started endocrine therapy time diagnosis current breast cancer', 'Patients receiving planning receive trastuzumab concurrent bisphosphonate therapy allowed patients prior exposure mechanistic target rapamycin serinethreonine kinase mTOR inhibitors rapamycin everolimus temsirolimus deforolimus patients prior treatment investigational drug preceding 28 days planning receive investigational drug duration study', 'Absolute neutrophil count ANC >= 1500mL obtained 28 days prior registration', 'Hemoglobin >= 9 gdL obtained 28 days prior registration', 'Platelet count >= 100000mL obtained 28 days prior registration', 'Bilirubin =< 15 mgdL =< 30 mgdL Gilberts syndrome 28 days prior registration', 'Alanine aminotransferase ALT aspartate aminotransferase AST =< 15 x institutional upper limit normal IULN obtained 28 days prior registration', 'Alkaline phosphatase =< 15 x IULN obtained 28 days prior registration', 'Serum creatinine level =< IULN obtained 28 days prior registration', 'Fasting cholesterol =< 300 mgdL triglycerides =< 25 x IULN obtained 28 days prior registration patients lipid lowering agents reach values', 'Patients complete history physical examination 28 days prior registration', 'Patients performance status 02 Zubrod criteria', 'Patients grade IIIIV cardiac disease defined New York Heart Association Criteria patients cardiac disease resulting marked limitation physical activity resulting inability carry physical activity discomfort unstable angina pectoris myocardial infarction 6 months uncontrolled cardiac arrhythmia', 'Patients previously diagnosed diabetes uncontrolled diabetes defined hemoglobin Hg A1C > 7 28 days prior registration', 'Patients organ allograft history immune compromise patients receiving chronic systemic treatment corticosteroids immunosuppressive agent topical inhaled corticosteroids allowed', 'Patients known human immunodeficiency virus HIV positive enrolled baseline cluster differentiation CD4 count > 500 cellsmm3 AND taking antiretroviral therapy patients known hepatitis eligible known negative hepatitis panel exception previous history hepatitis A infection currently active allowed patients known uncontrolled underlying pulmonary disease', 'Patients able oral medications patients impairment gastrointestinal function gastrointestinal disease significantly alter absorption blinded drug ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome small bowel resection', 'Patients received immunization attenuated live vaccine intranasal influenza measles mumps rubella MMR oral polio varicella zoster yellow fever Bacillus Calmette–Guerin BCG vaccines seven days prior registration plans receive vaccination protocol treatment', 'Patients taken 14 days prior registration taking plan protocol treatment strong cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 inhibitors andor CYP3A4 inducers', 'No prior malignancy allowed adequately treated basal cell squamous cell skin cancer situ cervical cancer cancer patient diseasefree 5 years', 'Patients pregnant nursing womenmen reproductive potential agreed use effective nonhormonal contraceptive method woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation corresponding procedures men include castration vasectomy barrier contraceptive devices point previously celibate patient chooses heterosexually active protocol therapy heshe responsible beginning contraceptive measures', 'Patients pretreatment blood tissue specimens submitted translational medicine outlined patient consent residuals banked future research', 'Patients National Cancer Institute NCI Community Oncology Research Program NCORP Institutions offered opportunity participate S1207E01 Behavioral Health Outcomes study BAHO NOTE patients started endocrine therapy eligible BAHO study', 'Patients legally authorized representative informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered'], ['Patients newly diagnosed active multiple myeloma MM indicated assessment required 14 days tests establishing baseline disease status completed 28 days prior registration patients prior therapy 28 days prior initiation Induction course patients prior therapy', 'For Phase II portion patients highrisk MM based following criteria time initial diagnosis prior chemotherapy Poorrisk genomic signature according University Arkansas 70gene model available clinically myeloma prognostic risk score MyPRS score Signal Genetics Inc ANDOR Translocation 1416 andor translocation 1420 andor deletion 17p fluorescence insitu hybridization FISH cytogenetics ANDOR Primary plasma cell leukemia defined >= 2000 plasma cellsmL peripheral blood 20 manual differential count ANDOR Serum lactate dehydrogenase LDH >= 2 x institutional upper limit normal IULN ANDOR 1q21 amplification FISH analysis ANDOR High risk SKY92 signature All tests establishing high risk status completed 28 days prior registration patients prior therapy 28 days prior initiation Induction course patients prior therapy', 'Patients nonsecretory MM known amyloidosis eligible', 'Patients measurable disease 28 days prior registration prior initiation induction course patients prior therapy', 'Patients Phase I portion received ANY prior chemotherapy patients Phase II portion received prior cycle noninvestigational chemotherapy prior chemotherapy completed 56 days prior registration toxicities resolved =< grade 1 patients portion received prior treatment dexamethasone providing total number days treatment =< 14 days total treatment dose =< 360 mg', 'Patients received prior radiotherapy symptomatic localized bone lesions impending spinal cord compression radiotherapy completed 14 days prior registration toxicities resolved =< grade 1', 'Absolute neutrophil count ANC >= 1000 cellsmm3 growth factor support 14 days prior registration', 'Platelet count >= 70000 cellsmm3 patients bone marrow plasmacytosis < 50 >= 50000 cellsmm3 patients bone marrow plasmacytosis >= 50 14 days prior registration', 'Total bilirubin =< 15 x institutional upper limit normal IULN 14 days prior registration', 'Serum glutamic oxaloacetic transaminase SGOTaspartate aminotransferase AST serum glutamate pyruvate transaminase SGPTalanine aminotransferase ALT =< 25 x IULN 14 days prior registration', 'Creatinine clearance CrCL >= 30 mLmin measured 24hour urine collection estimated Cockcroft Gault formula 14 days prior registration', 'Patients active involvement central nervous CNS MM clinical evaluation patients documentation clinical signs symptoms consistent CNS involvement MM lumbar puncture negative CNS involvement MM lumbar puncture completed 14 days prior registration patients previous history documented CNS involvement clinical signs symptoms consistent CNS involvement required completed lumbar puncture prior registration note monitoring CNS involvement treatment intrathecal therapy recommended protocol treatment', 'Patients known human immunodeficiency virus positive HIV+ eligible providing meet following additional criteria 28 days prior registration Cluster differentiation CD4 cells >= 500mm3 Viral load < 50 copies HIV messenger ribonucleic acid mRNAmm3 combination antiretroviral therapy cART < 25000 copies HIV mRNA cART No zidovudine stavudine cART Patients HIV+ meet criteria eligible study', 'Patients baseline skeletal survey body xray document lytic lesions osteopenia compression fracture', 'Patients Zubrod performance status =< 2', 'Patients known hepatitis B hepatitis C infection eligible providing viral load < 800000 IUL 28 days prior registration', 'Patients POEMS syndrome plasma cell dyscrasia polyneuropathy organomegaly endocrinopathy monoclonal protein skin changes', 'Patients clinically significant illness including uncontrolled active infection requiring intravenous antibiotics New York Heart Association NYHA class III class IV heart failure unstable angina pectoris myocardial infarction past 6 months uncontrolled >= grade 3 cardiac arrhythmias uncontrolled hypertension uncontrolled diabetes mellitus patients undergone electrocardiogram EKG 28 days prior registration', 'Uncontrolled diabetes glycated hemoglobin Hg A1C > 7 14 days prior registration criterion patients confirmed diagnosis diabetes mellitus stable dietary therapeutic regimen condition months', 'Uncontrolled blood pressure hypertension systolic blood pressure SBP > 140 mm Hg diastolic blood pressure DBP > 90 mm Hg 14 days prior registration patients permitted receiving multiple antihypertensive medications indicated study blood pressure measurements 14 days prior registration day 1 cycle 1 SBP =< 140 DBP =< 90 exception healthcare provider patient single blood pressure elevation rechecking normal blood pressure', 'Patients history physical examination 28 days prior registration', 'Patients psychiatric illness potentially interfere completion treatment according protocol', 'Females childbearing potential FCBP negative serum urine pregnancy test sensitivity 25 mIUmL 10 – 14 days prior registration Note pregnancy testing required 24 hours prior treatment cycle 1 day 1 furthermore commit continued abstinence heterosexual intercourse begin TWO acceptable methods birth control highly effective method additional effective method AT THE SAME TIME 28 days starting lenalidomide FCBP agree ongoing pregnancy testing men agree use latex condom sexual contact FCBP successful vasectomy FCBP sexually mature woman 1 undergone hysterectomy bilateral oophorectomy 2 naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months', 'No prior malignancy allowed following adequately treated basal cell squamous cell skin cancer situ cervical cancer adequately treated stage I II cancer patient currently complete remission cancer patient disease free years', 'Patients offered participation banking specimens future research patient’s consent specimens serum bone marrow biopsy core submitted repository patient consent obtained specimens submitted', 'Patients registered mandatory Revlimid Risk Evaluation Mitigation Strategy REMS program willing able comply requirements Revlimid REMS program', 'Patients legally authorized representative informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered'], ['Diagnosed glioblastoma gliosarcoma small cell large cell glioblastoma glioblastoma oligo features glioblastoma primitive neuroectodermal tumorlike components GBMPNET features anaplastic astrocytoma anaplastic oligodendroglioma anaplastic oligoastrocytoma clinically stable completed radiation therapy excluding stereotactic radiosurgery > 21 days =< 24 months prior enrollment NOTE clinical stability defined stable improved Karnofsky performance status KPS compared prior month', '>= 6 score worst fatigue question BFI Brief Fatigue Inventory question 3 required patient complete entire BFI meet criterion', 'Undergone surgery gross total subtotal resection biopsy treated concurrent radiation therapy chemotherapy standard care glioblastoma gliosarcoma small cell large cell glioblastoma glioblastoma oligo features glioblastoma primitive neuroectodermal tumorlike components GBMPNET features anaplastic astrocytoma anaplastic oligodendroglioma anaplastic oligoastrocytoma patients Note radiation completed chemotherapy allowed patients currently Optune device eligible participate trial', 'Negative serum pregnancy test =< 7 days prior registration women determined childbearing potential treating physician', 'Ability complete questionnaires assistance', 'Eastern Cooperative Oncology Group ECOG performance status PS 0 1 2 3', 'Provide informed written consent', 'Willing return enrolling institution followup Active Monitoring phase study', 'Stable dose corticosteroid >= 14 days prior registration', 'Any following Pregnant women Nursing women Men women childbearing potential unwilling employ adequate contraception', 'History hypersensitivity psychostimulants', 'History steroid psychosis', 'Currently taking medications attention deficit hyperactivity disorder history currently taking medications severe anxiety disorder schizophrenia substance abuse patient record andor selfreport Note Patients childhood attention deficit hyperactivity disorder ADHD longer require treatment eligible participate', 'Currently pharmacologic agents nonpharmacologic interventions specifically treat fatigue including psychostimulants antidepressants acupuncture excluded Note antidepressants treat items fatigue hot flashes depression allowed patient stable dose >= 30 days prior registration plans continue duration trial erythropoietin agents treat anemia allowed exercise allowed', 'Anticipating surgery', 'Uncontrolled hypothyroidism profound anemia hemoglobin level <10 gdL =< 28 days prior registration untreated clinical depression physician discretion Patients stable controlled depression receiving treatment hypothyroidism eligible stable dose past 30 days plan continue duration trial', 'Active history Tourette’s syndrome tic disorder', 'History active glaucoma', 'History intractable epilepsy', 'Any following comorbid systemic illnesses severe concurrent disease judgment investigator patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribed regimens History myocardial infarction Unstable angina Left ventricular hypertrophy Mitral valve prolapse syndrome', 'Receiving medications substances strong moderate inhibitors cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 use following strong moderate inhibitors prohibited =< 7 days prior registration Strong inhibitors CYP3A4 > 5fold increase plasma area curve AUC values 80 decrease clearance Indinavir Crixivan Nelfinavir Viracept Atazanavir Reyataz Ritonavir Norvir Clarithromycin Biaxin Biaxin XL Itraconazole Sporanox Ketoconazole Nizoral Nefazodone Serzone Saquinavir Fortovase Invirase Telithromycin Ketek Moderate Inhibitors CYP3A4 > 2fold increase plasma AUC values 5080 decrease clearance Aprepitant Emend Erythromycin Erythrocin EES EryTab Eryc EryPed PCE Fluconazole Diflucan Grapefruit juice Verapamil Calan Calan SR CoveraHS Isoptin SR Verelan Verelan PM Diltiazem Cardizem Cardizem CD Cardizem LA Cardizem SR Cartia XT Dilacor XR Diltia XT Taztia XT Tiazac', 'Receiving medications substances inducers CYP3A4 use following inducers prohibited =< 7 days prior registration Inducers CYP3A4 Efavirenz Sustiva Nevirapine Viramune Carbamazepine Carbatro Epitol Equetro Tegretol TegretolXR Modafinil Provigil Phenobarbital Luminal Phenytoin Dilantin Phenytek Pioglitazone Acto Rifabutin Mycobutin Rifampin Rifadin St John’s wort'], ['Pathologically confirmed diagnosis breast cancer clinical stage III T13 N0 M0 T02 N1 M0 diagnosis needle biopsy patients diagnosed surgical excision excluded patients enrolled receipt completion neoadjuvant chemotherapy clinical stage determined based prechemotherapy assessment', 'Patients Estrogen receptor ER negativeprogesterone receptor PR negative < 10 immunohistochemistry IHC staining HER2 negative breast cancer OR ER negativePR negative < 10 IHC staining HER2 positive tumors HER2 status determined 2013 American Society Clinical Oncology ASCO College American Pathologists CAP guidelines HER2 considered positive IHC 3+ staining b positive single probe situ hybridization ISH dual probe ISH HER2 considered negative IHC 0 1+ staining b ISH negative single probe ISH dual probe ISH For patients enrolling neoadjuvant therapy ER PR HER2 markers based assessment prior initiating neoadjuvant treatment', 'No patients previous ipsilateral contralateral invasive breast cancer ductal carcinoma situ DCIS', 'No patients bilateral breast cancer', 'No patients known deleterious mutations breast cancer BRCA genes', 'No history receiving endocrine therapy tamoxifen aromatase inhibitors therapeutic measures agents previously chemoprevention allowed', 'Patients receiving neoadjuvant chemotherapy recently completed neoadjuvant chemotherapy undergo surgery 6 weeks eligible', 'No patients scheduled receive partial breast irradiation following breast conserving surgery', 'Eligible BCT based clinical examination mammography standard practice given institution ultrasound andor tomogram women appropriately selected BCT based standard imaging studies additional imaging recommended clarify local disease extent eligible trial patients neoadjuvant therapy eligibility BCT determined completion therapy repeat mammogram + ultrasound US affected required completion neoadjuvant chemotherapy determine eligibility BCT', 'No patients multicentric multifocal disease scheduled undergo multiple lumpectomies multifocal disease encompassed single operative bed enrolled patients multifocal multicentric disease enrolled completion neoadjuvant chemotherapy histologic confirmation multifocalitymulticentricity completed initiation chemotherapy', 'Suitable undergo MRI receive contrast agent gadolinium exclusions follow No history untreatable claustrophobia No presence metallic objects implanted medical devices body cardiac pacemaker aneurysm clips surgical clips prostheses artificial hearts valves steel parts metal fragments shrapnel tattoos near eye steel implants No history sickle cell disease No contraindication intravenous contrast administration No known allergylike reaction gadolinium moderate severe allergic reactions allergens defined American College Radiology ACR patient eligible willing undergo pretreatment defined institutions policy andor ACR guidance No findings consistent renal failure determined glomerular filtration rate GFR < 30 mLmin173 m2 based serum creatinine level obtained 28 days prior registration Weight lower allowable MRI table', 'No prior MRI study breast 12 months prior registration', 'Nonpregnant nonlactating patients childbearing potential negative pregnancy test 7 days prior registration perimenopausal patients amenorrheic > 12 months considered childbearing potential', 'Signed studyspecific informed consent prior registration'], ['Patients HCC diagnosis initial recurrent progressive andor refractory therapies criterion listed =< 360 days prior study entry Pathologically histologically cytologically proven diagnosis HCC At solid liver lesion vascular tumor thrombosis involving portal vein inferior vena cava IVC andor hepatic vein > 1 cm arterial enhancement delayed washout multiphasic computerized tomography CT magnetic resonance imaging MRI setting cirrhosis chronic hepatitis B C cirrhosis For patients CURRENT disease vascular enhancing vascular thrombosis involving portal vein IVC andor hepatic vein demonstrating early arterial enhancement delayed washout multiphasic CT MRI patient known HCC diagnosed previously < 720 days', 'Patients measurable hepatic disease andor presence vascular tumor thrombosis involving portal vein IVC andor hepatic vein measurable Response Evaluation Criteria Solid Tumors RECIST liver CT MRI 28 days PRIOR TO STUDY ENTRY', 'Appropriate protocol entry based following minimum diagnostic workup Historyphysical examination including examination encephalopathy ascites weight height blood pressure 14 days prior study entry Assessment radiation oncologist medical oncologist hepatologist specializes treatment HCC 28 days prior study entry Prerandomization scan REQUIRED patients Within 28 days prior study entry multiphasic liver CT multiphasic liver magnetic resonance MR scan Within 28 days prior study entry CT chest CT MR abdomen CT MR pelvis positron emission tomography PET CT chestabdomenpelvis', 'Zubrod performance status 02 28 days prior study entry', 'Absolute neutrophil count ANC >= 1500 cellsmm3 obtained 14 days prior study entry', 'Platelets >= 60000 cellsmm3 obtained 14 days prior study entry', 'Hemoglobin >= 80 gdl Note use transfusion intervention achieve hemoglobin Hgb >= 80 gdl acceptable obtained 14 days prior study entry', 'Aspartate aminotransferase AST alanine aminotransferase ALT < 6 times upper limit normal ULN obtained 14 days prior study entry', 'Serum creatinine =< 2 x ULN creatinine clearance >= 60 mLmin obtained 14 days prior study entry', 'Patients Barcelona Clinic Liver Cancer BCLC stage intermediate B advanced C 28 days prior study entry', 'ChildPugh score A 14 days prior study entry international normalized ratio INR < 28 days acceptable', 'Women childbearing potential male participants agree practice adequate contraception study 6 months following dose radiation therapy RT 28 days following dose sorafenib whichever later', 'Unsuitable resection transplant radiofrequency ablation RFA', 'Unsuitable refractory transarterial hepatic chemoembolization TACE drug eluting beads DEB following reasons described Raoul et al 2011 Technical contraindications arteriovenous fistula including surgical portosystemic shunt spontaneous portosystemic shunt Severe reduction portal vein flow tumor portal vein IVC atrial invasion bland portal vein occlusion Medical contraindications including congestive heart failure angina severe peripheral vascular disease Presence extrahepatic disease No response post TACE DEB progressive HCC despite TACE prior TACE DEB allowed > 28 days study entry Serious toxicity following prior TACE DEB prior TACE DEB > 28 days study entry Other medical comorbidities making TACE DEB unsafe andor risky combination relative contraindications including age > 80 years tumor > 10 cm > 50 replacement liver HCC extensive multinodular bilobar HCC biliary drainage', 'Patients treated prior surgery eligible study meet eligibility criteria', 'Patient able provide studyspecific informed consent prior study entry', 'Prior invasive malignancy nonmelanomatous skin cancer T1 renal cell carcinoma disease free minimum 2 years note carcinoma situ breast oral cavity cervix permissible', 'Prior sorafenib use > 60 days andor grade 3 4 sorafenib related toxicity note prior chemotherapy HCC different cancer allowable', 'Prior radiotherapy region liver result excessive doses normal tissues overlap radiation therapy fields', 'Prior selective internal radiotherapyhepatic arterial yttrium therapy time', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months PRIOR TO registration Transmural myocardial infarction 6 months prior study entry Unstable ventricular arrhythmia 6 months prior study entry Acute bacterial fungal infection requiring intravenous antibiotics 28 days prior study entry Hepatic insufficiency resulting clinical jaundice encephalopathy andor variceal bleed 28 days prior study entry Bleeding 28 days prior study entry cause requiring transfusion Thrombolytic therapy 28 days prior study entry subcutaneous heparin permitted Known bleeding clotting disorder Uncontrolled psychotic disorder', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception exclusion necessary treatment involved study significantly teratogenic', 'Maximal diameter hepatocellular carcinoma > 15 cm', 'Total sum maximum diameters definite parenchymal hepatocellular carcinomas liver maximum diameter single conglomerate HCC > 20 cm', 'More 5 discrete intrahepatic parenchymal foci definite HCC', 'Direct tumor extension stomach duodenum small bowel large bowel', 'Measurable common main branch biliary duct involvement HCC', 'Extrahepatic metastases malignant nodes enhance typical features HCC > 30 cm sum maximal diameters presence 34 cm metastatic lymph node 2 cm lung lesions note benign nonenhancing periportal lymphadenopathy unusual presence hepatitis permitted sum enlarged nodes > 20 cm', 'Prior liver transplant', 'Human immunodeficiency virus HIV positive CD4 count < 350 cellsmicroliter note patients HIV positive eligible provided treatment highly active antiretroviral therapy HAART CD4 count >= 350 cellsmicroliter known detectable viral load time study entry note HIV testing required eligibility protocol'], ['The patient signed dated Institutional Review Board IRBapproved consent form conforms federal institutional guidelines', 'The patient Eastern Cooperative Oncology Group ECOG performance status 0 1', 'Patient clinically T13 N1 breast cancer time diagnosis neoadjuvant therapy clinical axillary nodal involvement assessed palpation ultrasound CT scan magnetic resonance imaging MRI positron emission tomography PET scan PETCT scan', 'Patient pathologic confirmation axillary nodal involvement presentation neoadjuvant therapy based positive fine needle aspirate FNA demonstrating malignant cells positive core needle biopsy demonstrating invasive adenocarcinoma FNA core needle biopsy performed palpation image guidance documentation axillary nodal positivity sentinel node biopsy neoadjuvant therapy permitted', 'Patients estrogen receptor ER analysis performed primary breast tumor neoadjuvant therapy according current American Society Clinical Oncology ASCOCollege American Pathologists CAP guideline recommendations hormone receptor testing negative ER assessment progesterone receptor PgR performed according current ASCOCAP guideline recommendations hormone receptor testing', 'Patients HER2 testing performed primary breast tumor neoadjuvant chemotherapy according current ASCOCAP guideline recommendations human epidermal growth factor receptor 2 testing breast cancer patients primary tumor HER2positive HER2negative eligible', 'Patient completed minimum 8 weeks standard neoadjuvant chemotherapy consisting anthracycline andor taxanebased regimen', 'For patients receive adjuvant chemotherapy surgery maximum 12 weeks intended chemotherapy administered completed randomization treatment delays occur chemotherapy completed 14 weeks dose schedule adjuvant chemotherapy investigators discretion Note preferred intended chemotherapy administered neoadjuvant setting', 'Patients HER2positive tumors received neoadjuvant antiHER2 therapy portion neoadjuvant chemotherapy regimen medically contraindicated', 'At time definitive surgery removed axillary nodes histologically free cancer acceptable procedures assessment axillary nodal status time surgery include Axillary node dissection Sentinel node biopsy provided 2 sentinel lymph nodes removed removal 3 sentinel lymph nodes use dual tracer lymphatic mapping strongly recommended Sentinel node biopsy followed axillary node dissection Note patients eligible residual invasive carcinoma surgical breast specimen evidence pathologic complete response patients pathologically nodepositive time surgery based sentinel node biopsy candidates A011202 study developed Alliance Oncology National Cancer Institute NCI Cooperative Group A011202 open investigators institution patients approached participating A011202 study', 'Patients pathologic staging ypN0i+ ypN0mol+ eligible', 'Patient undergone total mastectomy lumpectomy eligible patients nipplesparing mastectomy eligible', 'For patients undergo lumpectomy margins resected specimen reexcision histologically free invasive tumor DCIS determined local pathologist additional operative procedures performed obtain clear margins tumor present resected margin reexcisions patient undergo total mastectomy eligible patients margins positive lobular carcinoma situ LCIS eligible additional resection', 'For patients undergo mastectomy margins histologically free residual microscopic gross tumor', 'The interval surgery breast cancer including reexcision margins randomization 70 days adjuvant chemotherapy administered interval chemotherapy treatment randomization 70 days', 'The patient recovered surgery incision completely healed signs infection', 'If adjuvant chemotherapy administered chemotherapyrelated toxicity interfere delivery radiation therapy resolved', 'Definitive clinical radiologic evidence metastatic disease', 'T4 tumors including inflammatory breast cancer', 'Documentation axillary nodal positivity neoadjuvant therapy sentinel node biopsy', 'N2 N3 disease detected clinically imaging', 'Patients histologically positive axillary nodes post neoadjuvant therapy', 'Patients microscopic positive margins definitive surgery', 'Synchronous previous contralateral invasive breast cancer DCIS patients synchronous andor previous contralateral LCIS eligible', 'Any prior history including index cancer ipsilateral invasive breast cancer ipsilateral DCIS treated radiation therapy patients synchronous previous ipsilateral LCIS eligible', 'History nonbreast malignancies situ cancers treated local excision basal cell squamous cell carcinomas skin 5 years prior randomization', 'Any radiation therapy currently diagnosed breast cancer prior randomization', 'Any continued use sex hormonal therapy birth control pills ovarian hormone replacement therapy patients eligible medications discontinued prior randomization', 'Prior breast thoracic radiation therapy RT condition', 'Active collagen vascular disease specifically dermatomyositis creatinine phosphokinase CPK level normal active skin rash systemic lupus erythematosus scleroderma', 'Pregnancy lactation time study entry Note pregnancy testing performed 2 weeks prior randomization according institutional standards women childbearing potential', 'Other nonmalignant systemic disease preclude patient receiving study treatment prevent required followup', 'Psychiatric addictive disorders conditions opinion investigator preclude patient meeting study requirements'], ['Patients postmenopausal postmenopausal defined women meeting following criteria >= 60 years age < 60 years age amenorrheic >= 12 months prior day 1 uterusovaries intact < 60 years age menstrual period 612 months prior day 1 intact uterusovaries meets biochemical criteria menopause folliclestimulating hormone FSH estradiol institutional standard postmenopausal status < 60 years age uterus meets biochemical criteria menopause FSH estradiol institutional standards postmenopausal status < 60 years age history bilateral oophorectomy surgery completed 4 weeks prior day 1 Prior radiation castration amenorrhea 6 months', 'NOTE use luteinizing hormonereleasing hormone LHRH agonists leuprolide goserelin allowed', 'Patients estrogen andor progesterone receptor positive histologically confirmed stage IIII adenocarcinoma breast', 'Patients completed planned local therapy definitive surgery radiation therapy adjuvant chemotherapy breast cancer prior registration addition prior local therapy adjuvant chemotherapy completed prior participant completion baseline Patient Reported Outcomes PRO instruments Health Assessment Questionnaire HAQ PROMIS Physical Function Functional Assessment Cancer Therapy FACT Breast Endocrine Symptoms ES collection optional blood banking future research', 'NOTE concomitant treatment ongoing trastuzumab Herceptin targetedbiologic agents allowed concomitant treatment type chemotherapy hormonal therapy allowed', 'Patients received prior AI therapy exemestane letrozole anastrozole preoperativeadjuvant therapy prevention breast cancer prior tamoxifen allowed', 'Plan treat anastrozole 12 months', 'Eastern Cooperative Oncology Group ECOG performance status 02', 'Patients diseasefree prior invasive malignancies >= 5 years exception curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix prior early stage breast cancers allowed long prior treatment include aromatase inhibitors', 'Patients currently taking taken past 6 months medication active chronic conditions including rheumatoid arthritis carpal tunnel syndrome tenosynovitis systemic lupus erythematosus gout fibromyalgia severe osteoarthritis involving hands wrists hips knees feet ankles includes analgesic medications medications taken purpose treating pain effect pain antidepressants help pain neuropathy corticosteroid shots arthritis Note patients taking daily low dose aspirin allowed participate trial', 'Patients prior history deep vein thrombosis DVT pulmonary embolism past 5 years', 'Patients worst pain rated worse 3 10 following question pain score 0 1 2 3 “In past week pain scale 0 10 0 equals pain 10 means worst pain imagine NOTE question patient’s pain completed week prior registration question asked orally prior consent 7 days prior registration response recorded registration checklist', 'Patients adequate hepatic hematologic renal functioning able administered anastrozole discretion treating physician'], ['Pathologically proven diagnosis malignant major salivary gland tumor malignant minor salivary gland tumor head neck following histologic subtypes Intermediategrade adenocarcinoma intermediategrade mucoepidermoid carcinoma Highgrade adenocarcinoma highgrade mucoepidermoid carcinoma salivary duct carcinoma Highgrade acinic cell carcinoma highgrade > 30 solid component adenoid cystic carcinoma Patients diagnoses undifferentiated poorly differentiated carcinoma carcinomaex pleomorphic adenoma carcinoma specified NOS considered trial', 'Surgical resection curative intent 8 weeks prior registration', 'Pathologic stage T34 N13 T12 N0 close =< 1 mm microscopically positive surgical margin American Joint Committee Cancer AJCC 7th edition patients free distant metastases based following minimum diagnostic workup Historyphysical examination 8 weeks prior registration Radiologic confirmation absence hematogenous metastasis 12 weeks prior registration minimum contrast computed tomography CT imaging chest required positron emission tomography PETCT acceptable', 'Zubrod performance status 01', 'Absolute neutrophil count ANC >= 1800 cellsmm3 8 weeks prior registration', 'Platelets >= 100000 cellsmm3 8 weeks prior registration', 'Hemoglobin >= 80 gdl Note use transfusion intervention achieve hemoglobin Hgb >= 80 gdl acceptable 8 weeks prior registration', 'Serum creatinine < 20 mgdl 8 weeks prior registration', 'Total bilirubin < 2 x institutional upper limit normal ULN 8 weeks prior registration', 'Aspartate aminotransferase AST alanine aminotransferase ALT < 3 x institutional ULN 8 weeks prior registration', 'Negative serum pregnancy test 2 weeks prior registration women childbearing potential', 'Women childbearing potential male participants sexually active practice adequate contraception treatment 6 weeks following treatment', 'All patients Medical Oncology evaluation 4 weeks prior registration', 'Patients deemed able comply treatment plan followup schedule', 'Patients provide study specific informed consent prior study entry including consent mandatory tissue submission central review', 'Patients residual macroscopic disease surgery', 'Prior invasive malignancy nonmelanomatous skin cancer disease free minimum 3 years example carcinoma situ breast oral cavity cervix permissible', 'Prior systemic chemotherapy radiation therapy salivary gland malignancy note prior chemotherapy different cancer allowable', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months Transmural myocardial infarction 6 months Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration Hepatic insufficiency resulting clinical jaundice andor coagulation defects note coagulation parameters required entry protocol Acquired immune deficiency syndrome AIDS based current Centers Disease Control CDC definition note human immunodeficiency virus HIV testing required entry protocol Preexisting >= grade 2 neuropathy Prior organ transplant', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception', 'Significant preexisting hearing loss defined patient treating physician'], ['Histologically cytologically confirmed newly diagnosed nonsquamous NSCLC', 'Unresectable stage IIIA IIIB disease patients surgically staged confirm N2 N3 disease patients invasive mediastinal staging mediastinoscopy mediastinotomy endobronchial ultrasound transbronchial aspiration EBUSTBNA endoscopic ultrasound EUS videoassisted thoracoscopic surgery VATS', 'Patients tumor T node N2 N3 eligible patients T3 N1N3 disease eligible deemed unresectable patients T4 N eligible', 'Patients measurable disease lesions accurately measured 1 dimension longest dimension plane measurement recorded minimum size 10 mm computed tomography CT scan CT scan slice thickness greater 5 mm', 'Patients pleural effusion transudate cytologically negative nonbloody eligible radiation oncologist feels tumor encompassed reasonable field radiotherapy', 'If pleural effusion seen chest CT chest xray small tap patient eligible patients develop new pleural effusion thoracotomy invasive thoracic procedure eligible', 'The institution’s preenrollment biomarker screening Clinical Laboratory Improvement Amendments CLIA certified lab documents presence known “sensitive” mutations epidermal growth factor receptor tyrosine kinase EGFR TK domain exon 19 deletion L858 andor EML4anaplastic lymphoma kinase ALK fusion arrangement primary tumor metastatic lymph node tissue testing mutations', 'The institution’s preenrollment biomarker screening CLIA certified lab documents absence T790M mutation EGFR TK domain', 'Appropriate stage protocol entry including distant metastases based following minimum diagnostic workup Historyphysical examination including recording pulse blood pressure BP weight body surface area 45 days prior registration Whole body fludeoxyglucosepositron emission tomography FDGPETCT orbits midthighs 30 days prior registration PETCT negative distant metastasis CT scan contrast chest upper abdomen include liver adrenals medically contraindicated 30 days prior registration Magnetic resonance imaging MRI brain contrast CT scan contrast MRI medically contraindicated 30 days prior registration', 'Zubrod performance status 01 14 days prior registration', 'Absolute neutrophil count ANC >= 1000 cellsmm3', 'Platelets >= 100000 cellsmm3', 'Hemoglobin >= 80 gdl Note use transfusion intervention achieve hemoglobin Hgb >= 80 gdl acceptable', 'Serum creatinine < 15 mgdL calculated creatinine clearance >= 50 mlmin CockcroftGault formula 14 days prior registration', 'Aspartate aminotransferase ASTalanine aminotransferase ALT =< 25 x upper limit normal ULN 14 days prior registration', 'Bilirubin normal institutional limits 14 days prior registration', 'Negative serum pregnancy test 14 days prior registration women childbearing potential', 'Patient provide study specific informed consent prior study entry including consent mandatory screening tissue', 'Prior invasive malignancy nonmelanomatous skin cancer disease free minimum 730 days 2 years example carcinoma situ breast oral cavity cervix permissible', 'Prior systemic chemotherapy study cancer note prior chemotherapy different cancer allowable', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Atelectasis entire lung', 'Contralateral hilar node involvement', 'Exudative bloody cytologically malignant effusions', 'Severe active comorbidity defined follows Unstable angina andor congestive heart failure requiring hospitalization 6 months Transmural myocardial infarction 6 months Acute bacterial fungal infection requiring intravenous antibiotics time registration Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy time registration hepatic insufficiency resulting clinical jaundice andor coagulation defects Acquired immune deficiency syndrome AIDS based current Centers Disease Control Prevention CDC definition note human immunodeficiency virus HIV testing required entry protocol protocolspecific requirements exclude immunocompromised patients', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception', 'Prior allergic reaction study drugs involved protocol'], ['Clinical stage T13 N1 M0 breast cancer diagnosis prior start neoadjuvant chemotherapy American Joint Committee Cancer AJCC staging 7th edition', 'No inflammatory breast cancer', 'No malignancy 5 years registration exception basal cell squamous cell carcinoma skin treated local resection carcinoma situ cervix', 'All patients axillary ultrasound fine needle aspiration FNA core needle biopsy axillary lymph nodes documenting axillary metastasis time diagnosis prior 14 days starting neoadjuvant chemotherapy Note Biopsy intramammary nodes fulfill eligibility criteria', 'Patients estrogen receptor progesterone receptor HER2 status immunohistochemistry IHC andor situ hybridization ISH evaluated diagnostic core biopsy prior start neoadjuvant chemotherapy Note If HER2 status clearly determined equivocalindeterminate patients enrolled', 'Patients completed planned neoadjuvant chemotherapy prior surgery sandwich chemotherapy allowed anthracyclinecytoxan taxane chemotherapy planned given surgery patients completed 4 cycles neoadjuvant chemotherapy consisting anthracycline andor taxanebased regimen evidence disease progression breast lymph nodes Note Delaysdose modifications toxicitiesadverse events allowed long minimum 4 cycles neoadjuvant chemotherapy administered 4 cycles neoadjuvant chemotherapy NAC administered discretion treating medical oncologist', 'Patients HER2 positive tumors received neoadjuvant trastuzumab trastuzumab + pertuzumab approved antiHER2 therapy portion neoadjuvant chemotherapy regimen therapy Food Drug Administration FDAapproved targeted antiHER2 therapy additional therapies allowed nontrastuzumab regimens administered context Institutional Review Board IRBapproved clinical trial', 'All patients clinically negative axilla bulky adenopathy physical examination documented completion neoadjuvant chemotherapy Note ultrasound axilla required completion neoadjuvant chemotherapy performed findings NOT impact eligibility', 'No 8 weeks neoadjuvant endocrine therapy prior start neoadjuvant chemotherapy', 'No neoadjuvant radiation therapy', 'No SLN surgeryexcisional biopsy pathological confirmation axillary status prior neoadjuvant chemotherapy', 'No prior history ipsilateral breast cancer invasive disease ductal carcinoma situ DCIS lobular carcinoma situ LCIS benign breast disease allowed', 'No prior ipsilateral axillary surgery excisional biopsy lymph nodes treatment hidradenitis', 'No history prior concurrent contralateral invasive breast cancer benign breast disease LCIS DCIS contralateral breast allowed', 'Patients pregnant nursing Note Perimenopausal women amenorrheic > 12 months considered childbearing potential', 'Eastern Cooperative Oncology Group ECOG Zubrod performance status 01', 'INTRAOPERATIVE REGISTRATIONRANDOMIZATION CRITERIA', 'Breast surgery lumpectomy mastectomy sentinel lymph node surgery completed 56 days completion dose neoadjuvant chemotherapy', 'A minimum 1 sentinel node maximum 8 total nodes sentinel + nonsentinel identified excised 8 nodes identified surgeon pathologist NOT allowed Note Patients identifiable sentinel lymph node proceed registrationrandomization', 'At lymph node sentinel nonsentinel metastasis greater 02 mm greatest dimension identified intraoperative pathologic assessment Note Isolated tumor cells metastases equal 02 mm treated node negative disease N0i+ Note If final pathology 8 lymph nodes seen pathologically patient discontinue study Axillary lymph node dissection ALND performed prior registrationrandomization Note Patients positive lymph nodes sentinel nonsentinel sentinel lymph node surgery proceed registrationrandomization considered discussion NRG NSABP B51RTOG 1304 study “A Randomized Phase III Clinical Trial Evaluating Role Postmastectomy Chest Wall Regional Nodal XRT Postlumpectomy Regional Nodal XRT Patients Documented Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy”', 'POSTOPERATIVE REGISTRATIONRANDOMIZATION CRITERIA', 'For cases ALND performed following true 1 intraoperative evaluation sentinel lymph node bewas performed final pathology identified positive lymph node sentinel nonsentinel metastasis greater 02 mm OR 2 lymph node sentinel nonsentinel considered negative intraoperative evaluation positive final pathology metastasis greater 02 mm', 'Breast surgery lumpectomy mastectomy sentinel lymph node surgery completed 56 days completion dose neoadjuvant chemotherapy negative margin breast conservation mastectomy final pathology negative margin defined tumor ink', 'At lymph node sentinel nonsentinel metastasis greater 02 mm greatest dimension identified final pathology cases intraoperative evaluation performed negative completion dissection performed', 'At 8 lymph nodes sentinel nonsentinel pathologists actually excised sentinel lymph node procedure Note Isolated tumor cells metastases equal 02 mm treated node negative disease N0i+', 'For patients undergo contralateral breast surgery invasive disease contralateral breast patient eligible registration randomization'], ['Patients histologically cytologically confirmed metastatic endometrial cancer eligible histologies experimental cohort endometrioid serous eligible histologies exploratory cohort carcinosarcoma clear cell mixed adenosquamous rare subtype endometrial cancer', 'Patients measurable disease defined lesion accurately measured dimension longest diameter recorded nonnodal lesions short axis nodal lesions >= 10 mm computed tomography CT scan magnetic resonance imaging MRI calipers clinical exam >= 15 mm short axis nodal lesions patients radiographic evidence disease progression following recent line treatment', 'Prior therapy Eligible subjects 1 line systemic cytotoxic treatment adjuvant therapy documented progression 12 months completion 1 line cytotoxic therapy metastatic disease NOTE eligible patients allowed 2 lines systemic cytotoxic treatment 1 line allowed metastatic disease acceptance progression 12 months adjuvant inclusion require patient rechallenge chemotherapy chemo progressed soon adjuvant therapy prior hormonal therapy metastaticrecurrent disease allowed prior targeted therapy directed cMET vascular endothelial growth factor VEGF pathways allowed', 'Eastern Cooperative Oncology Group ECOG performance status =< 2 Karnofsky >= 60', 'Life expectancy greater 3 months', 'Absolute neutrophil count >= 15 x 109L', 'Platelets >= 100 x 109L', 'Total bilirubin =< 15 x upper limit normal ULN', 'Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOTalanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT =< 30 X institutional upper limit normal', 'Creatinine =< 15 x ULN OR creatinine clearance >= 50 mLmin173 m2 patients creatinine levels institutional normal', 'Hemoglobin >= 90 gL', 'Serum albumin >= 28 gL', 'Lipase < 20 x ULN radiologicclinical evidence pancreatitis', 'Urine proteincreatinine ratio UPCR =< 1', 'Serum phosphorus calcium magnesium potassium >= lower limit normal LLN', 'Women childbearing potential negative pregnancy test screening women childbearing potential include women experienced menarche undergone successful surgical sterilization hysterectomy bilateral tubal ligation bilateral oophorectomy postmenopausal postmenopausal defined amenorrhea >= 12 consecutive months note women amenorrheic 12 months considered childbearing potential amenorrhea possibly prior chemotherapy antiestrogens ovarian suppression reversible reason', 'Women childbearing potential agree use adequate contraception prior study entry duration study participation woman pregnant suspect pregnant participating study inform treating physician immediately sexually active subjects agree use medically accepted barrier methods contraception male female condom course study 4 months dose study drugs oral contraceptives subjects reproductive potential agree use barrier method second method birth control course study 4 months dose study drugs', 'Patients consent analysis archival tissue archival sample available sufficient tumor biopsy performed minimum 28 days prior start treatment felt clinically reasonable', 'Ability understand willingness sign written informed consent document', 'Patients chemotherapy including investigational cytotoxic chemotherapy biologic agents cytokines antibodies radiotherapy 4 weeks 6 weeks nitrosoureas mitomycin C dose study treatment recovered adverse events agents administered 4 weeks earlier', 'Prior treatment cabozantinib', 'The subject received radiation therapy To bone metastasis 14 days dose study treatment To sites 28 days dose study treatment', 'The subject received radionuclide treatment 6 weeks dose study treatment', 'The subject received prior treatment small molecule kinase inhibitor hormonal therapy including investigational kinase inhibitors hormones 14 days halflives compound active metabolites whichever longer dose study treatment', 'The subject received type investigational agent 28 days dose study treatment', 'The subject recovered baseline Common Terminology Criteria Adverse Events CTCAE =< grade 1 related toxicity prior therapies alopecia nonclinically significant adverse events AEs', 'Any prior malignancy patient disease free 3 years exception adequately treated cured basal squamous cell skin cancer superficial bladder cancer carcinoma situ site cancer', 'Patients known brain metastases excluded clinical trial', 'The subject prothrombin time PTinternational normalized ratio INR partial thromboplastin time PTT test >= 13 x laboratory ULN =< 7 days dose study treatment', 'Therapeutic anticoagulation warfarin antiplatelet agents clopidogrel thrombin Factor Xa inhibitors allowed therapeutic anticoagulation low molecular weight heparin LMWH allowed prophylactic anticoagulation low dose aspirin =< 81 mgday lowdose warfarin =< 1 mgday LMWH', 'The subject requires chronic concomitant treatment strong CYP3A4 inducers dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentine phenobarbital St John’s wort', 'The subject experienced following Clinicallysignificant gastrointestinal bleeding 6 months dose study treatment Hemoptysis >= 05 teaspoon 25 mL red blood 3 months dose study treatment Any signs indicative pulmonary hemorrhage 3 months dose study treatment', 'The subject tumor contact invading encasing major blood vessels', 'The subject evidence tumor invading gastrointestinal GI tract esophagus stomach small large bowel rectum anus evidence endotracheal endobronchial tumor 28 days dose cabozantinib', 'The subject uncontrolled significant intercurrent recent illness including limited following conditions Cardiovascular disorders including Congestive heart failure CHF New York Heart Association NYHA class III moderate class IV severe time screening Concurrent uncontrolled hypertension defined sustained blood pressure BP > 140 mmHg systolic > 90 mmHg diastolic despite optimal antihypertensive treatment 7 days dose study treatment Any history congenital long QT syndrome Any following 6 months dose study treatment Unstable angina pectoris Clinicallysignificant cardiac arrhythmias Stroke including transient ischemic attack TIA ischemic event Myocardial infarction Thromboembolic event requiring therapeutic anticoagulation note subjects venous filter vena cava filter eligible study', 'Gastrointestinal disorders particularly associated high risk perforation fistula formation including Any following 28 days dose study treatment Intraabdominal tumormetastases invading GI mucosa Active peptic ulcer disease Inflammatory bowel disease including ulcerative colitis Crohn’s disease diverticulitis cholecystitis symptomatic cholangitis appendicitis Malabsorption syndrome Any following 6 months dose study treatment Abdominal fistula Gastrointestinal perforation Bowel obstruction gastric outlet obstruction Intraabdominal abscess note complete resolution intraabdominal abscess confirmed prior initiating treatment cabozantinib abscess occurred 6 months dose study treatment', 'Other disorders associated high risk fistula formation including percutaneous endoscopic gastrostomy PEG tube placement 3 months dose study therapy', 'Other clinically significant disorders Active uncontrolled infection requiring intravenous systemic treatment 14 days dose study treatment Serious nonhealing woundulcerbone fracture 28 days dose study treatment History organ transplant Concurrent uncompensated hypothyroidism thyroid dysfunction 7 days dose study treatment History major surgery follows Major surgery 3 months dose cabozantinib wound healing complications 6 months dose cabozantinib wound complications Minor surgery 1 month dose cabozantinib wound healing complications 3 months dose cabozantinib wound complications In addition complete wound healing prior surgery confirmed 28 days dose cabozantinib irrespective time surgery', 'The subject unable swallow tablets', 'The subject corrected QT interval calculated Fridericia formula QTcF > 500 ms =< 7 days dose study treatment', 'The subject unable unwilling abide study protocol cooperate fully investigator designee', 'History allergic reactions attributed compounds similar chemical biologic composition XL184', 'Pregnant women excluded study breastfeeding discontinued mother treated XL184', 'Known human immunodeficiency virus HIVpositive patients combination antiretroviral therapy ineligible'], ['Eastern Cooperative Oncology Group ECOG performance status 02', 'Postmenopausal verified Post bilateral surgical oophorectomy No spontaneous menses >= 1 year No menses < 1 year folliclestimulating hormone FSH estradiol levels postmenopausal range according institutional standards', 'Pathologic confirmation invasive breast cancer diagnosed core needle biopsy', 'Clinical T2T4c N M0 invasive breast cancer American Joint Committee Cancer AJCC 7th edition clinical staging goal surgery complete excision tumor breast lymph node Primary tumor Palpable Its largest tumor diameter > 20 cm physical examination radiological assessment Bidimensional measurement tape ruler caliper technique provided Note Patients contralateral ductal carcinoma situ andor invasive breast cancer eligible Patients multifocal breast cancer defined lesion invasive breast cancer breast separated dominant breast lesion 5 cm radiologically normal breast tissue eligible lesions biopsied biopsy required meet ERhuman epidermal growth factor receptor 2 HER2 eligibility requirements research biopsies Ki67 assessment radiological measures performed dominant breast lesion', 'Invasive breast cancer estrogen receptor ER positive Allred score 6 7 8 local institution standard protocol Allred score reported diagnostic pathology report ER positivity > 66 cells eligible ER positivity =< 66 staining intensity weak intermediate strong needed calculate Allred score determine eligibility', 'Invasive breast cancer HER2 negative patient considered HER2 negative breast cancer following following applies 0 1+ immunohistochemistry IHC situ hybridization ISH 0 1+ IHC ISH ratio HER2 gene copychromosome 17 < 2 2+ IHC ISH ratio HER2 gene copychromosome 17 < 2', 'Documentation mammogram ultrasound including ductal carcinoma situ DCIS invasive cancer diseased breast performed 56 days prior registration mammogram unaffected contralateral breast required 12 months prior registration', 'Absolute neutrophil count ANC > 1000mm3 =< 14 days prior registration', 'Platelet count > 100000mm3 =< 14 days prior registration', 'Total bilirubin < 15 x upper limits normal ULN =< 14 days prior registration', 'Creatinine < 15 x upper limits normal ULN =< 14 days prior registration', 'Serum alanine aminotransferase ALT < 25 x upper limits normal ULN =< 14 days prior registration', 'Tissue acquisition patient agree provide required research biopsies baseline week 4 surgery integral integrated biomarker correlative studies', 'Premenopausal status', 'Inflammatory breast cancer defined clinically significant erythema breast andor documented dermal lymphatic invasion direct skin invasion tumor peau d’orange erythema', 'An excisional biopsy breast cancer', 'Hormone replacement therapy type megestrol acetate raloxifene week prior registration', 'Tumor ER Allred score 05 HER2 positive IHC 3+ amplified fluorescence situ hybridization FISH > 20', 'Surgical axillary staging procedure prior study entry Note fine needle aspiration FNA core needle biopsy axillary node permitted', 'Clinical radiographic evidence metastatic disease metastatic workup required recommended patients clinical stage III disease Note isolated ipsilateral supraclavicular node involvement permitted', 'Breast implants contraindicated implant precludes required research biopsies interferes palpating breast lesion', 'Treatment cancer including surgery radiation therapy chemotherapy biotherapy hormonal therapy investigational agent prior study entry', 'History invasive breast cancer contralateral DCIS'], ['PHASE I ARMS A B C D E F G H I X Y Z', 'Patients pathologically confirmed relapsed refractory classical Hodgkin lymphoma cHL biopsy relapse acceptable histologies including lymphocyte predominant LP HL permitted', 'Patients relapsed line chemotherapy relapsed autologous allogeneic stem cell transplant primary refractory disease upper limit number prior therapies status post allogeneic stem cell transplant active graft versus host disease', 'Patients received prior brentuximab vedotin received brentuximab vedotin 6 months prior registration relapsed 6 months receiving previous brentuximab vedotin patients received prior nivolumab PD1PDL1 axis agents patients nivolumabbrentuximab cohorts ONLY D E F Y received prior ipilimumab', 'Patients received prior activating immunotherapies checkpoint inhibitors received 6 months prior registration unresolved complication therapy time registration purposes study monoclonal antibodies antibody drug conjugates considered activating immunotherapies additional time restrictions prior exposure agents prior brentuximab vedotin', 'Eastern Cooperative Oncology Group ECOGAmerican College Radiology Imaging Network ACRIN performance status 02', 'Patients measurable disease baseline measurements evaluations obtained 4 weeks registration study abnormal positron emission tomography PET scans constitute evaluable disease verified diagnostic quality computed tomography CT scan patients use imaging modality CT PETCT study', 'Women pregnant breastfeeding risk fetal harm chemotherapeutic agents prescribed protocol females childbearing potential blood test urine study 2 weeks prior registration rule pregnancy female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria 1 undergone hysterectomy bilateral oophorectomy 2 naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months', 'Women childbearing potential WOCBP sexually active males abstain sexual intercourse duration participation study agree use single barrier contraception birth control pills implants week prior start study drug continuing 5 months dose study drug female patients 7 months dose study drug male patients sexually active WOCBP woman pregnant suspect pregnant partner participating study participating partner inform treating physician immediately', 'Patients evidence dyspnea rest pulse oximetry > 92 breathing room air', 'Patients forced expiratory volume 1 second FEV1forced vital capacity FVC > 60 pulmonary function test PFT large mediastinal mass HL carbon monoxide diffusion capacity DLCO FEV1 FVC > 50 predicted value pulmonary function tests obtained month prior registration', 'Absolute neutrophil count ANC >= 1500mcL 15 x 109L obtained 2 weeks prior registration', 'Platelets >= 75000mcL 75 x 109L obtained 2 weeks prior registration', 'Aspartate aminotransferase ASTalanine aminotransferase ALT =< 25 x upper limit normal ULN obtained 2 weeks prior registration', 'Bilirubin =< 2 x upper limit normal ULN documented Gilbert’s syndrome bilirubin =< 3 x upper limit normal ULN permitted obtained 2 weeks prior registration', 'Calculated creatinine clearance CockcroftGault formula >= 30 mlmin obtained 2 weeks prior registration', 'No evidence prior malignancy adequately treated nonmelanoma skin cancer situ cervical carcinoma surgically radiationcured malignancy continuously disease free >= 5 years interfere interpretation radiographic response', 'Patient current prior history central nervous CNS involvement', 'All prior therapy completed 21 days prior enrollment concomitant anti lymphoma therapy including systemic corticosteroids purpose treatment lymphoma allowed topical steroids allowed', 'No history Steven’s Johnson’s syndrome toxic epidermal necrolysis TENs syndrome motor neuropathy', 'Human immunodeficiency virus HIV positive patients allowed study CD4 count > 400 stable antiviral regimen patients poorly controlled HIV chronic active viral infections excluded', 'Patients autoimmune disorders conditions immunosuppression require current ongoing treatment systemic corticosteroids systemic immunosuppressants including oral steroids prednisone dexamethasone continuous use topical steroid creams ointments ophthalmologic steroids history occasional continuous use steroid inhalers allowed Replacement doses steroids patients adrenal insufficiency allowed patients discontinue use classes medication 2 weeks prior initiation study treatment eligible judgment treating physician investigator patient likely require resumption treatment classes drugs study Exclusion study includes patients history symptomatic autoimmune disease rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus Sjogrens syndrome autoimmune vasculitis Wegener’s Granulomatosis motor neuropathy considered autoimmune origin GuillainBarre syndrome Myasthenia Gravis CNS autoimmune disease Multiple sclerosis patients autoimmune hypothyroid disease type I diabetes replacement treatment eligible', 'Patients grade 2 greater peripheral sensory neuropathy', 'Patients New York Heart Association NYHA class III IV heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias electrocardiographic evidence acute ischemia', 'Patients previously existing hypersensitivity brentuximab vedotin ipilimumab', 'Patients medical psychiatric illness likely interfere study participation', 'Patients participating clinical trial taking experimental medications 21 days prior registration', 'Routine vaccinations including seasonal influenza given 2 weeks prior study treatment vaccines prohibited study given 6 weeks cycle 1 7 days treatment', 'Patients registering Arms D E F G H I X Y currently smoking tobacco substances smoked past 6 months', 'RANDOMIZED PHASE II ARMS K AND L Patients pathologically confirmed relapsed refractory classical Hodgkin lymphoma cHL biopsy relapse acceptable histologies including lymphocyte predominant LP HL permitted', 'RANDOMIZED PHASE II ARMS K AND L Patients relapsed line chemotherapy relapsed autologous stem cell transplant primary refractory disease upper limit number prior therapies patient received prior allogeneic stem cell transplant', 'RANDOMIZED PHASE II ARMS K AND L Patients received prior brentuximab vedotin received brentuximab vedotin 6 months prior registration relapsed 6 months receiving previous brentuximab vedotin patients received prior nivolumab PD1PDL1 axis agents patients received prior ipilimumab', 'RANDOMIZED PHASE II ARMS K AND L Patients received prior activating immunotherapies checkpoint inhibitor therapies purposes study monoclonal antibodies antibody drug conjugates considered activating immunotherapies additional time restrictions prior exposure agents prior brentuximab vedotin', 'RANDOMIZED PHASE II ARMS K AND L ECOGACRIN performance status 02', 'RANDOMIZED PHASE II ARMS K AND L Patients measurable disease baseline measurements evaluations obtained 4 weeks registration study abnormal PET scans constitute evaluable disease verified diagnostic quality CT scan patients use imaging modality CT PETCT study', 'RANDOMIZED PHASE II ARMS K AND L Women pregnant breastfeeding risk fetal harm chemotherapeutic agents prescribed protocol females childbearing potential blood test urine study 24 hours prior enrollment rule pregnancy female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria 1 undergone hysterectomy bilateral oophorectomy 2 naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months', 'RANDOMIZED PHASE II ARMS K AND L Women childbearing potential WOCBP sexually active males abstain sexual intercourse duration participation study agree use double barrier contraception birth control pills implants week prior start study drug continuing 5 months dose study drug female patients 7 months dose study drug male patients sexually active WOCBP woman pregnant suspect pregnant partner participating study participating partner inform treating physician immediately', 'RANDOMIZED PHASE II ARMS K AND L Patients evidence dyspnea rest pulse oximetry > 92 breathing room air', 'RANDOMIZED PHASE II ARMS K AND L Patients FEV1FVC > 60 pulmonary function test PFT large mediastinal mass HL carbon monoxide diffusion capacity DLCO FEV1 FVC > 50 predicted value pulmonary function tests obtained month prior registration', 'RANDOMIZED PHASE II ARMS K AND L ANC >= 1500mcL 15 x 09L obtained 2 weeks prior registration', 'RANDOMIZED PHASE II ARMS K AND L Platelets >= 75000mcL 75 x 109L obtained 2 weeks prior registration', 'RANDOMIZED PHASE II ARMS K AND L ASTALT =< 25 x upper limit normal ULN obtained 2 weeks prior registration', 'RANDOMIZED PHASE II ARMS K AND L Bilirubin =< 2 x upper limit normal ULN documented Gilbert’s syndrome Bilirubin =< 3 x upper limit normal ULN permitted obtained 2 weeks prior registration', 'RANDOMIZED PHASE II ARMS K AND L Calculated creatinine clearance CockcroftGault formula >= 30 mlmin obtained 2 weeks prior registration', 'RANDOMIZED PHASE II ARMS K AND L No evidence prior malignancy adequately treated nonmelanoma skin cancer situ cervical carcinoma surgically radiationcured malignancy continuously disease free >= 5 years interfere interpretation radiographic response', 'RANDOMIZED PHASE II ARMS K AND L Patient current prior history CNS involvement', 'RANDOMIZED PHASE II ARMS K AND L All prior therapy completed 21 days prior enrollment 6 weeks nitrosoureas mitomycin C concomitant anti lymphoma therapy including systemic corticosteroids purpose treatment lymphoma allowed topical steroids allowed', 'RANDOMIZED PHASE II ARMS K AND L No history Steven’s Johnson’s syndrome TENs syndrome motor neuropathy', 'RANDOMIZED PHASE II ARMS K AND L HIV positive patients eligible provided meet protocol criteria including following Long term survival expected cHL HIV viral loads undetectable standard clinical HIV testing Willing adhere effective combination antiretroviral therapy', 'RANDOMIZED PHASE II ARMS K AND L Patients autoimmune disorders conditions immunosuppression require current ongoing treatment systemic corticosteroids systemic immunosuppressants including oral steroids prednisone dexamethasone continuous use topical steroid creams ointments ophthalmologic steroids history occasional continuous use steroid inhalers allowed replacement doses steroids patients adrenal insufficiency allowed patients discontinue use steroid medication 2 weeks prior initiation therapy eligible judgment treating physician investigator patient likely require resumption treatment classes drugs study exclusion study includes patients history symptomatic autoimmune disease rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus Sjogrens syndrome autoimmune vasculitis Wegener’s Granulomatosis motor neuropathy considered autoimmune origin GuillainBarre syndrome Myasthenia Gravis CNS autoimmune disease Multiple sclerosis patients autoimmune hypothyroid disease type I diabetes replacement treatment eligible', 'RANDOMIZED PHASE II ARMS K AND L Patients grade 2 greater peripheral sensory neuropathy', 'RANDOMIZED PHASE II ARMS K AND L Patients NYHA class III IV heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias electrocardiographic evidence acute ischemia', 'RANDOMIZED PHASE II ARMS K AND L Patients previously existing hypersensitivity brentuximab vedotin ipilimumab', 'RANDOMIZED PHASE II ARMS K AND L Patients medical psychiatric illness likely interfere study participation', 'RANDOMIZED PHASE II ARMS K AND L Patients participating clinical trial taking experimental medications 21 days prior registration', 'RANDOMIZED PHASE II ARMS K AND L Routine vaccinations including seasonal influenza given 2 weeks prior study treatment vaccines prohibited study given 6 weeks cycle 1 7 days treatment', 'RANDOMIZED PHASE II ARMS K AND L Patients currently smoking tobacco agents', 'RANDOMIZED PHASE II ARMS K AND L Patients history evidence cardiovascular risks including following QT interval corrected heart rate Bazett’s formula QTcB >= 480 msec baseline History acute coronary syndromes including myocardial infarction unstable angina coronary angioplasty stenting past 24 weeks prior registration History prior registration evidence current >= class II congestive heart failure defined New York Heart Association NYHA functional classification Left ventricular ejection fraction LVEF =< lower limit normal cardiac echocardiogram echo multigated acquisition scan MUGA Intracardiac defibrillator History abnormal cardiac valve morphology >= grade 2 documented ECHO subjects grade 1 abnormalities mild regurgitationstenosis entered study subjects moderate valvular thickening entered study History evidence current clinically significant uncontrolled cardiac arrhythmias clarification subjects atrial fibrillation controlled > 30 days prior dosing eligible Treatment refractory hypertension defined blood pressure systolic > 140 mmHg andor diastolic > 90 mm Hg controlled antihypertensive therapy'], ['Histologically confirmed diagnosis symptomatic multiple myeloma relapsed disease myeloma previously responded prior therapy MR better subsequently progressed', 'Patient measurable disease nonmeasurable disease defined following holding true Measurable disease Serum Mprotein >= 05 gdL andor Urine Mprotein >= 200 mg24 hours andor Involved serum free light chain level >= 10 mgdL AND abnormal serum free light chain ratio For nonmeasurable disease Baseline marrow burden myeloma 30', 'Progression lenalidomide line therapy lenalidomiderefractory disease Lenalidomiderefractory disease defined disease progression progression 60 days dose lenalidomidebased treatment patients received 2 cycles lenalidomidebased regimen evaluable refractoriness examples 1 progression lenalidomide maintenance therapy initial induction + consolidation 2 initial response followed progression continuous lenalidomidedexamethasone + elotuzumab daratumumab', 'Pomalidomide naive disease', 'Proteasome inhibitor naive sensitive disease proteasome inhibitor sensitive disease defined PR better prior proteasome inhibitorbased therapy maintained >= 60 days dose proteasome inhibitor A patient receives induction therapy lenalidomide bortezomib dexamethasone achieves PR better subsequently progresses continued lenalidomide lenalidomidedexamethasone eligible provided progression occurs 60 days discontinuation bortezomib similarly ixazomib exposure allowed provided meet definition proteasome inhibitor sensitive disease', '1 prior line systemic therapy multiple myeloma line therapy myeloma defined 1 planned cycles single agent combination therapy planned series treatment regimens administered sequential manner lenalidomide bortezomib dexamethasone induction therapy 4 cycles followed autologous stem cell transplantation lenalidomide maintenance therapy considered 1 line prior therapy new line therapy begins planned therapy modified include treatment agents combination result disease progression disease relapse treatmentrelated toxicity patient progressing face lenalidomide maintenance therapy bortezomib dexamethasone added regimen new line therapy begins planned treatmentfree interval interrupted need start treatment disease relapseprogression patient relapsed myeloma achieves partial response planned 8 cycles cyclophosphamide bortezomib dexamethasone enjoys 8month period therapy experiences disease progression requiring reinitiation therapy', 'Allogeneic stem cell transplantation allowed provided patient >= 1 year transplant time registration immunosuppressive therapy treatprevent graftversushost disease evidence active graft versus host disease evidence active infection', 'No chemotherapy radiation therapy 14 days prior registration', 'No investigational therapy 14 days prior registration', 'No major surgery 28 days prior registration', 'No GCSF filgrastim GMCSF sargramostim 7 days registration pegfilgrastim 14 days registration meet eligibility criteria', 'No platelet transfusions 7 days registration meet eligibility criteria Note red blood cell transfusions allowed time', 'A female childbearing potential sexually mature female 1 undergone hysterectomy bilateral oophorectomy 2 naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months Women childbearing potential Must negative serum urine pregnancy test sensitivity 25 mlUml 14 days prior registration agree repeat test 24 hours starting pomalidomide Must commit complete abstinence heterosexual contact begin TWO acceptable methods birth control highly effective method additional effective barrier method AT THE SAME TIME starting pomalidomide Must agree ongoing pregnancy testing Must agree pregnant breast feed child treatment protocol Men practice complete abstinence agree use condom sexual contact female childbearing potential successful vasectomy Note All participants counseled minimum 28 days pregnancy precautions risks fetal exposure', 'Eastern Cooperative Oncology Group ECOG performance status 02', 'Absolute neutrophil count ANC >= 10 x 109L', 'Platelet count >= 50 x 109L', 'Calculated Calc creatinine clearance >= 30 mLmin calculated utilizing CockcroftGault formula 24hour urine collection', 'Total bilirubin < 15 x upper limits normal ULN', 'Aspartate aminotransferase AST alanine aminotransferase ALT < 25 x upper limits normal ULN', 'Note GCSF platelet transfusions increase counts meet eligibility criteria', 'Patients following Central nerve involvement Primary refractory multiple myeloma primary refractory multiple myeloma defined disease nonresponsive – patients achieved minimal response MR better – therapy course disease includes patients achieve MR better significant change Mprotein evidence clinical progression patients meet criteria true progressive disease PD Primary secondary plasma cell leukemia Lightchain AL amyloidosis polyneuropathy organomegaly endocrinopathy monoclonal gammopathy skin changes POEMS syndrome Known active hepatitis C based +hepatitis C virus HCV antibody confirmed +HCV RNA Liver disease history positive serology Note patients prior history hepatitis C successfully eradicated antiviral therapy eligible Known hepatitis B surface antigen positivity Previous hypersensitivity components study treatment Prior history erythema multiforme thalidomide lenalidomide treatment', '=< grade 2 peripheral neuropathy', 'Adequate cardiac function defined No electrocardiogram EKG evidence acute ischemia No EKG evidence active clinically significant conduction abnormalities No EKG evidence > grade 2 > 480 ms corrected QT QTc prolongation Prior study entry EKG abnormality screening felt patient risk documented investigator medically significant No uncontrolled angina severe ventricular arrhythmias No clinically significant pericardial disease No history myocardial infarction 6 months prior registration No class 3 higher New York Heart Association congestive heart failure', 'No strong inducers cytochrome P450 CYP 3A4 CYP1A2 strong inhibitors CYP3A4 CYP1A2 14 days prior registration Note Ixazomib substrate CYP3A4 CYP1A2', 'Patients human immunodeficiency virus HIV infection eligible provided meet following No history acquired immunodeficiency syndrome AIDSdefining conditions HIV related illness Cluster differentiation CD4+ cells nadirs > 350mm3 28 days prior registration Treatment sensitive HIV antiHIV therapy HIV viral load < 50 copiesmm3 28 days prior registration Note HIV+ patients enroll study assigned treatment ixazomib need modify antiretroviral therapy prior receiving protocol therapy strong inducers potent inhibitors cytochrome P450 3A4', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Patients randomized Arm 1 opt switch 3drug regimen following disease progression patients reregistered study meet eligibility criteria', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Patient measurable disease nonmeasurable disease progression pomalidomide + dexamethasone defined following holding true Measurable disease Serum Mprotein >= 05 gdL andor Urine Mprotein >= 200 mg24 hours andor Involved serum free light chain level >= 10 mgdL AND abnormal serum free light chain ratio For nonmeasurable disease Marrow burden myeloma 30', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Women childbearing potential Must negative serum urine pregnancy test 72 hours prior reregistration Must commit complete abstinence heterosexual contact begin TWO acceptable methods birth control highly effective method additional effective barrier method AT THE SAME TIME starting pomalidomide Must agree ongoing pregnancy testing Must agree pregnant breast feed child treatment protocol Men practice complete abstinence agree use condom sexual contact female childbearing potential successful vasectomy Note All participants counseled minimum 28 days pregnancy precautions risks fetal exposure', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 ECOG performance status 02', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Absolute neutrophil count ANC >= 10 x 109L', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Platelet count >= 50 x 109L', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Calc creatinine clearance >= 30 mLmin Calculated utilizing CockcroftGault formula 24hour urine collection', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Total bilirubin < 15 x upper limits normal ULN', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 AST ALT < 25 x upper limits normal ULN', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 Note GCSF platelet transfusions increase counts meet eligibility criteria', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 =< grade 2 peripheral neuropathy', 'REREGISTRATION ELIGIBILITY CRITERIA STEP 2 No strong inducers cytochrome P450 CYP 3A4 CYP1A2 strong inhibitors CYP3A4 CYP1A2 Note Ixazomib substrate CYP3A4 CYP1A2'], ['PREREGISTRATION', 'Diagnostic bone marrow peripheral blood specimens submitted immunophenotyping selected molecular testing establishment BCRABL status testing performed Eastern Cooperative Oncology Group ECOGAmerican College Radiation Imaging Network ACRIN Leukemia Translational Research Laboratory LTRL reported institution NOTE IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE SUBMITTED TO THE ECOGACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW ASSESSMENTS OF MRD CAN BE DONE IN ADDITION TO ALLOWING THE LTRL TO CONFIRM ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCRABL STATUS IT IS ALSO IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS MULLIGHANWILLMAN WITHOUT ADEQUATE BASELINE SAMPLES PATIENTS WILL NOT BE ABLE TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL IF A BONE MARROW ASPIRATE IS NOT AVAILABLE FOR LTRL SUBMISSION AT BASELINE IT IS IMPERATIVE THAT DR PAIETTA FROM THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WBC AND BLAST COUNT BEFORE BLOOD ONLY IS SUBMITTED NOTE Hydroxyurea given 5 days prior initiation protocol therapy control leukocyte count andor symptoms signs corticosteroids given preregistration protocol submission baseline marrow blood samples control leukocyte count andor symptoms signs prior initiation protocol therapy needed corticosteroids given prior preregistration contact study chair patient eligible participate', 'INDUCTION ELIGIBILITY CRITERIASTEP 1', 'New diagnosis B lineage ALL bone marrow peripheral blood immunophenotyping cases myeloid antigen expression unequivocal lymphoid immunophenotype eligible', 'Negativity Philadelphia chromosome established conventional cytogenetics fluorescence situ hybridization FISH andor polymerase chain reaction PCR patients negative Philadelphia chromosome conventional cytogenetics FISH PCR performed BCRABL exclude occult translocations', 'Cytogenetic analysis performed diagnostic bone marrow preferred adequate number circulating blasts peripheral blood FISH testing common Blineage ALL abnormalities including t922 BCRABL1 t1221 ETSvariant gene 6 ETV6runtrelated transcription factor 1 RUNX1 t119 preBcell leukemia homeobox 1 PBX1transcription factor 3 TCF3 +4+10+17 centromeric Cen4Cen10Cen17 t11q23var myeloidlymphoid mixed lineage leukemia MLL deletion del9p cyclindependent kinase inhibitor 2A CDKN2ACen9 t14var immunoglobulin heavy chain IGH encouraged circulating blasts adequate marrow sample obtained cytogenetic analysis patient enroll trial', 'Serum direct bilirubin < 2 mgdl serum total bilirubin =< 3 obtained =< 48 hours prior registration NOTE stipulation normal hepatic function apply liver dysfunction leukemia infiltration', 'Serum creatinine < 2 mgdl obtained =< 48 hours prior registration NOTE stipulation normal hepatic function apply liver dysfunction leukemia infiltration', 'Patient human leukocyte antigen HLA typed A B C DR DQ induction therapy phase written explanation undergoing HLA typing flow sheet', 'Patients known human immunodeficiency virus HIV infection eligible meet following criteria No history acquired immune deficiency syndrome AIDSrelated complications history low CD4+ Tcell count < 200mm3 prior initiation combination antiretroviral therapy study CD4+ Tcell count informative leukemia exclusion criterion low Patient healthy basis HIV disease high likelihood near normal life span leukemia Patient serum HIV viral load < 200 copiesmm3 Patient combination antiretroviral therapy minimal pharmacokinetic interactions study therapy minimal overlapping clinical toxicity protocol therapy Patient receiving protease inhibitors daily formulations containing cobicistat stavudine regimens containing stavudine zidovudine It recommended utilize regimen integrase inhibitor dolutegravir combined disoproxil fumarateemtricitabine dolutegravir combined tenofovir alafenamideemtricitabine', 'Patient antecedent hematologic disorder', 'Patient history recent myocardial infarction months uncontrolled congestive heart failure uncontrolled cardiac arrhythmia', 'Patient history presence clinically relevant central nervous CNS pathology epilepsy seizure paresis aphasia stroke severe brain injuries dementia Parkinson’s disease cerebellar disease organic brain syndrome psychosis significant CNS abnormalities', 'Patient normal cardiac ejection fraction pretreatment multigated acquisition scan MUGA echocardiogram 4 weeks prior registration resting ejection fraction >= 40 >= 5 increase exercise shortening fraction echocardiogram >= 24 normal range values institution', 'Patient active uncontrolled infection', 'Women pregnant breastfeeding pregnant breastfeed protocol therapy 3 months protocol therapy woman childbearing potential abstain sexual activity willing use 2 highly effective forms contraception protocol therapy additional 3 months dose protocolspecified therapy females childbearing potential blood test urine study 2 weeks prior registration rule pregnancy female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria undergone hysterectomy bilateral oophorectomy naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months', 'Men female partner childbearing potential willing use 2 highly effective forms contraception protocol therapy additional 3 months dose protocolspecified therapy men pregnant partner willing use condom sexual activity protocol therapy 3 months dose protocolspecified therapy', 'ECOG performance score 03', 'Patient given written informed consent', 'POSTINDUCTION THERAPY ELIGIBILITY CRITERIA PRIOR TO INTENSIFICATIONSTEP 2', 'ECOG performance status 02', 'Patients achieved CR CRi', 'Patients achieved CR CRi maintained peripheral blood evidence CR CRi', 'Patient CNS cerebrospinal fluid CSF negative leukemia', 'Patients resolved infectious complications related induction', 'Any significant medical complications related induction resolved', 'Serum creatinine =< 20 mgdl obtained =< 48 hours prior registration', 'Serum direct bilirubin < 2 mgdL serum total bilirubin =< 3 obtained =< 48 hours prior registration', 'Aspartate aminotransferase AST alanine aminotransferase ALT < 3 x upper limit normal ULN obtained =< 48 hours prior registration', 'RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMABSTEP 3', 'Patients ECOG performance status 02', 'Patients maintained peripheral blood evidence remission CR CRi confirmed restaging bone marrow BM aspirate biopsy', 'Patients resolved infectious complications related therapy', 'Any significant medical complications related therapy resolved', 'Direct total bilirubin < 15 x ULN related Gilbert’s Meulengracht’s syndrome values obtained 48 hours prior randomization', 'Serum creatinine < 15 x ULN values obtained 48 hours prior randomization', 'Bone marrow aspirates submitted centralized minimal residual disease MRD assessment performed ECOGACRIN Leukemia Translational Research Laboratory', 'MRD results reported submitting institution NOTE FOR MRD ASSESSMENTS AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION SITE MUST BE SUBMITTED THE NEEDLE CAN BE REDIRECTED THROUGH THE SAME SKIN PUNCTURE SITE ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE FOR MRD TESTING DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME ASPIRATION SITE In Blineage ALL MRD levels peripheral blood dilute marrow aspiration 300 lower average bone marrow given time point submitting pull separate aspiration site ensure MRD determinations randomization trial interpretation accurate NOTE failure submit bone marrow aspirates result major violation time audit', 'CRITERIA FOR ALLOGENEIC TRANSPLANTATION', 'A suitable donor identified restrictions donor type include matched sibling matched mismatched unrelated donor family haplotype matched donor cord blood donor single double', 'Patients meet eligibility criteria RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMABSTEP 3', 'Patients considered reliable comply medication regimen followup social support necessary allow compliance', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients ECOG performance status 03', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients maintained peripheral blood evidence remission CR CRi confirmed restaging BM aspirate biopsy', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Patients resolved infectious complications related therapy', 'CRITERIA FOR MAINTENANCE THERAPYSTEP 4 Any significant medical complications related therapy resolved', 'Mature B ALL Burkitt’slike leukemia excluded enrollment trial prestudy bone marrow biopsy aspirate completed =< 1 week prior registration', 'Patient concurrent active malignancy receiving treatment', 'Patient intercurrent organ damage medical problems jeopardize outcome therapy psychiatric disorder drug abuse pregnancy'], ['Newly diagnosed patients histologically proven ALCL International Classification Diseases Oncology ICD0 code 97143', 'Disease cluster differentiation CD30 positive', 'Disease anaplastic lymphoma kinase ALK positive defined local institutional standards', 'Patients stage II III IV disease', 'Patients life expectancy >= 8 weeks', 'Total bilirubin =< 15 x upper limit normal ULN age 7 days prior enrollment', 'Alanine aminotransferase ALT serum glutamate pyruvate transaminase SGPT < 25 x upper limit normal ULN age purpose study ULN ALT 45 UL 7 days prior enrollment', 'If lab abnormality thought lymphoma patient eligible dose adjustments', 'Shortening fraction >= 27 echocardiogram', 'Ejection fraction >= 50 radionuclide angiogram', 'Patients history pulmonary dysfunction evidence dyspnea rest exercise intolerance pulmonary insufficiency pulse oximetry > 92 breathing room air current dysfunction lymphoma case patient eligible', 'Patients central nervous CNS disease eligible', 'Patients disease limited skin eligible regardless widespread', 'Patients stage I disease eligible', 'Patients received prior cytotoxic chemotherapy current diagnosis ALCL cancer diagnosed previously eligible', 'Previous steroid treatment andor radiation treatment allowed emergent management mediastinal mass emergent steroid treatment andor radiation treatment stop protocol therapy initiated', 'Intrathecal chemotherapy prior enrollment allowed current diagnosis ALCL long adequate cerebrospinal fluid CSF obtained prior administration intrathecal chemotherapy subsequently demonstrated negative ALCL', 'Female patients pregnant eligible pregnancy tests obtained girls post menarchal', 'Lactating females eligible agreed breastfeed infants', 'Sexually active patients reproductive potential eligible agree use effective contraceptive method duration treatment 3 months stopping treatment', 'Patients Down syndrome eligible methotrexate potential effects', 'Patients immunodeficiency existed prior diagnosis primary immunodeficiency syndromes organ transplant recipients eligible', 'Cytochrome P450 family 3 subfamily A polypeptide 4 CYP3A4 substrates narrow therapeutic indices Patients chronically receiving medications known metabolized CYP3A4 narrow therapeutic indices including pimozide aripiprazole triazolam ergotamine halofantrine eligible topical use medications applicable allowed', 'CYP3A4 inhibitors patients chronically receiving drugs known potent CYP3A4 inhibitors 7 days prior study enrollment including limited ketoconazole itraconazole clarithromycin erythromycin ritonavir indinavir nelfinavir saquinavir delavirdine nefazodone diltiazem verapamil grapefruit juice eligible topical use medications applicable 2 ketoconazole cream allowed', 'CYP3A4 inducers patients chronically receiving drugs known potent CYP3A4 inducers 12 days prior study enrollment including limited carbamazepine phenobarbital phenytoin rifabutin rifampin ritonavir St John’s wort eligible topical use medications applicable allowed', 'Patients known positive human immunodeficiency virus HIV eligible note inclusion HIV positive patients considered later date', 'Patients weigh < 10 eligible'], ['INCLUSION CRITERIA FOR PHYSICIANS', 'Oncology physicians work National Cancer Institute NCI Community Oncology Research Program NCORP practice site plans leave NCORP practice site retire time enrollment study', 'INCLUSION CRITERIA FOR PATIENTS', 'Diagnosis advanced solid tumor malignancy advanced cancer lymphoma situations stage IV cancer patients diagnosis stage III cancer lymphoma eligible cure possible anticipated clinical staging pathological confirmation advanced disease allowed', 'Plan start new cancer treatment regimen 4 weeks time baseline registration treatment regimen discretion treating oncology physician regimen include chemotherapy drug agents similar prevalence toxicity patients receive monoclonal antibody therapy cancer therapies tyrosine kinase inhibitors eligible agents present prevalence toxicity similar chemotherapy therapies combination chemotherapy single agent combination Chemotherapy defined cytotoxic drugs addition agents monoclonal antibodies targeted agents prevalence grade 35 toxicity older patients similar chemotherapy > 50 allowed list allowable agents single combination meeting toxicity criteria available University Rochester Cancer Center URCC NCORP Research Base website study materials given rapidly changing landscape new drugs cancer study team led principal investigator PI update list accordingly reviewing toxicity profile new therapies potentially eligible participant receive approved drug regimen list contacting URCC NCORP Research Base study team required approval prior participant enrollment Patients receiving approved cancer treatment combination radiation eligible A patient enrolled treatment trial participate study inclusion exclusion criteria met', 'Plan chemotherapy allowable treatment 3 months minimum 70 days willing come study visits The plan treatment 3 months time study enrollment treatment stop earlier study discretion physician patient progression noted imaging toxicity patient preference', 'Have geriatric assessment domain meet cutoff score impairment polypharmacy', 'Able provide informed consent oncology physician determines patient decisionmaking capacity patientdesignated health care proxy authorized representative institutional policies sign consent baseline visit participant impaired BlessedOrientation Memory Concentration Test BOMC screening health care proxy authorized representative eligible enroll', 'Participant adequate understanding English language', 'EXCLUSION CRITERIA FOR PATIENTS', 'Have surgery planned 3 months consent patients previously received surgery eligible', 'Presence symptomatic brain metastases time study consent process patients history treated brain metastases eligible symptomatic time study enrollment'], ['Patients measurable stage III measurable stage IVA stage IVB measurable disease recurrent measurable disease endometrial carcinoma Histologic confirmation original primary tumor required patients following histologic epithelial cell types eligible Endometrioid adenocarcinoma serous adenocarcinoma undifferentiated carcinoma clear cell adenocarcinoma mixed epithelial carcinoma adenocarcinoma specified NOS', 'Measurable disease defined Response Evaluation Criteria Solid Tumors RECIST version 11 measurable disease defined lesion accurately measured dimension longest diameter recorded lesion >= 10 mm measured computed tomography CT magnetic resonance imaging MRI caliper measurement clinical exam >= 20 mm measured chest xray lymph nodes >= 15 mm short axis measured CT MRI', 'Patients Gynecologic Oncology Group GOG performance status 0 1 2', 'Absolute neutrophil count ANC greater equal 1500mcl', 'Platelets greater equal 100000mcl', 'Creatinine 14 mgdl', 'Bilirubin equal 15 x institutionallaboratory upper limit normal ULN', 'Aspartate aminotransferase AST alanine aminotransferase ALT equal 3 x ULN', 'Alkaline phosphatase equal 25 x ULN', 'Patients NOT received prior chemotherapy targeted therapy including chemotherapy radiation sensitization treatment endometrial carcinoma', 'Patients received prior radiation therapy treatment endometrial carcinoma prior radiation therapy included pelvic radiation therapy extended field pelvicparaaortic radiation therapy andor intravaginal brachytherapy radiation therapy completed 4 weeks prior date study therapy', 'Patients received prior hormonal therapy treatment endometrial carcinoma hormonal therapy discontinued week prior date study therapy', 'Patients able swallow retain orallyadministered medication', 'Patients signed approved informed consent authorization permitting release personal health information individuals impaired decisionmaking capacity eligible participate study', 'Patients NOT taking metformin metformin past 6 months', 'Patients history invasive malignancies exception nonmelanoma skin cancer excluded evidence malignancy present years', 'Uncontrolled intercurrent illness including limited ongoing active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia psychiatric illnesssocial situations limit compliance study requirements', 'Patients pregnant nursing patients reproductive age undergone hysterectomy use effective contraceptive method duration study', 'Any condition associated increased risk metforminassociated lactic acidosis congestive heart failure defined New York Heart Association NYHA class III IV functional status history acidosis type habitual intake 3 alcoholic beverages day'], ['Histologic documentation newly diagnosed World Health Organization WHO grade IV intracranial glioblastoma gliosarcoma GBM oligodendroglial features NOT PERMITTED study 1p19q codeleted sites submitting GBM oligodendroglial features asked provide results 1p19q codeletion status', 'Sufficient tissue available central pathology review MGMT methylation status evaluation', 'Patients local MGMT testing unmethylated allowed participate', 'Tumor MGMT promoter hypermethylation determined central testing MD Anderson', 'Confirmation central pathology review WHO grade IV glioblastoma gliosarcoma', 'Absolute neutrophil count ANC >= 1500 cellsmm3 14 days prior study registration', 'Platelets >= 100000 cellsmm3 14 days prior study registration', 'Creatinine =< 15 x upper limit normal ULN 14 days prior study registration', 'Bilirubin =< 15 x ULN 14 days prior study registration patient Gilbert’s disease', 'Alanine aminotransferase ALT =< 3 x ULN 14 days prior study registration', 'Aspartate aminotransferase AST =< 3 x ULN 14 days prior study registration', 'Eastern Cooperative Oncology Group ECOG performance status =< 2', 'Measurable disease nonmeasurable disease extent resection patients complete resection partial resection biopsy eligible', 'Progression patients deemed progressive disease based clinical deterioration chemoradiation radiographic progression outside radiation field eligible patients deemed pseudoprogression eligible', 'Prior treatment Must completed standard radiotherapy concomitant TMZ therapy defined determined study oncologist Besides concomitant TMZ radiation therapy neoadjuvant adjuvant given prior study registration including chemotherapy including Gliadelcarmustine BCNU wafers biologics immunotherapy radiation therapy exception Optune device NovoTTF100A started time end radiation therapy initiation Cycle 1 intent use Optune declared registration stratification No prior allogeneic bone marrow transplant double umbilical cord blood transplantation', 'Not pregnant nursing females childbearing potential negative urine serum pregnancy test 7 days registration start treatment female childbearing potential sexually mature female Has undergone hysterectomy bilateral oophorectomy Has naturally postmenopausal 12 consecutive months menses time preceding 12 consecutive months', 'Concomitant medications patients receiving anticoagulation stable dose 2 weeks prior registration', 'Comorbid conditions patients unable participate following Generalized partial seizure disorder uncontrolled time registration definition controlled generalized seizures patients stable dose antiseizure medication generalized seizures 10 days prior registration definition controlled partial seizures patients stable dose antiseizure medication 10 days prior registration patients occasional breakthrough partial seizures allowed treating physician’s discretion Grade 3 4 thromboembolic disease 6 months mo registration Known history prolonged QT syndrome', 'No history major surgery =< 14 days prior registration', 'Patients adequate organ marrow function measured 28 days prior administration ABT888 defined >= 100 gdL hemoglobin Hb blood transfusion past 28 days', 'No Patients treatmentrelated acute myeloid leukemia AML tAMLmyelodysplastic syndrome MDS features suggestive AMLMDS'], ['SCREENINGPRESCREENING REGISTRATION', 'Patients pathologically proven squamous cell carcinoma SCCA cancer lung confirmed tumor biopsy andor fineneedle aspiration disease stage IV SCCA recurrent primary diagnosis SCCA established current World Health Organization WHOInternational Association Study Lung Cancer IASLCclassification Thoracic Malignancies diagnosis based hematoxylin eosin HE stained slides specific defined immunohistochemistry IHC characteristic p40p63 positive transcription termination factor TTF1 negative required diagnosis mixed histologies allowed', 'Patients eligible screened progression prior treatment prescreened prior progression current treatment patients consent screening consent prescreening consent criteria Screening progression prior treatment eligible screening progression patients received line systemic therapy stage disease stages IIV progressed following recent line therapy patients prior systemic therapy stage IIII disease patient received treatment stage IV recurrent disease prior systemic therapy platinumbased chemotherapy regimen disease progression platinumbased chemotherapy occurred year date patient received therapy patients prior therapy stage IV recurrent disease patient received line platinumbased chemotherapy regimen checkpoint inhibitor therapy nivolumab pembrolizumab Prescreening prior progression current treatment eligible prescreening current treatment stage IV recurrent disease patient received dose current regimen patients previously received currently receiving platinumbased chemotherapy regimen checkpoint inhibitor therapy nivolumab pembrolizumab patients firstline platinumbased treatment eligible receiving cycle 1 day 1 infusion Note patients receive substudy assignment progress S1400 Notice Progression submitted', 'Patients adequate tumor tissue available defined >= 20 tumor cells >= 02 mm3 tumor volume The local interpreting pathologist review specimen The pathologist sign S1400 Local Pathology Review Form confirming tissue adequacy prior screeningprescreening registration Patients agree tissue submitted Foundation Medicine common broad platform Clinical Laboratory Improvement Act CLIA biomarker profiling cMET IHC archival tumor material exhausted new fresh tumor biopsy formalinfixed paraffinembedded FFPE obtained tumor block FFPE slides 45 microns submitted bone biopsies allowed FFPE slides submitted 12 unstained slides plus HE stained slide 13 unstained slides submitted strongly recommended 20 FFPE slides submitted Note previous nextgeneration deoxyribonucleic acid DNA sequencing NGS repeated outside study substudy assignment patients agree tissue remains NGS testing retained use translational medicine TM studies TM studies defined substudy patient enrolled', 'Patients known epidermal growth factor receptor EGFR mutation anaplastic lymphoma kinase ALK fusion EGFRALK testing required prior registration included Foundation Medicine Incorporated FMI testing screeningprescreening', 'Patients Zubrod performance status 01 documented 28 days prior screeningprescreening registration', 'Patients offered participation banking future use specimens', 'Patients willing provide prior smoking history required S1400 Onstudy Form', 'As Oncology Patient Enrollment Network OPEN registration process treating institutions identity provided order ensure current 365 days date institutional review board approval study entered', 'Patients informed investigational nature study sign written informed consent accordance institutional federal guidelines', 'United States US patients complete survey interview telephone email English offered participation S1400GEN survey ancillary study NOTE Patients enrolled S1400 prior revision 12 eligible S1400GEN survey ancillary study study physicians provide participants hard copy survey time informed consent improve tracking comprehension interview', 'SUBSTUDY REGISTRATION', 'Patients biomarker profiling results indicate presence EGFR mutation echinoderm microtubuleassociated proteinlike 4 EML4ALK fusion eligible', 'Patients progressed opinion treating investigator following recent line therapy', 'Patients received prior systemic therapy systemic chemotherapy immunotherapy investigational drug 21 days prior substudy registration patients recovered =< grade 1 effects prior therapy patients received radiation therapy 14 days prior substudy registration', 'Patients measurable disease documented computed tomography CT magnetic resonance imaging MRI CT combined positron emission tomography PETCT document nonmeasurable disease diagnostic quality measurable disease assessed 28 days prior substudy registration pleural effusions ascites laboratory parameters acceptable evidence disease nonmeasurable disease assessed 42 days prior substudy registration disease assessed documented Baseline Tumor Assessment Form patients measurable disease previous radiation therapy port demonstrate clearly progressive disease opinion treating investigator prior registration', 'Patients CT MRI scan brain evaluate central nervous CNS disease 42 days prior substudy registration patient leptomeningeal disease spinal cord compression brain metastases 1 metastases locally treated remained clinically controlled asymptomatic 14 days following treatment prior registration AND 2 patient residual neurological dysfunction corticosteroids 24 hours prior substudy registration', 'Patient fully recovered effects prior surgery 14 days prior substudy registration', 'Patients planning receive concurrent chemotherapy immunotherapy biologic hormonal therapy cancer treatment concurrent use hormones noncancerrelated conditions insulin diabetes hormone replacement therapy acceptable', 'Absolute neutrophil count ANC >= 1500mcl obtained 28 days prior substudy registration', 'Platelet count >= 100000 mcl obtained 28 days prior substudy registration', 'Hemoglobin >= 9 gdL obtained 28 days prior substudy registration', 'Serum bilirubin =< institutional upper limit normal IULN 28 days prior substudy registration patients liver metastases bilirubin =< 5 x IULN', 'Either alanine aminotransferase ALT aspartate aminotransferase AST =< 2 x IULN 28 days prior substudy registration ALT AST =< 2 IULN patients liver metastases ALT AST =< 5 x IULN ALT AST =< 5 x IULN', 'Serum creatinine =< IULN OR measured calculated creatinine clearance >= 50 mLmin following CockcroftGault Formula 28 days prior substudy registration', 'Patients Zubrod performance status 01 documented 28 days prior substudy registration', 'Patients grade IIIIV cardiac disease defined New York Heart Association Criteria patients cardiac disease resulting marked limitation physical activity resulting inability carry physical activity discomfort unstable angina pectoris myocardial infarction 6 months uncontrolled cardiac arrhythmia', 'Patients documented evidence acute hepatitis active uncontrolled infection', 'Patients known history human immunodeficiency virus HIV seropositivity Must undetectable viral load standard HIV assays clinical practice Must cluster differentiation CD4 count >= 400mcL Must require prophylaxis opportunistic infections fungal Mycobacterium avium complex mAC pneumocystis jiroveci pneumonia PCP prophylaxis Must newly diagnosed 12 months prior substudy registration', 'Prestudy history physical exam obtained 28 days prior substudy registration', 'No prior malignancy allowed following adequately treated basal cell squamous cell skin cancer situ cervical cancer adequately treated stage I II cancer patient currently complete remission cancer patient disease free years', 'Patients pregnant nursing womenmen reproductive potential agreed use effective contraceptive method woman considered reproductive potential menses time preceding 12 consecutive months addition routine contraceptive methods effective contraception includes heterosexual celibacy surgery intended prevent pregnancy sideeffect pregnancy prevention defined hysterectomy bilateral oophorectomy bilateral tubal ligation point previously celibate patient chooses heterosexually active time period use contraceptive measures outlined protocol heshe responsible beginning contraceptive measures', 'As OPEN registration process treating institution’s identity provided order ensure current 365 days date institutional review board approval study entered', 'Patients impaired decisionmaking capacity eligible long neurological psychological condition preclude safe participation study tracking pill consumption reporting adverse events investigator', 'Patients informed investigational nature study sign written informed consent accordance institutional federal guidelines'], ['First relapse BALL allowable sites disease include isolated bone marrow combined bone marrow CNS andor testicular isolated CNS andor testicular extramedullary sites limited CNS testicles', 'No waiting period patients relapse receiving standard maintenance therapy', 'Patients relapse frontline therapy phases maintenance fully recovered acute toxic effects prior chemotherapy immunotherapy radiotherapy prior entering study', 'Cytotoxic therapy 14 days completion cytotoxic therapy exception hydroxyurea permitted 24 hours prior start protocol therapy maintenance chemotherapy intrathecal chemotherapy methotrexate strongly preferred administered time required diagnostic lumbar puncture establish baseline CNS status', 'Biologic antineoplastic agent 7 days completion therapy biologic agent agents known adverse events occurring 7 days administration period extended time adverse events known occur', 'Stem cell transplant rescue patient prior stem cell transplant rescue', 'Patient prior treatment blinatumomab', 'With exception intrathecal chemotherapy methotrexate strongly preferred cytarabine permissible administered time required diagnostic lumbar puncture establish baseline CNS status patient received prior relapsedirected therapy protocol intended INITIAL treatment relapse', 'Patients performance status corresponding Eastern Cooperative Oncology Group ECOG scores 0 1 2 use Karnofsky patients > 16 years age Lansky patients =< 16 years age', 'Creatinine clearance radioisotope glomerular filtration rate GFR >= 70 mLmin173 m2 serum creatinine based agegender follows 1 < 2 years =< 06 mgdL 2 < 6 years =< 08 mgdL 6 < 10 years =< 1 mgdL 10 < 13 years =< 12 mgdL 13 < 16 years =< 15 mgdL males =< 14 mgdL females >= 16 years =< 17 mgdL males =< 14 mgdL females', 'Direct bilirubin < 30 mgdL', 'Shortening fraction >= 27 echocardiogram', 'Ejection fraction >= 50 radionuclide angiogram', 'All patients andor parent legal guardian sign written informed consent', 'All institutional Food Drug Administration FDA National Cancer Institute NCI requirements human studies met', 'Patients Philadelphia chromosome positivebreakpoint cluster region protein BCRAbelson murine leukemia viral oncogene homolog 1 ABL1+ ALL eligible', 'Patients Burkitt leukemialymphoma mature Bcell leukemia eligible', 'Patients Tlymphoblastic leukemia TALLlymphoblastic lymphoma TLL eligible', 'Patients Blymphoblastic lymphoma BLL eligible', 'Patients known optic nerve andor retinal involvement eligible patients presenting visual disturbances ophthalmologic exam indicated magnetic resonance imaging MRI determine optic nerve retinal involvement', 'Patients known following concomitant genetic syndromes Down syndrome Bloom syndrome ataxiatelangiectasia Fanconi anemia Kostmann syndrome Shwachman syndrome known bone marrow failure syndrome', 'Patients known human immunodeficiency virus HIV infection', 'Patients known allergy mitoxantrone cytarabine etoposide etoposide phosphate Etopophos', 'Lactating females plan breastfeed', 'Patients pregnant fetal toxicities teratogenic effects noted study drugs pregnancy test required female patients childbearing potential', 'Sexually active patients reproductive potential agreed use effective contraceptive method duration study participation', 'Patients preexisting significant central nervous pathology preclude treatment blinatumomab including history severe brain injury dementia cerebellar disease organic brain syndrome psychosis coordinationmovement disorder autoimmune disease CNS involvement eligible patients history cerebrovascular ischemiahemorrhage residual deficits eligible patients history cerebrovascular ischemiahemorrhage remain eligible provided neurologic deficits resolved', 'Patients uncontrolled seizure disorder eligible patients seizure disorders require antiepileptic drugs controlled stable doses antiepileptic drugs remain eligible'], ['Biopsy proven primary lesion andor lymph nodes diagnosis cancer nasopharynx', 'Sites required complete Step 1 registration submitting specimens EBV DNA analysis Patients detectable pretreatment plasma EBV DNA determined central lab prior Step 2 registration For patients detectable plasma EBV DNA tested credentialed central labs 28 days prior Step 1 registration test result eligibility need retesting use test result eligibility central lab enter test result pathology portal', 'Stage IIIVB disease American Joint Committee Cancer AJCC 7th edition ed evidence distant metastasis based following minimum diagnostic workup Historyphysical examination Medical Oncologist Clinical Oncologist Radiation Oncologist Ear Nose Throat specialist ENT include endoscopic evaluation complete list current medications assessment weight weight loss past 6 months 21 days prior registration Evaluation tumor extent required 28 days prior registration Magnetic resonance imaging MRI nasopharynx neck computed tomography CT nasopharynx neck =< 3 mm contiguous slices contrast bone windows evaluate base skull involvement Note If treatment planning CT scan =< 3 mm contiguous slices contrast read radiologist To rule distant metastasis patients undergo following imaging 28 days prior registration A CT scan contrast chest abdomen required pelvis optional total body PETCT scan noncontrast PETCT acceptable A bone scan suspicion bone metastases PETCT scan substitute bone scan', 'Zubrod performance status 01 21 days prior registration', 'Absolute neutrophil count ANC >= 1500 cellsmm3 21 days prior registration', 'Platelets >= 100000 cellsmm3 21 days prior registration', 'Hemoglobin >= 80 gdl 21 days prior registration Note use transfusion intervention achieve hemoglobin Hgb >= 80 gdl acceptable', 'Total bilirubin =< 15 x institutional upper limit normal ULN 21 days prior registration', 'Aspartate aminotransferase AST alanine aminotransferase ALT =< 15 x institutional ULN 21 days prior registration', 'Alkaline phosphatase =< 15 x institutional ULN 21 days prior registration', 'Serum creatinine =< 15 mgdl calculated creatinine clearance CC >= 50 mlmin determined 24hour urine collection estimated CockcroftGault formula 21 days prior registration', 'Negative serum pregnancy test 14 days prior registration women childbearing potential', 'Women childbearing potential male participants sexually active agree use medically effective means birth control protocol treatment', 'Patient provide study specific informed consent prior study entry including mandatory pretreatment plasma EBV DNA assay', 'Prior invasive malignancy node negative nonmelanomatous skin cancer disease free minimum 1095 days 3 years example carcinoma situ breast oral cavity cervix permissible', 'Prior systemic chemotherapy study cancer note prior chemotherapy different cancer allowable 6weeks recovery necessary regimen included nitrosourea mitomycin', 'Prior radiotherapy region study cancer result overlap radiation therapy fields', 'Patients hearing loss assessed primarily sensorineural nature requiring hearing aid intervention interfering clinically significant way activities daily living conductive hearing loss tumorrelated allowed', '>= Grade 2 peripheral sensory neuropathy CTCAE v 40', 'Severe active comorbidity defined follows Major medical psychiatric illness investigator’s opinion interfere completion therapy follow understanding risks potential complications therapy Unstable angina andor uncontrolled congestive heart failure past 6 months Myocardial infarction 6 months Acute bacterial fungal infection requiring intravenous antibiotics time registration note patients switched IV antibiotics currently oral antibiotics infection assessed adequately treated controlled eligible Chronic obstructive pulmonary disease exacerbation respiratory illness requiring hospitalization precluding study therapy 30 days prior registration Acquired immune deficiency syndrome AIDS based current Centers Disease Control Prevention CDC definition note human immunodeficiency virus HIV testing required entry protocol', 'Pregnancy women childbearing potential men sexually active willingable use medically acceptable forms contraception', 'Prior allergic reaction study drugs involved protocol', 'Patients undetectable pretreatment plasma EBV DNA'], ['Estrogen receptor ER andor progesterone receptor PR positive histologically confirmed adenocarcinoma breast staining >= 1 cells considered positive receptor status based time treatment prior study randomization site primary recurrent metastatic', 'Patients tumors HER2 immunohistochemistry IHC 3+ situ hybridization ISH >= 20 average HER2 copy number >= 60 signals cell eligible receptor status based time treatment prior study randomization site primary recurrent metastatic', 'Patients measurable nonmeasurable stage IIIlocally advanced metastatic carcinoma breast local therapy curative intent possible lesions evaluated =< 4 weeks prior study randomization diagnosticquality computed tomography CT scans oral intravenous IV contrast expected radiologic method alternative approved NOTE Where baseline imaging performed =< 6 weeks prior study randomization repeat imaging required NOTE As October 16 2016 accrual new patients having nonmeasurable disease stopped planned accrual target population reached', 'Preperi postmenopausal women men eligible trial postmenopausal defined Age >= 55 years year amenorrhea Age < 55 years year amenorrhea estradiol < 20 pgml Age < 55 prior hysterectomy intact ovaries estradiol < 20 pgml Prior bilateral oophorectomy NOTE Women fit criteria postmenopausal deemed preor perimenopausal preperimenopausal women men enroll provided agree receive concomitant luteinizing hormonereleasing hormone LHRH agonist preperimenopausal women commenced treatment LHRH agonist 4 weeks prior randomization patients received alternative LHRH agonist prior study entry switch goserelin duration trial', 'Sexually active males preperimenopausal women agree use accepted effective method contraception abstain sexual intercourse duration participation study 3 months discontinuation therapy', 'Women pregnant breastfeeding females childbearing potential blood test urine study =< 2 weeks prior randomization A female childbearing potential woman regardless sexual orientation undergone tubal ligation meets following criteria 1 undergone hysterectomy bilateral oophorectomy 2 naturally postmenopausal 24 consecutive months menses time preceding 24 consecutive months', 'Patients known central nervous metastasis history central nervous CNS metastases patients leptomeningeal disease eligible', 'Patients diseasefree prior invasive malignancies > 5 years exception curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix NOTE If history prior malignancy patients receiving specific treatment cancer', 'Patients meet following criteria Disease progression time nonsteroidal AI use advanced disease setting Relapse =< 12 months end adjuvant nonsteroidal AI therapy prior endocrine therapy advanced disease NOTE In setting treatment prior endocrine therapy completed >= 2 weeks prior cycle 1 day 1 C1D1 study treatment exception exemestane permitted advanced disease setting =< 4 weeks immediately prior C1D1 prior adjuvant exemestane allowed disease free interval > 12 months discontinuation exemestane prior faslodex everolimus palbociclib cyclindependent kinase CDK inhibitor ribociclib abemaciclib use allowed completed >= 2 weeks prior C1D1 failure adhere washout guideline result protocol violation', 'Patients received prior chemotherapy regimen metastatic disease provided treatment completed >= 3 weeks prior randomization', 'Patients treated bone modifying agents bisphosphonates RANKligand agents denosumab American Society Clinical Oncology ASCO guidelines possible patients requiring bone modifying agents start treatment >= 7 days prior study therapy continue agent study clinically compelled change', 'Prior radiotherapy general completed >= 2 weeks prior randomization patients recovered toxicity radiation NOTE Patients receive concurrent radiation therapy painful sites bony disease areas impending fracture long sites measurable nonmeasurable disease outside radiation therapy port available follow', 'Patients NOT receive concurrent anticancer therapy investigational agent specified protocol', 'Patients NOT receiving valproic acid histone deacetylase HDAC inhibitor previously received HDAC inhibitor prior enrollment valproic acid entinostat vorinostat discussed study chair patients received prior HDAC therapy treatment malignancy', 'Patients known allergies exemestane entinostat medications benzamide structure tiapride remoxipride clebropride', 'Patients NOT suffer medical psychiatric conditions interfere protocol compliance ability provide informed consent assessment response anticipated toxicities includes uncontrolled intercurrent illness including limited ongoing active infection', 'Patients recovered clinically relevant adverse events grade 1 baseline previous agents administered alopecia', 'Patients adequate hematologic liver renal function =< 28 days prior randomization NOTE It preferred laboratory values eligibility assessed dose prior treatment especially cases mostrecent treatment prior study entry chemotherapy', 'Hemoglobin HgB >= 90 gdL =< 28 days prior randomization', 'Platelet count >= 100000mcL =< 28 days prior randomization', 'Absolute neutrophil count >= 1500mcL =< 28 days prior randomization', 'Creatinine =< 20 mgdL =< 28 days prior randomization', 'Total bilirubin < 15 x institutional upper limit normal =< 3 mgdL case Gilbert’s syndrome =< 28 days prior randomization', 'Transaminases alanine aminotransferase ALT aspartate aminotransferase AST =< 25 x institutional upper limit normal =< 28 days prior randomization', 'Known human immunodeficiency virus HIVpositive patients cluster differentiation CD4 count > 250mm3', 'Patients Eastern Cooperative Oncology Group ECOG performance status 01', 'Patients life expectancy >= 12 weeks', 'Patients able swallow tablets']]\n"
     ]
    }
   ],
   "source": [
    "# Now we should remove the stopwords from each description, this will help filter out words so we can get better matches\n",
    "all_filtered_desc = []\n",
    "for trial in all_desc_no_punc:\n",
    "    \n",
    "    descriptions = []\n",
    "    \n",
    "    for desc in trial:\n",
    "        \n",
    "        df = remove_stopwords(desc)\n",
    "        descriptions.append(df)\n",
    "        \n",
    "    all_filtered_desc.append(descriptions)\n",
    "    \n",
    "print(all_filtered_desc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "50\n",
      "50\n"
     ]
    }
   ],
   "source": [
    "# testing the length of each list to see if they can be matched for a dictionary comprehension later\n",
    "print(len(all_filtered_desc))\n",
    "print(len(ids))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.4, 0.1, 0, 0, 0, 0, 0, 0, 0.30000000000000004, 0, 0, 0, 0.2, 0, 0, 0.1, 0.30000000000000004, 0, 0, 0.30000000000000004, 0, 0.2, 0.5, 0.1, 0, 0, 0.2, 0.1, 0.1, 0, 0.1, 0.1, 0, 0.2, 0.1, 0.2, 0.1, 0, 0.1, 0, 0, 0, 0.2, 0.1, 0.1, 0, 0.30000000000000004, 0, 0.1, 0.1]\n"
     ]
    }
   ],
   "source": [
    "# instantiate an empty list to load each trial score to it. This is where we use fuzzy logic to compare strings\n",
    "# the fuzz library has a few great functions like the token_set_ratio which does some text preprocessing to the strings\n",
    "# that it is matching. It uses the levenshtein distance measure to calcuate the similarities between strings\n",
    "# we then later say if the similarity between two strings is above a given threshold, then we will increse the metric by 0.1.\n",
    "all_scores1 = []\n",
    "for trial in all_filtered_desc:\n",
    "    \n",
    "    cdm = 0\n",
    "    desc_trial_score = []\n",
    "    \n",
    "    for desc in trial:\n",
    "        \n",
    "        desc_score = []\n",
    "        \n",
    "        for item in patient_cancer_data:\n",
    "            \n",
    "            score = fuzz.token_set_ratio(item, desc)\n",
    "            desc_score.append(score)\n",
    "            \n",
    "        desc_trial_score.append(desc_score)\n",
    "\n",
    "    #print(desc_trial_score)\n",
    "    \n",
    "    \n",
    "    \n",
    "    for row in desc_trial_score:\n",
    "        \n",
    "        for score in row:\n",
    "            \n",
    "            if score>70:\n",
    "                cdm+=0.1\n",
    "                \n",
    "    all_scores1.append(cdm)\n",
    "    \n",
    "print(all_scores1)\n",
    "            \n",
    "            \n",
    "        \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "50"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(all_scores)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Dictionary comprehension to link the scores to their respective trial so we can rank them and show the id as well\n",
    "ids_and_scores = {k:v for (k,v) in zip(ids, all_scores1)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCI-2011-01974 : 0.5\n",
      "NCI-2009-00595 : 0.4\n",
      "NCI-2011-02592 : 0.30000000000000004\n",
      "NCI-2011-01987 : 0.30000000000000004\n",
      "NCI-2011-01975 : 0.30000000000000004\n",
      "NCI-2014-00627 : 0.30000000000000004\n",
      "NCI-2012-02067 : 0.2\n",
      "NCI-2011-02000 : 0.2\n",
      "NCI-2011-02673 : 0.2\n",
      "NCI-2013-00426 : 0.2\n",
      "NCI-2013-00737 : 0.2\n",
      "NCI-2013-02167 : 0.2\n",
      "NCI-2011-00878 : 0.1\n",
      "NCI-2009-00470 : 0.1\n",
      "NCI-2012-00234 : 0.1\n",
      "NCI-2012-01995 : 0.1\n",
      "NCI-2012-01998 : 0.1\n",
      "NCI-2012-02045 : 0.1\n",
      "NCI-2012-02057 : 0.1\n",
      "NCI-2013-00370 : 0.1\n",
      "NCI-2013-00875 : 0.1\n",
      "NCI-2013-01340 : 0.1\n",
      "NCI-2013-01904 : 0.1\n",
      "NCI-2013-02284 : 0.1\n",
      "NCI-2014-00635 : 0.1\n",
      "NCI-2014-00746 : 0.1\n",
      "NCI-2011-01915 : 0\n",
      "NCI-2009-00336 : 0\n",
      "NCI-2011-01972 : 0\n",
      "NCI-2011-02623 : 0\n",
      "NCI-2011-02599 : 0\n",
      "NCI-2011-02611 : 0\n",
      "NCI-2012-00719 : 0\n",
      "NCI-2012-00707 : 0\n",
      "NCI-2012-01964 : 0\n",
      "NCI-2012-02608 : 0\n",
      "NCI-2012-03125 : 0\n",
      "NCI-2011-02037 : 0\n",
      "NCI-2011-01992 : 0\n",
      "NCI-2011-02029 : 0\n",
      "NCI-2011-03797 : 0\n",
      "NCI-2011-02674 : 0\n",
      "NCI-2012-02020 : 0\n",
      "NCI-2012-03198 : 0\n",
      "NCI-2013-00890 : 0\n",
      "NCI-2013-01275 : 0\n",
      "NCI-2013-01702 : 0\n",
      "NCI-2013-02229 : 0\n",
      "NCI-2014-00616 : 0\n",
      "NCI-2014-00631 : 0\n"
     ]
    }
   ],
   "source": [
    "# sort the values and then print the key value pair. \n",
    "ranked_ids = sorted(ids_and_scores.items() , reverse=True, key=lambda x: x[1])\n",
    "for elem in ranked_ids:\n",
    "    print(elem[0] , ':', elem[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Other Female Genital', 'Ovary'], ['Larynx', 'Lip, Oral Cavity and Pharynx'], ['Brain and Nervous System'], ['Brain and Nervous System'], ['Larynx', 'Lip, Oral Cavity and Pharynx'], ['Breast - Female'], ['Lymphoid Leukemia', \"Non-Hodgkin's Lymphoma\"], ['Brain and Nervous System', 'Soft Tissue / Sarcoma'], ['Lung'], ['Breast - Female'], ['Breast - Female'], ['Other Female Genital'], ['Colon', 'Rectum'], ['Multiple Myeloma'], ['Brain and Nervous System'], ['Lung'], ['Pancreas'], ['Cervix'], ['Myeloid and Monocytic Leukemia'], ['Liver'], ['Brain and Nervous System'], ['Ovary'], ['Urinary Bladder'], ['Rectum'], ['Leukemia, other', 'Lymphoid Leukemia'], ['Prostate'], [\"Non-Hodgkin's Lymphoma\"], ['Breast - Female', 'Breast - Male'], ['Multiple Myeloma'], ['Brain and Nervous System'], ['Breast - Female'], ['Liver'], ['Breast - Female'], ['Breast - Female'], ['Lip, Oral Cavity and Pharynx'], ['Lung'], ['Breast - Female', 'Breast - Male'], ['Corpus Uteri'], ['Breast - Female'], [\"Hodgkin's Lymphoma\"], ['Multiple Myeloma'], ['Lymphoid Leukemia'], [\"Non-Hodgkin's Lymphoma\"], ['Multiple'], ['Corpus Uteri'], ['Brain and Nervous System'], ['Lung'], ['Lymphoid Leukemia'], ['Lip, Oral Cavity and Pharynx'], ['Breast - Female', 'Breast - Male']]\n"
     ]
    }
   ],
   "source": [
    "# Create a similar data structure (2D array)\n",
    "trial_c_sites = []\n",
    "for item in a_sites:\n",
    "    trial_c_sites.append(item)\n",
    "print(trial_c_sites)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]\n"
     ]
    }
   ],
   "source": [
    "# this is the same process we had used on the descriptions, but it's being applied to anatomic sites\n",
    "all_scores = []\n",
    "for trial in trial_c_sites:\n",
    "    \n",
    "    csm = 0\n",
    "    trial_score = []\n",
    "    \n",
    "    for site in trial:\n",
    "        \n",
    "        c_score = fuzz.token_set_ratio(site, c_location)\n",
    "        trial_score.append(c_score)\n",
    "        \n",
    "        if c_score > 65:\n",
    "            csm+=1\n",
    "    all_scores.append(csm)\n",
    "print(all_scores)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "50\n"
     ]
    }
   ],
   "source": [
    "print(len(all_scores))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.4, 0.1, 0, 0, 0, 0, 0, 0, 0.30000000000000004, 0, 0, 0, 0.2, 0, 0, 0.1, 1.3, 0, 0, 0.30000000000000004, 0, 0.2, 0.5, 0.1, 0, 0, 0.2, 0.1, 0.1, 0, 0.1, 0.1, 0, 0.2, 0.1, 0.2, 0.1, 0, 0.1, 0, 0, 0, 0.2, 0.1, 0.1, 0, 0.30000000000000004, 0, 0.1, 0.1]\n"
     ]
    }
   ],
   "source": [
    "# calculate the overall score of each trial by adding their metrics\n",
    "overall_score = []\n",
    "for i in range(0, len(all_scores)):\n",
    "    overall_score.append( all_scores1[i] + all_scores[i])\n",
    "print(overall_score)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCI-2011-01987 : 1.3\n",
      "NCI-2011-01974 : 0.5\n",
      "NCI-2009-00595 : 0.4\n",
      "NCI-2011-02592 : 0.30000000000000004\n",
      "NCI-2011-01975 : 0.30000000000000004\n",
      "NCI-2014-00627 : 0.30000000000000004\n",
      "NCI-2012-02067 : 0.2\n",
      "NCI-2011-02000 : 0.2\n",
      "NCI-2011-02673 : 0.2\n",
      "NCI-2013-00426 : 0.2\n",
      "NCI-2013-00737 : 0.2\n",
      "NCI-2013-02167 : 0.2\n",
      "NCI-2011-00878 : 0.1\n",
      "NCI-2009-00470 : 0.1\n",
      "NCI-2012-00234 : 0.1\n",
      "NCI-2012-01995 : 0.1\n",
      "NCI-2012-01998 : 0.1\n",
      "NCI-2012-02045 : 0.1\n",
      "NCI-2012-02057 : 0.1\n",
      "NCI-2013-00370 : 0.1\n",
      "NCI-2013-00875 : 0.1\n",
      "NCI-2013-01340 : 0.1\n",
      "NCI-2013-01904 : 0.1\n",
      "NCI-2013-02284 : 0.1\n",
      "NCI-2014-00635 : 0.1\n",
      "NCI-2014-00746 : 0.1\n",
      "NCI-2011-01915 : 0\n",
      "NCI-2009-00336 : 0\n",
      "NCI-2011-01972 : 0\n",
      "NCI-2011-02623 : 0\n",
      "NCI-2011-02599 : 0\n",
      "NCI-2011-02611 : 0\n",
      "NCI-2012-00719 : 0\n",
      "NCI-2012-00707 : 0\n",
      "NCI-2012-01964 : 0\n",
      "NCI-2012-02608 : 0\n",
      "NCI-2012-03125 : 0\n",
      "NCI-2011-02037 : 0\n",
      "NCI-2011-01992 : 0\n",
      "NCI-2011-02029 : 0\n",
      "NCI-2011-03797 : 0\n",
      "NCI-2011-02674 : 0\n",
      "NCI-2012-02020 : 0\n",
      "NCI-2012-03198 : 0\n",
      "NCI-2013-00890 : 0\n",
      "NCI-2013-01275 : 0\n",
      "NCI-2013-01702 : 0\n",
      "NCI-2013-02229 : 0\n",
      "NCI-2014-00616 : 0\n",
      "NCI-2014-00631 : 0\n"
     ]
    }
   ],
   "source": [
    "# this stores the scores and the trial ID into a dictionary and then prints out the trials in order. \n",
    "ids_and_overall_scores = {k:v for (k,v) in zip(ids, overall_score)}\n",
    "ranked_overall_ids = sorted(ids_and_overall_scores.items() , reverse=True, key=lambda x: x[1])\n",
    "for elem in ranked_overall_ids:\n",
    "    print(elem[0] , ':', elem[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
